0000885725-19-000045.txt : 20191105 0000885725-19-000045.hdr.sgml : 20191105 20191105063321 ACCESSION NUMBER: 0000885725-19-000045 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191105 DATE AS OF CHANGE: 20191105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 191191665 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 10-Q 1 q32019form10-q.htm 10-Q Document
false--12-31Q3201900008857250.010.01200000000020000000001632148030138458176013937762390.060.073750.040.02850.033750.03850.07000.04125true27500000000.010.0150000000500000000000247566270247566270 0000885725 2019-01-01 2019-09-30 0000885725 bsx:A2018AcquisitionsMember 2019-01-01 2019-09-30 0000885725 bsx:A2019AcquisitionsMember 2019-01-01 2019-09-30 0000885725 bsx:BTGAcquisitionMember 2019-01-01 2019-09-30 0000885725 2019-10-22 0000885725 2019-07-01 2019-09-30 0000885725 2018-01-01 2018-09-30 0000885725 2018-07-01 2018-09-30 0000885725 2019-09-30 0000885725 2018-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000885725 us-gaap:TreasuryStockMember 2018-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000885725 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000885725 us-gaap:TreasuryStockMember 2018-03-31 0000885725 us-gaap:CommonStockMember 2018-09-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000885725 us-gaap:CommonStockMember 2018-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000885725 us-gaap:RetainedEarningsMember 2019-06-30 0000885725 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000885725 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0000885725 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000885725 us-gaap:CommonStockMember 2019-06-30 0000885725 us-gaap:RetainedEarningsMember 2017-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000885725 us-gaap:TreasuryStockMember 2018-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0000885725 us-gaap:CommonStockMember 2017-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000885725 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000885725 us-gaap:TreasuryStockMember 2019-06-30 0000885725 us-gaap:RetainedEarningsMember 2018-09-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000885725 us-gaap:TreasuryStockMember 2019-09-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000885725 us-gaap:RetainedEarningsMember 2019-09-30 0000885725 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000885725 us-gaap:CommonStockMember 2018-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000885725 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000885725 us-gaap:TreasuryStockMember 2017-12-31 0000885725 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000885725 us-gaap:CommonStockMember 2018-03-31 0000885725 us-gaap:CommonStockMember 2019-03-31 0000885725 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000885725 us-gaap:CommonStockMember 2019-09-30 0000885725 us-gaap:TreasuryStockMember 2018-09-30 0000885725 us-gaap:RetainedEarningsMember 2019-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000885725 us-gaap:RetainedEarningsMember 2018-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000885725 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000885725 us-gaap:RetainedEarningsMember 2018-06-30 0000885725 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000885725 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000885725 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000885725 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-01 2018-12-31 0000885725 us-gaap:RetainedEarningsMember 2018-03-31 0000885725 us-gaap:TreasuryStockMember 2019-03-31 0000885725 us-gaap:NewAccountingPronouncementMember us-gaap:RetainedEarningsMember 2017-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000885725 2018-09-30 0000885725 2017-12-31 0000885725 bsx:OperatingleaseliabilityotherlongtermliabilitiesMember us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-01-01 0000885725 bsx:OperatingleaserightofuseassetsotherlongtermassetsMember us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-01-01 0000885725 srt:MinimumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 srt:MaximumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MinimumMember bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MaximumMember bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-09-30 0000885725 bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MaximumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MinimumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:A2019AcquisitionsMember 2019-09-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-09-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-09-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-09-30 0000885725 bsx:A2018AcquisitionsMember 2019-09-30 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-09-30 0000885725 bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:A2018AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-09-30 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-09-30 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 bsx:A2018AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-09-30 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:BTGAcquisitionMember 2019-09-30 0000885725 bsx:BTGAcquisitionMember 2019-07-01 2019-09-30 0000885725 bsx:BTGintellectualpropertyMember 2019-09-30 0000885725 bsx:DivestedbusinessduetoBTGacquisitionMember 2019-08-21 0000885725 bsx:VertiflexInc.Member 2019-06-11 0000885725 bsx:Other2018AcquisitionsMember 2018-09-30 0000885725 bsx:Other2018AcquisitionsMember 2018-01-01 2018-09-30 0000885725 bsx:MillipedeInc.Member 2019-01-29 0000885725 2019-08-21 2019-08-21 0000885725 bsx:BTGAcquisitionMember 2019-08-19 0000885725 bsx:NxTheraMember 2018-04-30 0000885725 bsx:NVisionMember 2018-04-16 2018-04-16 0000885725 bsx:MillipedeInc.Member 2019-01-29 2019-01-29 0000885725 bsx:ClaretMember 2018-07-01 2018-09-30 0000885725 srt:MaximumMember 2019-01-01 2019-09-30 0000885725 bsx:ClaretMember 2018-08-02 2018-08-02 0000885725 bsx:CryterionMember 2018-07-05 0000885725 bsx:BTGAcquisitionMember 2019-08-19 2019-08-19 0000885725 bsx:NVisionMember 2018-04-16 0000885725 bsx:VertiflexInc.Member 2019-06-11 2019-06-11 0000885725 bsx:CryterionMember 2018-07-05 2018-07-05 0000885725 bsx:BTGAcquisitionMember 2019-01-01 2019-09-30 0000885725 bsx:NxTheraMember 2018-04-30 2018-04-30 0000885725 srt:MaximumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-09-30 0000885725 srt:MaximumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 srt:WeightedAverageMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 srt:MinimumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-09-30 0000885725 srt:WeightedAverageMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-09-30 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-09-30 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-09-30 0000885725 srt:MinimumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-09-30 0000885725 bsx:BTGAcquisitionMember 2018-12-31 0000885725 bsx:MedsurgMember 2019-09-30 0000885725 bsx:CardiovascularMember 2018-12-31 0000885725 bsx:RhythmandNeuroMember 2019-01-01 2019-09-30 0000885725 bsx:CardiovascularMember 2019-01-01 2019-09-30 0000885725 bsx:RhythmandNeuroMember 2019-09-30 0000885725 bsx:MedsurgMember 2019-01-01 2019-09-30 0000885725 bsx:RhythmandNeuroMember 2018-12-31 0000885725 bsx:CardiovascularMember 2019-09-30 0000885725 bsx:BTGAcquisitionMember 2019-09-30 0000885725 bsx:MedsurgMember 2018-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 us-gaap:OtherIntangibleAssetsMember 2019-09-30 0000885725 us-gaap:OtherIntangibleAssetsMember 2018-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2019-09-30 0000885725 us-gaap:GoodwillMember 2019-09-30 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-12-31 0000885725 us-gaap:PatentsMember 2019-09-30 0000885725 us-gaap:PatentsMember 2018-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 us-gaap:GoodwillMember 2018-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000885725 us-gaap:FairValueInputsLevel3Member 2019-01-01 2019-09-30 0000885725 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member 2019-01-01 2019-09-30 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-09-30 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-09-30 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-09-30 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-07-01 2018-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2019-09-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:InterestExpenseMember 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-01-01 2018-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-07-01 2018-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-07-01 2018-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-09-30 0000885725 bsx:BTGAcquisitionMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000885725 bsx:BTGAcquisitionMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 bsx:BTGAcquisitionMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000885725 bsx:AggregateSeniorUnsecuredDelayedDrawTermLoanMember us-gaap:UnsecuredDebtMember 2018-12-19 0000885725 bsx:RequirementfirsttwoquartersfollowingqualifiedacquisitionMember 2019-09-30 0000885725 us-gaap:CommercialPaperMember 2019-01-01 2019-09-30 0000885725 bsx:CurrentRequirementMember 2019-09-30 0000885725 bsx:August2019TermLoanMember 2019-01-01 2019-09-30 0000885725 bsx:TenderOfferMember us-gaap:SubsequentEventMember 2019-10-22 0000885725 bsx:TwoYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2018-12-19 0000885725 bsx:January2020NotesMember 2019-09-30 0000885725 bsx:RequirementsixthquarterandthereafterfollowingqualifiedacquisitionMember 2019-09-30 0000885725 us-gaap:SeniorNotesMember 2019-09-30 0000885725 bsx:February2019AggregateOfferingMember 2019-02-25 0000885725 bsx:CovenantRequirementDomain 2019-09-30 0000885725 bsx:RequirementfourthquarterfollowingqualifiedacquisitionMember 2019-09-30 0000885725 bsx:March2039NotesMember 2019-09-30 0000885725 bsx:TwoYearDelayedDrawTermLoanMember 2019-01-01 2019-09-30 0000885725 bsx:March2029NotesMember 2019-09-30 0000885725 bsx:March2049NotesMember 2019-09-30 0000885725 bsx:March2028NotesMember 2019-09-30 0000885725 bsx:May2020NotesMember 2019-09-30 0000885725 bsx:January2020NotesMember 2019-02-25 2019-02-25 0000885725 bsx:March2024NotesMember 2019-09-30 0000885725 bsx:ThreeYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2019-08-19 0000885725 bsx:March2026NotesMember 2019-09-30 0000885725 bsx:ThreeYearDelayedDrawTermLoanMember 2019-01-01 2019-09-30 0000885725 bsx:May2025NotesMember 2019-09-30 0000885725 us-gaap:SeniorNotesMember 2018-12-31 0000885725 bsx:May2022NotesMember 2019-09-30 0000885725 bsx:October2023NotesMember 2019-09-30 0000885725 bsx:ThreeYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2018-12-19 0000885725 bsx:RequirementthirdquarterfollowingqualifiedacquisitionMember 2019-09-30 0000885725 us-gaap:RevolvingCreditFacilityMember bsx:The2018FacilityDomain 2019-09-30 0000885725 bsx:August2019TermLoanMember 2018-12-31 0000885725 bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember 2019-09-30 0000885725 bsx:May2020NotesMember 2019-02-25 2019-02-25 0000885725 bsx:TwoYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2019-08-19 0000885725 us-gaap:CommercialPaperMember 2018-12-31 0000885725 us-gaap:CommercialPaperMember 2019-09-30 0000885725 us-gaap:CommercialPaperMember 2018-01-01 2018-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2019-01-01 2019-09-30 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2018-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2019-01-01 2019-09-30 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2019-09-30 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2019-09-30 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2018-01-01 2018-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2018-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2018-01-01 2018-12-31 0000885725 bsx:November2035NotesMember 2019-09-30 0000885725 bsx:March2024NotesMember 2018-12-31 0000885725 bsx:May2022NotesMember 2018-12-31 0000885725 bsx:May2020NotesMember 2018-12-31 0000885725 bsx:January2040NotesMember 2019-09-30 0000885725 bsx:January2040NotesMember 2018-12-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2019-09-30 0000885725 bsx:August2021TermLoanMember 2019-09-30 0000885725 bsx:March2028NotesMember 2018-12-31 0000885725 us-gaap:InterestRateSwapMember 2018-12-31 0000885725 bsx:March2026NotesMember 2018-12-31 0000885725 bsx:May2025NotesMember 2018-12-31 0000885725 bsx:January2020NotesMember 2018-12-31 0000885725 bsx:March2049NotesMember 2018-12-31 0000885725 bsx:March2029NotesMember 2018-12-31 0000885725 bsx:August2021TermLoanMember 2018-12-31 0000885725 bsx:November2035NotesMember 2018-12-31 0000885725 us-gaap:InterestRateSwapMember 2019-09-30 0000885725 us-gaap:CapitalLeaseObligationsMember 2018-12-31 0000885725 bsx:August2022TermLoanMember 2019-09-30 0000885725 bsx:August2022TermLoanMember 2018-12-31 0000885725 bsx:March2039NotesMember 2018-12-31 0000885725 bsx:October2023NotesMember 2018-12-31 0000885725 bsx:ActualCovenantMember 2019-09-30 0000885725 us-gaap:RevolvingCreditFacilityMember bsx:The2018FacilityDomain 2018-12-31 0000885725 2019-06-30 0000885725 2018-06-30 0000885725 srt:MaximumMember 2019-09-30 0000885725 srt:MinimumMember 2019-09-30 0000885725 us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2019-10-16 0000885725 us-gaap:SubsequentEventMember 2019-10-16 0000885725 bsx:MaximumContingentPaymentMember 2018-09-12 0000885725 bsx:NonAcquisitionRelatedMember 2019-09-30 0000885725 bsx:AssignedtoonejudgeinMAMember us-gaap:SubsequentEventMember 2019-10-16 0000885725 2019-03-31 0000885725 bsx:UpfrontCashMember 2018-09-12 0000885725 2019-01-01 2019-03-31 0000885725 bsx:MedsurgMember 2019-07-01 2019-09-30 0000885725 bsx:SpecialChargesMember 2018-07-01 2018-09-30 0000885725 bsx:RhythmandNeuroMember 2018-01-01 2018-09-30 0000885725 bsx:RhythmandNeuroMember 2018-07-01 2018-09-30 0000885725 bsx:RhythmandNeuroMember 2019-07-01 2019-09-30 0000885725 bsx:ExcludesBTGAcquisitionMember 2019-01-01 2019-09-30 0000885725 bsx:MedsurgMember 2018-01-01 2018-09-30 0000885725 bsx:CardiovascularMember 2019-07-01 2019-09-30 0000885725 bsx:SpecialChargesMember 2018-01-01 2018-09-30 0000885725 bsx:SpecialChargesMember 2019-07-01 2019-09-30 0000885725 bsx:MedsurgMember 2018-07-01 2018-09-30 0000885725 bsx:CardiovascularMember 2018-01-01 2018-09-30 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2018-01-01 2018-09-30 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2019-07-01 2019-09-30 0000885725 bsx:BTGAcquisitionMember 2019-07-01 2019-09-30 0000885725 bsx:CardiovascularMember 2018-07-01 2018-09-30 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2019-01-01 2019-09-30 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2018-07-01 2018-09-30 0000885725 bsx:SpecialChargesMember 2019-01-01 2019-09-30 0000885725 bsx:ExcludesBTGAcquisitionMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:BTGSpecPharmaMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalCrmReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalCrmReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:BTGInterventionalMedicineMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:BTGSpecPharmaMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:BTGInterventionalMedicineMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 srt:AsiaPacificMember 2018-01-01 2018-09-30 0000885725 bsx:LatinAmericaandCanadaMember 2018-07-01 2018-09-30 0000885725 srt:AsiaPacificMember 2019-07-01 2019-09-30 0000885725 country:US 2018-01-01 2018-09-30 0000885725 bsx:EmergingMarketsMember 2019-07-01 2019-09-30 0000885725 bsx:EmergingMarketsMember 2018-07-01 2018-09-30 0000885725 bsx:EmergingMarketsMember 2018-01-01 2018-09-30 0000885725 us-gaap:EMEAMember 2018-01-01 2018-09-30 0000885725 bsx:LatinAmericaandCanadaMember 2019-01-01 2019-09-30 0000885725 bsx:LatinAmericaandCanadaMember 2019-07-01 2019-09-30 0000885725 country:US 2019-07-01 2019-09-30 0000885725 country:US 2018-07-01 2018-09-30 0000885725 country:US 2019-01-01 2019-09-30 0000885725 srt:AsiaPacificMember 2019-01-01 2019-09-30 0000885725 bsx:EmergingMarketsMember 2019-01-01 2019-09-30 0000885725 us-gaap:EMEAMember 2019-01-01 2019-09-30 0000885725 us-gaap:EMEAMember 2019-07-01 2019-09-30 0000885725 srt:AsiaPacificMember 2018-07-01 2018-09-30 0000885725 bsx:LatinAmericaandCanadaMember 2018-01-01 2018-09-30 0000885725 us-gaap:EMEAMember 2018-07-01 2018-09-30 iso4217:GBP bsx:units xbrli:pure iso4217:USD iso4217:GBP xbrli:shares iso4217:USD xbrli:shares utreg:Rate xbrli:shares bsx:claims bsx:reportablesegments

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☑
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2019
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File No. 1-11083
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
 
 
 
 
04-2695240
(State or other jurisdiction of incorporation or organization)
 
 
 
 
(I.R.S. Employer Identification No.)
 
 
 
 
 
 
300 Boston Scientific Way
.
Marlborough
.
Massachusetts
01752-1234
(Address of Principal Executive Offices)
(Zip Code)
508 683-4000
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol
 
Name of each exchange on which registered
Common Stock, $0.01 par value
 
BSX
 
New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☑
Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
 
 
Emerging growth company
☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
The number of shares outstanding of Common Stock, $0.01 par value per share, as of October 22, 2019 was 1,393,823,592.



TABLE OF CONTENTS

 
 
Page No.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

2

PART I
FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions, except per share data)
2019
 
2018
 
2019
 
2018
Net sales
$
2,707

 
$
2,393

 
$
7,831

 
$
7,262

Cost of products sold
777

 
672

 
2,265

 
2,084

Gross profit
1,930

 
1,720

 
5,566

 
5,179

 
 
 
 
 
 
 
 
Operating expenses:
 
 
 
 
 
 
 
Selling, general and administrative expenses
1,012

 
870

 
2,849

 
2,616

Research and development expenses
306

 
289

 
866

 
825

Royalty expense
15

 
17

 
48

 
52

Amortization expense
178

 
148

 
498

 
437

Intangible asset impairment charges
—

 
—

 
105

 
35

Contingent consideration expense (benefit)
8

 
(13
)
 
(9
)
 
(12
)
Restructuring charges (credits)
3

 
3

 
10

 
20

Litigation-related net charges (credits)
25

 
18

 
(108
)
 
18

 
1,547

 
1,333

 
4,258

 
3,992

Operating income (loss)
383

 
388

 
1,308

 
1,187

 
 
 
 
 
 
 
 
Other income (expense):
 
 
 
 
 
 
 
Interest expense
(95
)
 
(58
)
 
(294
)
 
(177
)
Other, net
(197
)
 
126

 
(322
)
 
116

Income (loss) before income taxes
91

 
456

 
693

 
1,126

Income tax expense (benefit)
(35
)
 
24

 
(11
)
 
(159
)
Net income (loss)
$
126

 
$
432

 
$
704

 
$
1,285

 
 
 
 
 
 
 
 
Net income (loss) per common share — basic
$
0.09

 
$
0.31

 
$
0.51

 
$
0.93

Net income (loss) per common share — assuming dilution
$
0.09

 
$
0.31

 
$
0.50

 
$
0.92

 
 
 
 
 
 
 
 
Weighted-average shares outstanding
 
 
 
 
 
 
 
Basic
1,393.1

 
1,382.8

 
1,390.6

 
1,380.0

Assuming dilution
1,412.2

 
1,403.9

 
1,409.7

 
1,399.8










See notes to the unaudited condensed consolidated financial statements.

3

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (UNAUDITED)

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions)
2019
 
2018
 
2019
 
2018
Net income (loss)
$
126

 
$
432

 
$
704

 
$
1,285

Other comprehensive income (loss), net of tax:
 
 
 
 
 
 
 
Foreign currency translation adjustment
(2
)
 
(6
)
 
4

 
(42
)
Net change in derivative financial instruments
62

 
47

 
102

 
125

Net change in defined benefit pensions and other items
—

 
—

 
(1
)
 
—

Total other comprehensive income (loss)
60

 
40

 
105

 
82

Total comprehensive income (loss)
$
186

 
$
472

 
$
809

 
$
1,367











































See notes to the unaudited condensed consolidated financial statements.

4

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
 
As of
(in millions, except share and per share data)
September 30, 2019
 
December 31, 2018
 
(unaudited)
 
 
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
277

 
$
146

Trade accounts receivable, net
1,796

 
1,608

Inventories
1,566

 
1,166

Prepaid income taxes
189

 
161

Other current assets
1,020

 
921

Total current assets
4,847

 
4,003

Property, plant and equipment, net
1,942

 
1,782

Goodwill
10,015

 
7,911

Other intangible assets, net
8,074

 
6,372

Other long-term assets
1,879

 
932

TOTAL ASSETS
$
26,756

 
$
20,999

 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Current debt obligations
$
1,297

 
$
2,253

Accounts payable
512

 
349

Accrued expenses
1,932

 
2,246

Other current liabilities
513

 
412

Total current liabilities
4,254

 
5,260

Long-term debt
9,590

 
4,803

Deferred income taxes
807

 
328

Other long-term liabilities
2,406

 
1,882

 
 
 
 
Commitments and contingencies

 

 
 
 
 
Stockholders’ equity
 
 
 
Preferred stock, $0.01 par value - authorized 50,000,000 shares, none issued and outstanding


 


Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,641,342,509 shares as of September 30, 2019 and 1,632,148,030 shares as of December 31, 2018
16

 
16

Treasury stock, at cost - 247,566,270 shares as of September 30, 2019 and December 31, 2018
(1,717
)
 
(1,717
)
Additional paid-in capital
17,510

 
17,346

Accumulated deficit
(6,249
)
 
(6,953
)
Accumulated other comprehensive income (loss), net of tax
138

 
33

Total stockholders’ equity
9,699

 
8,726

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
$
26,756

 
$
20,999




See notes to the unaudited condensed consolidated financial statements.

5

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (UNAUDITED)
 
Common Stock
 
Treasury Stock
 
Additional Paid-In Capital
 
Accumulated Deficit
 
Accumulated Other Comprehensive Income (Loss), Net of Tax
(in millions, except share data)
Shares Issued
 
Par Value
 
 
 
 
Balance as of December 31, 2017
1,621,062,898

 
$
16

 
$
(1,717
)
 
$
17,161

 
$
(8,390
)
 
$
(59
)
 
 
 
 
 
 
 
 
 
 
 
 
Net income (loss)
 
 
 
 
 
 
 
 
298

 
 
Cumulative effect adjustments for ASC Update Adoptions(1)
 
 
 
 
 
 
 
 
(233
)
 
 
Total other comprehensive income (loss)
 
 
 
 
 
 
 
 
 
 
(69
)
Impact of stock-based compensation plans, net of tax
6,125,111

 
 
 
 
 
23

 
 
 
 
Balance as of March 31, 2018
1,627,188,009

 
$
16

 
$
(1,717
)
 
$
17,184

 
$
(8,326
)
 
$
(128
)
Net income (loss)
 
 
 
 
 
 
 
 
555

 
 
Total other comprehensive income (loss)
 
 
 
 
 
 
 
 
 
 
112

Impact of stock-based compensation plans, net of tax
1,688,243

 
 
 
 
 
47

 
 
 
 
Balance as of June 30, 2018
1,628,876,252

 
$
16

 
$
(1,717
)
 
$
17,231

 
$
(7,770
)
 
$
(16
)
Net income (loss)
 
 
 
 
 
 
 
 
432

 
 
Total other comprehensive income (loss)
 
 
 
 
 
 
 
 
 
 
40

Impact of stock-based compensation plans, net of tax
2,395,031

 
 
 
 
 
73

 
 
 
 
Balance as of September 30, 2018
1,631,271,283

 
$
16

 
$
(1,717
)
 
$
17,304

 
$
(7,339
)
 
$
25

Net income (loss)
 
 
 
 
 
 
 
 
386

 
 
Total other comprehensive income (loss)
 
 
 
 
 
 
 
 
 
 
8

Impact of stock-based compensation plans, net of tax
876,747

 
 
 
 
 
42

 
 
 
 
Balance as of December 31, 2018
1,632,148,030

 
$
16

 
$
(1,717
)
 
$
17,346

 
$
(6,953
)
 
$
33

Net income (loss)
 

 
 

 
 
 
 

 
424

 
 

Total other comprehensive income (loss)
 

 
 

 
 
 
 

 
 
 
54

Impact of stock-based compensation plans, net of tax
6,001,343

 
 
 
 
 
28

 
 
 
 
Balance as of March 31, 2019
1,638,149,373

 
$
16

 
$
(1,717
)
 
$
17,374

 
$
(6,528
)
 
$
87

Net income (loss)
 
 
 
 
 
 
 
 
154

 
 
Total other comprehensive income (loss)
 
 
 
 
 
 
 
 
 
 
(9
)
Impact of stock-based compensation plans, net of tax
949,557

 
 
 
 
 
48

 
 
 
 
Balance as of June 30, 2019
1,639,098,930

 
$
16

 
$
(1,717
)
 
$
17,422

 
$
(6,375
)
 
$
78

Net income (loss)

 
 
 
 
 
 
 
126

 
 
Total other comprehensive income (loss)
 
 
 
 
 
 
 
 
 
 
60

Impact of stock-based compensation plans, net of tax
2,243,579

 
 
 
 
 
89

 
 
 
 
Balance as of September 30, 2019
1,641,342,509

 
$
16

 
$
(1,717
)
 
$
17,510

 
$
(6,249
)
 
$
138


(1) In 2018, we recorded cumulative effect adjustments to retained earnings to reflect the adoption of Accounting Standards Codification (ASC) Update No. 2014-09, Update No. 2016-16 and Update No. 2016-01. Please refer to Note A – Significant Accounting Policies included in Item 8 of our most recent Annual Report on Form 10-K for more information.





See notes to the unaudited condensed consolidated financial statements.

6

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
 
Nine Months Ended
September 30,
(in millions)
2019
 
2018
Cash provided by (used for) operating activities
$
1,144

 
$
291

 
 
 
 
Investing activities:
 
 
 
Purchases of property, plant and equipment
(275
)
 
(210
)
Proceeds from sale of property, plant and equipment
5

 
—

Payments for acquisitions of businesses, net of cash acquired
(4,382
)
 
(968
)
Payments for investments and acquisitions of certain technologies
(137
)
 
(148
)
Proceeds from divestiture of certain businesses
90

 
—

Payments for settlements of hedge contracts
(294
)
 
—

Cash provided by (used for) investing activities
(4,992
)
 
(1,326
)
 
 
 
 
Financing activities:
 
 
 
Payment of contingent consideration amounts and royalty rights previously established in purchase accounting
(135
)
 
(16
)
Payments on short-term borrowings
(1,000
)
 
—

Proceeds from short-term borrowings, net of debt issuance costs
—

 
999

Net increase (decrease) in commercial paper
13

 
(403
)
Payments on borrowings from credit facilities
—

 
(569
)
Proceeds from borrowings on credit facilities
—

 
569

Payments on long-term borrowings and debt extinguishment costs
(1,472
)
 
(602
)
Proceeds from long-term borrowings, net of debt issuance costs
6,243

 
989

Cash used to net share settle employee equity awards
(64
)
 
(54
)
Proceeds from issuances of shares of common stock
113

 
94

Cash provided by (used for) financing activities
3,697

 
1,007

 
 
 
 
Effect of foreign exchange rates on cash
(2
)
 
(9
)
 
 
 
 
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents
(153
)
 
(37
)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period
829

 
1,017

Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period
$
676

 
$
980

 
 
 
 
Supplemental Information
 
 
 
Stock-based compensation expense
$
116

 
$
104

Fair value of contingent consideration recorded in purchase accounting
127

 
190

 
As of September 30,
Reconciliation to amounts within the unaudited condensed consolidated balance sheets:
2019
 
2018
Cash and cash equivalents
$
277

 
$
168

Restricted cash and restricted cash equivalents included in Other current assets
357

 
781

Restricted cash equivalents included in Other long-term assets
43

 
31

Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period
$
676

 
$
980



See notes to the unaudited condensed consolidated financial statements.

7

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE A – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

On August 19, 2019, we announced the closing of our acquisition of BTG plc (BTG Acquisition or BTG). Refer to Note B – Acquisitions and Strategic Investments for more information.

Subsequent Events

We evaluate events occurring after the date of our most recent accompanying unaudited condensed consolidated balance sheet for potential recognition or disclosure in our financial statements. Those items requiring disclosure (nonrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note E – Borrowings and Credit Arrangements and Note I – Commitments and Contingencies for more information.

Accounting Standards Implemented Since December 31, 2018

ASC Update No. 2016-02

In February 2016, the Financial Accounting Standards Board (FASB) issued ASC Update No. 2016-02, Leases (FASB ASC Topic 842, Leases). We adopted the standard as of January 1, 2019, using the modified retrospective approach and the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements. Under this method, we applied the new leasing rules on the date of adoption and recognized the cumulative effect of initially applying the standard as an adjustment to our opening balance sheet, rather than at the earliest comparative period presented in the financial statements. Prior periods presented are in accordance with the previous lease guidance under FASB ASC Topic 840, Leases.

In addition, we applied the package of practical expedients permitted under FASB ASC Topic 842 transition guidance to our entire lease portfolio at January 1, 2019. As a result, we were not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases and (iii) the treatment of initial direct costs for any existing leases. Furthermore, we elected not to separate lease and non-lease components for the majority of our leases. Instead, for all applicable classes of underlying assets, we accounted for each separate lease component and the non-lease components associated with that lease component, as a single lease component.

As a result of adopting FASB ASC Topic 842 on January 1, 2019, we recognized right-of-use assets of $271 million and corresponding liabilities of $278 million for our existing operating lease portfolio on our unaudited condensed consolidated balance sheet. Operating lease right-of-use assets are presented within Other long-term assets and corresponding liabilities are presented within Other current liabilities and Other long-term liabilities on our unaudited condensed consolidated balance sheets. Finance leases are immaterial to our unaudited condensed consolidated financial statements. Refer to Note E – Borrowings and Credit Arrangements for additional information. There was no material impact to our unaudited condensed consolidated statements of operations or unaudited condensed consolidated statements of cash flows. Please refer to Note G – Leases for information regarding our lease portfolio as of September 30, 2019 as accounted for under FASB ASC Topic 842.

To meet the reporting and disclosure requirements of FASB ASC Topic 842, we implemented a new lease administration and lease accounting system in 2018 that tracks all of our material leasing arrangements. In addition, we designed and implemented new processes and internal controls during the first quarter of 2019 to ensure the completeness and accuracy of the transition adjustment

8

and subsequent financial reporting under FASB ASC Topic 842. We also established monitoring controls to ensure we have appropriate mechanisms in place to identify material leases in a timely manner, particularly contracts that may contain embedded lease features.

NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS

Our unaudited condensed consolidated financial statements include the operating results for acquired entities from the respective date of acquisition. With the exception of the acquisition of BTG, which was completed on August 19, 2019, we have not presented supplemental pro forma financial information for acquisitions given their results are not material to our unaudited condensed consolidated financial statements. Transaction costs for all acquisitions in 2019 and 2018 were immaterial to our unaudited condensed consolidated financial statements and were expensed as incurred.

2019 Acquisitions

We recorded immaterial purchase price adjustments to the preliminary purchase price allocations of previous acquisitions during the measurement period in the first nine months of 2019.

BTG plc

On August 19, 2019, we announced the closing of our acquisition of BTG, a public company organized under the laws of England and Wales. BTG has three key portfolios, the largest of which is its interventional medicine portfolio (Interventional Medicine) that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease. In addition to the Interventional Medicine product lines, the BTG portfolio also includes a specialty pharmaceutical business (Specialty Pharmaceuticals) comprised of acute care antidotes to treat overexposure to certain medications and toxins and a licensing portfolio (Licensing) that generates net royalties related to BTG intellectual property and product license agreements.

The transaction price consisted of upfront cash in the aggregate amount of £3.312 billion for the entire issued ordinary share capital of BTG (or $4.023 billion based on the exchange rate of U.S. $1.21: £1.00 at closing on August 19, 2019), whereby BTG shareholders received 840 pence in cash for each BTG share. The transaction price of $4.023 billion included $404 million of cash and cash equivalents acquired. We implemented the BTG Acquisition by way of a court-sanctioned scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006, as amended.

After closing the BTG Acquisition, we terminated the £150 million BTG revolving credit facility, which contained an option to increase the facility by £150 million and was scheduled to expire in November 2020. The termination was effective on August 27, 2019, and there were no amounts outstanding at the time of close of the BTG Acquisition.

Purchase Price Allocation

We accounted for the BTG Acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (FASB ASC Topic 805), we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The preliminary BTG Acquisition purchase price was comprised of the amounts presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed from the BTG Acquisition. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period as required by FASB ASC Topic 805. As of September 30, 2019, the valuation studies necessary to determine the fair market value of the assets acquired and liabilities assumed are preliminary, including the projection of the underlying cash flows used to determine the fair value of the identified tangible, intangible and financial assets and liabilities. Given the size and breadth of the BTG Acquisition, we anticipate that the purchase price allocation will take longer than prior acquisitions and potentially up to the one year allowed under FASB ASC Topic 805 to adequately analyze all the factors used in establishing the fair value of assets acquired and liabilities assumed as of the acquisition date, including, but not limited to, intangible assets, inventories, financial assets, real and personal property, leases, certain assumed liabilities, including reserves and deferred revenues, tax-related items, and the related tax and foreign currency effects of any changes made.

Any potential adjustments made could be material in relation to the preliminary values presented below:
(in millions)
 
Payment for acquisition, net of cash acquired
$
3,619




9

The following summarizes the BTG Acquisition preliminary purchase price allocation as of September 30, 2019:
(in millions)
 
Goodwill
$
1,549

Trade accounts receivable, net
107

Inventories
205

Other current assets
259

Other intangible assets, net
1,869

Other long-term assets
604

Accrued expenses and other current liabilities
(305
)
Other long-term liabilities
(289
)
Deferred tax liability
(380
)
 
$
3,619



As a result of the BTG Acquisition, we recognized goodwill of $1.549 billion, which is attributable to the synergies expected to arise from the BTG Acquisition and revenue and cash flow projections associated with future technologies. The goodwill is not deductible for tax purposes. As of September 30, 2019, given the preliminary nature of the purchase price allocation, we have not yet allocated goodwill to the relevant reporting units.

We acquired certain intellectual property and related licensing arrangements, principally relating to Zytiga™, as part of the BTG Acquisition that provides the contractual right to receive future royalty payments. The licensing arrangements were accounted for as financial assets as part of acquisition accounting and were recognized at fair value based upon a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. Additionally, as part of the intellectual property related to the licensing arrangements that we acquired we also have the contractual obligation to remit a portion of the cash flows received to the inventors associated with the intellectual property. As such, as part of acquisition accounting we have recorded a financial liability related to the future cash flows we are required to remit to the inventors when we collect the royalty payments. The amount recognized for the financial asset was $633 million in aggregate, comprised of $200 million included in Other current assets and $432 million included in Other long-term assets. The amount recognized for the financial liability was $395 million, comprised of $153 million included in Accrued expenses and other current liabilities and $241 million included in Other long-term liabilities.

We allocated a portion of the BTG Acquisition preliminary purchase price to specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
 
 
 
 
Technology-related
$
1,794

 
10
-
17
 
10
%
-
12%
Other intangible assets
75

 
2
-
11
 
11%
 
$
1,869

 
 
 
 
 
 
 
 


As a result of the BTG Acquisition, we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom (U.K.) employees (U.K. Plan). The U.K. Plan was closed to new entrants as of June 1, 2004. Prior to the acquisition close date of August 19, 2019, the Trustees of the U.K. Plan executed buy-in arrangements (Buy-in Contracts), under which the benefit obligation of the pension plan is not transferred to the insurers, and we remain responsible for paying pension benefits. Effectively, the Buy-in Contracts are intended to provide payments designed to equal all future designated contractual benefit payments to covered participants. We do not anticipate any additional material contributions or payments to the U.K. Plan or the insurer.


10

The following assumptions were used to measure the fair value of the benefit obligation and associated plan assets:
 
Discount Rate
 
Expected Return on Plan Assets
 
Rate of Compensation Increase
U.K. Plan
0.4%
 
0.4%
 
3.4%


As of the measurement date of August 19, 2019, the funded status recognized in our unaudited condensed consolidated balance sheets was as follows:
(in millions)
 
Fair value of plan assets
$
213

Benefit obligation
(216
)
Funded status
$
(3
)

BTG Pro Forma Financial Information (unaudited)
BTG contributed $71 million to our Net sales and immaterial amounts to our Net income (loss) for the period from August 19, 2019 through September 30, 2019.

The unaudited estimated pro forma results presented below include the effects of the BTG Acquisition as if it was consummated on January 1, 2018. In the third quarter and first nine months of 2019, we incurred nonrecurring charges that we attributed to the BTG Acquisition, which are presented in our unaudited condensed consolidated statements of operations for these periods. These nonrecurring charges that are attributable to the BTG Acquisition include immaterial amounts of acquisition-related costs, stock-based compensation expenses as a result of the change in control and retention bonuses and severance payments, adjusted for the related tax effects. We have reflected these nonrecurring charges as adjustments to the pro forma earnings presented below for the third quarter and first nine months of 2019 and 2018.

Additionally, these pro forma amounts have been calculated after applying our accounting policies and adjusting the results of BTG to reflect the additional costs associated with fair value adjustments relating to inventories, property, plant, and equipment, and intangible assets as if the BTG Acquisition had occurred on January 1, 2018, with the consequential tax effects. Additionally, the pro forma amounts have been adjusted to reflect the amortization of deferred financing costs and interest expense associated with additional financing entered into as part of the BTG Acquisition. The pro forma results exclude BTG’s historical licensing revenue and related cost of sales, as these arrangements are accounted for as part of the BTG Acquisition as a financial asset and liability and are not accounted for within the scope of FASB ASC Topic 606, Revenue from Contracts with Customers.

The supplemental pro forma information presented below is for informational purposes only and should be read in conjunction with our historical financial statements. The pro forma results do not include any anticipated synergies or other expected benefits of the BTG Acquisition. Accordingly, the unaudited estimated pro forma financial information below is not necessarily indicative of what the actual results of operations of the combined companies would have been had the BTG Acquisition occurred as of January 1, 2018, nor are they indicative of future results of operations. We believe that the pro forma assumptions and adjustments are reasonable and appropriate under the circumstances and are factually supported based on information currently available.

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions, except per share data)
2019
 
2018
 
2019
 
2018
Net sales
$
2,795

 
$
2,561

 
$
8,237

 
$
7,740

Net income (loss)
152

 
332

 
599

 
950

Net income (loss) per common share — basic
$
0.11

 
$
0.24

 
$
0.43

 
$
0.69

Net income (loss) per common share — assuming dilution
$
0.11

 
$
0.24

 
$
0.42

 
$
0.68



11

Transaction with Varian Medical Systems, Inc.

On August 21, 2019, we completed the sale of our drug-eluting and bland embolic microsphere portfolio to Varian Medical Systems, Inc. (Varian) in connection with the BTG Acquisition. The transaction price consisted of an upfront cash payment of $90 million, a portion of which is allocated to the fair value of the services to be rendered under the Transition Services Agreement and Transition Manufacturing Agreement entered into with Varian as part of this transaction. Additionally, we transferred certain contingent consideration arrangements arising from our initial acquisition of the portfolio to Varian and agreed to indemnify Varian for any payments ultimately arising under the terms of the contingent consideration arrangement. Accordingly, as part of the disposal, we recorded a liability of $16 million to recognize the fair value of this guarantee based on our potential obligation resulting from the indemnifications. The maximum amount payable under this guarantee is $200 million in accordance with FASB ASC Topic 460, Guarantees, which is consistent with the contingent consideration arrangement executed with our initial acquisition of the portfolio in accordance with FASB ASC Topic 805.

Vertiflex, Inc.

On June 11, 2019, we announced the closing of our acquisition of Vertiflex, Inc. (Vertiflex), a privately-held company which has developed and commercialized the Superion™ Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS). The transaction price consisted of an upfront cash payment of $465 million and contingent payments that are based on a percentage of Vertiflex sales growth in the first three years following the acquisition close. We estimate the sales-based contingent payments to be in a range of zero to $100 million; however, the payments are uncapped over the three year term. Vertiflex is part of our Neuromodulation business.

Millipede, Inc.

On January 29, 2019, we announced the closing of our acquisition of Millipede, Inc. (Millipede), a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation. We have been an investor in Millipede since the first quarter of 2018 as part of an investment and acquisition option agreement, whereby we purchased a portion of the outstanding shares of Millipede, along with newly issued shares of the company, for an upfront cash payment of $90 million. We held an interest of approximately 20 percent immediately prior to the acquisition date. In the fourth quarter of 2018, upon the recent successful completion of a first-in-human clinical study, we exercised our option to acquire the remaining shares of Millipede. We remeasured the fair value of our previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests. The transaction price for the remaining stake consisted of an upfront cash payment of $325 million and up to an additional $125 million payment upon achievement of a commercial milestone. Millipede is part of our Interventional Cardiology business.

Purchase Price Allocation

We accounted for our 2019 acquisitions of Vertiflex and Millipede as business combinations, and in accordance with FASB ASC Topic 805, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components:
(in millions)
 
Payments for acquisitions, net of cash acquired
$
763

Fair value of contingent consideration
127

Fair value of prior interests
102

 
$
992




12

The preliminary purchase price allocations of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of September 30, 2019:
(in millions)
 
Goodwill
$
575

Amortizable intangible assets
220

Indefinite-lived intangible assets
240

Other assets acquired
24

Liabilities assumed
(12
)
Net deferred tax liabilities
(56
)
 
$
992



We allocated a portion of the preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, to the specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
Technology-related
$
210

 
12
 
15%
Other intangible assets
10

 
12
 
15%
Indefinite-lived intangible assets:
 
 
 
 
 
In-process research and development (IPR&D)
240

 
N/A
 
19%
 
$
461

 
 
 
 


2018 Acquisitions

We recorded immaterial purchase price adjustments to the preliminary purchase price allocations of previous acquisitions during the measurement period in the first nine months of 2019.

Claret Medical, Inc.

On August 2, 2018, we announced the closing of our acquisition of Claret Medical, Inc. (Claret), a privately-held company that has developed and commercialized the Sentinel™ Cerebral Embolic Protection System. The device is used to protect the brain during certain interventional procedures, predominately in patients undergoing transcatheter aortic valve replacement (TAVR). The transaction price consisted of an upfront cash payment of $220 million and an additional $50 million payment for reaching a reimbursement-based milestone that was achieved in the third quarter of 2018. Claret is part of our Interventional Cardiology business.

Cryterion Medical, Inc.

On July 5, 2018, we announced the closing of our acquisition of Cryterion Medical, Inc. (Cryterion), a privately-held company developing a single-shot cryoablation platform for the treatment of atrial fibrillation. We have been an investor in Cryterion since 2016 and held an interest of approximately 35 percent immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of $202 million. Cryterion is part of our Electrophysiology business.

NxThera, Inc.

On April 30, 2018, we announced the closing of our acquisition of NxThera, Inc. (NxThera), a privately-held company that developed the Rezūm™ System, a minimally invasive therapy in a growing category of treatment options for patients with benign prostatic hyperplasia (BPH). We held a minority interest immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of approximately $240 million and up to approximately $85 million in payments contingent upon commercial milestones over the four years following the date of acquisition. NxThera is part of our Urology and Pelvic Health business.


13

nVision Medical Corporation

On April 16, 2018, we announced the closing of our acquisition of nVision Medical Corporation (nVision), a privately-held company focused on women’s health. nVision developed the first and only device cleared by the U.S. Food and Drug Administration (FDA) to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. The transaction price consisted of an upfront cash payment of $150 million and up to an additional $125 million in payments contingent upon clinical and commercial milestones over the four years following the date of acquisition. nVision is part of our Urology and Pelvic Health business.

In addition, we completed other individually immaterial acquisitions in the first nine months of 2018 for total consideration of $158 million in cash at closing plus aggregate contingent consideration of up to $62 million.

We recorded gains of $142 million in the third quarter of 2018 and $182 million in the first nine months of 2018 within Other, net on our unaudited condensed consolidated statements of operations based on the difference between the book values and the fair values of our previously-held investments immediately prior to the acquisition dates. The aggregate fair value of our previously-held investments immediately prior to the acquisition dates was $251 million. We remeasured the fair value of each previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests.

Purchase Price Allocation

We accounted for our 2018 acquisitions as business combinations, and in accordance with FASB ASC Topic 805, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The components of the aggregate purchase prices are as follows for our 2018 acquisitions as of September 30, 2019:
(in millions)
 
Payments for acquisitions, net of cash acquired
$
969

Fair value of contingent consideration
190

Fair value of prior interests
251

 
$
1,410



The following summarizes the aggregate purchase price allocations for our 2018 acquisitions as of September 30, 2019:
(in millions)
 
Goodwill
$
618

Amortizable intangible assets
707

Indefinite-lived intangible assets
213

Other assets acquired
19

Liabilities assumed
(14
)
Net deferred tax liabilities
(134
)
 
$
1,410



We allocated a portion of the aggregate purchase prices to specific intangible asset categories as follows for our 2018 acquisitions as of September 30, 2019:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
 
 
 
 
Technology-related
$
697

 
10
-
14
 
17
%
-
23%
Other intangible assets
10

 
6
-
13
 
13
%
-
15%
Indefinite-lived intangible assets:
 
 
 
 
 
 
 
 
 
IPR&D
213

 
N/A
 
15%
 
$
920

 
 
 
 
 
 
 
 


14


Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations as well as revenue and cash flow projections associated with future technologies and has been allocated to our reportable segments based on the relative expected benefit. Based on preliminary estimates updated for applicable regulatory changes, the goodwill recorded relating to our 2019 and 2018 acquisitions is not deductible for tax purposes.

Contingent Consideration

Changes in the fair value of our contingent consideration liability were as follows:
(in millions)
 
Balance as of December 31, 2018
$
347

Amount recorded related to current year acquisitions
127

Contingent consideration arrangements transferred to Varian
(16
)
Contingent consideration expense (benefit)
(9
)
Contingent consideration payments
(68
)
Balance as of September 30, 2019
$
380



As of September 30, 2019, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay was $747 million, which includes our estimate of maximum contingent payments of $100 million associated with the Vertiflex acquisition described above. The maximum decreased $126 million compared to the amount as of December 31, 2018 primarily due to the contingent consideration arrangement which is now accounted for as a guarantee in connection with our transaction with Varian as discussed in the BTG section above.

The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:
Contingent Consideration Liability
Fair Value as of September 30, 2019
Valuation Technique
Unobservable Input
Range
Weighted Average (1)
R&D, Regulatory and Commercialization-based Milestones
$220 million
Discounted Cash Flow
Discount Rate
2
%
-
3%
3%
Probability of Payment
50
%
-
90%
84%
Projected Year of Payment
2019

-
2027
2020
Revenue-based Payments
$160 million
Discounted Cash Flow
Discount Rate
11
%
-
15%
13%
Probability of Payment
60
%
-
100%
99%
Projected Year of Payment
2019

-
2026
2021

(1)
Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to some of our research and development (R&D), commercialization-based and revenue-based milestones are discounted back to the current period using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of September 30, 2019.


15

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:


As of
(in millions)
September 30, 2019
 
December 31, 2018
Equity method investments
$
270

 
$
303

Measurement alternative investments (1)
173

 
94

Notes receivable
23

 
26

 
$
468

 
$
424


(1)
Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

These investments are classified as Other long-term assets within our accompanying unaudited condensed consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.

As of September 30, 2019, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $308 million, which represents amortizable intangible assets, IPR&D, goodwill and deferred tax liabilities.

NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:
 
As of September 30, 2019
 
As of December 31, 2018
(in millions)
Gross Carrying Amount
 
Accumulated Amortization/ Write-offs
 
Gross Carrying Amount
 
Accumulated Amortization/ Write-offs
Amortizable intangible assets
 
 
 
 
 
 
 
Technology-related
$
12,018

 
$
(5,545
)
 
$
10,197

 
$
(5,266
)
Patents
524

 
(404
)
 
520

 
(393
)
Other intangible assets
1,748

 
(1,047
)
 
1,666

 
(958
)
 
$
14,290

 
$
(6,996
)
 
$
12,383

 
$
(6,617
)
Indefinite-lived intangible assets
 
 
 
 
 
 
 
Goodwill
$
19,915

 
$
(9,900
)
 
$
17,811

 
$
(9,900
)
IPR&D
661

 
—

 
486

 
—

Technology-related
120

 
—

 
120

 
—

 
$
20,695

 
$
(9,900
)
 
$
18,417

 
$
(9,900
)


The following represents our goodwill balance allocated to our global reportable segments and unallocated amounts:
(in millions)
MedSurg
 
Rhythm and Neuro
 
Cardiovascular
 
BTG Acquisition(1)
 
Total
As of December 31, 2018
$
2,063

 
$
1,924

 
$
3,925

 
$
—

 
$
7,911

Impact of foreign currency fluctuations and other changes in carrying amount
(3
)
 
—

 
2

 
1

 
(1
)
Goodwill acquired
—

 
268

 
307

 
1,549

 
2,124

Goodwill divested
—

 
—

 
(19
)
 
—

 
(19
)
As of September 30, 2019
$
2,060

 
$
2,191

 
$
4,214

 
$
1,550

 
$
10,015


(1)
As a result of the BTG Acquisition, we recognized goodwill attributable to the synergies expected to arise from the BTG Acquisition and revenue and cash flow projections associated with future technologies. The goodwill is not deductible for tax purposes. As of September 30, 2019, given the preliminary nature of the BTG Acquisition purchase price allocation, we have not yet allocated goodwill to the relevant reporting units and/or reportable segments.


16

Goodwill and Indefinite-Lived Intangible Asset Impairment Testing

We did not have any goodwill impairments in the third quarter and first nine months of 2019 or 2018.

We test our goodwill balances in the second quarter of each year for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist. In the second quarter of 2019, we performed our annual goodwill impairment test for all of our reporting units and concluded that the fair value of each reporting unit exceeded its carrying value.

In performing the goodwill impairment assessment, we utilized both the optional qualitative assessment and the quantitative approach prescribed under FASB ASC Topic 350, Intangibles - Goodwill and Other. In 2019, we performed a qualitative assessment for our Urology and Pelvic Health, Neuromodulation and Endoscopy reporting units since their fair values have exceeded carrying value by greater than 100 percent. The remaining reporting units were quantitatively tested for impairment. For the reporting units subject to a qualitative assessment, if it is determined that it is more likely than not that the fair value of the reporting unit is less than its carrying value, the quantitative approach of the goodwill impairment test is necessary. In 2019, for all reporting units tested using the qualitative assessment, we concluded that it was unnecessary to perform the quantitative impairment test. For all reporting units tested using the quantitative approach, we concluded that the fair value of each reporting unit exceeded its carrying value.

We did not have any Intangible asset impairment charges in the third quarter of 2019 or 2018. We recorded immaterial Intangible asset impairment charges in the first nine months of 2019 and 2018.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified.

In the third quarter of 2019, we performed our annual impairment test of all IPR&D projects and our indefinite-lived core technology assets using the optional qualitative assessment approach and determined that the assets were not impaired. We also verified that the classification of IPR&D projects and our indefinite-lived core technology assets we continue to recognize on our unaudited condensed consolidated balance sheets as indefinite-lived assets continues to be appropriate.

Refer to Critical Accounting Policies and Estimates within Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations contained in our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.

NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.


17

Currency Derivative Instruments
Risk Management Strategy
Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecast intercompany and third-party transactions, net investments in certain subsidiaries and the purchase price of any acquisition that is denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in Euro, Japanese yen, Chinese renminbi and British pound sterling. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Derivative Designations and Hedging Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) on our unaudited condensed consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within the Cost of products sold caption of our unaudited condensed consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within Accumulated other comprehensive income (loss), net of tax (AOCI) to earnings at that time.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro, Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. We elected to use the spot method to assess effectiveness for our derivatives that are designated as net investment hedges. Under the spot method, the change in fair value attributable to changes in the spot rate is recorded in the Foreign currency translation adjustment (CTA) component of OCI. We have elected to exclude the spot-forward difference from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. Amortization of the spot-forward difference is then reclassified from AOCI to current period earnings as a reduction to Interest expense on our unaudited condensed consolidated statements of operations.

We also use forward currency contracts that are not part of designated hedging relationships under FASB ASC Topic 815 as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within the Other, net caption of our unaudited condensed consolidated statements of operations.

Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the purchase price of the BTG Acquisition. As of September 30, 2019, we settled all outstanding contracts, resulting in a cumulative loss on the contracts of $294 million that was recognized over time in earnings as we adjusted for changes in fair value until the final fair value was determined at maturity. We received £3.312 billion of cash to fund the BTG Acquisition, which translated into $4.303 billion based on hedged currency exchange rates. We recognized a $207 million loss in the third quarter of 2019 and a $323 million loss in the first nine months of 2019 in Other, net due to changes in fair value of the contracts.


18

Interest Rate Derivative Instruments
Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. Under these agreements we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Derivative Designations and Hedging Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of September 30, 2019 and $1.000 billion outstanding as of December 31, 2018, which were intended to manage our earnings and cash flow exposure to changes in the benchmark interest rate in connection with the forecasted issuance of fixed-rate debt. For outstanding designated cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs, at which time we recognize the gain or loss within Interest expense over the same period that the hedged items affect earnings, so long as the hedge relationship remains effective. If we determine the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the amount of gains or losses from AOCI to earnings at that time.

During the fourth quarter of 2018, we entered into interest rate derivative contracts designated as cash flow hedges having a notional amount of $1.000 billion to hedge interest rate risk. In the first quarter of 2019, we terminated these instruments in connection with our senior notes issuance in the same period as discussed in Note E – Borrowings and Credit Arrangements. We recognized an immaterial loss within OCI in the first nine months of 2019 and are reclassifying the amortization of the loss from AOCI into earnings as a component of Interest expense over the same period that the hedged item affects earnings, so long as the hedge relationship remains effective. We are also continuing to reclassify in a similar manner the amortization of the gains or losses of our other previously terminated interest rate derivative instruments that were designated as cash flow hedges. The balance of the deferred loss on our terminated cash flow hedges within AOCI was immaterial as of September 30, 2019 and December 31, 2018. We recognized immaterial gains and losses in Interest expense relating to the amortization of our terminated cash flow hedges in the current and prior periods.

We had no interest rate derivative instruments designated as fair value hedges outstanding as of September 30, 2019 and December 31, 2018. Prior to 2018, we terminated interest rate derivative instruments that were designated as fair value hedges and are continuing to recognize the amortization of the gains or losses originally recorded within the Long-term debt caption on our unaudited condensed consolidated balance sheets into earnings as a component of Interest expense over the same period that the discount or premium associated with the hedged items affects earnings. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense, which generally offset. The balance of the deferred gains on our terminated fair value hedges within Long-term debt was immaterial as of September 30, 2019 and December 31, 2018. We recognized immaterial gains in Interest expense relating to the amortization of the terminated fair value hedges in the current and prior periods.

The following table presents the contractual amounts of our derivative instruments outstanding:
(in millions)
 
FASB ASC Topic 815 Designation
 
As of
 
September 30, 2019
 
December 31, 2018
Forward currency contracts
 
Cash flow hedge
 
$
4,030

 
$
3,962

Forward currency contracts
 
Net investment hedge
 
1,935

 
1,483

Forward currency contracts
 
Non-designated
 
3,522

 
5,880

Interest rate derivative contracts
 
Cash flow hedge
 
—

 
1,000

Total Notional Outstanding
 
 
 
$
9,487

 
$
12,326



The remaining time to maturity as of September 30, 2019 is within 60 months for all designated forward currency contracts and generally less than one year for all non-designated forward currency contracts.

19

The following presents the effect of our derivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 on our accompanying unaudited condensed consolidated statements of operations. Refer to Note M – Changes in Other Comprehensive Income for the total amounts relating to derivative instruments presented within the unaudited condensed consolidated statements of comprehensive income (loss).
 
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
 
Amount Recognized in OCI on Derivative
 
Unaudited Condensed Consolidated Statements of Operations (1)
 
Amount Reclassified from AOCI into Earnings
(in millions)
Pre-Tax Gain (Loss)
Tax Benefit (Expense)
Gain (Loss) Net of Tax
 
Location of Amount Reclassified
Total Amount of Line Item Presented
 
Pre-Tax (Gain) Loss
Tax (Benefit) Expense
(Gain) Loss Net of Tax
Three Months Ended September 30, 2019
Forward currency contracts
 
 
 
 
 
 
 
 
Cash flow hedges
$
101

$
(23
)
$
78

 
Cost of products sold
$
777

 
$
(22
)
$
5

$
(17
)
Net investment hedges (2)
64

(14
)
50

 
Interest expense
95

 
(12
)
3

(9
)
Interest rate derivative contracts
 
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
95

 
1

—

1

Three Months Ended September 30, 2018
Forward currency contracts
 
 
 
 
 
 
 
 
Cash flow hedges
$
58

$
(13
)
$
45

 
Cost of products sold
$
672

 
$
2

$
—

$
2

Net investment hedges (2)
4

(1
)
3

 
Interest expense
58

 
(10
)
2

(8
)
Nine Months Ended September 30, 2019
Forward currency contracts
 
 
 
 
 
 
 
 
Cash flow hedges
$
176

$
(40
)
$
136

 
Cost of products sold
$
2,265

 
$
(47
)
$
10

$
(36
)
Net investment hedges (2)
92

(21
)
71

 
Interest expense
294

 
(33
)
7

(25
)
Interest rate derivative contracts
 
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
294

 
3

(1
)
2

Nine Months Ended September 30, 2018
Forward currency contracts
 
 
 
 
 
 
 
 
Cash flow hedges
$
135

$
(30
)
$
105

 
Cost of products sold
$
2,084

 
$
27

$
(6
)
$
21

Net investment hedges (2)
25

(6
)
19

 
Interest expense
177

 
(17
)
4

(13
)
Interest rate derivative contracts
 
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
177

 
(1
)
—

(1
)

(1)
In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings. All other amounts included in earnings related to hedging relationships were immaterial.
(2)
For our outstanding net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in AOCI or earnings.


20

As of September 30, 2019, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
Designated Derivative Instrument
 
FASB ASC Topic 815 Designation
 
Location on Unaudited Condensed Consolidated Statements of Operations
 
Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Forward currency contracts
 
Cash flow hedge
 
Cost of products sold
 
$
104

Forward currency contracts
 
Net investment hedge
 
Interest expense
 
48

Interest rate derivative contracts
 
Cash flow hedge
 
Interest expense
 
(5
)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
 
 
Location on Unaudited Condensed Consolidated Statements of Operations
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions)
 
 
2019
 
2018
 
2019
 
2018
Net gain (loss) on currency hedge contracts
 
Other, net
 
$
(202
)
 
$
16

 
$
(334
)
 
$
25

Net gain (loss) on currency transaction exposures
 
Other, net
 
(4
)
 
(23
)
 
—

 
(40
)
Net currency exchange gain (loss)
 
 
 
$
(207
)
 
$
(6
)
 
$
(334
)
 
$
(15
)


Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the purchase price of the BTG Acquisition. As of September 30, 2019, we settled all outstanding contracts. We recognized a $207 million loss in the third quarter of 2019 and a $323 million loss in the first nine months of 2019 in Net gain (loss) on currency hedge contracts due to changes in fair value of the contracts.


21

Fair Value Measurements

FASB ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820) and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date given the applicable current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative assets and liabilities:
 
 
Location on Unaudited Condensed Consolidated Balance Sheets (1)
 
As of
(in millions)
 
 
September 30, 2019
 
December 31, 2018
Derivative Assets:
 
 
 
 
 
 
Designated Derivative Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current assets
 
$
98

 
$
55

Forward currency contracts
 
Other long-term assets
 
358

 
183

 
 
 
 
456

 
237

Non-Designated Derivative Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current assets
 
48

 
67

Total Derivative Assets
 
 
 
$
504

 
$
304

 
 
 
 
 
 
 
Derivative Liabilities:
 
 
 
 
 
 
Designated Derivative Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current liabilities
 
$
3

 
$
2

Forward currency contracts
 
Other long-term liabilities
 
5

 
3

Interest rate contracts
 
Other current liabilities
 
—

 
44

 
 
 
 
8

 
49

Non-Designated Derivative Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current liabilities
 
40

 
31

Total Derivative Liabilities
 
 
 
$
48

 
$
80

(1)
We classify derivative assets and liabilities as current when the settlement date of the derivative contract is one year or less.
Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.

22

Assets and liabilities measured at fair value on a recurring basis consist of the following:
 
As of
 
September 30, 2019
 
December 31, 2018
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets
 
 
 

 
 
 
 
 
 
 
 

 
 
 
 
Money market and government funds
$
26

 
$
—

 
$
—

 
$
26

 
$
13

 
$
—

 
$
—

 
$
13

Derivative instruments
—

 
504

 
—

 
504

 
—

 
304

 
—

 
304

Licensing arrangements
—

 
—

 
633

 
633

 
—

 
—

 
—

 
—

 
$
26

 
$
504

 
$
633

 
$
1,163

 
$
14

 
$
304

 
$
—

 
$
318

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Derivative instruments
$
—

 
$
48

 
$
—

 
$
48

 
$
—

 
$
80

 
$
—

 
$
80

Contingent consideration
—

 
—

 
380

 
380

 
—

 
—

 
347

 
347

Licensing arrangements
—

 
—

 
341

 
341

 
—

 
—

 
—

 
—

 
$
—

 
$
48

 
$
720

 
$
768

 
$
—

 
$
80

 
$
347

 
$
427



Our investments in money market and government funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents within our accompanying unaudited condensed consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $26 million invested in money market and government funds as of September 30, 2019, we had $249 million in interest bearing and non-interest-bearing bank accounts. In addition to $13 million invested in money market and government funds as of December 31, 2018, we had $133 million in interest bearing and non-interest-bearing bank accounts.

Our recurring fair value measurements using Level 3 inputs relates to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability.

In addition, our recurring fair value measurements using Level 3 inputs relate to our licensing arrangements. In the third quarter of 2019, we acquired intellectual property and related licensing arrangements as of the result of the BTG Acquisition that provides the contractual right to receive future royalty payments. As part of the licensing arrangements we acquired, we also have the contractual obligation to remit a portion of the cash flows received to the inventors associated with the intellectual property. We have elected the fair value option to account for the licensing arrangements financial asset and financial liability in accordance with FASB ASC Topic 825, Financial Instruments.

As of September 30, 2019, we have recorded the preliminary fair values of the financial asset and financial liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The preliminary fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. As discussed in Note B – Acquisitions and Strategic Investments, given the size and breadth of the BTG Acquisition, we anticipate that the purchase price allocation will take longer than prior acquisitions and potentially up to the one year allowed under FASB ASC Topic 805 to adequately analyze all the factors used in establishing the fair value of assets acquired and liabilities assumed as of the acquisition date, including the licensing arrangements financial asset and liability and the related tax and foreign currency effects of any changes made.

The recurring Level 3 fair value measurements of our licensing arrangements include the following significant unobservable inputs:
Licensing Arrangements
Fair Value as of September 30, 2019
Valuation Technique
Unobservable Input
Range
Weighted Average (1)
Financial Asset
$633 million
Discounted Cash Flow
Discount Rate
9%
9%
Projected Year of Payment
2019
-
2027
2023
Financial Liability
$341 million
Discounted Cash Flow
Discount Rate
9%
9%
Projected Year of Payment
2019
-
2027
2023
(1)
Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

23


Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements financial assets and liability as of September 30, 2019.
Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments.

Refer to Note C – Goodwill and Other Intangible Assets for a discussion of the fair values.

The fair value of our outstanding debt obligations was $11.990 billion as of September 30, 2019 and $7.239 billion as of December 31, 2018. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, amortized cost for commercial paper and face value for term loans and credit facility borrowings outstanding. Refer to Note E – Borrowings and Credit Arrangements for a discussion of our debt obligations.

NOTE E – BORROWINGS AND CREDIT ARRANGEMENTS

We had total debt of $10.888 billion as of September 30, 2019 and $7.056 billion as of December 31, 2018. The debt maturity schedule for our long-term debt obligations is presented below:
(in millions, except interest rates)
 
Issuance Date
 
Maturity Date
 
As of
 
Semi-annual Coupon Rate
 
September 30,
2019
 
December 31,
2018
 
January 2020 Notes
 
December 2009
 
January 2020
 
$
—

 
$
850

 
6.000%
May 2020 Notes
 
May 2015
 
May 2020
 
—

 
600

 
2.850%
August 2021 Term Loan
 
August 2019
 
August 2021
 
1,000

 
—

 
 
May 2022 Notes
 
May 2015
 
May 2022
 
500

 
500

 
3.375%
August 2022 Term Loan
 
August 2019
 
August 2022
 
1,000

 
—

 
 
October 2023 Notes
 
August 2013
 
October 2023
 
450

 
450

 
4.125%
March 2024 Notes
 
February 2019
 
March 2024
 
850

 
—

 
3.450%
May 2025 Notes
 
May 2015
 
May 2025
 
750

 
750

 
3.850%
March 2026 Notes
 
February 2019
 
March 2026
 
850

 
—

 
3.750%
March 2028 Notes
 
February 2018
 
March 2028
 
1,000

 
1,000

 
4.000%
March 2029 Notes
 
February 2019
 
March 2029
 
850

 
—

 
4.000%
November 2035 Notes
 
November 2005
 
November 2035
 
350

 
350

 
7.000%
March 2039 Notes
 
February 2019
 
March 2039
 
750

 
—

 
4.550%
January 2040 Notes
 
December 2009
 
January 2040
 
300

 
300

 
7.375%
March 2049 Notes
 
February 2019
 
March 2049
 
1,000

 
—

 
4.700%
Unamortized Debt Issuance Discount
and Deferred Financing Costs
 
 
 
2020 - 2049
 
(79
)
 
(29
)
 
 
Unamortized Gain on Fair Value Hedges
 
 
 
2020 - 2023
 
14

 
26

 
 
Finance Lease Obligation (1)
 
 
 
Various
 
6

 
6

 
 
Long-term debt
 
 
 
 
 
$
9,590

 
$
4,803

 
 
Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
(1)
Effective January 1, 2019, we adopted FASB ASC Topic 842, which requires that we recognize finance lease obligations in our unaudited condensed consolidated balance sheet. As of December 31, 2018, these leases were referred to as capital lease obligations in accordance with FASB ASC Topic 840. Please refer to Note A – Basis of Presentation for additional information.

24


Revolving Credit Facility

As of September 30, 2019 and December 31, 2018, we maintained a $2.750 billion revolving credit facility (2018 Facility) with a global syndicate of commercial banks that matures on December 19, 2023 with one-year extension options subject to certain conditions. This facility provides backing for the commercial paper program. The 2018 Credit Agreement for the 2018 Facility requires that we comply with certain covenants, including financial covenants as described within Debt Covenants below. There were no amounts outstanding under our revolving credit facility as of September 30, 2019 and December 31, 2018.

Term Loans

On February 25, 2019, upon the closing of our senior notes offering in aggregate principal amount of $4.300 billion described below, we terminated the $1.000 billion Term Loan Credit Agreement, entered into on August 20, 2018 and amended on December 19, 2018 (August 2019 Term Loan). The August 2019 Term Loan was scheduled to mature on August 19, 2019. As of December 31, 2018, we had $1.000 billion outstanding under our August 2019 Term Loan, which was presented within Current debt obligations on our accompanying unaudited condensed consolidated balance sheets.

On December 19, 2018, we entered into a $2.000 billion senior unsecured delayed-draw term loan facility consisting of a $1.000 billion two-year delayed draw term loan credit facility maturing in two years from the date of the closing of the BTG Acquisition (Two-Year Delayed Draw Term Loan) and a $1.000 billion three-year delayed draw term loan credit facility maturing in three years from the date of the closing of the BTG Acquisition (Three-Year Delayed Draw Term Loan). Borrowings are available in U.S. dollars and bear interest at LIBOR or a base rate, in each case plus an applicable margin based on our public debt ratings. We are required to pay customary ticking fees on the average daily unused commitments based on our public debt ratings. The facilities contain customary representations and covenants, as described within Debt Covenants below. The facilities contain customary events of default, which may result in the acceleration of any outstanding commitments, and also contain customary U.K. certain funds provisions. Any proceeds from the facilities will be available to finance the BTG Acquisition and pay related transaction costs, as defined by the facilities. On August 19, 2019, for the purpose of funding the BTG Acquisition, we borrowed $1.000 billion under the Two-Year Delayed Draw Term Loan and $1.000 billion under the Three-Year Delayed Draw Term Loan. As of September 30, 2019, our average interest rates on the borrowings were 3.37 percent for the Two-Year Delayed Draw Term Loan and 3.47 percent for the Three-Year Delayed Draw Term Loan.

Debt Covenants

As of and through September 30, 2019, we were in compliance with all the required covenants related to our debt obligations. For additional information regarding the terms of our debt agreements, refer to Note E – Borrowings and Credit Arrangements to our consolidated financial statements in our most recent Annual Report on Form 10-K.

All existing credit arrangements described above require that we maintain certain financial covenants, as follows:
 
 
Covenant Requirement
 
Actual
 
 
as of September 30, 2019
 
as of September 30, 2019
Maximum leverage ratio (1)
 
4.75 times
 
4.27 times
(1)
Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, for the preceding four consecutive fiscal quarters.

Our covenants require that we maintain a maximum leverage ratio of 3.75 times, provided, however, that for the two consecutive fiscal quarters ended immediately following the consummation of a Qualified Acquisition, as defined by each agreement, the maximum leverage ratio shall be 4.75 times, and then subject to a step-down for each succeeding fiscal quarter end to 4.50 times, 4.25 times, 4.00 times and then back to 3.75 times for each fiscal quarter end thereafter. On August 19, 2019, we announced the closing of our acquisition of BTG, a Qualified Acquisition, and our maximum leverage ratio was 4.75 times as of September 30, 2019. Refer to Note B – Acquisitions and Strategic Investments for more information.

Our covenants provide for an exclusion from the calculation of consolidated EBITDA, as defined by the agreements, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of September 30, 2019, we had $314 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments do not exceed $2.624 billion in the aggregate. As of September 30, 2019, we had $1.262 billion of the litigation exclusion remaining.

25


Any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all credit facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our credit facility may negatively impact the credit ratings assigned to our commercial paper program which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper
 
As of
(in millions, except maturity and yield)
September 30, 2019
 
December 31, 2018
Commercial paper outstanding (at par)
$
1,293

 
$
1,248

Maximum borrowing capacity
2,750

 
2,750

Borrowing capacity available
1,457

 
1,502

Weighted average maturity
40 days

 
27 days

Weighted average yield
2.43
%
 
3.04
%


Senior Notes

We had senior notes outstanding of $7.650 billion as of September 30, 2019 and $4.800 billion as of December 31, 2018.

In February 2019, we completed an offering of $4.300 billion in aggregate principal amount of senior notes comprised of $850 million of 3.450% senior notes due March 2024, $850 million of 3.750% senior notes due March 2026, $850 million of 4.000% senior notes due March 2029, $750 million of 4.550% senior notes due March 2039 and $1.000 billion of 4.700% senior notes due March 2049. We used a portion of the net proceeds from the offering to repay the $850 million plus accrued interest and premium of our 6.000% senior notes due in January 2020, the $600 million plus accrued interest and premium of our 2.850% senior notes due in May 2020 and the $1.000 billion plus accrued interest of our August 2019 Term Loan. In the third quarter of 2019, the remaining proceeds were used to finance a portion of the BTG Acquisition.

Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see Other Arrangements below).

On October 22, 2019, we announced the commencement of a cash tender offer (Tender Offer) for up to $1.000 billion combined aggregate principal amount (Aggregate Maximum Principal Amount) of our outstanding 4.125% senior notes due October 2023, 4.000% senior notes due March 2028, 3.850% senior notes due May 2025 and 3.375% senior notes due May 2022 (collectively, Tender Offer Notes). The Tender Offer is being made exclusively pursuant to an offer to purchase dated October 22, 2019, which sets forth the terms and conditions of the Tender Offer. Consummation of the Tender Offer is subject to satisfaction or waiver of the conditions described in the offer to purchase, including the financing condition that we shall have closed one or more debt financings resulting in net proceeds in an amount, together with cash on hand, not less than the amount required, upon the terms and subject to the conditions of the Tender Offer, to purchase all the securities validly tendered and accepted for purchase in the Tender Offer and to pay accrued interest thereon and fees and expenses associated therewith.

The Tender Offer will expire at midnight, Eastern Standard Time, on November 19, 2019, unless extended or terminated by us. However, because the aggregate principal amount of Tender Offer Notes validly tendered and not validly withdrawn as of the early tender date at 5:00 p.m. Eastern Standard Time, on November 4, 2019, would cause the Aggregate Maximum Principal Amount to be exceeded and we do not expect to increase the Aggregate Maximum Principal Amount, we do not expect to accept any further tenders of Tender Offer Notes.

Bridge Facility

On February 25, 2019, upon the closing of our senior notes offering in aggregate principal amount of $4.300 billion described above, we terminated the Bridge Facility entered into on November 20, 2018. The termination was pursuant to the terms of the Bridge Facility, which required full termination upon the refinancing of the January 2020 Notes and May 2020 Notes discussed above. There were no amounts borrowed under the Bridge Facility as of December 31, 2018.


26

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in the accompanying unaudited condensed consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
Factoring Arrangements
As of September 30, 2019
 
As of December 31, 2018
Amount
De-recognized
 
Average
Interest Rate
 
Amount
De-recognized
 
Average
Interest Rate
Euro denominated
$
146

 
1.7
%
 
$
165

 
2.7
%
Yen denominated
210

 
0.6
%
 
195

 
0.9
%


Refer to Note E – Borrowing and Credit Arrangements to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information on our borrowings and credit agreements.

NOTE F – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions in our accompanying unaudited condensed consolidated balance sheets are as follows:

Cash, cash equivalents, restricted cash and restricted cash equivalents
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Cash and cash equivalents
$
277

 
$
146

Restricted cash and restricted cash equivalents included in Other current assets
357

 
655

Restricted cash equivalents in Other long-term assets
43

 
27

 
$
676

 
$
829



Trade accounts receivable, net
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Accounts receivable
$
1,871

 
$
1,676

Allowance for doubtful accounts
(75
)
 
(68
)
 
$
1,796

 
$
1,608



The following is a rollforward of our allowance for doubtful accounts:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions)
2019
 
2018
 
2019
 
2018
Beginning balance
$
73

 
$
63

 
$
68

 
$
68

Net charges to expenses
8

 
6

 
19

 
15

Utilization of allowances
(5
)
 
(4
)
 
(11
)
 
(17
)
Ending balance
$
75

 
$
66

 
$
75

 
$
66



Inventories
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Finished goods
$
940

 
$
760

Work-in-process
206

 
100

Raw materials
420

 
306

 
$
1,566

 
$
1,166



Property, plant and equipment, net
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Land
$
112

 
$
97

Buildings and improvements
1,160

 
1,100

Equipment, furniture and fixtures
3,368

 
3,224

Capital in progress
357

 
319

 
4,996

 
4,740

Less: accumulated depreciation
3,055

 
2,958

 
$
1,942

 
$
1,782



Depreciation expense was $79 million for the third quarter of 2019, $74 million for the third quarter of 2018, $220 million for the
first nine months of 2019 and $212 million for the first nine months of 2018.

Accrued expenses
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Legal reserves
$
328

 
$
712

Payroll and related liabilities
693

 
630

Rebates
280

 
229

Contingent consideration
112

 
138

Other
518

 
538

 
$
1,932

 
$
2,246



Other long-term liabilities
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Income taxes
$
671

 
$
739

Legal reserves
240

 
217

Contingent consideration
268

 
209

Other
1,227

 
717

 
$
2,406

 
$
1,882



NOTE G – LEASES

We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term, and as a result, the remaining lease

27

term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. For leases executed in 2019 and later, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 60 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.

We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

The following table presents supplemental balance sheet information related to our operating leases:
(in millions)
As of September 30, 2019
Assets
 
Operating lease right-of-use assets in Other long-term assets
$
306

Liabilities
 
Operating lease liabilities in Other current liabilities
62

Operating lease liabilities in Other long-term liabilities 
251



The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
 
As of September 30, 2019
Weighted average remaining lease term
5.6 years
Weighted average discount rate
3.7%


Our operating lease cost was $21 million in the third quarter of 2019 and $57 million for the first nine months of 2019.

The following table presents supplemental cash flow information related to our operating leases:
(in millions)
Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of operating lease liabilities
 
Operating cash flows from operating leases
$
55



Right-of-use assets obtained in exchange for operating lease obligations totaled $84 million for the first nine months of 2019.


28

The following table presents the maturities of our operating lease liabilities as of September 30, 2019:
Fiscal year
Operating Leases
(in millions)
2019 (excluding the first nine months of 2019)
$
22

2020
76

2021
65

2022
52

2023
41

Thereafter
95

Total future minimum operating lease payments
350

Less: imputed interest
37

Present value of operating lease liabilities
$
314



As of September 30, 2019, we have additional leases for office space and R&D space, that have not yet commenced, of $68 million. These leases will commence during the fourth quarter of 2019 and 2020, with lease terms of 1 month to 15 years.

NOTE H – INCOME TAXES

Our effective tax rate from continuing operations is presented below:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
2019
 
2018
 
2019
 
2018
Effective tax rate from continuing operations
(38.7
)%
 
5.3
%
 
(1.6
)%
 
(14.1
)%


The change in our reported tax rates for the third quarter and first nine months of 2019, as compared to the same periods in 2018, relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These receipts and charges include intangible asset impairment charges, acquisition-related items, restructuring items, litigation-related items as well as certain discrete tax items primarily related to share-based payments and the 2018 settlement of our transfer pricing dispute with the Internal Revenue Service (IRS) for the 2001 through 2010 tax years.

As of September 30, 2019, we had $405 million of gross unrecognized tax benefits, of which a net $320 million, if recognized, would affect our effective tax rate. As of December 31, 2018, we had $427 million of gross unrecognized tax benefits, of which a net $332 million, if recognized, would affect our effective tax rate.

It is reasonably possible that within the next 12 months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $99 million.

NOTE I – COMMITMENTS AND CONTINGENCIES

The medical device market in which we primarily participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

29


In the normal course of business, product liability, securities and commercial claims are asserted against us. Similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.

Our accrual for legal matters that are probable and estimable was $568 million as of September 30, 2019 and $929 million as of December 31, 2018 and includes certain estimated costs of settlement, damages and defense. The decrease in our legal accrual was mainly due to settlement payments associated with product liability cases or claims related to transvaginal surgical mesh products. A portion of our legal accrual is already funded through our qualified settlement fund (QSF), which is included in other restricted cash and restricted cash equivalents balance of $357 million as of September 30, 2019 and $655 million as of December 31, 2018. Refer to Note F – Supplemental Balance Sheet Information for additional information.

We recorded litigation-related net charges of $25 million in the third quarter of 2019 and litigation-related net credits of $108 million in the first nine months of 2019. In the first quarter of 2019, we recorded $148 million of the total $180 million one-time settlement payment received from Edwards Lifesciences Corporation in January 2019 to Litigation-related net charges (credits) on our unaudited condensed consolidated financial statements. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) in our unaudited condensed consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses. As such, a portion of the related gain from this settlement was recorded in Selling, general and administrative expenses on our unaudited condensed consolidated statements of operations. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants.

In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the periods ended March 31, 2019 and June 30, 2019 and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be estimated.

Patent Litigation

On November 20, 2017, The Board of Regents, University of Texas System (UT) and TissueGen.Inc., served a lawsuit against us in the Western District of Texas. The complaint against us alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas.

Product Liability Litigation

As of October 16, 2019, approximately 53,000 product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us. As of October 16, 2019, we have entered into master settlement agreements in principle or are in the final stages of entering one with certain plaintiffs' counsel

30

to resolve an aggregate of approximately 52,000 cases and claims. These master settlement agreements provide that the settlement and distribution of settlement funds to participating claimants are conditional upon, among other things, achieving minimum required claimant participation thresholds. Of the approximately 52,000 cases and claims, approximately 43,500 have met the conditions of the settlement and are final. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. On April 16, 2019, the U.S. Food and Drug Administration (FDA) ordered that all manufacturers of surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse stop selling and distributing their products in the United States immediately, stemming from the FDA’s 2016 reclassification of these devices to class III (high risk) devices, and as a result, the Company ceased global sales and distribution of surgical mesh products indicated for transvaginal pelvic organ prolapse. The pending cases are in various federal and state courts in the U.S. and include eight putative class actions. Generally, the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products. The plaintiffs assert design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. Over 3,100 of the cases have been specially assigned to one judge in state court in Massachusetts. On February 7, 2012, the Judicial Panel on Multi-District Litigation (MDL) established MDL-2326 in the U.S. District Court for the Southern District of West Virginia and transferred the federal court transvaginal surgical mesh cases to MDL-2326 for coordinated pretrial proceedings. During the fourth quarter of 2013, we received written discovery requests from certain state attorneys general offices regarding our transvaginal surgical mesh products. We have responded to those requests. There were also fewer than 25 cases in Canada, inclusive of one certified and three putative class actions and fewer than 25 claims in the United Kingdom. We have reached a tentative agreement to settle the Canadian class actions.

We have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products. While we believe that our accrual associated with this matter is adequate, changes to this accrual may be required in the future as additional information becomes available. While we continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims and intend to vigorously contest the cases and claims asserted against us that do not settle, the final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Initial trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Other Proceedings

On November 1, 2017 we entered into a definitive agreement with Channel Medsystems, Inc. (Channel) pursuant to which we could have been obligated to pay $145 million in cash up-front and a maximum of $130 million in contingent payments to acquire Channel. The agreement contained a provision allowing Channel to sell the remaining equity interests of the company to us upon achievement of a regulatory milestone and an option allowing us to acquire the remaining equity interests. We sent a notice of termination of that agreement to Channel in the second quarter of 2018. On September 12, 2018, Channel filed a complaint in Delaware Chancery Court against us for alleged breach of the agreement. Channel alleges that we breached the agreement by terminating it. We have answered the complaint, denied the claims by Channel and have counterclaimed to recover part of our investment in Channel, alleging fraud in the inducement. On April 2, 2019, Channel announced its receipt of FDA approval of the Cerene™ Cryotherapy Device. Trial testimony was taken in April 2019, and the post-trial briefing and hearing have been completed. During the third quarter of 2019, Channel notified us that they were exercising their option to sell the remaining equity interests in Channel to us. We responded to the notification that we did not intend to purchase Channel since the previous agreement had been terminated.

On September 6, 2019, Boston Scientific Corporation, Boston Scientific Scimed, Inc., and Fortis Advisors, LLC, as a Securityholder Representative for the former Securityholders of nVision Medical Corp. filed a declaratory judgment action against BioCardia, Inc. in the United States District Court for the Northern District of California to address threats and allegations by BioCardia challenging inventorship and ownership of various patents that Boston Scientific Corporation acquired through an April 13, 2018 merger with nVision as well as related threats and allegations by BioCardia of trade secret misappropriation and unjust enrichment.

On April 18, 2019, Blue Cross & Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research & Development, LLC and BTG International Limited in the United States District Court for the Eastern District of Virginia. The complaint alleges that the defendants violated the Sherman Act and the antitrust and consumer protections laws of several states by pursuing patent litigation relating to ZYTIGA™ in order to delay generic entry. On June 21, 2019, the case was transferred to the United States District Court for the District of New Jersey and has been consolidated with similar complaints.

On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research & Development, LLC, and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint filed on behalf of the United States, 28 states, and the District

31

of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant.

Matters Concluded Since December 31, 2018

On January 15, 2019, we announced that we reached an agreement with Edwards Lifesciences Corporation (Edwards) to settle all outstanding patent disputes between us and Edwards in all venues around the world. All pending cases or appeals in courts and patent offices between the two companies have been or will be dismissed, and the parties will not litigate patent disputes related to current portfolios of transcatheter aortic valves, certain mitral valve repair devices, and left atrial appendage closure devices. Any injunctions currently in place will be lifted. Under the terms of the agreement, Edwards made a one-time payment to us of $180 million. No further royalties will be owed by either party under the agreement. All other terms remain confidential. The previously disclosed matters that have been resolved as a result of this settlement include:

•
On October 30, 2015, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation and Edwards Lifesciences Services GmbH in Düsseldorf District Court in Germany for patent infringement. We allege that Edwards’ SAPIEN 3™ Heart Valve infringes our patent related to adaptive sealing technology. On February 25, 2016, we extended the action to allege infringement of a second patent related to adaptive sealing technology. The trial began on February 7, 2017. On March 9, 2017, the court found that Edwards infringed both patents and Edwards appealed.

•
On November 9, 2015, Edwards Lifesciences, LLC filed an invalidity claim against one of our subsidiaries, Sadra Medical, Inc. (Sadra), in the High Court of Justice, Chancery Division Patents Court in the United Kingdom, alleging that a European patent owned by Sadra relating to a repositionable heart valve is invalid. On January 15, 2016, we filed our defense and counterclaim for a declaration that our European patent is valid and infringed by Edwards. On February 25, 2016, we amended our counterclaim to allege infringement of a second patent related to adaptive sealing technology. A trial was held from January 18 to January 27, 2017. On March 3, 2017, the court found one of our patents valid and infringed and some claims of the second patent invalid and the remaining claims not infringed. Both parties have filed an appeal. On March 28, 2018, the Court of Appeals affirmed the decision of the High Court.

•
On November 23, 2015, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '672) owned by Edwards is infringed by our Lotus™ Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we did not infringe the Spenser '672 patent. Edwards filed an appeal.

•
On November 23, 2015, Edwards Lifesciences Corporation filed a patent infringement action against us and Boston Scientific Medizintechnik GmbH in the District Court of Düsseldorf, Germany alleging an European patent (Bourang) owned by Edwards is infringed by our Lotus Valve System. The trial began on February 7, 2017. On March 28, 2017, the European Patent Office revoked the Bourang patent and on April 3, 2017, the court suspended the infringement action pending Edwards' appeal of the revocation of the patent at the European Patent Office.

•
On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation (Edwards) in the U.S. District Court for the District of Delaware for patent infringement. We allege that Edwards’ SAPIEN 3 Valve infringes a patent related to adaptive sealing technology. On June 9, 2016, Edwards filed a counterclaim alleging that our Lotus Valve System infringes three patents owned by Edwards. On October 12, 2016, Edwards filed a petition for inter partes review of our patent with the U.S. Patent and Trademark Office (USPTO), Patent Trial and Appeal Board. On March 29, 2017, the USPTO granted the inter partes review request. On April 18, 2017, Edwards filed a second petition for inter partes review of our patent with the USPTO. On March 23, 2018, the USPTO found our patent invalid. The Company filed an appeal before the United States Court of Appeals for the Federal Circuit on May 24, 2018.

•
On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation in the U.S. District Court for the Central District of California for patent infringement. We allege that Edwards’ aortic valve delivery systems infringe eight of our catheter related patents. On October 13, 2016, Edwards filed a petition for inter partes review of one asserted patent with the USPTO, Patent Trial and Appeal Board. On April 21, 2017, the USPTO denied the petition. On April 19 and 20, 2017, Edwards filed multiple inter partes review petitions against the patents in suit. On September 8, 2017, the court granted a stay of the action pending an inter partes review of the patents in suit.


32

•
On April 26, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '550) owned by Edwards is infringed by our Lotus™ Transcatheter Heart Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we infringed the Spenser '550 patent. The Company filed an appeal. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.

•
On October 27, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific, LTD, in the Federal Court of Canada alleging that three Canadian patents (Spenser) owned by Edwards are infringed by our Lotus Transcatheter Heart Valve System.

•
On December 22, 2016, Edwards Lifesciences PVT, Inc. and Edwards Lifesciences SA (AG) filed a plenary summons against Boston Scientific Limited and Boston Scientific Group Public Company in the High Court of Ireland alleging that a European patent (Spenser) owned by Edwards is infringed by our Lotus Valve System. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.

•
On August 1, 2018, the Company filed a patent infringement action on the merits in Dusseldorf, Germany against Edwards Lifesciences Corporation and Edwards Lifesciences GmbH (collectively Edwards) alleging that the Sapien 3™ Device and Sapien 3 Ultra Device infringed a patent owned by the Company.

•
On August 3, 2018, the Company filed a preliminary injunction request in Dusseldorf, Germany against Edwards Lifesciences Corporation and Edwards Lifesciences GmbH (collectively Edwards) alleging that the Sapien 3 Ultra Device infringed a patent owned by the Company. On October 23, 2018, the court found that the Sapien 3 Ultra Device infringed the patent. Edwards had the right to appeal.

•
On August 22, 2018, Edwards Lifesciences LLC filed a patent infringement action against Boston Scientific Corporation, in the U. S. District Court of Delaware, alleging that two U.S. patents (Schweich) owned by them are infringed by our Watchman™ Left Atrial Appendage Closure Device, Watchman Delivery System and Watchman Access System.

On December 14, 2016, we learned that the Associacao Brasileira de Medicina de Grupo d/b/a ABRAMGE filed a complaint against us, Arthrex and Zimmer Biomet Holdings, in the U.S. District Court for the District of Delaware. This complaint, which ABRAMGE never served against us, alleges that the defendants or their agents paid kickbacks to health care providers in order to increase sales and prices and are liable under a variety of common law theories. On February 6, 2017, ABRAMGE filed and served an amended complaint on us and the other defendants. The amended complaint does not contain any material changes in the allegations against us. Subsequently, on March 2, 2017, ABRAMGE filed a motion to consolidate this lawsuit with two other similar suits that it had brought against Stryker and Abbott Laboratories, in a multidistrict litigation proceeding. On April 13, 2017, we filed a motion to dismiss the amended complaint, as well as a separate opposition to the multidistrict litigation motion and on May 31, 2017, the Joint Panel on Multi-District Litigation denied ABRAMGE’s motion for the multidistrict litigation. On September 1, 2017, ABRAMGE filed a motion for leave to file a Second Amended Complaint, while our motion to dismiss the Amended Complaint remained pending. On September 15, 2017, we filed an opposition to the motion seeking leave to amend. On November 8, 2018, the Court granted ABRAMGE’s motion for leave to file a Second Amended Complaint, while also granting us leave to renew our motion to dismiss. We filed our motion to dismiss the Second Amended Complaint on January 18, 2019. On February 28, 2019, ABRAMGE dismissed its Second Amended Complaint, concluding the lawsuit.

On or about January 12, 2016, Teresa L. Stevens filed a claim against us and three other defendants asserting, for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the U.S. District Court for the Southern District of West Virginia, before the same Court that is hearing the mesh MDL. The complaint, which alleges Racketeer Influenced and Corrupt Organizations Act (RICO) violations, fraud, misrepresentation, deceptive trade practices and unjust enrichment, seeks both equitable relief and damages under state and federal law. On January 26, 2016, the Court issued an order staying the case and directing the plaintiff to submit information to allow the FDA to issue a determination with respect to her allegations. In addition, we were in contact with the U.S. Attorney’s Office for the Southern District of West Virginia and responded voluntarily to their requests in connection with that office’s review of the allegations concerning the use of mesh resin in the complaint. We reached a settlement on this matter and this case was dismissed on May 13, 2019.

On February 27, 2017, Carolyn Turner filed a complaint against us and five other defendants asserting for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the U.S. District Court for the Middle District of Florida, Orlando Division and alleges violations of the RICO, negligence, strict liability, breach of an express or implied warranty, intentional and negligent misrepresentation, fraud and unjust enrichment. Ms. Turner served this complaint

33

against us on April 7, 2017. As of April 27, 2017, this case was stayed, pending resolution of the transfer petition to the mesh multidistrict litigation. We reached a settlement on this matter and this case was dismissed on February 25, 2019.

On April 24, 2019, a class action complaint was filed in the U.S. District Court for the Southern District of New York against Boston Scientific Corporation, Michael F. Mahoney, our Chief Executive Officer, and Daniel J. Brennan, our Chief Financial Officer. The complaint alleges violations of federal securities laws based on false and/or misleading statements and failure to disclose facts related to the Company’s transvaginal surgical mesh products. On September 20, 2019, the case was dismissed with prejudice.

NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions)
2019

2018
 
2019
 
2018
Weighted average shares outstanding - basic
1,393.1

 
1,382.8

 
1,390.6

 
1,380.0

Net effect of common stock equivalents
19.0

 
21.0

 
19.1

 
19.9

Weighted average shares outstanding - assuming dilution
1,412.2

 
1,403.9

 
1,409.7

 
1,399.8


The impact of stock options outstanding with exercise prices greater than the average fair market value of our common stock was immaterial for all periods presented.

We issued approximately two million shares of our common stock in the third quarter of 2019, approximately two million shares of our common stock in the third quarter of 2018, approximately nine million shares of our common stock in the first nine months of 2019 and approximately 10 million shares of our common stock in the first nine months of 2018, following the exercise of stock options, vesting of deferred stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock in the first nine months of 2019 or 2018.

NOTE K – SEGMENT REPORTING

We have three reportable segments comprised of MedSurg, Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments.

Each of our reportable segments generates revenues from the sale of medical devices. We measure and evaluate our reportable segments based on reportable segment net sales, operating income of reportable segments, excluding intersegment profits, and reportable segment operating income as a percentage of reportable segment net sales. Reportable segment operating income as a percentage of reportable segment net sales is defined as operating income of reportable segments divided by reportable segment net sales. Our presentation of reportable segment net sales and operating income of reportable segments includes the impact of foreign currency fluctuations, since our chief operating decision maker (CODM) reviews operating results both including and excluding the impact of foreign currency fluctuations, and the following presentation more closely aligns to our unaudited condensed consolidated financial statements. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our CODM considers to be non-operational, such as amounts related to amortization expense, intangible asset impairment charges, acquisition-related items, restructuring and restructuring-related items, litigation-related items and medical device regulation charges. Although we exclude these amounts from operating income of reportable segments, they are included in Income (loss) before income taxes on the unaudited condensed consolidated statements of operations and are included in the reconciliation below.


34

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows (in millions, except percentages):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Net sales
2019
 
2018
 
2019
 
2018
MedSurg
$
845

 
$
746

 
$
2,429

 
$
2,207

Rhythm and Neuro
780

 
740

 
2,323

 
2,252

Cardiovascular
1,011

 
908

 
3,009

 
2,806

Reportable segment net sales
2,636

 
2,393

 
7,760

 
7,262

BTG Acquisition(1)
71

 
n/a

 
71

 
n/a

Net sales
$
2,707

 
$
2,393

 
$
7,831

 
$
7,262

 
 
 
 
 
 
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Income (loss) before income taxes
2019
 
2018
 
2019
 
2018
MedSurg
$
319

 
$
274

 
$
870

 
$
807

Rhythm and Neuro
166

 
168

 
488

 
481

Cardiovascular
281

 
268

 
857

 
858

Operating income of reportable segments
766

 
710

 
2,216

 
2,146

BTG Acquisition(1)
16

 
n/a

 
16

 
n/a

Corporate expenses, including hedging activities
(75
)
 
(97
)
 
(215
)
 
(297
)
Intangible asset impairment charges, acquisition/divestiture-related, restructuring- and restructuring-related, litigation-related net (charges) credits and medical device regulation charges
(146
)
 
(77
)
 
(210
)
 
(225
)
Amortization expense
(178
)
 
(148
)
 
(498
)
 
(437
)
Operating income (loss)
383

 
388

 
1,308

 
1,187

Other expense, net
(292
)
 
68

 
(615
)
 
(61
)
Income (loss) before income taxes
$
91

 
$
456

 
$
693

 
$
1,126

 
 
 
 
 
 
 
 
Reportable segment operating income as a percentage of reportable segment net sales
Three Months Ended September 30,
 
Nine Months Ended September 30,
2019
 
2018
 
2019
 
2018
MedSurg
37.8
%
 
36.8
%
 
35.8
%
 
36.6
%
Rhythm and Neuro
21.3
%
 
22.7
%
 
21.0
%
 
21.4
%
Cardiovascular
27.8
%
 
29.5
%
 
28.5
%
 
30.6
%

(1)
For the first nine months of 2019, there have been no changes to our internal reporting structure, and accordingly, we have not revised our segment reporting or geographic presentation. We will continue to integrate the BTG Acquisition into our operations in the fourth quarter and will reassess our operating and reportable segments as well as geographic presentation for any changes related to our internal reporting structure as well as to the information regularly reviewed by the CODM. To the extent any changes in our operating and reportable segments are identified, these will be reflected in our segment reporting information in the period in which the change occurs. Our results of operations include the results of BTG following the acquisition date of August 19, 2019. The BTG Acquisition reconciling item above excludes certain adjustments that our CODM considers to be non-operational, such as acquisition-related items.


35

NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our unaudited condensed consolidated statements of operations. The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Businesses
2019
 
2018
 
2019
 
2018
Endoscopy
 
 
 
 
 
 
 
U.S.
$
277

 
$
247

 
$
800

 
$
724

International
209

 
196

 
596

 
580

Worldwide
486

 
443

 
1,396

 
1,304

 
 
 
 
 
 
 
 
Urology and Pelvic Health
 
 
 
 
 
 
 
U.S.
257

 
214

 
737

 
623

International
102

 
89

 
297

 
280

Worldwide
359

 
303

 
1,033

 
904

 
 
 
 
 
 
 
 
Cardiac Rhythm Management
 
 
 
 
 
 
 
U.S.
284

 
289

 
860

 
869

International
194

 
186

 
607

 
594

Worldwide
478

 
475

 
1,467

 
1,462

 
 
 
 
 
 
 
 
Electrophysiology
 
 
 
 
 
 
 
U.S.
38

 
37

 
113

 
111

International
43

 
39

 
132

 
119

Worldwide
81

 
76

 
245

 
230

 
 
 
 
 
 
 
 
Neuromodulation
 
 
 
 
 
 
 
U.S.
183

 
155

 
487

 
446

International
39

 
34

 
125

 
113

Worldwide
222

 
189

 
612

 
559

 
 
 
 
 
 
 
 
Interventional Cardiology
 
 
 
 
 
 
 
U.S.
327

 
283

 
942

 
859

International
373

 
332

 
1,126

 
1,062

Worldwide
700

 
615

 
2,067

 
1,922

 
 
 
 
 
 
 
 
Peripheral Interventions
 
 
 
 
 
 
 
U.S.
155

 
152

 
466

 
449

International
156

 
142

 
475

 
436

Worldwide
311

 
293

 
942

 
885

 
 
 
 
 
 
 
 
BTG Acquisition(1)
 
 
 
 
 
 
 
Interventional Medicine
48

 
 n/a

 
48

 
 n/a

Specialty Pharmaceuticals
23

 
 n/a

 
23

 
 n/a

Worldwide
71

 
n/a

 
71

 
n/a

 
 
 
 
 
 
 
 
Net Sales
$
2,707

 
$
2,393

 
$
7,831

 
$
7,262

(1)
For the first nine months of 2019, there have been no changes to our internal reporting structure, and accordingly, we have not revised our segment reporting or geographic presentation. We will continue to integrate the BTG Acquisition into our operations in the fourth quarter and will reassess our operating and reportable segments as well as geographic presentation for any changes related to our internal reporting structure as well as to the information regularly reviewed by the CODM. To the extent any changes in our operating and reportable segments are identified, these will be reflected in our segment reporting information in the period in which the change occurs. Our results of operations include the results of BTG following the acquisition date of August 19, 2019. BTG net sales are substantially U.S. based.


36

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Geographic Regions (Excluding BTG Acquisition)
2019
 
2018
 
2019
 
2018
U.S.
$
1,521

 
$
1,375

 
$
4,402

 
$
4,078

EMEA (Europe, Middle East and Africa)
530

 
498

 
1,662

 
1,619

APAC (Asia-Pacific)
484

 
425

 
1,402

 
1,282

Latin America and Canada
101

 
94

 
293

 
282

BTG Acquisition(1) (Worldwide)
71

 
n/a

 
71

 
n/a

Net Sales
$
2,707

 
$
2,393

 
$
7,831

 
$
7,262

 
 
 
 
 
 
 
 
Emerging Markets(2) (Excluding BTG Acquisition)
$
310

 
$
267

 
$
925

 
$
812


(1)
Our results of operations include the results of BTG following the acquisition date of August 19, 2019. BTG net sales are substantially U.S. based.
(2)
We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam. We have revised prior year amounts to the current year’s presentation. The revision had an immaterial impact on prior year Emerging Markets sales.

Deferred Revenue

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying unaudited condensed consolidated balance sheets. Our deferred revenue balance was $398 million as of September 30, 2019 and $373 million as of December 31, 2018. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We recognized revenue of $35 million in the third quarter of 2019 and $107 million in the first nine months of 2019 that was included in the above December 31, 2018 contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit and record the amount for estimated sales returns as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.


37

NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME

The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax:
(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of June 30, 2019
$
(46
)
 
$
150

 
$
—

 
$
(26
)
 
$
78

Other comprehensive income (loss) before reclassifications
7

 
78

 
—

 
—

 
86

(Income) loss amounts reclassified from accumulated other comprehensive income
(9
)
 
(16
)
 
—

 
—

 
(26
)
Total other comprehensive income (loss)
(2
)
 
62

 
—

 
—

 
60

Balance as of September 30, 2019
$
(48
)
 
$
213

 
$
—

 
$
(26
)
 
$
138



(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of June 30, 2018
$
(68
)
 
$
79

 
$
—

 
$
(27
)
 
$
(16
)
Other comprehensive income (loss) before reclassifications
2

 
45

 
—

 
—

 
47

(Income) loss amounts reclassified from accumulated other comprehensive income
(8
)
 
1

 
—

 
—

 
(7
)
Total other comprehensive income (loss)
(6
)
 
47

 
—

 
—

 
40

Balance as of September 30, 2018
$
(74
)
 
$
126

 
$
—

 
$
(27
)
 
$
25



(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of December 31, 2018
$
(53
)
 
$
111

 
$
—

 
$
(25
)
 
$
33

Other comprehensive income (loss) before reclassifications
30

 
136

 
—

 
(1
)
 
165

(Income) loss amounts reclassified from accumulated other comprehensive income
(25
)
 
(34
)
 
—

 
—

 
(59
)
Total other comprehensive income (loss)
4

 
102

 
—

 
(1
)
 
105

Balance as of September 30, 2019
$
(48
)
 
$
213

 
$
—

 
$
(26
)
 
$
138


(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of December 31, 2017
$
(32
)
 
$
1

 
$
(1
)
 
$
(27
)
 
$
(59
)
Other comprehensive income (loss) before reclassifications
(29
)
 
105

 
—

 
—

 
76

(Income) loss amounts reclassified from accumulated other comprehensive income
(13
)
 
20

 
1

 
—

 
8

Total other comprehensive income (loss)
(42
)
 
125

 
—

 
—

 
82

Balance as of September 30, 2018
$
(74
)
 
$
126

 
$
—

 
$
(27
)
 
$
25



38


Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustments and our cash flow hedges recorded in Net change in derivative financial instruments.

As a result of adopting ASC Update No. 2016-01 in the first quarter of 2018, we recorded a cumulative effect adjustment to retained earnings to reclassify unrealized gains and losses from our equity investments previously recorded to Accumulated other comprehensive income (loss), net of tax. These equity investments were classified as available-for-sale securities under the former accounting guidance, and we now refer to these investments as publicly-held equity securities. Please refer to Note A – Significant Accounting Policies included in Item 8 of our most recent Annual Report on Form 10-K for more information.

The Net change in defined benefit pensions and other items before reclassifications and reclassified from Accumulated other comprehensive income (loss), net of tax were reduced by immaterial income tax impacts in the third quarter and first nine months of 2019 and 2018.

NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our unaudited condensed consolidated financial statements.

Standards to be Implemented

ASC Update No. 2016-13

In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (Update No. 2016-13). The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018. We plan to adopt Update No. 2016-13 in the first quarter of 2020, and we are in the process of determining the effect that the adoption will have on our financial position and results of operations.

ASC Update No. 2018-15

In August 2018, the FASB issued ASC Update No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (Update No. 2018-15). The purpose of Update No. 2018-15 is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Update No. 2018-15 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period. We plan to adopt Update No. 2018-15 in the first quarter of 2020, and we are in the process of determining the effect that the adoption will have on our financial position and results of operations.

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our unaudited condensed consolidated financial statements.


39

ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Introduction

Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties. Our mission is to transform lives through innovative medical solutions that improve the health of patients around the world. Our products and technologies are used to diagnose or treat a wide range of medical conditions, including cardiovascular, digestive, respiratory, urological, pelvic health and neurological conditions. We continue to innovate in these areas and are intent on extending our innovations into new geographies and high-growth adjacency markets. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries.

On August 19, 2019, we announced the closing of our acquisition of BTG plc (BTG Acquisition or BTG), a public company organized under the laws of England and Wales. BTG has three key portfolios, the largest of which is its interventional medicine portfolio (Interventional Medicine) that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease. In addition to the Interventional Medicine product lines, the BTG Acquisition also includes a specialty pharmaceutical business (Specialty Pharmaceuticals) comprised of acute care antidotes to treat overexposure to certain medications and toxins and a licensing portfolio (Licensing) that generates net royalties related to BTG intellectual property and product license agreements.

Financial Summary

Three Months Ended September 30, 2019

Our net sales for the third quarter of 2019 were $2.707 billion, as compared to $2.393 billion for the third quarter of 2018. This increase of $314 million, or 13.1 percent, included operational net sales growth of 14.2 percent and the negative impact of 110 basis points from foreign currency fluctuations.1 Operational net sales included $122 million in the third quarter of 2019 due to the acquisitions of Claret Medical, Inc. (Claret) in the third quarter of 2018, Augmenix, Inc. (Augmenix) in the fourth quarter of 2018, Vertiflex, Inc. (Vertiflex) in the second quarter of 2019 and BTG in the third quarter of 2019, each with no prior period related net sales. Refer to Quarterly Results and Business Overview for a discussion of our net sales by global business.

Our reported net income for the third quarter of 2019 was $126 million, or $0.09 per diluted share. Our reported results for the third quarter of 2019 included certain charges and/or credits totaling $424 million (after-tax), or $0.30 per diluted share. Excluding these items, adjusted net income for the third quarter of 2019 was $550 million, or $0.39 per diluted share.1   

Our reported net income for the third quarter of 2018 was $432 million, or $0.31 per diluted share. Our reported results for the third quarter of 2018 included certain charges and/or credits totaling $53 million (after-tax), or $0.04 per diluted share. Excluding these items, adjusted net income for the third quarter of 2018 was $485 million, or $0.35 per diluted share.1 















1Operational net sales growth rates, which exclude the impact of foreign currency fluctuations, and adjusted net income and adjusted net income per share, which exclude certain items required by generally accepted accounting principles in the United States (U.S. GAAP), are not prepared in accordance with U.S. GAAP and should not be considered in isolation from, or as a replacement for, the most directly comparable GAAP measure. Refer to Additional Information for a discussion of management’s use of these non-GAAP financial measures.

40

The following is a reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to Quarterly Results and Business Overview and Additional Information for a discussion of these reconciling items:
 
Three Months Ended September 30, 2019
(in millions, except per share data)
Net Income (Loss)
 
Impact per Share
GAAP net income (loss)
$
126

 
$
0.09

Non-GAAP adjustments:
 
 
 
Medical device regulation charges
2

 
0.00

Amortization expense
157

 
0.11

Acquisition/divestiture-related net charges (credits)
236

 
0.17

Restructuring and restructuring-related net charges (credits)
12

 
0.01

Litigation-related net charges (credits)
19

 
0.01

Investment impairment charges
1

 
0.00

Discrete tax items
(2
)
 
(0.00
)
Adjusted net income
$
550

 
$
0.39


 
Three Months Ended September 30, 2018
(in millions, except per share data)
Net Income (Loss)
 
Impact per Share
GAAP net income (loss)
$
432

 
$
0.31

Non-GAAP adjustments:
 
 
 
Amortization expense
132

 
0.09

Acquisition-related net charges (credits)
(107
)
 
(0.08
)
Restructuring and restructuring-related net charges (credits)
12

 
0.01

Litigation-related net charges (credits)
14

 
0.01

Investment impairment charges
3

 
0.00

Adjusted net income
$
485

 
$
0.35



41

Nine Months Ended September 30, 2019

Our net sales for the first nine months of 2019 were $7.831 billion, as compared to $7.262 billion for the first nine months of 2018. This increase of $569 million, or 7.8 percent, included operational net sales growth of 10.0 percent and the negative impact of 220 basis points from foreign currency fluctuations. Operational net sales included $198 million in the first nine months of 2019 due to the acquisitions of NxThera, Inc. (NxThera) in the second quarter of 2018, Claret in the third quarter of 2018, Augmenix in the fourth quarter of 2018, Vertiflex in the second quarter of 2019 and BTG in the third quarter of 2019, each with no prior period related net sales. Refer to Quarterly Results and Business Overview for a discussion of our net sales by global business.

Our reported net income for the first nine months of 2019 was $704 million, or $0.50 per diluted share. Our reported results for the first nine months of 2019 included certain charges and/or credits totaling $887 million (after-tax), or $0.63 per diluted share. Excluding these items, adjusted net income for the first nine months of 2019 was $1.590 billion, or $1.13 per diluted share.  

Our reported net income for the first nine months of 2018 was $1.285 billion, or $0.92 per diluted share. Our reported results for the first nine months of 2018 included certain charges and/or credits totaling $223 million (after-tax), or $0.16 per diluted share. Excluding these items, adjusted net income for the first nine months of 2018 was $1.508 billion, or $1.08 per diluted share.  
 







































42

The following is a reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to Quarterly Results and Business Overview and Additional Information for a discussion of these reconciling items:
 
Nine Months Ended September 30, 2019
(in millions, except per share data)
Net income (loss)
 
Impact per share
GAAP net income (loss)
$
704

 
$
0.50

Non-GAAP adjustments:
 
 
 
Medical device regulation charges
2

 
0.00

Amortization expense
444

 
0.31

Intangible asset impairment charges
97

 
0.07

Acquisition/divestitures-related net charges (credits)
391

 
0.28

Restructuring and restructuring-related net charges (credits)
31

 
0.02

Litigation-related net charges (credits)
(96
)
 
(0.07
)
Investment impairment charges
3

 
0.00

Discrete tax items
16

 
0.01

Adjusted net income
$
1,590

 
$
1.13


 
Nine Months Ended September 30, 2018
(in millions, except per share data)
Net income (loss)
 
Impact per share
GAAP net income (loss)
$
1,285

 
$
0.92

Non-GAAP adjustments:
 
 
 
Amortization expense
380

 
0.27

Intangible asset impairment charges
31

 
0.02

Acquisition-related net charges (credits)
(79
)
 
(0.06
)
Restructuring and restructuring-related net charges (credits)
47

 
0.03

Litigation-related net charges (credits)
14

 
0.01

Investment impairment charges
7

 
0.01

Discrete tax items
(177
)
 
(0.13
)
Adjusted net income
$
1,508

 
$
1.08


Cash provided by operating activities was $1.144 billion for the first nine months of 2019. As of September 30, 2019, we had total debt of $10.888 billion, Cash and cash equivalents of $277 million and working capital of $593 million. Refer to Liquidity and Capital Resources for further discussion.













43

Quarterly Results and Business Overview

The following section describes an overview of our product offerings and results of operations by business unit. For additional information on our businesses and their product offerings, see Item 1. Business of our most recent Annual Report on Form 10-K.

Net Sales

The following table provides our net sales by business and the relative change in growth on a reported basis:
 
Three Months Ended September 30,
 

(in millions)
2019
 
2018
 
Change
Endoscopy
$
486

 
$
443

 
9.6%
Urology and Pelvic Health
359

 
303

 
18.6%
MedSurg
845

 
746

 
13.2%
Cardiac Rhythm Management
478

 
475

 
0.6%
Electrophysiology
81

 
76

 
5.8%
Neuromodulation
222

 
189

 
17.5%
Rhythm and Neuro
780

 
740

 
5.4%
Interventional Cardiology
700

 
615

 
13.9%
Peripheral Interventions
311

 
293

 
5.9%
Cardiovascular
1,011

 
908

 
11.3%
Interventional Medicine
48

 
 n/a

 
n/a
Specialty Pharmaceuticals
23

 
 n/a

 
n/a
BTG Acquisition(1)
71

 
n/a

 
n/a
Net Sales
$
2,707

 
$
2,393

 
13.1%

 
Nine Months Ended September 30,
 
 
(in millions)
2019
 
2018
 
Change
Endoscopy
$
1,396

 
$
1,304

 
7.1%
Urology and Pelvic Health
1,033

 
904

 
14.3%
MedSurg
2,429

 
2,207

 
10.0%
Cardiac Rhythm Management
1,467

 
1,462

 
0.3%
Electrophysiology
245

 
230

 
6.4%
Neuromodulation
612

 
559

 
9.4%
Rhythm and Neuro
2,323

 
2,252

 
3.2%
Interventional Cardiology
2,067

 
1,922

 
7.6%
Peripheral Interventions
942

 
885

 
6.5%
Cardiovascular
3,009

 
2,806

 
7.2%
Interventional Medicine
48

 
 n/a

 
n/a
Specialty Pharmaceuticals
23

 
 n/a

 
n/a
BTG Acquisition(1)
71

 
n/a

 
n/a
Net Sales
$
7,831

 
$
7,262

 
7.8%
(1)
For the first nine months of 2019, there have been no changes to our internal reporting structure, and accordingly, we have not revised our segment reporting or geographic presentation. We will continue to integrate the BTG Acquisition into our operations in the fourth quarter and will reassess our operating and reportable segments as well as geographic presentation for any changes related to our internal reporting structure as well as to the information regularly reviewed by the chief operating decision maker (CODM). To the extent any changes in our operating and reportable segments are identified, these will be reflected in our segment reporting information in the period in which the change occurs. Our results of operations include the results of BTG following the acquisition date of August 19, 2019. BTG net sales are substantially U.S. based.



44

MedSurg

Endoscopy

Our Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with innovative, less-invasive technologies.

Our net sales of Endoscopy products of $486 million represented 18 percent of our consolidated net sales for the third quarter of 2019. Our Endoscopy net sales increased $42 million, or 9.6 percent, in the third quarter of 2019, compared to the prior year period. This increase included operational net sales growth of 10.4 percent and a negative impact of 80 basis points from foreign currency fluctuations, compared to the prior year period. This year-over-year increase was primarily driven by growth in our biliary franchise with both our SpyGlass™ DS Direct Visualization System, AXIOS™ Stent and Electrocautery Enhanced Delivery System, our hemostasis franchise featuring our Resolution 360™ Clip and our infection prevention products.

Urology and Pelvic Health

Our Urology and Pelvic Health business develops and manufactures devices to treat various urological and pelvic conditions for both male and female anatomies.

Our net sales of Urology and Pelvic Health products of $359 million represented 13 percent of our consolidated net sales for the third quarter of 2019. Our Urology and Pelvic Health net sales increased $56 million, or 18.6 percent, in the third quarter of 2019, compared to the prior year period. This increase included operational net sales growth of 19.4 percent and a negative impact of 80 basis points from foreign currency fluctuations, compared to the prior year period. This year-over-year increase was primarily attributable to growth in sales of our prostate health product family, including the SpaceOAR™ Hydrogel System purchased as part of our Augmenix acquisition in the fourth quarter of 2018 and the Rezūm™ System purchased as part of our NxThera acquisition in the second quarter of 2018, and our stone franchise, including our LithoVue™ Digital Flexible Ureteroscope.

Rhythm and Neuro

Cardiac Rhythm Management

Our Cardiac Rhythm Management business develops and manufactures a variety of implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities.

Our net sales of Cardiac Rhythm Management products of $478 million represented 18 percent of our consolidated net sales for the third quarter of 2019. Our Cardiac Rhythm Management net sales increased $3 million, or 0.6 percent, in the third quarter of 2019, compared to the prior year period. This increase included operational net sales growth of 1.8 percent and a negative impact of 120 basis points from foreign currency fluctuations, compared to the prior year period. The year-over-year increase was primarily due to the global strength of our cardiac resynchronization therapy defibrillator (CRT-D), implantable cardioverter defibrillator (ICD) and subcutaneous implantable cardiac defibrillator (S-ICD) products. Our CRT-D and ICD growth was driven by the ongoing global commercialization of our RESONATE™ family of ICD and CRT-D devices which includes our HeartLogic™ Heart Failure (HF) Diagnostic and our CRT-D product replacement cycle driving market share growth. Our defibrillator growth was partially offset by declines in our pacemaker portfolio due to share loss in certain markets as a result of competitive products.

Electrophysiology

Our Electrophysiology business develops and manufactures less-invasive medical technologies used in the diagnosis and treatment of rate and rhythm disorders of the heart.

Our net sales of Electrophysiology products of $81 million represented 3 percent of our consolidated net sales for the third quarter of 2019. Our Electrophysiology net sales increased $4 million, or 5.8 percent, in the third quarter of 2019, compared to the prior year period. This increase included operational net sales growth of 7.0 percent and a negative impact of 120 basis points from foreign currency fluctuations, compared to the prior year period. This year-over-year increase was primarily driven by global expansion of our Rhythmia™ Mapping System products and capital equipment offerings, expanded portfolio of navigation enabled open-irrigated catheters, including our Blazer IntellaNav MiFi™ Open-Irrigated catheter, and advanced diagnostic catheters, including the IntellaMap Orion™ Mapping Catheter. Our growth was partially offset by softer performance across our portfolio of core diagnostic and therapeutic devices.


45

Neuromodulation

Our Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain.

Our net sales of Neuromodulation products of $222 million represented 8 percent of our consolidated net sales for the third quarter of 2019. Our Neuromodulation net sales increased $33 million, or 17.5 percent, in the third quarter of 2019, compared to the prior year period. This increase included operational net sales growth of 18.3 percent and a negative impact of 80 basis points from foreign currency fluctuations, compared to the prior year period. This year-over-year increase was primarily due to sales performance of our deep brain stimulation (DBS) systems, international markets and Superion™ Indirect Decompression System purchased as part of our Vertiflex acquisition in the second quarter of 2019.

Cardiovascular

Interventional Cardiology

Our Interventional Cardiology business develops and manufactures technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders, including structural heart conditions.

Our net sales of Interventional Cardiology products of $700 million represented 26 percent of our consolidated net sales for the third quarter of 2019. Our Interventional Cardiology net sales increased $85 million, or 13.9 percent, in the third quarter of 2019, compared to the prior year period. This increase included operational net sales growth of 15.3 percent and a negative impact of 140 basis points from foreign currency fluctuations, compared to the prior year period. This year-over-year increase was primarily driven by strong sales growth in our structural heart therapies, including our ACURATE™ Transcatheter Aortic Valve Replacement (TAVR), our LOTUS Edge™ Aortic Valve System as well as our Sentinel™ Cerebral Embolic Protection System purchased as part of our Claret acquisition in the third quarter of 2018. In addition, sales of our WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device continued to contribute to our strong growth, along with our complex percutaneous coronary interventions (PCI) product offerings. Our growth was partially offset by declines in sales of our coronary stent product offerings.

Peripheral Interventions

Our Peripheral Interventions business develops and manufactures products to diagnose and treat peripheral arterial and venous diseases, as well as products to diagnose, treat and ease various forms of cancer.

Our net sales of Peripheral Interventions products of $311 million represented 11 percent of our consolidated net sales for the third quarter of 2019. Our Peripheral Interventions net sales increased $17 million, or 5.9 percent, in the third quarter of 2019, compared to the prior year period. This increase included operational net sales growth of 6.9 percent and a negative impact of 100 basis points from foreign currency fluctuations, compared to the prior year period. This year-over-year increase was primarily driven by our Eluvia™ Drug Eluting Vascular Stent System, peripheral angioplasty balloon technologies, atherectomy technologies and sales growth in China.

Emerging Markets (Excluding BTG Acquisition)

As part of our strategic imperative to drive global expansion, we are seeking to grow net sales and market share by expanding our global presence, including in Emerging Markets. We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. The revision had an immaterial impact on prior year Emerging Markets sales. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam. Our Emerging Markets net sales represented 11 percent of our consolidated net sales in the third quarter of 2019 and 11 percent in the third quarter of 2018. In the third quarter of 2019, our Emerging Markets net sales grew 16.1 percent on a reported basis including operational net sales growth of 19.3 percent and a negative impact of 320 basis points from foreign currency fluctuations, compared to the prior year period.


46

Gross Profit

Our Gross profit was $1.930 billion for the third quarter of 2019, $1.720 billion for the third quarter of 2018, $5.566 billion for the first nine months of 2019 and $5.179 billion for the first nine months of 2018. As a percentage of net sales, our Gross profit decreased to 71.3 percent in the third quarter of 2019, as compared to 71.9 percent in the third quarter of 2018. As a percentage of net sales, our Gross profit decreased to 71.1 percent in the first nine months of 2019, as compared to 71.3 percent in the first nine months of 2018. The following is a reconciliation of our gross profit margins and a description of the drivers of the changes from period to period:

Three Months
 
Nine Months
Gross profit margin - period ended September 30, 2018
71.9%
 
71.3%
Manufacturing cost reductions
0.9
 
0.8
Sales pricing and mix
(0.6)
 
(0.7)
Inventory step-up due to acquisition accounting
(0.5)
 
(0.2)
Net impact of foreign currency fluctuations
0.6
 
0.8
All other, including inventory charges and other period expense
(1.0)
 
(0.9)
Gross profit margin - period ended September 30, 2019
71.3%
 
71.1%

The primary factors contributing to the decrease in our gross profit margin in the third quarter and first nine months of 2019, as compared to the same periods in 2018, was unfavorable product mix and period expenses, partially offset by the positive impacts of cost reductions resulting from our process improvement programs and restructuring programs. In addition, foreign currency fluctuations positively impacted gross profit margin in 2019. In connection with the BTG Acquisition, we recorded a step-up in value from the manufacturing cost of the inventory acquired to fair value as of the acquisition date. The step-up in value is amortized through Cost of products sold over the average estimated inventory turnover period.

Operating Expenses

The following table provides a summary of certain of our operating expenses:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
(in millions)
$
% of Net Sales
 
$
% of Net Sales
 
$
% of Net Sales
 
$
% of Net Sales
Selling, general and administrative (SG&A) expenses
$
1,012

37.4
%
 
$
870

36.4
%
 
$
2,849

36.4
%
 
$
2,616

36.0
%
Research and development (R&D) expenses
306

11.3
%
 
289

12.1
%
 
866

11.1
%
 
825

11.4
%
Royalty expense
15

0.6
%
 
17

0.7
%
 
48

0.6
%
 
52

0.7
%

SG&A Expenses

In the third quarter of 2019, our SG&A expenses increased $142 million, or 16 percent, as compared to the third quarter of 2018 and were 100 basis points higher as a percentage of net sales. In the first nine months of 2019, our SG&A expenses increased $233 million, or nine percent, as compared to the first nine months of 2018 and were 40 basis points higher as a percentage of net sales. The increase in SG&A expenses as a percentage of net sales for the third quarter and first nine months of 2019, as compared to the same periods in the prior year, was due to increased acquisition-related charges primarily associated with the BTG Acquisition partially offset by ongoing optimization initiatives. For the first nine months of 2019, these increased SG&A expenses were also partially offset by a $25 million net gain recorded in the first quarter primarily associated with a portion of the Edwards litigation settlement. For further details regarding the presentation of the Edwards litigation settlement see Litigation-related net charges (credits) below.


47

R&D Expenses

We remain committed to advancing medical technologies and investing in meaningful R&D projects across our businesses. In the third quarter of 2019, our R&D expenses increased $17 million, or six percent, as compared to the third quarter of 2018 and were 80 basis points lower as a percentage of net sales. In the first nine months of 2019, our R&D expenses increased $41 million, or five percent, as compared to the first nine months of 2018, and were 30 basis points lower as a percentage of net sales. R&D expenses increased in the third quarter and first nine months of 2019, as compared to the same periods in the prior year, as a result of investments across our businesses and in recent acquisitions in order to maintain a pipeline of new products that we believe will enhance the lives of patients worldwide and contribute to profitable sales growth. The decrease in R&D expenses as a percentage of net sales in both periods of 2019 was attributable to leverage from increased sales.

Royalty Expense

In the third quarter of 2019, our Royalty expense decreased $1 million, or eight percent, as compared to the third quarter of 2018, and was 10 basis points lower as a percentage of net sales. In the first nine months of 2019, our Royalty expense decreased $4 million, or eight percent, as compared to the first nine months of 2018, and was 10 basis points lower as a percentage of net sales. The decrease in Royalty expense in the third quarter and first nine months of 2019, as compared to the same periods in the prior year, relates primarily to expired royalties in certain countries.

The following table provides a summary of certain of our other operating expenses, which are excluded by management for purposes of evaluating operating performance:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions)
2019
 
2018
 
2019
 
2018
Amortization expense
$
178

 
$
148

 
$
498

 
$
437

Intangible asset impairment charges
—

 
—

 
105

 
35

Contingent consideration expense (benefit)
8

 
(13
)
 
(9
)
 
(12
)
Restructuring charges (credits)
3

 
3

 
10

 
20

Restructuring-related charges (credits)
11

 
12

 
28

 
38

Litigation-related net charges (credits)
25

 
18

 
(108
)
 
18


Amortization Expense

In the third quarter of 2019, our Amortization expense increased $29 million, or 20 percent, as compared to third quarter of 2018. In the first nine months of 2019, our Amortization expense increased $62 million, or 14 percent, as compared to first nine months of 2018. The increase in Amortization expense in the third quarter and first nine months of 2019, as compared to the same periods in the prior year, was primarily due to amortizable intangible assets acquired as part of our recent acquisitions.

Intangible Asset Impairment Charges

In the first nine months of 2019 and 2018, our Intangible asset impairment charges were primarily associated with technology-related amortizable intangible assets.

Contingent Consideration Expense (Benefit)

To recognize changes in the fair value of our contingent consideration liability, we recorded a net expense in the third quarter of 2019, a net benefit in the third quarter of 2018, a net benefit in the first nine months of 2019 and a net benefit in the first nine months of 2018. Refer to Note B – Acquisitions and Strategic Investments to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for additional details related to our contingent consideration arrangements.

Restructuring and Restructuring-related Activities

In the third quarter and first nine months of 2019 and 2018, our restructuring and restructuring-related charges were immaterial.

Refer to Note G – Restructuring-related Activities to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional details related to our restructuring plans.

48


Litigation-related net charges (credits)

Litigation-related net charges (credits) included for the first nine months of 2019 a gain of $148 million recorded in the first quarter of 2019, which represents a portion of the total $180 million one-time settlement payment received from Edwards Lifesciences Corporation in January 2019. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) in our unaudited condensed consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within SG&A expenses. As such, a portion of the related gain from this settlement was recorded in SG&A expenses on our unaudited condensed consolidated statements of operations.

We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation, and therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants. Refer to Note I – Commitments and Contingencies to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for discussion of our material legal proceedings.

Interest Expense
The following table provides a summary of our Interest expense and average borrowing rate:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
2019
 
2018
 
2019
 
2018
Interest expense (in millions)
$
(95
)
 
$
(58
)
 
$
(294
)
 
$
(177
)
Average borrowing rate
3.5
%
 
3.2
%
 
4.1
%
 
3.6
%

Interest expense increased in the third quarter of 2019, as compared to the same period in the prior year, primarily due to the increase in our average debt balance following the February 2019 senior notes offering. A portion of the proceeds from the February 2019 senior notes offering were used to finance the BTG Acquisition. In addition, Interest expense in the first nine months of 2019 included debt extinguishment charges and accelerated debt issuance costs incurred following our February 2019 senior notes offering and subsequent repayment of $1.450 billion in existing senior notes and termination of the Bridge Facility. Refer to Liquidity and Capital Resources and Note D – Hedging Activities and Fair Value Measurements and Note E – Borrowings and Credit Arrangements to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for information regarding our debt obligations and related derivative instruments and hedging activities.

Other, net

The following are the components of Other, net:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions)
2019
 
2018
 
2019
 
2018
Interest income
$
8

 
$
—

 
$
29

 
$
2

Net foreign currency gain (loss)
(207
)
 
(6
)
 
(334
)
 
(15
)
Net gains (losses) on investments
(5
)
 
137

 
(17
)
 
135

Other income (expense), net
7

 
(4
)
 
—

 
(6
)
 
$
(197
)
 
$
126

 
$
(322
)
 
$
116


Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the purchase price of the BTG Acquisition. As of September 30, 2019, we settled all outstanding contracts. We recognized a $207 million loss in the third quarter of 2019 and a $323 million loss in the first nine months of 2019 in Other, net due to changes in fair value of the contracts. These amounts are included in Acquisition/divestiture-related net charges (credits) presented in the reconciliation of our results of operations prepared in accordance with U.S. GAAP to those adjusted results considered by management. Refer to Financial Summary for the reconciliation and Additional Information for a discussion of management's use of non-GAAP financial measures.


49

We recorded gains of $142 million in the third quarter of 2018 and $182 million in the first nine months of 2018 based on the difference between the book values and the fair values of our previously-held investments immediately prior to the acquisition dates. The aggregate fair value of our previously-held investments immediately prior to the acquisition dates was $251 million. We remeasured the fair value of each previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests. Gains and losses recorded on previously-held investments are excluded by management for purposes of evaluating operating performance and are presented within Acquisition/divestiture-related net charges (credits).

Tax Rates

Our effective tax rate from continuing operations is presented below:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
2019
 
2018
 
2019
 
2018
Effective tax rate from continuing operations
(38.7
)%
 
5.3
%
 
(1.6
)%
 
(14.1
)%

The change in our reported tax rates for the third quarter and first nine months of 2019, as compared to the same periods in 2018, relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These receipts and charges include intangible asset impairment charges, acquisition-related items, restructuring items, litigation-related items as well as certain discrete tax items primarily related to share-based payments and the 2018 settlement of our transfer pricing dispute with the Internal Revenue Service (IRS) for the 2001 through 2010 tax years.

Critical Accounting Policies and Estimates
Our financial results are affected by the selection and application of accounting policies and methods. In the nine months ended September 30, 2019, there were no changes to the application of critical accounting policies previously disclosed in our most recent Annual Report on Form 10-K.

Liquidity and Capital Resources

Based on our current business plan, we believe our existing balance of Cash and cash equivalents, future cash generated from operations, access to capital markets and existing credit facilities will be sufficient to fund our operations, invest in our infrastructure, pay our legal-related liabilities, pay taxes due, fund possible mergers and/or acquisitions and service and repay our existing debt for the next twelve months.

As of September 30, 2019, we had $277 million of unrestricted Cash and cash equivalents on hand, comprised of $26 million invested in money market and government funds and $249 million in interest bearing and non-interest-bearing bank accounts. We invest excess cash on hand in short-term financial instruments that earn market interest rates while mitigating principal risk through instrument and counterparty diversification, as well as what we believe to be prudent instrument selection. We limit our direct exposure to securities in any one industry or issuer. We also have access to our $2.750 billion commercial paper program, which is backed by our 2018 revolving credit facility. As of September 30, 2019, we had $1.293 billion in commercial paper debt outstanding resulting in an additional $1.457 billion of available liquidity.

On August 19, 2019, for the purpose of funding the BTG Acquisition, as described in Note B – Acquisitions and Strategic Investments to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q, we borrowed $1.000 billion under the Two-Year Delayed Draw Term Loan, which matures on August 19, 2021, and $1.000 billion under the Three-Year Delayed Draw Term Loan, which matures on August 19, 2022. As of September 30, 2019, we had $1.000 billion outstanding under our Two-Year Delayed Draw Term Loan and $1.000 billion outstanding under our Three-Year Delayed Draw Term Loan presented within Long-term debt on our accompanying unaudited condensed consolidated balance sheets. As of December 31, 2018, we had no amounts borrowed under the Two-Year Delayed Draw Term Loan and Three-Year Delayed Draw Term Loan.

In February 2019, we completed an offering of $4.300 billion in aggregate principal amount of senior notes. We used a portion of the net proceeds from the offering to repay the $850 million plus accrued interest and premium of our 6.000% senior notes due in January 2020 (January 2020 Notes), the $600 million plus accrued interest and premium of our 2.850% senior notes due in May 2020 (May 2020 Notes) and the $1.000 billion plus accrued interest of our August 2019 Term Loan. In the third quarter of 2019, the remaining proceeds were used to finance a portion of the BTG Acquisition.

Upon the closing of our senior notes offering in February 2019, we terminated the Bridge Facility entered into on November 20, 2018. The termination was pursuant to the terms of the Bridge Facility, which required full termination upon the refinancing of the January 2020 Notes and May 2020 Notes.

For additional information on our credit facilities, term loans and senior notes, refer to Note E – Borrowings and Credit Arrangements to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q and Note E – Borrowing and Credit Arrangements to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.

50


In addition, we are initiating a process to explore the divestiture of the royalty stream associated with the Zytiga™ licensing arrangements obtained as part of the BTG Acquisition.

The following provides a summary and description of our net cash inflows (outflows):
 
Nine Months Ended September 30,
(in millions)
2019
 
2018
Cash provided by (used for) operating activities
$
1,144

 
$
291

Cash provided by (used for) investing activities
(4,992
)
 
(1,326
)
Cash provided by (used for) financing activities
3,697

 
1,007


Operating Activities

In the first nine months of 2019, cash provided by operating activities increased $853 million as compared to the first nine months of 2018. The increase was primarily due to the one-time settlement payment of $180 million that we received from Edwards Lifesciences Corporation in January 2019 and the IRS final net tax settlement payment of $303 million plus $307 million of estimated interest that we remitted in the second quarter of 2018.

Investing Activities

In the first nine months of 2019, cash used for investing activities primarily included Payments for acquisitions of businesses, net of cash acquired of $4.382 billion relating to our acquisitions of BTG, Vertiflex and Millipede, Inc. (Millipede), Purchases of property, plant and equipment of $275 million, Payments for investments and acquisitions of certain technologies of $137 million and Proceeds from divestiture of certain businesses of $90 million relating to the sale of our drug-eluting and bland embolic microsphere portfolio to Varian Medical Systems, Inc. (Varian) in connection with the BTG Acquisition. Cash used for investing activities also included Payments for settlements of hedge contracts of $294 million relating to certain of our non-designated forward currency contracts entered into for the purpose of managing our exposure to currency exchange rate risk related to the purchase price of the BTG Acquisition. As of September 30, 2019, we settled all outstanding contracts, resulting in a cumulative loss and cash payment of $294 million. Refer to Note D – Hedging Activities and Fair Value Measurements to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for further information.

In the first nine months of 2018, cash used for investing activities primarily included Payments for acquisitions of businesses, net of cash acquired of $968 million relating to our acquisitions including NxThera, Claret, Cryterion Medical, Inc. (Cryterion) and nVision Medical Corporation (nVision), Purchases of property, plant and equipment of $210 million and Payments for investments and acquisitions of certain technologies of $148 million, including our $90 million investment in Millipede.

Financing Activities

Our cash flows provided by financing activities primarily related to issuances and repayments of debt in the first nine months of 2019 and 2018. In the first nine months of 2019, our cash flows provided by financing activities primarily included Proceeds from long-term borrowings, net of debt issuance costs of $6.243 billion, Payments on long-term borrowings and debt extinguishment costs of $1.472 billion and Payments on short-term borrowings of $1.000 billion.

In the first nine months of 2018, our cash flows provided by financing activities primarily included Proceeds from short-term borrowings, net of debt issuance costs of $999 million, Proceeds from long-term borrowings, net of debt issuance costs of $989 million, Payments on long-term borrowings and debt extinguishment costs of $602 million and net decrease in commercial paper of $403 million.


51

Debt

The following table presents the current and long-term portions of our total debt:
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Current debt obligations
$
1,297

 
$
2,253

Long-term debt
9,590

 
4,803

Total debt
$
10,888

 
$
7,056


The following table presents the portions of our total debt that are comprised of fixed and variable rate debt instruments, which are presented on an amortized cost basis:
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Fixed-rate debt instruments
$
7,586

 
$
4,797

Variable rate debt instruments
3,301

 
2,259

Total debt
$
10,888

 
$
7,056


As of and through September 30, 2019, we were in compliance with all the required covenants related to our debt obligations.

On October 22, 2019, we announced the commencement of a cash tender offer (Tender Offer) for up to $1.000 billion combined aggregate principal amount (Aggregate Maximum Principal Amount) of our outstanding 4.125% senior notes due October 2023, 4.000% senior notes due March 2028, 3.850% senior notes due May 2025 and 3.375% senior notes due May 2022 (collectively, Tender Offer Notes). The Tender Offer is being made exclusively pursuant to an offer to purchase dated October 22, 2019, which sets forth the terms and conditions of the Tender Offer. Consummation of the Tender Offer is subject to satisfaction or waiver of the conditions described in the offer to purchase, including the financing condition that we shall have closed one or more debt financings resulting in net proceeds in an amount, together with cash on hand, not less than the amount required, upon the terms and subject to the conditions of the Tender Offer, to purchase all the securities validly tendered and accepted for purchase in the Tender Offer and to pay accrued interest thereon and fees and expenses associated therewith.

The Tender Offer will expire at midnight, Eastern Standard Time, on November 19, 2019, unless extended or terminated by us. However, because the aggregate principal amount of Tender Offer Notes validly tendered and not validly withdrawn as of the early tender date at 5:00 p.m. Eastern Standard Time, on November 4, 2019, would cause the Aggregate Maximum Principal Amount to be exceeded and we do not expect to increase the Aggregate Maximum Principal Amount, we do not expect to accept any further tenders of Tender Offer Notes.

We expect these proposed transactions to be effectively leverage neutral. We do not expect the Tender Offer or any financing to fund the Tender Offer to materially impact our compliance with existing debt covenants.

For additional details related to our debt obligations, including our debt covenant requirements, refer to Note E – Borrowings and Credit Arrangements to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q and Note E – Borrowing and Credit Arrangements to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.
Equity
We received $113 million in the first nine months of 2019 and $94 million in the first nine months of 2018 in proceeds from stock issuances related to our stock option and employee stock purchase plans. Proceeds from the exercise of employee stock options and employee stock purchases vary from period to period based upon, among other factors, fluctuations in the trading price of our common stock and in the exercise and stock purchase patterns of our employees.
We did not repurchase any shares of our common stock in the first nine months of 2019 or 2018. As of September 30, 2019, the remaining authorization to repurchase shares under our 2013 share repurchase program was $535 million.

52

Contractual Obligations and Commitments

Certain of our acquisitions involve the payment of contingent consideration. See Note B – Acquisitions and Strategic Investments to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for further details regarding the estimated potential amount of future contingent consideration we could be required to pay associated with our acquisitions.

On August 21, 2019, we completed the sale of our drug-eluting and bland embolic microsphere portfolio to Varian in connection with the BTG Acquisition. The transaction price consists of an upfront cash payment of $90 million, a portion of which is allocated to the fair value of the services to be rendered under the Transition Services Agreement and Transition Manufacturing Agreement entered into with Varian as part of this transaction. Additionally, we transferred certain contingent consideration arrangements arising from our initial acquisition of the portfolio to Varian and agreed to indemnify Varian for any payments ultimately arising under the terms of the contingent consideration arrangement. Accordingly, as part of the disposal, we recorded a liability of $16 million related to this guarantee to recognize the fair value of the obligation resulting from the indemnifications. The maximum amount payable under this guarantee is $200 million. Refer to Note B – Acquisitions and Strategic Investments to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for additional information.

There have been no other material changes to our contractual obligations and commitments as reported in our most recent Annual Report filed on Form 10-K, with the exception of our debt obligations discussed in Liquidity and Capital Resources and Note E – Borrowings and Credit Arrangements to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q.
Legal Matters
For a discussion of our material legal proceedings see Note I – Commitments and Contingencies to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q and Note J – Commitments and Contingencies to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K.
Recent Accounting Pronouncements
Information regarding new accounting pronouncements implemented since December 31, 2018 is included in Note A – Basis of Presentation and information regarding new accounting pronouncements to be implemented is included in Note N – New Accounting Pronouncements to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q.

Additional Information

Cybersecurity

We have established controls and procedures to escalate enterprise level issues, including cybersecurity matters, to the appropriate management levels within our organization and our Board of Directors, or members or committees thereof, as appropriate. Under our framework, cybersecurity issues are analyzed by subject matter experts and a crisis committee for potential financial, operational, and reputational risks, based on, among other factors, the nature of the matter and breadth of impact. Matters determined to present potential material impacts to the Company’s financial results, operations, and/or reputation are immediately reported by management to the Board of Directors, or individual members or committees thereof, as appropriate, in accordance with our escalation framework. In addition, we have established procedures to ensure that management responsible for overseeing the effectiveness of disclosure controls is informed in a timely manner of known cybersecurity risks and incidents that may materially impact our operations and that timely public disclosure is made as appropriate. 
Stock Trading Policy

Our directors and executive officers are subject to our Stock Trading Policy, which is designed to facilitate compliance with insider trading laws and governs transactions in our common stock and related derivative securities. Our policy designates certain regular periods, dictated by release of financial results, in which trading is restricted for individuals in information-sensitive positions, including directors and executive officers. In addition, additional periods of trading restriction may be imposed as determined by the President, General Counsel, or Chief Financial Officer in light of material pending developments. Further, during permitted windows, individuals in information-sensitive positions are required to seek pre-clearance for trades from the General Counsel, who assesses whether there are any important pending developments, including cybersecurity matters, which need to be made public before the individual may participate in the market.

53


Periodically, certain of our executive officers adopt written stock trading plans in accordance with Rule 10b5-1 under the Exchange Act and our own Stock Trading Policy. A Rule 10b5-1 Trading Plan is a written document that pre-establishes the amount, prices and dates (or formulas for determining the amounts, prices and dates) of future purchases or sales of our stock, including shares issued upon exercise of stock options or vesting of deferred stock units. These plans are entered into at a time when the person is not in possession of material non-public information about our Company. We disclose details regarding individual Rule 10b5-1 Trading Plans on the Investor Relations section of our website, under the Governance Overview section.

Use of Non-GAAP Financial Measures

To supplement our unaudited condensed consolidated financial statements presented on a GAAP basis, we disclose certain non-GAAP financial measures, including adjusted net income (earnings) and adjusted net income (earnings) per share that exclude certain amounts and operational net sales growth that exclude the impact of foreign currency fluctuations. These non-GAAP financial measures are not in accordance with generally accepted accounting principles in the United States and should not be considered in isolation from or as a replacement for the most directly comparable GAAP financial measures. Further, other companies may calculate these non-GAAP financial measures differently than we do, which may limit the usefulness of those measures for comparative purposes.

To calculate adjusted net income (earnings) and adjusted net income (earnings) per share we exclude certain charges (credits) from GAAP net income. Amounts are presented after-tax using our effective tax rate, unless the amount is a significant unusual or infrequently occurring item in accordance with FASB ASC section 740-270-30, "General Methodology and Use of Estimated Annual Effective Tax Rate." Please refer to Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our most recent Annual Report filed on Form 10-K filed with the Securities and Exchange Commission (SEC) for an explanation of each of these adjustments and the reasons for excluding each item. The following is an explanation of each incremental or revised adjustment type that management excluded as part of these non-GAAP financial measures, since our most recent Annual Report on Form 10-K, as well as the reason for excluding each item:

•
Acquisition / divestiture-related net charges (credits) or payments- These adjustments may consist of (a) contingent consideration fair value adjustments; (b) gains on previously held investments; (c) due diligence, deal fees and costs, inventory step-up amortization, integration and exit costs, other fees, and accelerated compensation expense; and (d) separation costs and gains primarily associated with the sale of a business or portion of a business. The contingent consideration adjustments represent accounting adjustments to state contingent consideration liabilities at their estimated fair value. These adjustments can be highly variable depending on the assessed likelihood and amount of future contingent consideration payments. Due diligence, deal fees, inventory step-up amortization, integration and exit costs include legal, tax, severance and other expenses and gains associated with prior and potential future acquisitions and divestitures can be highly variable and not representative of ongoing operations. Deal fees and costs in 2019 included expenses for instruments entered into solely for the purpose of financing or hedging the BTG Acquisition, including net interest expense and hedging expenses. Subsequent to September 30, 2019, we did not incur and will not incur any hedging gains or losses related to the BTG Acquisition, and we are not classifying interest expense as an acquisition / divestiture-related item. Acquisition / divestiture-related net charges (credits) are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

•
Medical device regulation charges or payments- These adjustments represent incremental costs or payments specific to complying with the new European Union Medical Device Regulation (EU MDR) for previously registered products. EU MDR is a replacement of the existing European Medical Devices Directive (MDD) regulatory framework, and manufacturers of currently marketed medical devices are required to comply with EU MDR beginning in May 2020. We expect to incur expenditures in connection with the new registration of medical devices that previously had been registered under MDD. We consider the adoption of EU MDR to be a significant change to a regulatory framework, and therefore, these expenditures are not considered to be ordinary course expenditures in connection with regulatory matters. As such, these medical device regulation charges are excluded from management's assessment of operating performance and from our operating segments' measures of profit and loss used for making operating decisions and assessing performance.

The GAAP financial measures most directly comparable to adjusted net income and adjusted net income per share are GAAP net income and GAAP net income per share.

To calculate operational net sales growth rates, which exclude the impact of foreign currency fluctuations, we convert actual net sales from local currency to U.S. dollars using constant foreign currency exchange rates in the current and prior period. The

54

GAAP financial measure most directly comparable to operational growth rate percentages is growth rate percentages using net sales on a GAAP basis.

Reconciliations of each of these non-GAAP financial measures to the corresponding GAAP financial measure are included in the relevant sections of this Quarterly Report.

Management uses these supplemental non-GAAP financial measures to evaluate performance period over period, to analyze the underlying trends in our business, to assess our performance relative to our competitors and to establish operational goals and forecasts that are used in allocating resources. In addition, management uses these non-GAAP financial measures to further its understanding of the performance of our operating segments. The adjustments excluded from our non-GAAP financial measures are consistent with those excluded from our operating segments’ measures of net sales and profit or loss. These adjustments are excluded from the segment measures reported to our chief operating decision maker that are used to make operating decisions and assess performance.

We believe that presenting adjusted net income, adjusted net income per share that exclude certain amounts and operational net sales growth that exclude the impact of changes in foreign currency exchange rates, in addition to the corresponding GAAP financial measures, provides investors greater transparency to the information used by management for its operational decision-making and allows investors to see our results “through the eyes” of management. We further believe that providing this information assists our investors in understanding our operating performance and the methodology used by management to evaluate and measure such performance.

Safe Harbor for Forward-Looking Statements

Certain statements that we may make from time to time, including statements contained in this Quarterly Report on Form 10-Q and information incorporated by reference herein, constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend,” “aiming” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.

The forward-looking statements in this Quarterly Report on Form 10-Q are based on certain risks and uncertainties, including the risk factors described in Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K and the specific risk factors discussed herein and in connection with forward-looking statements throughout this Quarterly Report on Form 10-Q, which could cause actual results to vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this Quarterly Report. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. Risks and uncertainties that may cause such differences include, among other things: future economic, political, competitive, reimbursement and regulatory conditions, new product introductions and the market acceptance of those products, markets for our products, expected pricing environment, expected procedural volumes, the closing and integration of acquisitions, clinical trial results, demographic trends, intellectual property rights, litigation, financial market conditions, the execution and effect of our restructuring program, the execution and effect of our business strategy, including our cost-savings and growth initiatives and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K filed with the SEC, which we may update in Part II, Item 1A. Risk Factors in subsequent Quarterly Reports on Form 10-Q that we will file hereafter, and Part II, Item 1A. Risk Factors in this Quarterly Report on Form 10-Q. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this Quarterly Report.

The following are some of the important risk factors that could cause our actual results to differ materially from our expectations in any forward-looking statements. For further discussion of these and other risk factors, see Part I, Item 1A. Risk Factors in our most recent Annual Report on Form 10-K and Part II, Item 1A. Risk Factors in this Quarterly Report on Form 10-Q.


55

Our Businesses
 
•
Our ability to increase net sales, expand the market, capture market share and adapt to market volatility,

•
The ongoing impact on our business of physician alignment to hospitals, governmental investigations and audits of hospitals and other market and economic conditions on the overall number of procedures performed,

•
Competitive offerings and related declines in average selling prices for our products,

•
The performance of, and physician and patient confidence in, our products and technologies or those of our competitors,

•
The impact and outcome of ongoing and future clinical trials and market studies undertaken by us, our competitors or other third parties or perceived product performance of our or our competitors' products,
 
•
Variations in clinical results, reliability or product performance of our and our competitors' products,

•
Our ability to acquire or develop, launch and supply new or next-generation products and technologies worldwide and in line with our commercialization strategies in a timely and successful manner and with respect to our recent acquisitions,

•
The effect of consolidation and competition in the markets in which we do business or plan to do business,

•
Disruption in the manufacture or supply of certain components, materials or products or the failure to secure in a timely manner alternative manufacturing or additional or replacement components, materials or products,

•
Our ability to retain and attract key personnel,

•
The impact of enhanced requirements to obtain regulatory approval in the U.S. and around the world, including the associated timing and cost of product approval, and
 
•
The impact of increased pressure on the availability and rate of third-party reimbursement for our products and procedures in the U.S. and around the world, including with respect to the timing and costs of creating and expanding markets for new products and technologies.

Regulatory Compliance, Litigation and Data Protection

•
The impact of healthcare policy changes and legislative or regulatory efforts in the U.S., the EU and around the world to modify product approval or reimbursement processes, including a trend toward demonstrating clinical outcomes, comparative effectiveness and cost efficiency, as well as the impact of other healthcare reform legislation,

•
Risks associated with our regulatory compliance and quality systems and activities in the U.S., the EU and around the world, including meeting regulatory standards applicable to manufacturing and quality processes,

•
Our ability to minimize or avoid future field actions or FDA warning letters relating to our products and processes and the ongoing inherent risk of potential physician advisories related to medical devices,

•
The impact of increased scrutiny of and heightened global regulatory enforcement facing the medical device industry arising from political and regulatory changes, economic pressures or otherwise, including under U.S. Anti-Kickback Statute, U.S. False Claims Act and similar laws in other jurisdictions, U.S. Foreign Corrupt Practices Act (FCPA) and similar laws in other jurisdictions, and U.S. and foreign export control, trade embargo and customs laws,

•
Costs and risks associated with litigation,

•
The effect of our litigation and risk management practices, including self-insurance and compliance activities on our loss contingencies, legal provision and cash flows,
 
•
The impact of, diversion of management attention as a result of and costs to cooperate with, litigate and/or resolve governmental investigations and our class action, product liability, contract and other legal proceedings,

•
The possibility of failure to protect our intellectual property rights and the outcome of patent litigation, and

56


•
Our ability to properly operate our information systems that support our business operations and protect our data integrity and products from a cyber-attack or other breach that has a material adverse effect on our business, reputation or results of operations.

Innovation and Certain Growth Initiatives

•
The timing, size and nature of our strategic growth initiatives and market opportunities, including with respect to our internal research and development platforms and externally available research and development platforms and technologies and the ultimate cost and success of those initiatives and opportunities,

•
Our ability to complete planned clinical trials successfully, obtain regulatory approvals and launch new and next generation products in a timely manner consistent with cost estimates, including the successful completion of projects from in-process research and development,

•
Our ability to identify and prioritize our internal research and development project portfolio and our external investment portfolio on profitable revenue growth opportunities as well as to keep them in line with the estimated timing and costs of such projects and expected revenue levels for the resulting products and technologies,

•
Our ability to successfully develop, manufacture and market new products and technologies in a timely manner and the ability of our competitors and other third parties to develop products or technologies that render our products or technologies noncompetitive or obsolete,

•
Our ability to execute appropriate decisions to discontinue, write-down or reduce the funding of any of our research and development projects, including projects from in-process research and development, in our growth adjacencies or otherwise,

•
Our dependence on acquisitions, alliances or investments to introduce new products or technologies and to enter new or adjacent growth markets and our ability to fund them or to fund contingent payments with respect to those acquisitions, alliances and investments, and

•
The potential failure to successfully integrate and realize the expected benefits from the strategic acquisitions, alliances and investments we have consummated or may consummate in the future.

International Markets

•
Our dependency on international net sales to achieve growth, including in emerging markets,

•
The impact of changes in our international structure and leadership,

•
The timing and collectability of customer payments,

•
The political and economic conditions (including the impact of the United Kingdom's exit from the EU, often referred to as "Brexit"),

•
Protection of our intellectual property,

•
Our ability to comply with established and developing U.S. and foreign legal and regulatory requirements, including FCPA and similar laws in other jurisdictions,

•
Our ability to comply with U.S. and foreign export control, trade embargo and customs laws,

•
The impact of changes in reimbursement practices and policies in both the U.S. and abroad,

•
Our ability to maintain or expand our worldwide market positions in the various markets in which we compete or seek to compete, including through investments in product diversification and emerging markets such as Brazil, Russia, India and China,

•
Our ability to execute and realize anticipated benefits from our investments in emerging markets, and

57


•
The potential effect of foreign currency fluctuations and interest rate fluctuations on our net sales, expenses and resulting margins.

Liquidity

•
Our ability to generate sufficient cash flow to fund operations, capital expenditures, global expansion initiatives, any litigation settlements and judgments, share repurchases and strategic investments and acquisitions as well as maintaining our investment grade ratings and managing our debt levels and covenant compliance,

•
Our ability to access the public and private capital markets when desired and to issue debt or equity securities on terms reasonably acceptable to us,

•
The unfavorable resolution of open tax matters, exposure to additional tax liabilities and the impact of changes in U.S. and international tax laws,

•
The impact of examinations and assessments by domestic and international taxing authorities on our tax provision, financial condition or results of operations,

•
The possibility of counterparty default on our derivative financial instruments,

•
The impact of potential intangible asset impairment charges, including on our results of operations, and

•
Our ability to collect outstanding and future receivables and/or sell receivables under our factoring programs.

Cost Reduction and Optimization Initiatives

•
Risks associated with significant changes made or expected to be made to our organizational and operational structure, pursuant to our restructuring plans as well as any further restructuring or optimization plans we may undertake in the future and our ability to recognize benefits and cost reductions from such programs and

•
Business disruption and employee distraction as we execute our global compliance program, restructuring and optimization plans and divestitures of assets or businesses and implement our other strategic and cost reduction initiatives.




58

ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We develop, manufacture and sell medical devices globally and our earnings and cash flows are exposed to market risk from changes in currency exchange rates and interest rates. We address these risks through a risk management program that includes the use of derivative financial instruments. We operate the program pursuant to documented corporate risk management policies. We do not enter derivative transactions for speculative purposes. Gains and losses on derivative financial instruments substantially offset losses and gains on underlying hedged exposures. Furthermore, we manage our exposure to counterparty risk on derivative instruments by entering into contracts with a diversified group of major financial institutions and by actively monitoring outstanding positions.
Our currency risk consists primarily of foreign currency denominated firm commitments, forecasted foreign currency denominated intercompany and third-party transactions and net investments in certain subsidiaries. We use both nonderivative (primarily European manufacturing operations) and derivative instruments to manage our earnings and cash flow exposure to changes in currency exchange rates. We had currency derivative instruments outstanding in the contract amount of $9.487 billion as of September 30, 2019 and $11.326 billion as of December 31, 2018. A ten percent appreciation in the U.S. dollar’s value relative to the hedged currencies would increase the derivative instruments’ fair value by $456 million as of September 30, 2019 as compared to $181 million as of December 31, 2018. A ten percent depreciation in the U.S. dollar’s value relative to the hedged currencies would decrease the derivative instruments’ fair value by $558 million as of September 30, 2019 as compared to $222 million as of December 31, 2018. Any increase or decrease in the fair value of our currency exchange rate sensitive derivative instruments would be substantially offset by a corresponding decrease or increase in the fair value of the hedged underlying asset, liability or forecasted transaction, resulting in minimal impact on our unaudited condensed consolidated statements of operations.
Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. We had no interest rate derivative instruments outstanding as of September 30, 2019 and $1.000 billion outstanding in the contract amount as of December 31, 2018. As of September 30, 2019, $7.650 billion in aggregate principal amount of our outstanding debt obligations were at fixed interest rates, representing approximately 70 percent of our total debt. As of September 30, 2019, our outstanding debt obligations at fixed interest rates were comprised of senior notes.

Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the purchase price of the BTG Acquisition. As of September 30, 2019, we settled all outstanding contracts, resulting in a cumulative loss on the contracts of $294 million that was recognized over time in earnings as we adjusted for changes in fair value until the final fair value was determined at maturity. We recognized a $207 million loss in the third quarter of 2019 and a $323 million loss in the first nine months of 2019 in Other, net due to changes in fair value of the contracts.

Refer to Note D – Hedging Activities and Fair Value Measurements to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q for further information regarding our derivative financial instruments.


59

ITEM 4.
CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer (CEO) and our Chief Financial Officer (CFO), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2019 pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act). Disclosure controls and procedures are designed to ensure that material information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such material information is accumulated and communicated to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. Based on their evaluation, our CEO and CFO concluded that, as of September 30, 2019, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting in the three month period ended September 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

On August 19, 2019, we announced the closing of our acquisition of BTG plc (BTG). In accordance with the SEC Staff interpretive guidance for newly acquired businesses, we are permitted to omit an assessment of an acquired business's internal control over financial reporting from our assessment of internal control for up to one year from the acquisition date. As such, we intend to exclude BTG from our annual assessment of internal controls over financial reporting as of December 31, 2019, as the acquisition was completed on August 19, 2019. BTG represents 17 percent of our total assets as of September 30, 2019 and 1 percent of our total revenues for the first nine months of 2019.

60

PART II
OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

See Note H – Income Taxes and Note I – Commitments and Contingencies to our unaudited condensed consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q, which is incorporated herein by reference.

ITEM 1A. RISK FACTORS

In addition to the information set forth below and other information contained elsewhere in this report, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors in our most recent Annual Report filed on Form 10-K, which could materially affect our business, financial condition or future results.
We are subject to a number of market, business, financial, legal and regulatory risks and uncertainties with respect to our international operations that could have a material impact on our business, financial condition or results of operations.
International net sales, excluding sales from the BTG Acquisition, accounted for 42 percent in the third quarter and 43 percent in the first nine months of 2019 of our global net sales. An important part of our strategy is to continue pursuing growth opportunities in net sales and market share outside of the U.S. by expanding global presence, including in Emerging Markets. Our international operations are subject to a number of market, business and financial risks and uncertainties, including those related to geopolitical and economic instability, foreign currency exchange and interest rate fluctuations, competitive product offerings, local changes in health care financing and payment systems and health care delivery systems, local product preferences and requirements, including preferences for local manufacturers, workforce instability, less intellectual property protection in certain countries than exists in the U.S. and, in certain foreign countries, longer accounts receivable cycles. Such risks and uncertainties may adversely impact our ability to implement our growth strategy in these markets and, as a result, our sales growth, market share and operating profits from our international operations may be adversely affected.
Our international operations are subject to established and developing legal and regulatory requirements for medical devices in each country in which our products are marketed and sold. Most foreign countries have medical device regulations. Further, most countries outside of the U.S. require product approvals be renewed or recertified on a regular basis in order to continue to be marketed and sold there. In addition, several countries that previously did not have regulatory requirements for medical devices have established such requirements in recent years and other countries have expanded, or plan to expand, existing regulations, including requiring local clinical data in addition to global clinical data. These factors have caused or may cause us to experience more uncertainty, risk, expense and delay in commercializing products in certain foreign jurisdictions, which could affect our ability to obtain approvals for our products in those jurisdictions and adversely impact our net sales, market share and operating profits from our international operations.
Further, international markets are affected by economic pressure to contain healthcare costs, which can lead to more rigorous evidence requirements and lower reimbursement rates for either our products directly or procedures in which our products are used. Governments and payers may also institute changes in health care delivery systems that may reduce funding for services or encourage greater scrutiny of health care costs. In addition, certain international markets may also be affected by foreign government efforts to reference reimbursement rates in other countries. All of these types of changes may ultimately reduce selling prices of our products and/or reduce the number of procedures in which our products are used, which may adversely impact our net sales, market share and operating profits from our international operations.

In addition, our international operations are subject to other established and developing U.S. and foreign legal and regulatory requirements, including FCPA and/or similar laws in other countries and U.S. and foreign import and export controls and licensing requirements, trade protection and embargo measures and customs laws. Global businesses, including those in the medical device industry, are facing increasing scrutiny of, and heightened enforcement efforts with respect to, their international operations. Any alleged or actual failure to comply with legal and regulatory requirements may subject us to government scrutiny, civil and/or criminal proceedings, sanctions and other liabilities, which may have a material adverse effect on our international operations, financial condition, results of operations and/or liquidity.

In a referendum on June 23, 2016, voters approved the exit of the United Kingdom (UK) from the European Union (EU). Following a formal notification by the UK to the EU that it intends to leave the EU, and after several extensions to the deadline for doing so agreed between the UK and the EU, the current date on which the UK will legally withdraw from the EU is January 31, 2020. However, there will be a general election in the UK on December 12, 2019 in which all seats of the House of Commons will be contested, and the composition of the House of Commons after the election will determine the identity of the Prime Minister and

61

the government. This will affect the terms of its withdrawal and the nature of its future relationship with the EU, which are still being decided, with the various major parties offering significantly different visions for whether and how the UK will withdraw from the EU and the subsequent relationship with the EU. Future exit of the UK from the EU will have numerous consequences in all areas of our business, including, economic, regulatory and operational, and the actual impact depends on the ultimate outcome, and is very difficult to assess at this time. Changes in industry regulations could have an effect on existing CE certificates being renewed and new certificates being issued which would impact the ability to trade; however, it is impossible to assess the full impact at this stage.

At this stage, the materiality to us of the Brexit risk factor remains unknown and unquantifiable. However, we have implemented a Brexit Response Team and have put in place mitigation procedures to reduce any significant operational risks that have been identified to date.
Any significant changes in the political and economic, financial, competitive, legal and regulatory or reimbursement conditions where we conduct, or plan to expand, our international operations may have a material impact on our business, financial condition or results of operations.
Disruptions in the supply of the materials and components used in manufacturing our products or the sterilization of our products by third-party vendors could adversely affect our results of operations and financial condition.
We purchase the majority of the materials and components used in manufacturing our products from third-party vendors. Certain of these materials and components are purchased from single sources due to quality considerations, expertise, costs or constraints resulting from regulatory requirements. In certain cases, we may not be able to establish additional or replacement vendors for such materials or components in a timely or cost effective manner, largely as a result of FDA regulations that require validation of materials and components prior to their use in our products and the complex nature of our and many of our vendors' manufacturing processes. A reduction or interruption in the supply of materials and components used in manufacturing our products, an inability to timely develop and validate alternative sources if required or a significant increase in the price of such materials or components could adversely affect our results of operations and financial condition.
In addition, many of our products require sterilization prior to sale and we utilize a mix of internal resources and contract sterilizers to perform this service. To the extent we or our contract sterilizers are unable to sterilize our products, whether due to capacity, availability of materials for sterilization, regulatory or other constraints, including federal and state regulations on the use of ethylene oxide, we may be unable to transition to other contract sterilizers, sterilizer locations or sterilization methods in a timely or cost effective manner or at all, which could have a material impact on our results of operations and financial condition.

As previously disclosed, one of our contract sterilizers, Sterigenics U.S. LLC (Sterigenics), uses ethylene oxide to provide sterilization services for certain men’s health products within our Urology and Pelvic Health business. In October 2018, the DuPage County State's Attorney and Illinois Attorney General filed a lawsuit against Sterigenics over the emissions in connection with the use of ethylene oxide during sterilization at Sterigenics’ Willowbrook, Illinois plant. On February 15, 2019, the Illinois Environmental Protection Agency (EPA) took action to suspend operations at the Willowbrook facility. Effective March 28, 2019, the FDA granted Boston Scientific approval to sterilize men’s health products affected by the Sterigenics closure at an existing sterilization facility in our supply chain network. In addition, throughout the second quarter of 2019, we received the requisite approvals from regulatory agencies outside of the U.S. to sterilize our men’s health products at our existing sterilization facility.

Changes in tax laws, unfavorable resolution of tax contingencies, or exposure to additional income tax liabilities could have a material impact on our financial condition, results of operations and/or liquidity.

We are subject to income taxes as well as non-income based taxes and tariffs, in both the U.S. and various foreign jurisdictions. We are subject to ongoing tax audits in various jurisdictions. Tax authorities may disagree with certain positions we have taken and assess additional taxes. We regularly assess the likely outcomes of these audits to determine the appropriateness of our tax provision, and we have established contingency reserves for material, known tax exposures. However, the calculation of such tax exposures involves the application of complex tax laws and regulations in many jurisdictions, as well as interpretations as to the legality under European Union state aid rules of tax advantages granted in certain jurisdictions. Therefore, there can be no assurance that we will accurately predict the outcomes of these disputes or other tax audits or that issues raised by tax authorities will be resolved at a financial cost that does not exceed our related reserves and the actual outcomes of these disputes and other tax audits could have a material impact on our results of operations or financial condition.

Changes in tax laws and regulations, or their interpretation and application, in the jurisdictions where we are subject to tax could materially impact our effective tax rate. The U.S. enacted the Tax Cuts and Jobs Act (TCJA) on December 22, 2017 and we expect the U.S. Treasury to issue future notices and regulations under the TCJA. Certain provisions of the TCJA and the regulations issued

62

thereunder could have a significant impact on our future results of operations as could interpretations made by the Company in the absence of regulatory guidance and judicial interpretations.

Additionally, the Organization for Economic Co-operation and Development (OECD), the European Commission (EC) and individual taxing jurisdictions where we and our affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD has released its comprehensive plan to create an agreed set of international rules for fighting base erosion and profit shifting. In addition, the OECD, the EC and individual counties are examining changes to how taxing rights should be allocated among countries considering the digital economy. As a result, the tax laws in the U.S. and other countries in which we and our affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect our business.

Our operations in Puerto Rico and Costa Rica presently benefit from various tax incentives and grants. Unless these incentives and grants are extended, they will expire between 2023 and 2028. If we are unable to renew, extend, or obtain new incentive and grants, the expiration of the existing incentives and grants could have a material impact on our financial results in future periods.

Furthermore, changes in customs laws and regulations in the U.S. and various foreign jurisdictions could have a material impact on our results of operations or financial condition.

ITEM 6. EXHIBITS (* documents filed or furnished with this report, # compensatory plans or arrangements)
31.1*
 
 
 
 
31.2*
 
 
 
 
32.1*
 
 
 
 
32.2*
 
 
 
 
101.SCH*
 
XBRL Taxonomy Extension Schema Document.
 
 
 
101.CAL*
 
XBRL Taxonomy Extension Calculation Linkbase Document.
 
 
 
101.DEF*
 
XBRL Taxonomy Extension Definition Linkbase Document.
 
 
 
101.LAB*
 
XBRL Taxonomy Extension Label Linkbase Document.
 
 
 
101.PRE*
 
XBRL Taxonomy Extension Presentation Linkbase Document.
 
 
 
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101)

63

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized on November 5, 2019.

 
BOSTON SCIENTIFIC CORPORATION
 
 
By:
/s/ Daniel J. Brennan
 
 
 
 
 
 
Name:
Daniel J. Brennan
 
 
Title:
Executive Vice President and
Chief Financial Officer 


64
 EX-31.1 2 exhibit311-ceo302q32019.htm EXHIBIT 31.1 Exhibit


EXHIBIT 31.1
 
CERTIFICATIONS
 
I, Michael F. Mahoney, certify that:
 

1
I have reviewed this Quarterly Report on Form 10-Q of Boston Scientific Corporation;
 
 
2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
 
3
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
 
4
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
 
 
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
 
 
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
 
 
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
 
 
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
 
 
5
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
 
 
 
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
 
 
 
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
November 5, 2019
 
/s/ Michael F. Mahoney
 
 
Michael F. Mahoney
 
 
President and Chief Executive Officer



 EX-31.2 3 exhibit312-cfo302q32019.htm EXHIBIT 31.2 Exhibit


EXHIBIT 31.2
 
CERTIFICATIONS
 
I, Daniel J. Brennan, certify that:


1
I have reviewed this Quarterly Report on Form 10-Q of Boston Scientific Corporation;
 
 
2
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
 
 
3
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
 
 
4
The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 
 
 
 
a)   
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
 
 
 
b)    
 
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
 
 
 
c)    
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 
 
 
 
d)    
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
 
 
 
5
The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 
 
 
 
a)    
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 
 
 
 
b)    
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:
November 5, 2019
 
/s/ Daniel J. Brennan
 
 
Daniel J. Brennan
 
 
Executive Vice President and Chief Financial Officer



 EX-32.1 4 exhibit321-ceo906q32019.htm EXHIBIT 32.1 Exhibit


EXHIBIT 32.1
 
 
CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Boston Scientific Corporation (the “Company”) for the period ended September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Executive Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

 
(1)   
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)   
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 regardless of any general incorporation language in such filing.
 
 
 
By:
/s/ Michael F. Mahoney
 
Michael F. Mahoney
 
 
President and Chief Executive Officer
 
 
 
 
 
November 5, 2019
 
 



 EX-32.2 5 exhibit322-cfo906q32019.htm EXHIBIT 32.2 Exhibit


EXHIBIT 32.2
 
 
CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.
SECTION 1350 AS ADOPTED PURSUANT TO SECTION 906 OF THE
SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Boston Scientific Corporation (the “Company”) for the period ended September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned Chief Financial Officer of the Company hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that based on his knowledge:

 
(1)   
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2)   
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Boston Scientific Corporation.

This certification shall not be deemed "filed" for any purpose, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934 regardless of any general incorporation language in such filing.

 
 
 
By:
/s/ Daniel J. Brennan
 
Daniel J. Brennan
 
 
 Executive Vice President and Chief Financial Officer
 
 
 
 
 
November 5, 2019
 



 EX-101.SCH 6 bsx-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2102100 - Disclosure - Acquisitions and Strategic Investments link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Acquisitions (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401402 - Disclosure - Basis of Presentation ASUs Implemented (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Basis of Presentation Material Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Borrowings and Credit Arrangements link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Borrowings and Credit Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Borrowings and Credit Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Changes in Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 2215201 - Disclosure - Changes in Other Comprehensive Income Changes in Other Comprehensive Income (Policies) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Changes in Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2315302 - Disclosure - Changes in Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2211201 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Policies) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005001 - Statement - Condensed Consolidated Statements of Cash Flows Condensed Consolidated Statement of Cash Flows (Supplemental Disclosure) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Contingent Consideration (Tables) link:presentationLink link:calculationLink link:definitionLink 0002000 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink 2205201 - Disclosure - Fair Value Measurements Hedging Activities and Fair Value Measurements (Policies) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Goodwill and Other Intangible Assets link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Goodwill and Other Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Policies) link:presentationLink link:calculationLink link:definitionLink 2304302 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Hedging Activities and Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Hedging Activities and Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 2305302 - Disclosure - Hedging Activities and Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Leases Leases link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Leases Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Leases Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2209201 - Disclosure - Leases Leases (Policies) link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - Leases Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - New Accounting Pronouncements New ASU impacts (Details) link:presentationLink link:calculationLink link:definitionLink 2216201 - Disclosure - New Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Strategic Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2302303 - Disclosure - Strategic Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Supplemental Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Supplemental Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Weighted Average Shares Outstanding link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Weighted Average Shares Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Weighted Average Shares Outstanding (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bsx-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 bsx-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 bsx-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Organization, Consolidation and Presentation of Financial Statements [Abstract] BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Legal Costs, Policy [Policy Text Block] Legal Costs, Policy [Policy Text Block] Statement of Comprehensive Income [Abstract] Statement [Table] Statement [Table] Statement, Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Statement [Line Items] Statement [Line Items] Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Other comprehensive income (loss), net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Net change in derivative financial instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Net change in defined benefit pensions and other items Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Total other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Total comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Income Tax Disclosure [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Unrecognized Tax Benefits Unrecognized Tax Benefits Unrecognized Tax Benefits that Would Impact Effective Tax Rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Effective tax rate from continuing operations Effective Income Tax Rate Reconciliation, Percent Decrease in Unrecognized Tax Benefits is Reasonably Possible Decrease in Unrecognized Tax Benefits is Reasonably Possible Goodwill and Intangible Assets Disclosure [Abstract] GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Business Combinations [Abstract] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] 2019 Acquisitions [Member] 2019 Acquisitions [Member] 2019 Acquisitions [Member] 2018 Acquisitions [Member] 2018 Acquisitions [Member] 2018 Acquisitions [Member] Millipede, Inc. [Member] Millipede, Inc. [Member] Millipede, Inc. [Member] BTG Acquisition [Member] BTG Acquisition [Member] BTG Acquisition [Member] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Business Acquisition [Line Items] Business Acquisition [Line Items] Business Acquisition, Pro Forma Information [Table Text Block] Business Acquisition, Pro Forma Information [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Schedule of Defined Benefit Plans Disclosures [Table Text Block] Schedule of Defined Benefit Plans Disclosures [Table Text Block] Schedule of Net Funded Status [Table Text Block] Schedule of Net Funded Status [Table Text Block] Debt Disclosure [Abstract] Schedule of Short-term Debt [Table] Schedule of Short-term Debt [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Commercial Paper [Member] Commercial Paper [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Short-term Debt [Line Items] Short-term Debt [Line Items] Schedule of Short-term Debt [Table Text Block] Schedule of Short-term Debt [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] Schedule of Long-term Debt Instruments [Table Text Block] Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block] Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block] Summary of term loan and revolving credit facility agreement compliance with debt covenants. Transfer of Financial Assets Accounted for as Sales [Table Text Block] Transfer of Financial Assets Accounted for as Sales [Table Text Block] Disclosure of Securitized or Asset-backed Financing Arrangement Assets and Other Financial Assets Managed Together [Abstract] Disclosure of Securitized or Asset-backed Financing Arrangement Assets and Other Financial Assets Managed Together [Abstract] Entity [Abstract] Entity [Abstract] Entities [Table] Entities [Table] Entity Addresses, Address Type [Axis] Entity Addresses, Address Type [Axis] Address Type [Domain] Address Type [Domain] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Entity Information [Line Items] Entity Information [Line Items] Document Type Document Type Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Document Period End Date Document Period End Date Entity File Number Entity File Number Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Listing, Par Value Per Share Entity Listing, Par Value Per Share Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Condensed Consolidated Cash Flow Supplemental DIsclosure [Abstract] Condensed Consolidated Cash Flow Supplemental DIsclosure [Abstract] statement [Axis] statement [Axis] statement [Axis] statement [Domain] statement [Domain] [Domain] for statement [Axis] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Restricted cash and restricted cash equivalents included in Other current assets Restricted Cash and Cash Equivalents, Current Restricted cash equivalents included in Other long-term assets Restricted Cash Equivalents, Noncurrent Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Fair Value Disclosures [Abstract] Fair Value Measurement, Policy [Policy Text Block] Fair Value Measurement, Policy [Policy Text Block] Derivatives, Policy [Policy Text Block] Derivatives, Policy [Policy Text Block] New Accounting Pronouncements and Changes in Accounting Principles [Abstract] New Accounting Pronouncements or Change in Accounting Principle [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Operating lease, Liability [Axis] Operating lease, Liability [Axis] Operating lease, Liability [Axis] Operating lease, Liability [Domain] Operating lease, Liability [Domain] [Domain] for Operating lease, Liability [Axis] Operating lease, liability, other long-term liabilities [Member] Operating lease, liability, other long-term liabilities [Member] Operating lease, liability, other long-term liabilities [Member] Operating lease, right-of-use asset [Axis] Operating lease, right-of-use asset [Axis] Operating lease, right-of-use asset [Axis] Operating lease, right-of-use asset [Domain] Operating lease, right-of-use asset [Domain] [Domain] for Operating lease, right-of-use asset [Axis] Operating lease, right-of-use assets, other long-term assets [Member] Operating lease, right-of-use assets, other long-term assets [Member] Operating lease, right-of-use assets, other long-term assets [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-02 [Member] Accounting Standards Update 2016-02 [Member] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Lease, Practical Expedients, Package [true false] Lease, Practical Expedients, Package [true false] New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification Derivative Instruments and Hedging Activities Disclosure [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] Leases [Abstract] Lessee Disclosure [Abstract] Lessee Disclosure [Abstract] Assets and Liabilities, Lessee [Abstract] Assets and Liabilities, Lessee [Abstract] Operating Lease, Right-of-Use Asset Operating Lease, Right-of-Use Asset Operating Lease, Liability, Current Operating Lease, Liability, Current Operating Lease, Liability, Noncurrent Operating Lease, Liability, Noncurrent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Lessee, leases not yet commenced, amount Lessee, leases not yet commenced, amount Lessee, leases not yet commenced, amount Operating Lease, Payments Operating Lease, Payments Operating Lease, Cost Operating Lease, Cost Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Finance Lease, Weighted Average Discount Rate, Percent Finance Lease, Weighted Average Discount Rate, Percent Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Lessee, Operating Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, Payments, Due Year Two Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, Payments, Due Year Three Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, Payments, Due Year Four Lessee, Operating Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, Payments, Due Year Five Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, Payments, Due after Year Five Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, Payments, Due Lessee, Operating Lease, Liability, Undiscounted Excess Amount Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating Lease, Liability Operating Lease, Liability Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Lessee, Operating Lease, Term of Contract Lessee, Operating Lease, Term of Contract Lessee, Operating and Finance Leases, Option to Extend Lessee, Operating and Finance Leases, Option to Extend Lessee, Operating and Finance Leases, Option to Extend Schedule Of Business Acquisitions By Acquisition [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] divested business due to BTG acquisition [Member] divested business due to BTG acquisition [Member] divested business due to BTG acquisition [Member] BTG intellectual property [Member] BTG intellectual property [Member] BTG intellectual property [Member] BTG Acquisition [Member] Vertiflex, Inc. [Member] Vertiflex, Inc. [Member] Vertiflex, Inc. Claret [Member] Claret [Member] Claret [Member] Cryterion [Member] Cryterion [Member] Cryterion [Member] NxThera [Member] NxThera [Member] NxThera [Member] nVision [Member] nVision [Member] nVision [Member] Other 2018 Acquisitions [Member] Other 2018 Acquisitions [Member] Other 2018 Acquisitions - immaterial in the aggregate [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Technology-Based Intangible Assets [Member] Technology-Based Intangible Assets [Member] Other Intangible Assets [Member] Other Intangible Assets [Member] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name [Domain] Purchased research and development [Member] In Process Research and Development [Member] Minimum [Member] Maximum [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Revenue from Contract with Customer, Excluding Assessed Tax Revenue from Contract with Customer, Excluding Assessed Tax Proceeds from Divestiture of Businesses Proceeds from Divestiture of Businesses Business Acquisition, Pro Forma Revenue Business Acquisition, Pro Forma Revenue Assets for Plan Benefits, Defined Benefit Plan Assets for Plan Benefits, Defined Benefit Plan Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate Interest Expense Interest Expense Finite-lived Intangible Assets Acquired Finite-lived Intangible Assets Acquired Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Business Acquisition, Share Price Business Acquisition, Share Price Business Combination, Consideration Transferred Business Combination, Consideration Transferred Payments to Acquire Businesses, Net of Cash Acquired Payments to Acquire Businesses, Net of Cash Acquired Accounts, Notes, Loans and Financing Receivable, Net, Current Accounts, Notes, Loans and Financing Receivable, Net, Current Inventory, Net Inventory, Net Other Assets, Current Prepaid Expense and Other Assets, Current Other Intangible Assets, Net Intangible Assets, Net (Excluding Goodwill) Other Assets, Noncurrent Other Assets, Noncurrent Accrued Liabilities, Current Accrued Liabilities, Current Other Liabilities, Noncurrent Other Liabilities, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Deferred Tax Liabilities, Net, Noncurrent Cash Acquired from Acquisition Cash Acquired from Acquisition Termination Loans Termination Loans Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Payments to Acquire Businesses, Gross Payments to Acquire Businesses, Gross Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Other Nonoperating Income (Expense) Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Business Combination, Contingent Consideration, Liability Business Combination, Contingent Consideration, Liability Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value Goodwill Goodwill Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Indefinite-lived Intangible Assets Acquired Indefinite-lived Intangible Assets Acquired Range of Risk Adjusted Discount Rates used in Purchase Price Allocation Range of Risk Adjusted Discount Rates used in Purchase Price Allocation Range of Risk Adjusted Discount Rates used in Purchase Price Allocation Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination Exchange Rate, USD Exchange Rate, USD Exchange Rate, USD Intangible Assets Acquired, Finite and Indefinite-lived Intangible Assets Acquired, Finite and Indefinite-lived Intangible Assets Acquired, Finite and Indefinite-lived Goodwill, Acquired During Period Goodwill, Acquired During Period Revenues Revenues Other Assets Other Assets Other Liabilities Other Liabilities Accrued Liabilities and Other Liabilities Accrued Liabilities and Other Liabilities Defined Benefit Plan, Expected Return (Loss) on Plan Assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase Defined Benefit Plan, Benefit Obligation Defined Benefit Plan, Benefit Obligation Defined Benefit Plan, Funded (Unfunded) Status of Plan Defined Benefit Plan, Funded (Unfunded) Status of Plan Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Net Income (Loss) Business Acquisition, Pro Forma Earnings Per Share, Basic Business Acquisition, Pro Forma Earnings Per Share, Basic Business Acquisition, Pro Forma Earnings Per Share, Diluted Business Acquisition, Pro Forma Earnings Per Share, Diluted Earnings Per Share [Abstract] Weighted Average Number Of Shares Outstanding [Text Block] Earnings Per Share [Text Block] Statement of Stockholders' Equity [Abstract] Adjustments for New Accounting Pronouncement [Member] Adjustments for New Accounting Pronouncement [Member] Statement, Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Common Stock [Member] Common Stock [Member] Treasury Stock [Member] Treasury Stock [Member] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) [Member] AOCI Attributable to Parent [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning Balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Beginning Balance (Shares) Common Stock, Shares, Issued Cumulative Effect of New Accounting Principle in Period of Adoption Cumulative Effect of New Accounting Principle in Period of Adoption Total other comprehensive income (loss) Impact of stock-based compensation plans, net of tax (Shares) Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures Impact of stock-based compensation plans, net of tax Stock Granted, Value, Share-based Compensation, Net of Forfeitures Ending Balance Ending Balance (Shares) Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract] Changes in Other Comprehensive Income [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Comprehensive Income (Loss) Note [Text Block] Comprehensive Income (Loss) Note [Text Block] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Prepaid Expenses and Other Current Assets [Member] Prepaid Expenses and Other Current Assets [Member] Other Noncurrent Assets [Member] Other Noncurrent Assets [Member] Other Current Liabilities [Member] Other Current Liabilities [Member] Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities [Member] Cost of Sales [Member] Cost of Sales [Member] Interest Expense [Member] Interest Expense [Member] Other Nonoperating Income (Expense) [Member] Hedging Relationship [Axis] Hedging Relationship [Domain] Cash Flow Hedging [Member] Net Investment Hedging [Member] Net Investment Hedging [Member] Hedging Designation [Axis] Hedging Designation [Domain] Designated as Hedging Instrument [Member] Not Designated as Hedging Instrument [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Foreign Exchange Contract [Member] Foreign Exchange Contract [Member] Interest Rate Contract [Member] Interest Rate Contract [Member] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments in Hedges, Assets, at Fair Value Derivative Instruments in Hedges, Assets, at Fair Value Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Forward Currency Contracts, Time to Maturity Forward Currency Contracts, Time to Maturity Forward Currency Contracts, Time to Maturity in Months Payments for Hedge, Investing Activities Payments for Hedge, Investing Activities Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Derivative, Notional Amount Derivative, Notional Amount Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Cost of Goods and Services Sold Cost of Goods and Services Sold Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Foreign Currency Transaction Gain (Loss), before Tax Foreign Currency Transaction Gain (Loss), before Tax Net currency exchange gain (loss) Net currency exchange gain (loss) Net currency exchange gain (loss) Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value Derivative Asset, Fair Value, Gross Asset Derivative Asset, Fair Value, Gross Asset Derivative Instruments in Hedges, Liabilities, at Fair Value Derivative Instruments in Hedges, Liabilities, at Fair Value Cash Cash Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Derivative Liability, Fair Value, Gross Liability Derivative Liability, Fair Value, Gross Liability Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] R&D, Regulatory and Commercialization-based Milestone [Member] R&D, Regulatory and Commercialization-based Milestone [Member] R&D, Regulatory and Commercialization-based Milestone [Member] Weighted Average [Member] Weighted Average [Member] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Valuation Technique, Discounted Cash Flow [Member] Valuation Technique, Discounted Cash Flow [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Money Market Funds, at Carrying Value Money Market Funds, at Carrying Value Debt Instrument, Fair Value Disclosure Debt Instrument, Fair Value Disclosure Derivative Asset Derivative Asset Licensing arrangements, asset Licensing arrangements, asset Licensing arrangements, asset Derivative Liability Derivative Liability Business Combination, Contingent Consideration, Liability Licensing arrangements, liability Licensing arrangements, liability Licensing arrangements, liability Financial and Nonfinancial Liabilities, Fair Value Disclosure Financial and Nonfinancial Liabilities, Fair Value Disclosure Discount Rate, Fair Value Input Discount Rate, Fair Value Input Discount Rate, Fair Value Input Assets, Fair Value Disclosure Assets, Fair Value Disclosure Derivative [Table] Derivative [Table] Derivative [Line Items] Derivative [Line Items] Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Derivative Instruments, Gain (Loss) [Table Text Block] Derivative Instruments, Gain (Loss) [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block] Derivatives Not Designated as Hedging Instruments [Table Text Block] Derivatives Not Designated as Hedging Instruments [Table Text Block] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Fair Value Hierarchy and NAV [Domain] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Investments [Abstract] Investment [Table Text Block] Investment [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Supplemental Balance Sheet Information [Abstract] Supplemental Balance Sheet Information. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block] Trade accounts receivable, net [Table Text Block] Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Inventory Disclosure [Table Text Block] Schedule of Inventory, Current [Table Text Block] Property, plant and equipment, net [Table Text Block] Property, Plant and Equipment [Table Text Block] Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Liabilities [Table Text Block] Other long-term liabilities [Table Text Block] Other Noncurrent Liabilities [Table Text Block] Subsequent Events [Abstract] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Short-term Leases [Policy Text Block] Short-term Leases [Policy Text Block] Separation of Lease and Nonlease Components [Policy Text Block] Separation of Lease and Nonlease Components [Policy Text Block] Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments and Tax Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] BTG Spec Pharma [Member] BTG Spec Pharma [Member] BTG Spec Pharma [Member] BTG Interventional Medicine [Member] BTG Interventional Medicine [Member] BTG Interventional Medicine [Member] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Global Endoscopy (Endo) Reporting Unit [Member] Global Endoscopy (Endo) Reporting Unit [Member] Global Endoscopy (Endo) Reporting Unit [Member] Global Urology (Uro) Reporting Unit [Member] Global Urology and Pelvic Health Reporting Unit [Member] Global Urology and Pelvic Health Reporting Unit [Member] Global CRM Reporting Unit [Member] Global CRM Reporting Unit [Member] Global CRM Reporting Unit [Member] Global Electrophysiology (EP) Reporting Unit [Member] Global Electrophysiology (EP) Reporting Unit [Member] Global Electrophysiology (EP) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Global Neuromodulation (NM) Reporting Unit [Member] Global Interventional Cardiology (IC) Reporting Unit [Member] Global Interventional Cardiology (IC) Reporting Unit [Member] Global Interventional Cardiology (IC) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Global Peripheral Interventions (PI) Reporting Unit [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES International [Member] Non-US [Member] EMEA [Member] EMEA [Member] APAC [Member] Asia Pacific [Member] Latin America and Canada [Member] Latin America and Canada [Member] Latin America and Canada [Member] Emerging Markets [Member] Emerging Markets [Member] Emerging Markets [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Emerging Markets total countries Emerging Markets total number of countries Emerging Markets total number of countries Contract with Customer, Liability [Abstract] Contract with Customer, Liability [Abstract] Contract with Customer, Liability Contract with Customer, Liability Change in Contract with Customer, Liability [Abstract] Contract with Customer, Liability, Revenue Recognized Contract with Customer, Liability, Revenue Recognized Accounting Policies [Abstract] ASC Update No. 2016-01, Financial Instruments [Policy Text Block] ASC Update No. 2016-01, Financial Instruments [Policy Text Block] ASC Update No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities [Policy Text Block] Schedule of Weighted Average Number of Shares [Table Text Block] Schedule of Weighted Average Number of Shares [Table Text Block] ACQUISITIONS AND STRATEGIC INVESTMENTS Business Combination Disclosure [Text Block] Disaggregation of Revenue [Table Text Block] Disaggregation of Revenue [Table Text Block] Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Intangible Assets and Goodwill [Table Text Block] Schedule of Goodwill [Table Text Block] Schedule of Goodwill [Table Text Block] INCOME TAXES Income Tax Disclosure [Text Block] Income Statement [Abstract] Net sales Cost of products sold Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Selling, general and administrative expenses Selling, General and Administrative Expense Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Royalty expense Royalty Expense Amortization expense Amortization of Intangible Assets Intangible asset impairment charges Impairment of Intangible Assets (Excluding Goodwill) Contingent consideration expense (benefit) Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Restructuring charges (credits) Restructuring Charges Litigation-related net charges (credits) Litigation Settlement, Expense Operating expenses Operating Expenses Operating income (loss) Operating Income (Loss) Other income (expense): Other Nonoperating Income (Expense) [Abstract] Interest expense Other, net Other Nonoperating Income (Expense) Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax expense (benefit) Income Tax Expense (Benefit) Net income (loss) Net income (loss) per common share — basic Earnings Per Share, Basic Net income (loss) per common share — assuming dilution Earnings Per Share, Diluted Weighted-average shares outstanding Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic Weighted Average Number of Shares Outstanding, Basic Assuming dilution Weighted Average Number of Shares Outstanding, Diluted ASC Update No. 2016-13 [Policy Text Block] ASC Update No. 2016-13 [Policy Text Block] ASC Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments [Policy Text Block] ASC Update No. 2018-15, Internal-Use Software [Policy Text Block] ASC Update No. 2018-15, Internal-Use Software [Policy Text Block] ASC Update No. 2018-15, Internal-Use Software [Policy Text Block] SUPPLEMENTAL BALANCE SHEET INFORMATION Supplemental Balance Sheet Disclosures [Text Block] Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Trade accounts receivable, net Inventories Prepaid income taxes Deferred Tax Assets, Net of Valuation Allowance, Current Other current assets Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Goodwill Other intangible assets, net Other long-term assets TOTAL ASSETS Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Current debt obligations Debt, Current Accounts payable Accounts Payable, Current Accrued expenses Other current liabilities Other Liabilities, Current Total current liabilities Liabilities, Current Long-term debt Long-term Debt and Capital Lease Obligations Deferred income taxes Other long-term liabilities Commitments and contingencies Commitments and Contingencies Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.01 par value - authorized 50,000,000 shares, none issued and outstanding Preferred Stock, Value, Issued Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,641,342,509 shares as of September 30, 2019 and 1,632,148,030 shares as of December 31, 2018 Common Stock, Value, Issued Treasury stock, at cost - 247,566,270 shares as of September 30, 2019 and December 31, 2018 Treasury Stock, Value Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated other comprehensive income (loss), net of tax Total stockholders’ equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity Schedule of Income Tax Rate Reconciliation [Table] Schedule of Income Tax Rate Reconciliation [Table] Schedule of Income Tax Rate Reconciliation [Table] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Schedule of Income Tax Rate Reconciliation [Line Items] Schedule of Income Tax Rate Reconciliation [Line Items] [Line Items] for Schedule of Income Tax Rate Reconciliation [Table] Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block] Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block] Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block] Statement of Cash Flows [Abstract] Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Cash provided by (used for) operating activities Net Cash Provided by (Used in) Operating Activities Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Payments for acquisitions of businesses, net of cash acquired Payments for investments and acquisitions of certain technologies Payments to Acquire Investments Proceeds from divestiture of certain businesses Payments for settlements of hedge contracts Cash provided by (used for) investing activities Net Cash Provided by (Used in) Investing Activities Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Payment of contingent consideration amounts and royalty rights previously established in purchase accounting Business Acquisition Contingent Consideration Cash Payment Business Acquisition Contingent Consideration Cash Payment Payments on short-term borrowings Repayments of Short-term Debt Proceeds from short-term borrowings, net of debt issuance costs Proceeds from Short-term Debt Net increase (decrease) in commercial paper Proceeds from (Repayments of) Commercial Paper Payments on borrowings from credit facilities Repayments of Long-term Lines of Credit Proceeds from borrowings on credit facilities Proceeds from Long-term Lines of Credit Payments on long-term borrowings and debt extinguishment costs Repayments of Long-term Debt Proceeds from long-term borrowings, net of debt issuance costs Proceeds from Issuance of Long-term Debt and Capital Securities, Net Cash used to net share settle employee equity awards Payment to net share settle employee equity awards Payment to net share settle employee equity awards Proceeds from issuances of shares of common stock Proceeds from Issuance of Common Stock Cash provided by (used for) financing activities Net Cash Provided by (Used in) Financing Activities Effect of foreign exchange rates on cash Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period Supplemental Information Supplemental Cash Flow Information [Abstract] Stock-based compensation expense Share-based Compensation Fair value of contingent consideration recorded in purchase accounting Contingent consideration recognized in the period Contingent consideration recognized in the period Loss Contingencies [Table] Loss Contingencies [Table] Non Acquisition Related [Member] Non Acquisition Related [Member] Non Acquisition Related [Member] Upfront Cash [Member] Upfront Cash [Member] Upfront Cash [Member] Maximum Contingent Payment [Member] Maximum Contingent Payment [Member] Maximum Contingent Payment [Member] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Settled Litigation [Member] Settled Litigation [Member] Litigation Case [Axis] Litigation Case [Axis] Litigation Case [Domain] Litigation Case [Domain] Assigned to one judge in MA [Member] Assigned to one judge in MA [Member] Assigned to one judge in MA [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Accrual for legal matters that are probable and estimable Loss Contingency Accrual Restricted Cash and Cash Equivalents in Other current assets Litigation-related net charges (credits) Litigation Settlement Received, Gain Litigation Settlement Received, Gain Litigation Settlement Received, Gain Product liability cases or claims related to mesh product Product liability cases or claims related to mesh product Product liability cases or claims asserted related to mesh products Putative class actions in the U.S., Mesh Putative class actions in the U.S., Mesh Putative class actions in the U.S., Mesh Product liability cases or claims related to mesh product - Canada Product liability cases or claims related to mesh product - Canada Product liability cases or claims related to mesh product - Canada Certified class actions in Canada, Mesh Certified class actions in Canada, Mesh Certified class actions in Canada, Mesh Putative class actions in Canada, Mesh Putative class actions in Canada, Mesh Putative class actions in Canada, Mesh Product liability cases or claims related to mesh product - United Kingdom Product liability cases or claims related to mesh product - United Kingdom Product liability cases or claims related to mesh product - United Kingdom Total Product liability cases and claims settled related to Mesh product Total Product liability cases and claims settled related to Mesh product Total Product liability cases and claims settled related to Mesh product Alleged Breach of Purchase Agreement, Amount Alleged Breach of Purchase Agreement, Amount Alleged Breach of Purchase Agreement, Amount Segment Reporting [Abstract] Number of reportable segments Number of Reportable Segments Reconciliation of Revenue from Segments to Consolidated [Table] Reconciliation of Revenue from Segments to Consolidated [Table] Segments [Axis] Segments [Axis] Segment [Domain] Segments [Domain] MedSurg [Member] MedSurg [Member] MedSurg [Member] Rhythm and Neuro [Member] Rhythm and Neuro [Member] Rhythm and Neuro [Member] Cardiovascular [Member] Cardiovascular [Member] Cardiovascular [Member] Excludes BTG Acquisition [Member] Excludes BTG Acquisition [Member] Excludes BTG Acquisition [Member] Corporate expenses and currency exchange [Member] Corporate Expenses including hedging activities [Member] Corporate Expenses including hedging activities [Member] Special Charges [Member] Special Charges [Member] Segment Reporting, Revenue Reconciling Item [Line Items] Segment Reporting, Revenue Reconciling Item [Line Items] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract] Operating Income Allocated to Reportable Segments Operating Income Allocated to Reportable Segments Operating Income Allocated to Reportable Segments Reconciliation of Operating Profit (Loss) from Segments to Consolidated Operating Income Unallocated to Segment Operating Income Unallocated to Segment Amortization expense Operating income (loss) Other expense, net Nonoperating Income (Expense) Segment Operating Income as a Percentage of Net Sales Segment Operating Income as a Percentage of Net Sales Segment Operating Income as a Percentage of Net Sales Schedule of Investments [Table] Schedule of Investments [Table] Schedule of Investments [Line Items] Schedule of Investments [Line Items] Business Combination, Consideration Transferred Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Equity Method Investment, Difference Between Carrying Amount and Underlying Equity Equity method investments Equity Method Investments Measurement alternative investments (1) Equity Securities without Readily Determinable Fair Value, Amount Notes receivable Debt Securities, Available-for-sale Investments Investments COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Lessee Supplemental Balance Sheet Information [Table Text Block] Weighted average remaining lease term and discount rate [Table Text Block] Lease, Cost [Table Text Block] Supplemental Cash Flow Information Related to Leases [Table Text Block] Supplemental Cash Flow Information Related to Leases [Table Text Block] Supplemental Cash Flow Information Related to Leases [Table Text Block] Maturities of Lease Liabilities [Table Text Block] Maturities of Lease Liabilities [Table Text Block] Maturities of Lease Liabilities [Table Text Block] Revenue from Contract with Customer [Text Block] Revenue from Contract with Customer [Text Block] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] revenue-based payments [Member] revenue-based payments [Member] revenue-based payments [Member] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract] Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract] Business Combination, Contingent Consideration, Liability Beginning Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Payment of contingent consideration Payment of contingent consideration Payment of contingent consideration Business Combination, Contingent Consideration, Liability Ending Balance Business Combination, Contingent Consideration Arrangements [Abstract] Business Combination, Contingent Consideration Arrangements [Abstract] Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract] contingent consideration liability, probability of payment contingent consideration liability, probability of payment contingent consideration liability, probability of payment LEASES Leases of Lessee Disclosure [Text Block] Description of New Accounting Pronouncements Not yet Adopted [Text Block] Description of New Accounting Pronouncements Not yet Adopted [Text Block] BORROWINGS AND CREDIT ARRANGEMENTS Debt Disclosure [Text Block] Lessee, Leases [Policy Text Block] Lessee, Leases [Policy Text Block] Subsequent Events, Policy [Policy Text Block] Subsequent Events, Policy [Policy Text Block] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items] Cash and Cash Equivalents Restricted Cash Equivalents in Other long-term assets Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Trade accounts receivable, net Accounts, Notes, Loans and Financing Receivable, Net, Current [Abstract] Accounts receivable Accounts Receivable, Gross, Current Less: allowance for doubtful accounts Allowance for Doubtful Accounts Receivable, Current Trade accounts receivable, net Allowance for doubtful accounts SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Beginning balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Charges to expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Utilization of allowances SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Ending balance Inventories Inventory, Net [Abstract] Inventory, Finished Goods, Net of Reserves Inventory, Finished Goods, Net of Reserves Inventory, Work in Process, Net of Reserves Inventory, Work in Process, Net of Reserves Inventory, Raw Materials, Net of Reserves Inventory, Raw Materials, Net of Reserves Inventories Property, plant and equipment, net Property, Plant and Equipment, Net [Abstract] Land Land Buildings and improvements Buildings and Improvements, Gross Equipment, furniture and fixtures Equipment, furniture and fixtures Gross Equipment, furniture and fixtures Gross. Capital in progress Construction in Progress, Gross Property, plant and equipment Property, Plant and Equipment, Gross Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Supplemental Balance Sheet Information Supplemental Balance Sheet Information (Textuals) [Abstract] Supplemental Balance Sheet Information. Depreciation expense Depreciation Accrued expenses Accrued Liabilities, Current [Abstract] Legal reserves, current Estimated Litigation Liability, Current Payroll and related liabilities Employee-related Liabilities, Current Accrued Rebates, Current Accrued Rebates, Current Accrued Rebates, Current Business Combination, Contingent Consideration, Liability, Current Business Combination, Contingent Consideration, Liability, Current Other Other Accrued Liabilities, Current Accrued expenses Other long-term liabilities Other Liabilities, Noncurrent [Abstract] Accrued income taxes Accrued Income Taxes, Noncurrent Legal reserves, noncurrent Estimated Litigation Liability, Noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Business Combination, Contingent Consideration, Liability, Noncurrent Other Accrued Liabilities, Noncurrent Other Accrued Liabilities, Noncurrent Other long-term liabilities Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Condensed Consolidated Balance Sheet (Parenthetical) [Abstract] Preferred Stock, Par or Stated Value Per Share Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Preferred Stock, Shares Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Preferred Stock, Shares Outstanding Common Stock, Par or Stated Value Per Share Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Common Stock, Shares, Outstanding Treasury Stock, Shares Treasury Stock, Shares Debt Instrument [Table] Schedule of Long-term Debt Instruments [Table] Three-Year Delayed Draw Term Loan [Member] Three-Year Delayed Draw Term Loan [Member] Three-Year Delayed Draw Term Loan [Member] Two-Year Delayed Draw Term Loan [Member] Two-Year Delayed Draw Term Loan [Member] Two-Year Delayed Draw Term Loan [Member] Aggregate Senior Unsecured Delayed Draw Term Loan [Member] Aggregate Senior Unsecured Delayed Draw Term Loan [Member] Aggregate Senior Unsecured Delayed Draw Term Loan [Member] Yen Denominated Factoring Arrangements [Member] Yen Denominated Factoring Arrangements [Member] Yen denominated factoring arrangements. Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Euro Denominated Factoring Arrangements [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] February2019AggregateOffering [Member] February2019AggregateOffering [Member] February2019AggregateOffering [Member] January 2020 Notes [Member] January 2020 Notes [Member] January 2020 Notes [Member] May 2020 Notes [Member] May 2020 Notes [Member] May 2020 Notes [Member] Tender Offer [Member] Tender Offer [Member] Cash Tender Offer [Member] August 2021 Term Loan [Member] August 2021 Term Loan [Member] August 2021 Term Loan [Member] May 2022 Notes [Member] May 2022 Notes [Member] May 2022 Notes [Member] August 2022 Term Loan [Member] August 2022 Term Loan [Member] August 2022 Term Loan [Member] October 2023 Notes [Member] October 2023 Notes [Member] October 2023 Notes [Member] March 2024 Notes [Member] March 2024 Notes [Member] March 2024 Notes [Member] May 2025 Notes [Member] May 2025 Notes [Member] May 2025 Notes [Member] March 2026 Notes [Member] March 2026 Notes [Member] March 2026 Notes [Member] March 2028 Notes [Member] March 2028 Notes [Member] March 2028 Notes [Member] March 2029 Notes [Member] March 2029 Notes [Member] March 2029 Notes [Member] November 2035 Notes [Member] November 2035 Notes [Member] November 2035 Notes [Member] March 2039 Notes [Member] March 2039 Notes [Member] March 2039 Notes [Member] January 2040 Notes [Member] January 2040 Notes [Member] January 2040 Notes [Member] March 2049 Notes [Member] March 2049 Notes [Member] March 2049 Notes [Member] Unamortized Gain on Fair Value Hedges Interest Rate Swap [Member] Finance Lease Obligation (1) Capital Lease Obligations [Member] Senior Notes [Member] Senior Notes [Member] Unsecured Debt [Member] Unsecured Debt [Member] Debt Instrument, Redemption, Period Two [Member] Debt Instrument, Redemption, Period Two [Member] Debt Instrument, Redemption, Period Three [Member] Debt Instrument, Redemption, Period Three [Member] Lender Name [Axis] Lender Name [Axis] Line of Credit Facility, Lender [Domain] Line of Credit Facility, Lender [Domain] the 2018 Facility [Member] the 2018 Facility [Domain] the 2018 Facility Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Revolving Credit Facility [Member] Revolving Credit Facility [Member] Covenant [Axis] Covenant [Axis] Covenant. Covenant [Domain] Covenant [Domain] Covenant. Current Requirement [Member] Current Requirement [Member] Current Requirement. Current Requirement [Member] Covenant Requirement [Domain] Covenant Requirement [Domain] Requirement, first two quarters following qualified acquisition [Member] Requirement, first two quarters following qualified acquisition [Member] Requirement, first two quarters following qualified acquisition [Member] Actual, Covenant [Member] Actual, Covenant [Member] Actual Covenant. Requirement, third quarter following qualified acquisition [Member] Requirement, third quarter following qualified acquisition [Member] Requirement, third quarter following qualified acquisition [Member] Requirement, fourth quarter following qualified acquisition [Member] Requirement, fourth quarter following qualified acquisition [Member] Requirement, fourth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Requirement, fifth quarter following qualified acquisition [Member] Requirement, sixth quarter and thereafter following qualified acquisition [Member] Requirement, sixth quarter and thereafter following qualified acquisition [Member] Requirement, sixth quarter and thereafter following qualified acquisition [Member] August 2019 Term Loan [Member] August 2019 Term Loan [Member] August 2019 Term Loan [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Total debt Debt and Capital Lease Obligations Long-term Debt Long-term Debt Long-term Debt and Capital Lease Obligations Maximum Leverage Ratio Maximum Leverage Ratio Maximum leverage ratio permitted by revolving credit facility agreement. Debt Instrument, Interest Rate, Stated Percentage Debt Instrument, Interest Rate, Stated Percentage Extinguishment of Debt, Amount Extinguishment of Debt, Amount Short-term Debt Short-term Debt Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt, Current Line of Credit Facility, Maximum Borrowing Capacity Line of Credit Facility, Maximum Borrowing Capacity Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Exclusion from EBITDA for Restructuring Charges Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA Restructuring charges remaining to be excluded from calculation of consolidated EBITDA. Litigation and Debt Exclusion from EBITDA Litigation and Debt Exclusion from EBITDA Exclusion of litigation payments and any debt Issued to fund tax deficiency payments Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Legal payments remaining to be excluded from calculation of consolidated EBITDA Commercial Paper Commercial Paper Maximum Commercial Paper Outstanding with 2017 Facility Maximum Commercial Paper Outstanding with 2018 Facility Maximum Commercial Paper Outstanding with 2018 Facility Line of Credit Facility, Remaining Borrowing Capacity Line of Credit Facility, Remaining Borrowing Capacity Weighted Average Maturity, Days Weighted Average Maturity, Days Weighted Average Maturity, Days Short-term Debt, Weighted Average Interest Rate, at Point in Time Short-term Debt, Weighted Average Interest Rate, at Point in Time Long-term Line of Credit Long-term Line of Credit Debt Instrument, Interest Rate During Period Debt Instrument, Interest Rate During Period Transfers and Servicing of Financial Assets [Abstract] Transfers and Servicing of Financial Assets [Abstract] Transfer of Financial Assets Accounted for as Sales [Table] Transfer of Financial Assets Accounted for as Sales [Table] Transfer of Financial Assets Accounted for as Sales [Line Items] Transfer of Financial Assets Accounted for as Sales [Line Items] Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Transfer of Financial Assets Accounted for as Sales, Amount Derecognized Average interest rate of de-recognized receivables Receivable with Imputed Interest, Effective Yield (Interest Rate) Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Weighted Average Number of Shares Outstanding, Basic Weighted Average Number Diluted Shares Outstanding Adjustment Weighted Average Number Diluted Shares Outstanding Adjustment Weighted Average Number of Shares Outstanding, Diluted Stock Issued During Period, Shares, New Issues Stock Issued During Period, Shares, New Issues Schedule of Intangible Assets and Goodwill [Table] Schedule of Intangible Assets and Goodwill [Table] Schedule of Intangible Assets and Goodwill [Table] Intangible Assets [Axis] Intangible Assets [Axis] Intangible Assets [Axis] Intangible Assets [Domain] Intangible Assets [Domain] [Domain] for Intangible Assets [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Patents [Member] Patents [Member] Indefinite-lived Intangible Assets by Major Class [Axis] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Goodwill [Member] Goodwill [Member] In Process Research and Development [Member] Statement, Business Segments [Axis] Global Neuromodulation (NM) Reporting Unit [Member] Intangible Assets and Goodwill [Line Items] Intangible Assets and Goodwill [Line Items] [Line Items] for Schedule of Intangible Assets and Goodwill [Table] Impairment of Intangible Assets (Excluding Goodwill) Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Gross Finite-Lived Intangible Assets, Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Goodwill, Gross Goodwill, Gross Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-lived Intangible Assets (Excluding Goodwill) Indefinite-lived intangible assets, including goodwill Indefinite-lived intangible assets, including goodwill indefinite-lived intangible assets including goodwill Goodwill, Impaired, Accumulated Impairment Loss Goodwill, Impaired, Accumulated Impairment Loss Indefinite-lived intangible assets and goodwill, accumulated write-offs Indefinite-lived intangible assets, accumulated write-offs Indefinite-lived intangible assets, accumulated write-offs Goodwill [Roll Forward] Goodwill [Roll Forward] Goodwill Beginning Balance Goodwill, Translation and Purchase Accounting Adjustments Goodwill, Translation and Purchase Accounting Adjustments Goodwill Ending Balance Goodwill, Written off Related to Sale of Business Unit Goodwill, Written off Related to Sale of Business Unit SEGMENT REPORTING Segment Reporting Disclosure [Text Block] EX-101.PRE 10 bsx-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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� 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ *#1E3_'P132W 0 T@, !D ( !WSD M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ M*#1E3[O8K8JV 0 T@, !D ( !J3\ 'AL+W=O&PO=V]R:W-H965TKBMP$ -(# 9 " 7)) !X;"]W;W)K&UL4$L! A0#% @ *#1E3V_JO@BS 0 T@, !D M ( !8$L 'AL+W=O&PO=V]R:W-H M965T&UL4$L! M A0#% @ *#1E3S0CUVO! 0 -P0 !D ( !\%$ 'AL M+W=O;&PO=V]R:W-H965T&UL4$L! A0#% @ *#1E M3U^6*KL$ @ $ 8 !D ( !TE< 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *#1E3QH/.1GA 0 04 M !D ( !75X 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *#1E3W^VGK&R 0 T@, !D M ( !3F0 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ *#1E3[Z\)&3C 0 >04 !D ( !$VH 'AL+W=O MN#JAQ,, #9 M4@ &0 @ $M; >&PO=V]R:W-H965T&UL4$L! A0#% @ *#1E3Z:V M_W, @ S04 !D ( !'GT 'AL+W=O&PO=V]R:W-H965T6$ !X;"]W;W)K&UL4$L! A0#% @ *#1E3X8%4ZZ8" LSL !D M ( !59 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ *#1E3^E$O.A7 @ P0< !D ( ! M_:( 'AL+W=O&PO=V]R:W-H965T ( " ( 9 M " 6FI !X;"]W;W)K&UL4$L! A0#% M @ *#1E3S+^I#3U! DAH !D ( !&*P 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *#1E3[!#\DH\ MQ0 .SL# !0 ( !CKT 'AL+W-H87)E9%-T&UL M4$L! A0#% @ *#1E3QA[NVAA @ 6@P T ( !_((! M 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% @ *#1E M3V4-O+_] 0 #2( !H ( !.XH! 'AL+U]R96QS+W=OHX! end XML 13 R21.htm IDEA: XBRL DOCUMENT v3.19.3
Changes in Other Comprehensive Income
 9 Months Ended
Sep. 30, 2019
Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]  
Comprehensive Income (Loss) Note [Text Block]
NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME

The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax:
(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of June 30, 2019
$
(46
)
 
$
150

 
$
—

 
$
(26
)
 
$
78

Other comprehensive income (loss) before reclassifications
7

 
78

 
—

 
—

 
86

(Income) loss amounts reclassified from accumulated other comprehensive income
(9
)
 
(16
)
 
—

 
—

 
(26
)
Total other comprehensive income (loss)
(2
)
 
62

 
—

 
—

 
60

Balance as of September 30, 2019
$
(48
)
 
$
213

 
$
—

 
$
(26
)
 
$
138



(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of June 30, 2018
$
(68
)
 
$
79

 
$
—

 
$
(27
)
 
$
(16
)
Other comprehensive income (loss) before reclassifications
2

 
45

 
—

 
—

 
47

(Income) loss amounts reclassified from accumulated other comprehensive income
(8
)
 
1

 
—

 
—

 
(7
)
Total other comprehensive income (loss)
(6
)
 
47

 
—

 
—

 
40

Balance as of September 30, 2018
$
(74
)
 
$
126

 
$
—

 
$
(27
)
 
$
25



(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of December 31, 2018
$
(53
)
 
$
111

 
$
—

 
$
(25
)
 
$
33

Other comprehensive income (loss) before reclassifications
30

 
136

 
—

 
(1
)
 
165

(Income) loss amounts reclassified from accumulated other comprehensive income
(25
)
 
(34
)
 
—

 
—

 
(59
)
Total other comprehensive income (loss)
4

 
102

 
—

 
(1
)
 
105

Balance as of September 30, 2019
$
(48
)
 
$
213

 
$
—

 
$
(26
)
 
$
138


(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of December 31, 2017
$
(32
)
 
$
1

 
$
(1
)
 
$
(27
)
 
$
(59
)
Other comprehensive income (loss) before reclassifications
(29
)
 
105

 
—

 
—

 
76

(Income) loss amounts reclassified from accumulated other comprehensive income
(13
)
 
20

 
1

 
—

 
8

Total other comprehensive income (loss)
(42
)
 
125

 
—

 
—

 
82

Balance as of September 30, 2018
$
(74
)
 
$
126

 
$
—

 
$
(27
)
 
$
25



Refer to Note D – Hedging Activities and Fair Value Measurements for further detail on our net investment hedges recorded in Foreign currency translation adjustments and our cash flow hedges recorded in Net change in derivative financial instruments.

As a result of adopting ASC Update No. 2016-01 in the first quarter of 2018, we recorded a cumulative effect adjustment to retained earnings to reclassify unrealized gains and losses from our equity investments previously recorded to Accumulated other comprehensive income (loss), net of tax. These equity investments were classified as available-for-sale securities under the former accounting guidance, and we now refer to these investments as publicly-held equity securities. Please refer to Note A – Significant Accounting Policies included in Item 8 of our most recent Annual Report on Form 10-K for more information.

The Net change in defined benefit pensions and other items before reclassifications and reclassified from Accumulated other comprehensive income (loss), net of tax were reduced by immaterial income tax impacts in the third quarter and first nine months of 2019 and 2018.
XML 14 R25.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Leases (Policies)
 9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
Short-term Leases [Policy Text Block] Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases).
Separation of Lease and Nonlease Components [Policy Text Block] For leases executed in 2019 and later, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases.
XML 15 R29.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions (Tables)
 9 Months Ended
Sep. 30, 2019
2019 Acquisitions [Member]  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block]
(in millions)
 
Payments for acquisitions, net of cash acquired
$
763

Fair value of contingent consideration
127

Fair value of prior interests
102

 
$
992
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
(in millions)
 
Goodwill
$
575

Amortizable intangible assets
220

Indefinite-lived intangible assets
240

Other assets acquired
24

Liabilities assumed
(12
)
Net deferred tax liabilities
(56
)
 
$
992
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
Technology-related
$
210

 
12
 
15%
Other intangible assets
10

 
12
 
15%
Indefinite-lived intangible assets:
 
 
 
 
 
In-process research and development (IPR&D)
240

 
N/A
 
19%
 
$
461

 
 
 
 
2018 Acquisitions [Member]  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block] The components of the aggregate purchase prices are as follows for our 2018 acquisitions as of September 30, 2019:
(in millions)
 
Payments for acquisitions, net of cash acquired
$
969

Fair value of contingent consideration
190

Fair value of prior interests
251

 
$
1,410
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
(in millions)
 
Goodwill
$
618

Amortizable intangible assets
707

Indefinite-lived intangible assets
213

Other assets acquired
19

Liabilities assumed
(14
)
Net deferred tax liabilities
(134
)
 
$
1,410
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
 
 
 
 
Technology-related
$
697

 
10
-
14
 
17
%
-
23%
Other intangible assets
10

 
6
-
13
 
13
%
-
15%
Indefinite-lived intangible assets:
 
 
 
 
 
 
 
 
 
IPR&D
213

 
N/A
 
15%
 
$
920

 
 
 
 
 
 
 
 
BTG Acquisition [Member]  
Business Acquisition [Line Items]  
Business Acquisition, Pro Forma Information [Table Text Block]

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions, except per share data)
2019
 
2018
 
2019
 
2018
Net sales
$
2,795

 
$
2,561

 
$
8,237

 
$
7,740

Net income (loss)
152

 
332

 
599

 
950

Net income (loss) per common share — basic
$
0.11

 
$
0.24

 
$
0.43

 
$
0.69

Net income (loss) per common share — assuming dilution
$
0.11

 
$
0.24

 
$
0.42

 
$
0.68
Schedule of Business Acquisitions, by Acquisition [Table Text Block] The preliminary BTG Acquisition purchase price was comprised of the amounts presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed from the BTG Acquisition. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period as required by FASB ASC Topic 805. As of September 30, 2019, the valuation studies necessary to determine the fair market value of the assets acquired and liabilities assumed are preliminary, including the projection of the underlying cash flows used to determine the fair value of the identified tangible, intangible and financial assets and liabilities. Given the size and breadth of the BTG Acquisition, we anticipate that the purchase price allocation will take longer than prior acquisitions and potentially up to the one year allowed under FASB ASC Topic 805 to adequately analyze all the factors used in establishing the fair value of assets acquired and liabilities assumed as of the acquisition date, including, but not limited to, intangible assets, inventories, financial assets, real and personal property, leases, certain assumed liabilities, including reserves and deferred revenues, tax-related items, and the related tax and foreign currency effects of any changes made.

Any potential adjustments made could be material in relation to the preliminary values presented below:
(in millions)
 
Payment for acquisition, net of cash acquired
$
3,619
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
The following summarizes the BTG Acquisition preliminary purchase price allocation as of September 30, 2019:
(in millions)
 
Goodwill
$
1,549

Trade accounts receivable, net
107

Inventories
205

Other current assets
259

Other intangible assets, net
1,869

Other long-term assets
604

Accrued expenses and other current liabilities
(305
)
Other long-term liabilities
(289
)
Deferred tax liability
(380
)
 
$
3,619
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
We allocated a portion of the BTG Acquisition preliminary purchase price to specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
 
 
 
 
Technology-related
$
1,794

 
10
-
17
 
10
%
-
12%
Other intangible assets
75

 
2
-
11
 
11%
 
$
1,869

 
 
 
 
 
 
 
 
Schedule of Defined Benefit Plans Disclosures [Table Text Block]
The following assumptions were used to measure the fair value of the benefit obligation and associated plan assets:
 
Discount Rate
 
Expected Return on Plan Assets
 
Rate of Compensation Increase
U.K. Plan
0.4%
 
0.4%
 
3.4%
Schedule of Net Funded Status [Table Text Block]
As of the measurement date of August 19, 2019, the funded status recognized in our unaudited condensed consolidated balance sheets was as follows:
(in millions)
 
Fair value of plan assets
$
213

Benefit obligation
(216
)
Funded status
$
(3
)
XML 16 R48.htm IDEA: XBRL DOCUMENT v3.19.3
Borrowings and Credit Arrangements (Details) - USD ($)
$ in Millions
 9 Months Ended 12 Months Ended
Feb. 25, 2019
Sep. 30, 2019
Dec. 31, 2018
Oct. 22, 2019
Aug. 19, 2019
Dec. 19, 2018
Sep. 30, 2018
Debt Instrument [Line Items]              
Total debt   $ 10,888 $ 7,056        
Restricted Cash and Cash Equivalents in Other current assets   357 655       $ 781
Long-term Debt and Capital Lease Obligations   9,590 4,803        
Debt, Current   1,297 2,253        
Exclusion from EBITDA for Restructuring Charges   500          
Restructuring charges remaining to be excluded from calculation of consolidated EBITDA   314          
Litigation and Debt Exclusion from EBITDA   2,624          
Legal payments remaining to be excluded from calculation of consolidated EBITDA   1,262          
Commercial Paper [Member]              
Debt Instrument [Line Items]              
Commercial Paper   1,293 1,248        
Maximum Commercial Paper Outstanding with 2017 Facility   2,750 2,750        
Line of Credit Facility, Remaining Borrowing Capacity   $ 1,457 $ 1,502        
Weighted Average Maturity, Days   40 days 27 days        
Short-term Debt, Weighted Average Interest Rate, at Point in Time   2.43% 3.04%        
August 2019 Term Loan [Member]              
Debt Instrument [Line Items]              
Extinguishment of Debt, Amount   $ 1,000          
Short-term Debt     $ 1,000        
Current Requirement [Member]              
Debt Instrument [Line Items]              
Maximum Leverage Ratio   4.75          
Current Requirement [Member]              
Debt Instrument [Line Items]              
Maximum Leverage Ratio   3.75          
Requirement, first two quarters following qualified acquisition [Member]              
Debt Instrument [Line Items]              
Maximum Leverage Ratio   4.75          
Actual, Covenant [Member]              
Debt Instrument [Line Items]              
Maximum Leverage Ratio   4.27          
Requirement, third quarter following qualified acquisition [Member]              
Debt Instrument [Line Items]              
Maximum Leverage Ratio   4.50          
Requirement, fourth quarter following qualified acquisition [Member]              
Debt Instrument [Line Items]              
Maximum Leverage Ratio   4.25          
Requirement, fifth quarter following qualified acquisition [Member]              
Debt Instrument [Line Items]              
Maximum Leverage Ratio   4.00          
Requirement, sixth quarter and thereafter following qualified acquisition [Member]              
Debt Instrument [Line Items]              
Maximum Leverage Ratio   3.75          
the 2018 Facility [Member] | Revolving Credit Facility [Member]              
Debt Instrument [Line Items]              
Line of Credit Facility, Maximum Borrowing Capacity   $ 2,750 2,750        
February2019AggregateOffering [Member]              
Debt Instrument [Line Items]              
Long-term Debt $ 4,300            
January 2020 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 0 $ 850        
Debt Instrument, Interest Rate, Stated Percentage   6.00% 6.00%        
Extinguishment of Debt, Amount 850            
May 2020 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 0 $ 600        
Debt Instrument, Interest Rate, Stated Percentage   2.85% 2.85%        
Extinguishment of Debt, Amount $ 600            
August 2021 Term Loan [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 1,000 $ 0        
May 2022 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 500 $ 500        
Debt Instrument, Interest Rate, Stated Percentage   3.375% 3.375%        
August 2022 Term Loan [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 1,000 $ 0        
October 2023 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 450 $ 450        
Debt Instrument, Interest Rate, Stated Percentage   4.125% 4.125%        
March 2024 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 850 $ 0        
Debt Instrument, Interest Rate, Stated Percentage   3.45%          
May 2025 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 750 $ 750        
Debt Instrument, Interest Rate, Stated Percentage   3.85% 3.85%        
March 2026 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 850 $ 0        
Debt Instrument, Interest Rate, Stated Percentage   3.75%          
March 2028 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 1,000 $ 1,000        
Debt Instrument, Interest Rate, Stated Percentage   4.00% 4.00%        
March 2029 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 850 $ 0        
Debt Instrument, Interest Rate, Stated Percentage   4.00%          
November 2035 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 350 $ 350        
Debt Instrument, Interest Rate, Stated Percentage   7.00% 7.00%        
March 2039 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 750 $ 0        
Debt Instrument, Interest Rate, Stated Percentage   4.55%          
January 2040 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 300 $ 300        
Debt Instrument, Interest Rate, Stated Percentage   7.375% 7.375%        
March 2049 Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   $ 1,000 $ 0        
Debt Instrument, Interest Rate, Stated Percentage   4.70%          
Unamortized Gain on Fair Value Hedges              
Debt Instrument [Line Items]              
Long-term Debt   $ 14 26        
Finance Lease Obligation (1)              
Debt Instrument [Line Items]              
Long-term Debt   6 6        
Senior Notes [Member]              
Debt Instrument [Line Items]              
Long-term Debt   7,650 4,800        
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net   $ (79) (29)        
Three-Year Delayed Draw Term Loan [Member]              
Debt Instrument [Line Items]              
Debt Instrument, Interest Rate During Period   3.47%          
Three-Year Delayed Draw Term Loan [Member] | Debt Instrument, Redemption, Period Three [Member]              
Debt Instrument [Line Items]              
Long-term Line of Credit         $ 1,000 $ 1,000  
Two-Year Delayed Draw Term Loan [Member]              
Debt Instrument [Line Items]              
Debt Instrument, Interest Rate During Period   3.37%          
Two-Year Delayed Draw Term Loan [Member] | Debt Instrument, Redemption, Period Two [Member]              
Debt Instrument [Line Items]              
Long-term Line of Credit         $ 1,000 1,000  
Aggregate Senior Unsecured Delayed Draw Term Loan [Member] | Unsecured Debt [Member]              
Debt Instrument [Line Items]              
Long-term Line of Credit           $ 2,000  
Yen Denominated Factoring Arrangements [Member]              
Transfer of Financial Assets Accounted for as Sales [Line Items]              
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   $ 210 $ 195        
Average interest rate of de-recognized receivables   0.60% 0.90%        
Euro Denominated Factoring Arrangements [Member]              
Transfer of Financial Assets Accounted for as Sales [Line Items]              
Transfer of Financial Assets Accounted for as Sales, Amount Derecognized   $ 146 $ 165        
Average interest rate of de-recognized receivables   1.70% 2.70%        
Subsequent Event [Member] | Tender Offer [Member]              
Debt Instrument [Line Items]              
Long-term Debt       $ 1,000      
XML 17 R44.htm IDEA: XBRL DOCUMENT v3.19.3
Contingent Consideration (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Jun. 11, 2019
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]            
Business Combination, Contingent Consideration, Liability Beginning Balance     $ 347      
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases     127      
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred     (16)      
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability $ 8 $ (13) (9) $ (12)    
Payment of contingent consideration     (68)      
Business Combination, Contingent Consideration, Liability Ending Balance 380   380      
Business Combination, Contingent Consideration Arrangements [Abstract]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High         $ 747  
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]            
Business Combination, Contingent Consideration, Liability 380   347   380  
Vertiflex, Inc. [Member]            
Business Combination, Contingent Consideration Arrangements [Abstract]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High           $ 100
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low           $ 0
Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]            
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]            
Business Combination, Contingent Consideration, Liability Ending Balance 220   220      
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]            
Business Combination, Contingent Consideration, Liability 220   220   220  
Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]            
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]            
Business Combination, Contingent Consideration, Liability Ending Balance 160   160      
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]            
Business Combination, Contingent Consideration, Liability $ 160   $ 160   $ 160  
Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]            
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]            
contingent consideration liability, probability of payment         50.00%  
Discount Rate, Fair Value Input     2.00%      
Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]            
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]            
contingent consideration liability, probability of payment         60.00%  
Discount Rate, Fair Value Input     11.00%      
Maximum [Member]            
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]            
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability     $ (126)      
Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]            
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]            
contingent consideration liability, probability of payment         90.00%  
Discount Rate, Fair Value Input     3.00%      
Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]            
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]            
contingent consideration liability, probability of payment         100.00%  
Discount Rate, Fair Value Input     15.00%      
Weighted Average [Member] | Valuation Technique, Discounted Cash Flow [Member] | R&D, Regulatory and Commercialization-based Milestone [Member]            
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]            
contingent consideration liability, probability of payment         84.00%  
Discount Rate, Fair Value Input     3.00%      
Weighted Average [Member] | Valuation Technique, Discounted Cash Flow [Member] | revenue-based payments [Member]            
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]            
contingent consideration liability, probability of payment         99.00%  
Discount Rate, Fair Value Input     13.00%      
XML 18 R40.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue (Tables)
 9 Months Ended
Sep. 30, 2019
Disaggregation of Revenue [Abstract]  
Disaggregation of Revenue [Table Text Block] The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Businesses
2019
 
2018
 
2019
 
2018
Endoscopy
 
 
 
 
 
 
 
U.S.
$
277

 
$
247

 
$
800

 
$
724

International
209

 
196

 
596

 
580

Worldwide
486

 
443

 
1,396

 
1,304

 
 
 
 
 
 
 
 
Urology and Pelvic Health
 
 
 
 
 
 
 
U.S.
257

 
214

 
737

 
623

International
102

 
89

 
297

 
280

Worldwide
359

 
303

 
1,033

 
904

 
 
 
 
 
 
 
 
Cardiac Rhythm Management
 
 
 
 
 
 
 
U.S.
284

 
289

 
860

 
869

International
194

 
186

 
607

 
594

Worldwide
478

 
475

 
1,467

 
1,462

 
 
 
 
 
 
 
 
Electrophysiology
 
 
 
 
 
 
 
U.S.
38

 
37

 
113

 
111

International
43

 
39

 
132

 
119

Worldwide
81

 
76

 
245

 
230

 
 
 
 
 
 
 
 
Neuromodulation
 
 
 
 
 
 
 
U.S.
183

 
155

 
487

 
446

International
39

 
34

 
125

 
113

Worldwide
222

 
189

 
612

 
559

 
 
 
 
 
 
 
 
Interventional Cardiology
 
 
 
 
 
 
 
U.S.
327

 
283

 
942

 
859

International
373

 
332

 
1,126

 
1,062

Worldwide
700

 
615

 
2,067

 
1,922

 
 
 
 
 
 
 
 
Peripheral Interventions
 
 
 
 
 
 
 
U.S.
155

 
152

 
466

 
449

International
156

 
142

 
475

 
436

Worldwide
311

 
293

 
942

 
885

 
 
 
 
 
 
 
 
BTG Acquisition(1)
 
 
 
 
 
 
 
Interventional Medicine
48

 
 n/a

 
48

 
 n/a

Specialty Pharmaceuticals
23

 
 n/a

 
23

 
 n/a

Worldwide
71

 
n/a

 
71

 
n/a

 
 
 
 
 
 
 
 
Net Sales
$
2,707

 
$
2,393

 
$
7,831

 
$
7,262

(1)
For the first nine months of 2019, there have been no changes to our internal reporting structure, and accordingly, we have not revised our segment reporting or geographic presentation. We will continue to integrate the BTG Acquisition into our operations in the fourth quarter and will reassess our operating and reportable segments as well as geographic presentation for any changes related to our internal reporting structure as well as to the information regularly reviewed by the CODM. To the extent any changes in our operating and reportable segments are identified, these will be reflected in our segment reporting information in the period in which the change occurs. Our results of operations include the results of BTG following the acquisition date of August 19, 2019. BTG net sales are substantially U.S. based.

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Geographic Regions (Excluding BTG Acquisition)
2019
 
2018
 
2019
 
2018
U.S.
$
1,521

 
$
1,375

 
$
4,402

 
$
4,078

EMEA (Europe, Middle East and Africa)
530

 
498

 
1,662

 
1,619

APAC (Asia-Pacific)
484

 
425

 
1,402

 
1,282

Latin America and Canada
101

 
94

 
293

 
282

BTG Acquisition(1) (Worldwide)
71

 
n/a

 
71

 
n/a

Net Sales
$
2,707

 
$
2,393

 
$
7,831

 
$
7,262

 
 
 
 
 
 
 
 
Emerging Markets(2) (Excluding BTG Acquisition)
$
310

 
$
267

 
$
925

 
$
812


(1)
Our results of operations include the results of BTG following the acquisition date of August 19, 2019. BTG net sales are substantially U.S. based.
(2)
We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam. We have revised prior year amounts to the current year’s presentation. The revision had an immaterial impact on prior year Emerging Markets sales.

XML 19 R51.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Effective Income Tax Rate Reconciliation, Percent [Abstract]          
Unrecognized Tax Benefits $ 405   $ 405   $ 427
Unrecognized Tax Benefits that Would Impact Effective Tax Rate $ 320   $ 320   $ 332
Effective tax rate from continuing operations (38.70%) 5.30% (1.60%) (14.10%)  
Decrease in Unrecognized Tax Benefits is Reasonably Possible $ 99   $ 99    
XML 20 R55.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
units
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
units
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
Disaggregation of Revenue [Line Items]          
Emerging Markets total countries | units 20   20    
Revenue from Contract with Customer, Excluding Assessed Tax $ 2,707 $ 2,393 $ 7,831 $ 7,262  
Contract with Customer, Liability [Abstract]          
Contract with Customer, Liability 398   398   $ 373
Change in Contract with Customer, Liability [Abstract]          
Contract with Customer, Liability, Revenue Recognized 35   107    
United States          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 1,521 1,375 4,402 4,078  
EMEA [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 530 498 1,662 1,619  
APAC [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 484 425 1,402 1,282  
Latin America and Canada [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 101 94 293 282  
Emerging Markets [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 310 267 925 812  
Global Endoscopy (Endo) Reporting Unit [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 486 443 1,396 1,304  
Global Endoscopy (Endo) Reporting Unit [Member] | United States          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 277 247 800 724  
Global Endoscopy (Endo) Reporting Unit [Member] | International [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 209 196 596 580  
Global Urology (Uro) Reporting Unit [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 359 303 1,033 904  
Global Urology (Uro) Reporting Unit [Member] | United States          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 257 214 737 623  
Global Urology (Uro) Reporting Unit [Member] | International [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 102 89 297 280  
Global CRM Reporting Unit [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 478 475 1,467 1,462  
Global CRM Reporting Unit [Member] | United States          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 284 289 860 869  
Global CRM Reporting Unit [Member] | International [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 194 186 607 594  
Global Electrophysiology (EP) Reporting Unit [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 81 76 245 230  
Global Electrophysiology (EP) Reporting Unit [Member] | United States          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 38 37 113 111  
Global Electrophysiology (EP) Reporting Unit [Member] | International [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 43 39 132 119  
Global Neuromodulation (NM) Reporting Unit [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 222 189 612 559  
Global Neuromodulation (NM) Reporting Unit [Member] | United States          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 183 155 487 446  
Global Neuromodulation (NM) Reporting Unit [Member] | International [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 39 34 125 113  
Global Interventional Cardiology (IC) Reporting Unit [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 700 615 2,067 1,922  
Global Interventional Cardiology (IC) Reporting Unit [Member] | United States          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 327 283 942 859  
Global Interventional Cardiology (IC) Reporting Unit [Member] | International [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 373 332 1,126 1,062  
Global Peripheral Interventions (PI) Reporting Unit [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 311 293 942 885  
Global Peripheral Interventions (PI) Reporting Unit [Member] | United States          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 155 152 466 449  
Global Peripheral Interventions (PI) Reporting Unit [Member] | International [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 156 $ 142 475 $ 436  
BTG Spec Pharma [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 23   23    
BTG Interventional Medicine [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax 48   48    
BTG Acquisition [Member]          
Disaggregation of Revenue [Line Items]          
Revenue from Contract with Customer, Excluding Assessed Tax $ 71   $ 71    
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 277 $ 146
Trade accounts receivable, net 1,796 1,608
Inventories 1,566 1,166
Prepaid income taxes 189 161
Other current assets 1,020 921
Total current assets 4,847 4,003
Property, plant and equipment, net 1,942 1,782
Goodwill 10,015 7,911
Other intangible assets, net 8,074 6,372
Other long-term assets 1,879 932
TOTAL ASSETS 26,756 20,999
Current liabilities:    
Current debt obligations 1,297 2,253
Accounts payable 512 349
Accrued expenses 1,932 2,246
Other current liabilities 513 412
Total current liabilities 4,254 5,260
Long-term debt 9,590 4,803
Deferred income taxes 807 328
Other long-term liabilities 2,406 1,882
Commitments and contingencies
Stockholders’ equity    
Preferred stock, $0.01 par value - authorized 50,000,000 shares, none issued and outstanding
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,641,342,509 shares as of September 30, 2019 and 1,632,148,030 shares as of December 31, 2018 16 16
Treasury stock, at cost - 247,566,270 shares as of September 30, 2019 and December 31, 2018 (1,717) (1,717)
Additional paid-in capital 17,510 17,346
Accumulated deficit (6,249) (6,953)
Accumulated other comprehensive income (loss), net of tax 138 33
Total stockholders’ equity 9,699 8,726
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 26,756 $ 20,999
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Cash Flows Condensed Consolidated Statement of Cash Flows (Supplemental Disclosure) - USD ($)
$ in Millions
Sep. 30, 2019
Dec. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Cash and cash equivalents $ 277 $ 146 $ 168  
Restricted cash and restricted cash equivalents included in Other current assets 357 655 781  
Restricted cash equivalents included in Other long-term assets 43 27 31  
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period $ 676 $ 829 $ 980 $ 1,017
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.19.3
Borrowings and Credit Arrangements
 9 Months Ended
Sep. 30, 2019
Debt Disclosure [Abstract]  
BORROWINGS AND CREDIT ARRANGEMENTS
NOTE E – BORROWINGS AND CREDIT ARRANGEMENTS

We had total debt of $10.888 billion as of September 30, 2019 and $7.056 billion as of December 31, 2018. The debt maturity schedule for our long-term debt obligations is presented below:
(in millions, except interest rates)
 
Issuance Date
 
Maturity Date
 
As of
 
Semi-annual Coupon Rate
 
September 30,
2019
 
December 31,
2018
 
January 2020 Notes
 
December 2009
 
January 2020
 
$
—

 
$
850

 
6.000%
May 2020 Notes
 
May 2015
 
May 2020
 
—

 
600

 
2.850%
August 2021 Term Loan
 
August 2019
 
August 2021
 
1,000

 
—

 
 
May 2022 Notes
 
May 2015
 
May 2022
 
500

 
500

 
3.375%
August 2022 Term Loan
 
August 2019
 
August 2022
 
1,000

 
—

 
 
October 2023 Notes
 
August 2013
 
October 2023
 
450

 
450

 
4.125%
March 2024 Notes
 
February 2019
 
March 2024
 
850

 
—

 
3.450%
May 2025 Notes
 
May 2015
 
May 2025
 
750

 
750

 
3.850%
March 2026 Notes
 
February 2019
 
March 2026
 
850

 
—

 
3.750%
March 2028 Notes
 
February 2018
 
March 2028
 
1,000

 
1,000

 
4.000%
March 2029 Notes
 
February 2019
 
March 2029
 
850

 
—

 
4.000%
November 2035 Notes
 
November 2005
 
November 2035
 
350

 
350

 
7.000%
March 2039 Notes
 
February 2019
 
March 2039
 
750

 
—

 
4.550%
January 2040 Notes
 
December 2009
 
January 2040
 
300

 
300

 
7.375%
March 2049 Notes
 
February 2019
 
March 2049
 
1,000

 
—

 
4.700%
Unamortized Debt Issuance Discount
and Deferred Financing Costs
 
 
 
2020 - 2049
 
(79
)
 
(29
)
 
 
Unamortized Gain on Fair Value Hedges
 
 
 
2020 - 2023
 
14

 
26

 
 
Finance Lease Obligation (1)
 
 
 
Various
 
6

 
6

 
 
Long-term debt
 
 
 
 
 
$
9,590

 
$
4,803

 
 
Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
(1)
Effective January 1, 2019, we adopted FASB ASC Topic 842, which requires that we recognize finance lease obligations in our unaudited condensed consolidated balance sheet. As of December 31, 2018, these leases were referred to as capital lease obligations in accordance with FASB ASC Topic 840. Please refer to Note A – Basis of Presentation for additional information.

Revolving Credit Facility

As of September 30, 2019 and December 31, 2018, we maintained a $2.750 billion revolving credit facility (2018 Facility) with a global syndicate of commercial banks that matures on December 19, 2023 with one-year extension options subject to certain conditions. This facility provides backing for the commercial paper program. The 2018 Credit Agreement for the 2018 Facility requires that we comply with certain covenants, including financial covenants as described within Debt Covenants below. There were no amounts outstanding under our revolving credit facility as of September 30, 2019 and December 31, 2018.

Term Loans

On February 25, 2019, upon the closing of our senior notes offering in aggregate principal amount of $4.300 billion described below, we terminated the $1.000 billion Term Loan Credit Agreement, entered into on August 20, 2018 and amended on December 19, 2018 (August 2019 Term Loan). The August 2019 Term Loan was scheduled to mature on August 19, 2019. As of December 31, 2018, we had $1.000 billion outstanding under our August 2019 Term Loan, which was presented within Current debt obligations on our accompanying unaudited condensed consolidated balance sheets.

On December 19, 2018, we entered into a $2.000 billion senior unsecured delayed-draw term loan facility consisting of a $1.000 billion two-year delayed draw term loan credit facility maturing in two years from the date of the closing of the BTG Acquisition (Two-Year Delayed Draw Term Loan) and a $1.000 billion three-year delayed draw term loan credit facility maturing in three years from the date of the closing of the BTG Acquisition (Three-Year Delayed Draw Term Loan). Borrowings are available in U.S. dollars and bear interest at LIBOR or a base rate, in each case plus an applicable margin based on our public debt ratings. We are required to pay customary ticking fees on the average daily unused commitments based on our public debt ratings. The facilities contain customary representations and covenants, as described within Debt Covenants below. The facilities contain customary events of default, which may result in the acceleration of any outstanding commitments, and also contain customary U.K. certain funds provisions. Any proceeds from the facilities will be available to finance the BTG Acquisition and pay related transaction costs, as defined by the facilities. On August 19, 2019, for the purpose of funding the BTG Acquisition, we borrowed $1.000 billion under the Two-Year Delayed Draw Term Loan and $1.000 billion under the Three-Year Delayed Draw Term Loan. As of September 30, 2019, our average interest rates on the borrowings were 3.37 percent for the Two-Year Delayed Draw Term Loan and 3.47 percent for the Three-Year Delayed Draw Term Loan.

Debt Covenants

As of and through September 30, 2019, we were in compliance with all the required covenants related to our debt obligations. For additional information regarding the terms of our debt agreements, refer to Note E – Borrowings and Credit Arrangements to our consolidated financial statements in our most recent Annual Report on Form 10-K.

All existing credit arrangements described above require that we maintain certain financial covenants, as follows:
 
 
Covenant Requirement
 
Actual
 
 
as of September 30, 2019
 
as of September 30, 2019
Maximum leverage ratio (1)
 
4.75 times
 
4.27 times
(1)
Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, for the preceding four consecutive fiscal quarters.

Our covenants require that we maintain a maximum leverage ratio of 3.75 times, provided, however, that for the two consecutive fiscal quarters ended immediately following the consummation of a Qualified Acquisition, as defined by each agreement, the maximum leverage ratio shall be 4.75 times, and then subject to a step-down for each succeeding fiscal quarter end to 4.50 times, 4.25 times, 4.00 times and then back to 3.75 times for each fiscal quarter end thereafter. On August 19, 2019, we announced the closing of our acquisition of BTG, a Qualified Acquisition, and our maximum leverage ratio was 4.75 times as of September 30, 2019. Refer to Note B – Acquisitions and Strategic Investments for more information.

Our covenants provide for an exclusion from the calculation of consolidated EBITDA, as defined by the agreements, through maturity, of any non-cash charges and up to $500 million in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of September 30, 2019, we had $314 million of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments do not exceed $2.624 billion in the aggregate. As of September 30, 2019, we had $1.262 billion of the litigation exclusion remaining.

Any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all credit facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our credit facility may negatively impact the credit ratings assigned to our commercial paper program which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable.

Commercial Paper
 
As of
(in millions, except maturity and yield)
September 30, 2019
 
December 31, 2018
Commercial paper outstanding (at par)
$
1,293

 
$
1,248

Maximum borrowing capacity
2,750

 
2,750

Borrowing capacity available
1,457

 
1,502

Weighted average maturity
40 days

 
27 days

Weighted average yield
2.43
%
 
3.04
%


Senior Notes

We had senior notes outstanding of $7.650 billion as of September 30, 2019 and $4.800 billion as of December 31, 2018.

In February 2019, we completed an offering of $4.300 billion in aggregate principal amount of senior notes comprised of $850 million of 3.450% senior notes due March 2024, $850 million of 3.750% senior notes due March 2026, $850 million of 4.000% senior notes due March 2029, $750 million of 4.550% senior notes due March 2039 and $1.000 billion of 4.700% senior notes due March 2049. We used a portion of the net proceeds from the offering to repay the $850 million plus accrued interest and premium of our 6.000% senior notes due in January 2020, the $600 million plus accrued interest and premium of our 2.850% senior notes due in May 2020 and the $1.000 billion plus accrued interest of our August 2019 Term Loan. In the third quarter of 2019, the remaining proceeds were used to finance a portion of the BTG Acquisition.

Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see Other Arrangements below).

On October 22, 2019, we announced the commencement of a cash tender offer (Tender Offer) for up to $1.000 billion combined aggregate principal amount (Aggregate Maximum Principal Amount) of our outstanding 4.125% senior notes due October 2023, 4.000% senior notes due March 2028, 3.850% senior notes due May 2025 and 3.375% senior notes due May 2022 (collectively, Tender Offer Notes). The Tender Offer is being made exclusively pursuant to an offer to purchase dated October 22, 2019, which sets forth the terms and conditions of the Tender Offer. Consummation of the Tender Offer is subject to satisfaction or waiver of the conditions described in the offer to purchase, including the financing condition that we shall have closed one or more debt financings resulting in net proceeds in an amount, together with cash on hand, not less than the amount required, upon the terms and subject to the conditions of the Tender Offer, to purchase all the securities validly tendered and accepted for purchase in the Tender Offer and to pay accrued interest thereon and fees and expenses associated therewith.

The Tender Offer will expire at midnight, Eastern Standard Time, on November 19, 2019, unless extended or terminated by us. However, because the aggregate principal amount of Tender Offer Notes validly tendered and not validly withdrawn as of the early tender date at 5:00 p.m. Eastern Standard Time, on November 4, 2019, would cause the Aggregate Maximum Principal Amount to be exceeded and we do not expect to increase the Aggregate Maximum Principal Amount, we do not expect to accept any further tenders of Tender Offer Notes.

Bridge Facility

On February 25, 2019, upon the closing of our senior notes offering in aggregate principal amount of $4.300 billion described above, we terminated the Bridge Facility entered into on November 20, 2018. The termination was pursuant to the terms of the Bridge Facility, which required full termination upon the refinancing of the January 2020 Notes and May 2020 Notes discussed above. There were no amounts borrowed under the Bridge Facility as of December 31, 2018.

Other Arrangements

We have accounts receivable factoring programs in certain European countries and with commercial banks in Japan which include promissory notes discounting programs. We account for our factoring programs as sales under FASB ASC Topic 860, Transfers and Servicing. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from Trade accounts receivable, net in the accompanying unaudited condensed consolidated balance sheets, are aggregated by contract denominated currency below (in millions):
Factoring Arrangements
As of September 30, 2019
 
As of December 31, 2018
Amount
De-recognized
 
Average
Interest Rate
 
Amount
De-recognized
 
Average
Interest Rate
Euro denominated
$
146

 
1.7
%
 
$
165

 
2.7
%
Yen denominated
210

 
0.6
%
 
195

 
0.9
%


Refer to Note E – Borrowing and Credit Arrangements to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information on our borrowings and credit agreements.
XML 25 R17.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE I – COMMITMENTS AND CONTINGENCIES

The medical device market in which we primarily participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.

During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.

In the normal course of business, product liability, securities and commercial claims are asserted against us. Similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our financial position, results of operations and/or liquidity.

In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.

In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.

Our accrual for legal matters that are probable and estimable was $568 million as of September 30, 2019 and $929 million as of December 31, 2018 and includes certain estimated costs of settlement, damages and defense. The decrease in our legal accrual was mainly due to settlement payments associated with product liability cases or claims related to transvaginal surgical mesh products. A portion of our legal accrual is already funded through our qualified settlement fund (QSF), which is included in other restricted cash and restricted cash equivalents balance of $357 million as of September 30, 2019 and $655 million as of December 31, 2018. Refer to Note F – Supplemental Balance Sheet Information for additional information.

We recorded litigation-related net charges of $25 million in the third quarter of 2019 and litigation-related net credits of $108 million in the first nine months of 2019. In the first quarter of 2019, we recorded $148 million of the total $180 million one-time settlement payment received from Edwards Lifesciences Corporation in January 2019 to Litigation-related net charges (credits) on our unaudited condensed consolidated financial statements. We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as Litigation-related net charges (credits) in our unaudited condensed consolidated financial statements. All other legal and product liability charges, credits and costs are recorded within Selling, general and administrative expenses. As such, a portion of the related gain from this settlement was recorded in Selling, general and administrative expenses on our unaudited condensed consolidated statements of operations. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants.

In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the periods ended March 31, 2019 and June 30, 2019 and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be estimated.

Patent Litigation

On November 20, 2017, The Board of Regents, University of Texas System (UT) and TissueGen.Inc., served a lawsuit against us in the Western District of Texas. The complaint against us alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas.

Product Liability Litigation

As of October 16, 2019, approximately 53,000 product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us. As of October 16, 2019, we have entered into master settlement agreements in principle or are in the final stages of entering one with certain plaintiffs' counsel
to resolve an aggregate of approximately 52,000 cases and claims. These master settlement agreements provide that the settlement and distribution of settlement funds to participating claimants are conditional upon, among other things, achieving minimum required claimant participation thresholds. Of the approximately 52,000 cases and claims, approximately 43,500 have met the conditions of the settlement and are final. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. On April 16, 2019, the U.S. Food and Drug Administration (FDA) ordered that all manufacturers of surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse stop selling and distributing their products in the United States immediately, stemming from the FDA’s 2016 reclassification of these devices to class III (high risk) devices, and as a result, the Company ceased global sales and distribution of surgical mesh products indicated for transvaginal pelvic organ prolapse. The pending cases are in various federal and state courts in the U.S. and include eight putative class actions. Generally, the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products. The plaintiffs assert design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. Over 3,100 of the cases have been specially assigned to one judge in state court in Massachusetts. On February 7, 2012, the Judicial Panel on Multi-District Litigation (MDL) established MDL-2326 in the U.S. District Court for the Southern District of West Virginia and transferred the federal court transvaginal surgical mesh cases to MDL-2326 for coordinated pretrial proceedings. During the fourth quarter of 2013, we received written discovery requests from certain state attorneys general offices regarding our transvaginal surgical mesh products. We have responded to those requests. There were also fewer than 25 cases in Canada, inclusive of one certified and three putative class actions and fewer than 25 claims in the United Kingdom. We have reached a tentative agreement to settle the Canadian class actions.

We have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products. While we believe that our accrual associated with this matter is adequate, changes to this accrual may be required in the future as additional information becomes available. While we continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims and intend to vigorously contest the cases and claims asserted against us that do not settle, the final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Initial trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.

Other Proceedings

On November 1, 2017 we entered into a definitive agreement with Channel Medsystems, Inc. (Channel) pursuant to which we could have been obligated to pay $145 million in cash up-front and a maximum of $130 million in contingent payments to acquire Channel. The agreement contained a provision allowing Channel to sell the remaining equity interests of the company to us upon achievement of a regulatory milestone and an option allowing us to acquire the remaining equity interests. We sent a notice of termination of that agreement to Channel in the second quarter of 2018. On September 12, 2018, Channel filed a complaint in Delaware Chancery Court against us for alleged breach of the agreement. Channel alleges that we breached the agreement by terminating it. We have answered the complaint, denied the claims by Channel and have counterclaimed to recover part of our investment in Channel, alleging fraud in the inducement. On April 2, 2019, Channel announced its receipt of FDA approval of the Cerene™ Cryotherapy Device. Trial testimony was taken in April 2019, and the post-trial briefing and hearing have been completed. During the third quarter of 2019, Channel notified us that they were exercising their option to sell the remaining equity interests in Channel to us. We responded to the notification that we did not intend to purchase Channel since the previous agreement had been terminated.

On September 6, 2019, Boston Scientific Corporation, Boston Scientific Scimed, Inc., and Fortis Advisors, LLC, as a Securityholder Representative for the former Securityholders of nVision Medical Corp. filed a declaratory judgment action against BioCardia, Inc. in the United States District Court for the Northern District of California to address threats and allegations by BioCardia challenging inventorship and ownership of various patents that Boston Scientific Corporation acquired through an April 13, 2018 merger with nVision as well as related threats and allegations by BioCardia of trade secret misappropriation and unjust enrichment.

On April 18, 2019, Blue Cross & Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research & Development, LLC and BTG International Limited in the United States District Court for the Eastern District of Virginia. The complaint alleges that the defendants violated the Sherman Act and the antitrust and consumer protections laws of several states by pursuing patent litigation relating to ZYTIGA™ in order to delay generic entry. On June 21, 2019, the case was transferred to the United States District Court for the District of New Jersey and has been consolidated with similar complaints.

On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research & Development, LLC, and Johnson & Johnson (collectively, Janssen) were served with a qui tam complaint filed on behalf of the United States, 28 states, and the District
of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant.

Matters Concluded Since December 31, 2018

On January 15, 2019, we announced that we reached an agreement with Edwards Lifesciences Corporation (Edwards) to settle all outstanding patent disputes between us and Edwards in all venues around the world. All pending cases or appeals in courts and patent offices between the two companies have been or will be dismissed, and the parties will not litigate patent disputes related to current portfolios of transcatheter aortic valves, certain mitral valve repair devices, and left atrial appendage closure devices. Any injunctions currently in place will be lifted. Under the terms of the agreement, Edwards made a one-time payment to us of $180 million. No further royalties will be owed by either party under the agreement. All other terms remain confidential. The previously disclosed matters that have been resolved as a result of this settlement include:

•
On October 30, 2015, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation and Edwards Lifesciences Services GmbH in Düsseldorf District Court in Germany for patent infringement. We allege that Edwards’ SAPIEN 3™ Heart Valve infringes our patent related to adaptive sealing technology. On February 25, 2016, we extended the action to allege infringement of a second patent related to adaptive sealing technology. The trial began on February 7, 2017. On March 9, 2017, the court found that Edwards infringed both patents and Edwards appealed.

•
On November 9, 2015, Edwards Lifesciences, LLC filed an invalidity claim against one of our subsidiaries, Sadra Medical, Inc. (Sadra), in the High Court of Justice, Chancery Division Patents Court in the United Kingdom, alleging that a European patent owned by Sadra relating to a repositionable heart valve is invalid. On January 15, 2016, we filed our defense and counterclaim for a declaration that our European patent is valid and infringed by Edwards. On February 25, 2016, we amended our counterclaim to allege infringement of a second patent related to adaptive sealing technology. A trial was held from January 18 to January 27, 2017. On March 3, 2017, the court found one of our patents valid and infringed and some claims of the second patent invalid and the remaining claims not infringed. Both parties have filed an appeal. On March 28, 2018, the Court of Appeals affirmed the decision of the High Court.

•
On November 23, 2015, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '672) owned by Edwards is infringed by our Lotus™ Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we did not infringe the Spenser '672 patent. Edwards filed an appeal.

•
On November 23, 2015, Edwards Lifesciences Corporation filed a patent infringement action against us and Boston Scientific Medizintechnik GmbH in the District Court of Düsseldorf, Germany alleging an European patent (Bourang) owned by Edwards is infringed by our Lotus Valve System. The trial began on February 7, 2017. On March 28, 2017, the European Patent Office revoked the Bourang patent and on April 3, 2017, the court suspended the infringement action pending Edwards' appeal of the revocation of the patent at the European Patent Office.

•
On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation (Edwards) in the U.S. District Court for the District of Delaware for patent infringement. We allege that Edwards’ SAPIEN 3 Valve infringes a patent related to adaptive sealing technology. On June 9, 2016, Edwards filed a counterclaim alleging that our Lotus Valve System infringes three patents owned by Edwards. On October 12, 2016, Edwards filed a petition for inter partes review of our patent with the U.S. Patent and Trademark Office (USPTO), Patent Trial and Appeal Board. On March 29, 2017, the USPTO granted the inter partes review request. On April 18, 2017, Edwards filed a second petition for inter partes review of our patent with the USPTO. On March 23, 2018, the USPTO found our patent invalid. The Company filed an appeal before the United States Court of Appeals for the Federal Circuit on May 24, 2018.

•
On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation in the U.S. District Court for the Central District of California for patent infringement. We allege that Edwards’ aortic valve delivery systems infringe eight of our catheter related patents. On October 13, 2016, Edwards filed a petition for inter partes review of one asserted patent with the USPTO, Patent Trial and Appeal Board. On April 21, 2017, the USPTO denied the petition. On April 19 and 20, 2017, Edwards filed multiple inter partes review petitions against the patents in suit. On September 8, 2017, the court granted a stay of the action pending an inter partes review of the patents in suit.

•
On April 26, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '550) owned by Edwards is infringed by our Lotus™ Transcatheter Heart Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we infringed the Spenser '550 patent. The Company filed an appeal. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.

•
On October 27, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific, LTD, in the Federal Court of Canada alleging that three Canadian patents (Spenser) owned by Edwards are infringed by our Lotus Transcatheter Heart Valve System.

•
On December 22, 2016, Edwards Lifesciences PVT, Inc. and Edwards Lifesciences SA (AG) filed a plenary summons against Boston Scientific Limited and Boston Scientific Group Public Company in the High Court of Ireland alleging that a European patent (Spenser) owned by Edwards is infringed by our Lotus Valve System. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.

•
On August 1, 2018, the Company filed a patent infringement action on the merits in Dusseldorf, Germany against Edwards Lifesciences Corporation and Edwards Lifesciences GmbH (collectively Edwards) alleging that the Sapien 3™ Device and Sapien 3 Ultra Device infringed a patent owned by the Company.

•
On August 3, 2018, the Company filed a preliminary injunction request in Dusseldorf, Germany against Edwards Lifesciences Corporation and Edwards Lifesciences GmbH (collectively Edwards) alleging that the Sapien 3 Ultra Device infringed a patent owned by the Company. On October 23, 2018, the court found that the Sapien 3 Ultra Device infringed the patent. Edwards had the right to appeal.

•
On August 22, 2018, Edwards Lifesciences LLC filed a patent infringement action against Boston Scientific Corporation, in the U. S. District Court of Delaware, alleging that two U.S. patents (Schweich) owned by them are infringed by our Watchman™ Left Atrial Appendage Closure Device, Watchman Delivery System and Watchman Access System.

On December 14, 2016, we learned that the Associacao Brasileira de Medicina de Grupo d/b/a ABRAMGE filed a complaint against us, Arthrex and Zimmer Biomet Holdings, in the U.S. District Court for the District of Delaware. This complaint, which ABRAMGE never served against us, alleges that the defendants or their agents paid kickbacks to health care providers in order to increase sales and prices and are liable under a variety of common law theories. On February 6, 2017, ABRAMGE filed and served an amended complaint on us and the other defendants. The amended complaint does not contain any material changes in the allegations against us. Subsequently, on March 2, 2017, ABRAMGE filed a motion to consolidate this lawsuit with two other similar suits that it had brought against Stryker and Abbott Laboratories, in a multidistrict litigation proceeding. On April 13, 2017, we filed a motion to dismiss the amended complaint, as well as a separate opposition to the multidistrict litigation motion and on May 31, 2017, the Joint Panel on Multi-District Litigation denied ABRAMGE’s motion for the multidistrict litigation. On September 1, 2017, ABRAMGE filed a motion for leave to file a Second Amended Complaint, while our motion to dismiss the Amended Complaint remained pending. On September 15, 2017, we filed an opposition to the motion seeking leave to amend. On November 8, 2018, the Court granted ABRAMGE’s motion for leave to file a Second Amended Complaint, while also granting us leave to renew our motion to dismiss. We filed our motion to dismiss the Second Amended Complaint on January 18, 2019. On February 28, 2019, ABRAMGE dismissed its Second Amended Complaint, concluding the lawsuit.

On or about January 12, 2016, Teresa L. Stevens filed a claim against us and three other defendants asserting, for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the U.S. District Court for the Southern District of West Virginia, before the same Court that is hearing the mesh MDL. The complaint, which alleges Racketeer Influenced and Corrupt Organizations Act (RICO) violations, fraud, misrepresentation, deceptive trade practices and unjust enrichment, seeks both equitable relief and damages under state and federal law. On January 26, 2016, the Court issued an order staying the case and directing the plaintiff to submit information to allow the FDA to issue a determination with respect to her allegations. In addition, we were in contact with the U.S. Attorney’s Office for the Southern District of West Virginia and responded voluntarily to their requests in connection with that office’s review of the allegations concerning the use of mesh resin in the complaint. We reached a settlement on this matter and this case was dismissed on May 13, 2019.

On February 27, 2017, Carolyn Turner filed a complaint against us and five other defendants asserting for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the U.S. District Court for the Middle District of Florida, Orlando Division and alleges violations of the RICO, negligence, strict liability, breach of an express or implied warranty, intentional and negligent misrepresentation, fraud and unjust enrichment. Ms. Turner served this complaint
against us on April 7, 2017. As of April 27, 2017, this case was stayed, pending resolution of the transfer petition to the mesh multidistrict litigation. We reached a settlement on this matter and this case was dismissed on February 25, 2019.

On April 24, 2019, a class action complaint was filed in the U.S. District Court for the Southern District of New York against Boston Scientific Corporation, Michael F. Mahoney, our Chief Executive Officer, and Daniel J. Brennan, our Chief Financial Officer. The complaint alleges violations of federal securities laws based on false and/or misleading statements and failure to disclose facts related to the Company’s transvaginal surgical mesh products. On September 20, 2019, the case was dismissed with prejudice.
XML 26 R38.htm IDEA: XBRL DOCUMENT v3.19.3
Weighted Average Shares Outstanding (Tables)
 9 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares [Table Text Block]
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions)
2019

2018
 
2019
 
2018
Weighted average shares outstanding - basic
1,393.1

 
1,382.8

 
1,390.6

 
1,380.0

Net effect of common stock equivalents
19.0

 
21.0

 
19.1

 
19.9

Weighted average shares outstanding - assuming dilution
1,412.2

 
1,403.9

 
1,409.7

 
1,399.8
XML 27 R34.htm IDEA: XBRL DOCUMENT v3.19.3
Borrowings and Credit Arrangements (Tables)
 9 Months Ended
Sep. 30, 2019
Short-term Debt [Line Items]  
Schedule of Long-term Debt Instruments [Table Text Block]
(in millions, except interest rates)
 
Issuance Date
 
Maturity Date
 
As of
 
Semi-annual Coupon Rate
 
September 30,
2019
 
December 31,
2018
 
January 2020 Notes
 
December 2009
 
January 2020
 
$
—

 
$
850

 
6.000%
May 2020 Notes
 
May 2015
 
May 2020
 
—

 
600

 
2.850%
August 2021 Term Loan
 
August 2019
 
August 2021
 
1,000

 
—

 
 
May 2022 Notes
 
May 2015
 
May 2022
 
500

 
500

 
3.375%
August 2022 Term Loan
 
August 2019
 
August 2022
 
1,000

 
—

 
 
October 2023 Notes
 
August 2013
 
October 2023
 
450

 
450

 
4.125%
March 2024 Notes
 
February 2019
 
March 2024
 
850

 
—

 
3.450%
May 2025 Notes
 
May 2015
 
May 2025
 
750

 
750

 
3.850%
March 2026 Notes
 
February 2019
 
March 2026
 
850

 
—

 
3.750%
March 2028 Notes
 
February 2018
 
March 2028
 
1,000

 
1,000

 
4.000%
March 2029 Notes
 
February 2019
 
March 2029
 
850

 
—

 
4.000%
November 2035 Notes
 
November 2005
 
November 2035
 
350

 
350

 
7.000%
March 2039 Notes
 
February 2019
 
March 2039
 
750

 
—

 
4.550%
January 2040 Notes
 
December 2009
 
January 2040
 
300

 
300

 
7.375%
March 2049 Notes
 
February 2019
 
March 2049
 
1,000

 
—

 
4.700%
Unamortized Debt Issuance Discount
and Deferred Financing Costs
 
 
 
2020 - 2049
 
(79
)
 
(29
)
 
 
Unamortized Gain on Fair Value Hedges
 
 
 
2020 - 2023
 
14

 
26

 
 
Finance Lease Obligation (1)
 
 
 
Various
 
6

 
6

 
 
Long-term debt
 
 
 
 
 
$
9,590

 
$
4,803

 
 
Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.
(1)
Effective January 1, 2019, we adopted FASB ASC Topic 842, which requires that we recognize finance lease obligations in our unaudited condensed consolidated balance sheet. As of December 31, 2018, these leases were referred to as capital lease obligations in accordance with FASB ASC Topic 840. Please refer to Note A – Basis of Presentation for additional information.
Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]
 
 
Covenant Requirement
 
Actual
 
 
as of September 30, 2019
 
as of September 30, 2019
Maximum leverage ratio (1)
 
4.75 times
 
4.27 times
(1)
Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, for the preceding four consecutive fiscal quarters.
Transfer of Financial Assets Accounted for as Sales [Table Text Block]
Factoring Arrangements
As of September 30, 2019
 
As of December 31, 2018
Amount
De-recognized
 
Average
Interest Rate
 
Amount
De-recognized
 
Average
Interest Rate
Euro denominated
$
146

 
1.7
%
 
$
165

 
2.7
%
Yen denominated
210

 
0.6
%
 
195

 
0.9
%
Commercial Paper [Member]  
Short-term Debt [Line Items]  
Schedule of Short-term Debt [Table Text Block]
Commercial Paper
 
As of
(in millions, except maturity and yield)
September 30, 2019
 
December 31, 2018
Commercial paper outstanding (at par)
$
1,293

 
$
1,248

Maximum borrowing capacity
2,750

 
2,750

Borrowing capacity available
1,457

 
1,502

Weighted average maturity
40 days

 
27 days

Weighted average yield
2.43
%
 
3.04
%
XML 28 R30.htm IDEA: XBRL DOCUMENT v3.19.3
Contingent Consideration (Tables)
 9 Months Ended
Sep. 30, 2019
Business Combinations [Abstract]  
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Changes in the fair value of our contingent consideration liability were as follows:
(in millions)
 
Balance as of December 31, 2018
$
347

Amount recorded related to current year acquisitions
127

Contingent consideration arrangements transferred to Varian
(16
)
Contingent consideration expense (benefit)
(9
)
Contingent consideration payments
(68
)
Balance as of September 30, 2019
$
380
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]
The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:
Contingent Consideration Liability
Fair Value as of September 30, 2019
Valuation Technique
Unobservable Input
Range
Weighted Average (1)
R&D, Regulatory and Commercialization-based Milestones
$220 million
Discounted Cash Flow
Discount Rate
2
%
-
3%
3%
Probability of Payment
50
%
-
90%
84%
Projected Year of Payment
2019

-
2027
2020
Revenue-based Payments
$160 million
Discounted Cash Flow
Discount Rate
11
%
-
15%
13%
Probability of Payment
60
%
-
100%
99%
Projected Year of Payment
2019

-
2026
2021

(1)
Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
XML 29 R50.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Leases (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
Rate
Sep. 30, 2019
USD ($)
Rate
Assets and Liabilities, Lessee [Abstract]    
Operating Lease, Right-of-Use Asset $ 306 $ 306
Operating Lease, Liability, Current 62 62
Operating Lease, Liability, Noncurrent 251 251
Lessee, Lease, Description [Line Items]    
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability   84
Lessee, leases not yet commenced, amount 68 68
Operating Lease, Payments   55
Operating Lease, Cost $ 21 $ 57
Operating Lease, Weighted Average Remaining Lease Term 5 years 7 months 6 days 5 years 7 months 6 days
Finance Lease, Weighted Average Discount Rate, Percent | Rate 3.70% 3.70%
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year $ 22 $ 22
Lessee, Operating Lease, Liability, Payments, Due Year Two 76 76
Lessee, Operating Lease, Liability, Payments, Due Year Three 65 65
Lessee, Operating Lease, Liability, Payments, Due Year Four 52 52
Lessee, Operating Lease, Liability, Payments, Due Year Five 41 41
Lessee, Operating Lease, Liability, Payments, Due after Year Five 95 95
Lessee, Operating Lease, Liability, Payments, Due 350 350
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 37 37
Operating Lease, Liability $ 314 $ 314
Minimum [Member]    
Lessee, Lease, Description [Line Items]    
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract 1 month 1 month
Lessee, Operating Lease, Term of Contract 1 year 1 year
Maximum [Member]    
Lessee, Lease, Description [Line Items]    
Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract 15 years 15 years
Lessee, Operating Lease, Term of Contract 60 years 60 years
Lessee, Operating and Finance Leases, Option to Extend   10 years
XML 30 R54.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Reporting (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
reportablesegments
Sep. 30, 2018
USD ($)
Segment Reporting [Abstract]        
Number of reportable segments | reportablesegments     3  
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax $ 2,707 $ 2,393 $ 7,831 $ 7,262
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Operating Income Allocated to Reportable Segments 766 710 2,216 2,146
Amortization expense (178) (148) (498) (437)
Operating income (loss) 383 388 1,308 1,187
Other expense, net (292) 68 (615) (61)
Income (loss) before income taxes 91 456 693 1,126
MedSurg [Member]        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenues 845 746 2,429 2,207
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Operating Income Allocated to Reportable Segments $ 319 $ 274 $ 870 $ 807
Segment Operating Income as a Percentage of Net Sales 37.80% 36.80% 35.80% 36.60%
Rhythm and Neuro [Member]        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenues $ 780 $ 740 $ 2,323 $ 2,252
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Operating Income Allocated to Reportable Segments $ 166 $ 168 $ 488 $ 481
Segment Operating Income as a Percentage of Net Sales 21.30% 22.70% 21.00% 21.40%
Cardiovascular [Member]        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenues $ 1,011 $ 908 $ 3,009 $ 2,806
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Operating Income Allocated to Reportable Segments $ 281 $ 268 $ 857 $ 858
Segment Operating Income as a Percentage of Net Sales 27.80% 29.50% 28.50% 30.60%
Excludes BTG Acquisition [Member]        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax $ 2,636   $ 7,760  
BTG Acquisition [Member]        
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Reconciliation of Operating Profit (Loss) from Segments to Consolidated (16)   (16)  
Corporate expenses and currency exchange [Member]        
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Reconciliation of Operating Profit (Loss) from Segments to Consolidated (75) $ (97) (215) $ (297)
Special Charges [Member]        
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]        
Reconciliation of Operating Profit (Loss) from Segments to Consolidated (146) $ (77) (210) $ (225)
BTG Acquisition [Member]        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue from Contract with Customer, Excluding Assessed Tax $ 71   $ 71  
XML 31 R9.htm IDEA: XBRL DOCUMENT v3.19.3
Basis of Presentation
 9 Months Ended
Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
BASIS OF PRESENTATION
NOTE A – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results that may be expected for the year ending December 31, 2019. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.

Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.

On August 19, 2019, we announced the closing of our acquisition of BTG plc (BTG Acquisition or BTG). Refer to Note B – Acquisitions and Strategic Investments for more information.

Subsequent Events

We evaluate events occurring after the date of our most recent accompanying unaudited condensed consolidated balance sheet for potential recognition or disclosure in our financial statements. Those items requiring disclosure (nonrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note E – Borrowings and Credit Arrangements and Note I – Commitments and Contingencies for more information.

Accounting Standards Implemented Since December 31, 2018

ASC Update No. 2016-02

In February 2016, the Financial Accounting Standards Board (FASB) issued ASC Update No. 2016-02, Leases (FASB ASC Topic 842, Leases). We adopted the standard as of January 1, 2019, using the modified retrospective approach and the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements. Under this method, we applied the new leasing rules on the date of adoption and recognized the cumulative effect of initially applying the standard as an adjustment to our opening balance sheet, rather than at the earliest comparative period presented in the financial statements. Prior periods presented are in accordance with the previous lease guidance under FASB ASC Topic 840, Leases.

In addition, we applied the package of practical expedients permitted under FASB ASC Topic 842 transition guidance to our entire lease portfolio at January 1, 2019. As a result, we were not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases and (iii) the treatment of initial direct costs for any existing leases. Furthermore, we elected not to separate lease and non-lease components for the majority of our leases. Instead, for all applicable classes of underlying assets, we accounted for each separate lease component and the non-lease components associated with that lease component, as a single lease component.

As a result of adopting FASB ASC Topic 842 on January 1, 2019, we recognized right-of-use assets of $271 million and corresponding liabilities of $278 million for our existing operating lease portfolio on our unaudited condensed consolidated balance sheet. Operating lease right-of-use assets are presented within Other long-term assets and corresponding liabilities are presented within Other current liabilities and Other long-term liabilities on our unaudited condensed consolidated balance sheets. Finance leases are immaterial to our unaudited condensed consolidated financial statements. Refer to Note E – Borrowings and Credit Arrangements for additional information. There was no material impact to our unaudited condensed consolidated statements of operations or unaudited condensed consolidated statements of cash flows. Please refer to Note G – Leases for information regarding our lease portfolio as of September 30, 2019 as accounted for under FASB ASC Topic 842.

To meet the reporting and disclosure requirements of FASB ASC Topic 842, we implemented a new lease administration and lease accounting system in 2018 that tracks all of our material leasing arrangements. In addition, we designed and implemented new processes and internal controls during the first quarter of 2019 to ensure the completeness and accuracy of the transition adjustment
and subsequent financial reporting under FASB ASC Topic 842. We also established monitoring controls to ensure we have appropriate mechanisms in place to identify material leases in a timely manner, particularly contracts that may contain embedded lease features.
XML 32 R1.htm IDEA: XBRL DOCUMENT v3.19.3
Cover Document - $ / shares
 9 Months Ended
Sep. 30, 2019
Oct. 22, 2019
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Transition Report false  
Document Period End Date Sep. 30, 2019  
Entity File Number 1-11083  
Entity Registrant Name BOSTON SCIENTIFIC CORPORATION  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 04-2695240  
Entity Address, Address Line One 300 Boston Scientific Way  
Entity Address, City or Town Marlborough  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 01752-1234  
City Area Code 508  
Local Phone Number 683-4000  
Title of 12(b) Security Common Stock, $0.01 par value  
Trading Symbol BSX  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Listing, Par Value Per Share $ 0.01  
Entity Common Stock, Shares Outstanding   1,393,823,592
Entity Central Index Key 0000885725  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2019  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 33 R5.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2019
Dec. 31, 2018
Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]    
Preferred Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Preferred Stock, Shares Authorized 50,000,000 50,000,000
Preferred Stock, Shares Issued 0 0
Preferred Stock, Shares Outstanding 0 0
Common Stock, Par or Stated Value Per Share $ 0.01 $ 0.01
Common Stock, Shares Authorized 2,000,000,000 2,000,000,000
Common Stock, Shares, Issued 1,641,342,509 1,632,148,030
Common Stock, Shares, Outstanding 1,393,776,239 1,384,581,760
Treasury Stock, Shares 247,566,270 247,566,270
XML 34 R12.htm IDEA: XBRL DOCUMENT v3.19.3
Hedging Activities and Fair Value Measurements
 9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value Disclosures [Text Block]
NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS

Derivative Instruments and Hedging Activities

We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.

Currency Derivative Instruments
Risk Management Strategy
Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecast intercompany and third-party transactions, net investments in certain subsidiaries and the purchase price of any acquisition that is denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates.

The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in Euro, Japanese yen, Chinese renminbi and British pound sterling. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.

Derivative Designations and Hedging Relationships

Certain of our currency derivative instruments are designated as cash flow hedges under FASB ASC Topic 815, Derivatives and Hedging (FASB ASC Topic 815), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the Net change in derivative financial instruments component of Other comprehensive income (loss), net of tax (OCI) on our unaudited condensed consolidated statements of comprehensive income (loss) until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within the Cost of products sold caption of our unaudited condensed consolidated statements of operations. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within Accumulated other comprehensive income (loss), net of tax (AOCI) to earnings at that time.

We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro, Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. We elected to use the spot method to assess effectiveness for our derivatives that are designated as net investment hedges. Under the spot method, the change in fair value attributable to changes in the spot rate is recorded in the Foreign currency translation adjustment (CTA) component of OCI. We have elected to exclude the spot-forward difference from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. Amortization of the spot-forward difference is then reclassified from AOCI to current period earnings as a reduction to Interest expense on our unaudited condensed consolidated statements of operations.

We also use forward currency contracts that are not part of designated hedging relationships under FASB ASC Topic 815 as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within the Other, net caption of our unaudited condensed consolidated statements of operations.

Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the purchase price of the BTG Acquisition. As of September 30, 2019, we settled all outstanding contracts, resulting in a cumulative loss on the contracts of $294 million that was recognized over time in earnings as we adjusted for changes in fair value until the final fair value was determined at maturity. We received £3.312 billion of cash to fund the BTG Acquisition, which translated into $4.303 billion based on hedged currency exchange rates. We recognized a $207 million loss in the third quarter of 2019 and a $323 million loss in the first nine months of 2019 in Other, net due to changes in fair value of the contracts.

Interest Rate Derivative Instruments
Risk Management Strategy

Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. Under these agreements we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with FASB ASC Topic 815.

Derivative Designations and Hedging Relationships

We had no interest rate derivative instruments designated as cash flow hedges outstanding as of September 30, 2019 and $1.000 billion outstanding as of December 31, 2018, which were intended to manage our earnings and cash flow exposure to changes in the benchmark interest rate in connection with the forecasted issuance of fixed-rate debt. For outstanding designated cash flow hedges, we record the changes in the fair value of the derivatives within OCI until the underlying hedged transaction occurs, at which time we recognize the gain or loss within Interest expense over the same period that the hedged items affect earnings, so long as the hedge relationship remains effective. If we determine the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the amount of gains or losses from AOCI to earnings at that time.

During the fourth quarter of 2018, we entered into interest rate derivative contracts designated as cash flow hedges having a notional amount of $1.000 billion to hedge interest rate risk. In the first quarter of 2019, we terminated these instruments in connection with our senior notes issuance in the same period as discussed in Note E – Borrowings and Credit Arrangements. We recognized an immaterial loss within OCI in the first nine months of 2019 and are reclassifying the amortization of the loss from AOCI into earnings as a component of Interest expense over the same period that the hedged item affects earnings, so long as the hedge relationship remains effective. We are also continuing to reclassify in a similar manner the amortization of the gains or losses of our other previously terminated interest rate derivative instruments that were designated as cash flow hedges. The balance of the deferred loss on our terminated cash flow hedges within AOCI was immaterial as of September 30, 2019 and December 31, 2018. We recognized immaterial gains and losses in Interest expense relating to the amortization of our terminated cash flow hedges in the current and prior periods.

We had no interest rate derivative instruments designated as fair value hedges outstanding as of September 30, 2019 and December 31, 2018. Prior to 2018, we terminated interest rate derivative instruments that were designated as fair value hedges and are continuing to recognize the amortization of the gains or losses originally recorded within the Long-term debt caption on our unaudited condensed consolidated balance sheets into earnings as a component of Interest expense over the same period that the discount or premium associated with the hedged items affects earnings. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in Interest expense, which generally offset. The balance of the deferred gains on our terminated fair value hedges within Long-term debt was immaterial as of September 30, 2019 and December 31, 2018. We recognized immaterial gains in Interest expense relating to the amortization of the terminated fair value hedges in the current and prior periods.

The following table presents the contractual amounts of our derivative instruments outstanding:
(in millions)
 
FASB ASC Topic 815 Designation
 
As of
 
September 30, 2019
 
December 31, 2018
Forward currency contracts
 
Cash flow hedge
 
$
4,030

 
$
3,962

Forward currency contracts
 
Net investment hedge
 
1,935

 
1,483

Forward currency contracts
 
Non-designated
 
3,522

 
5,880

Interest rate derivative contracts
 
Cash flow hedge
 
—

 
1,000

Total Notional Outstanding
 
 
 
$
9,487

 
$
12,326



The remaining time to maturity as of September 30, 2019 is within 60 months for all designated forward currency contracts and generally less than one year for all non-designated forward currency contracts.
The following presents the effect of our derivative instruments designated as cash flow and net investment hedges under FASB ASC Topic 815 on our accompanying unaudited condensed consolidated statements of operations. Refer to Note M – Changes in Other Comprehensive Income for the total amounts relating to derivative instruments presented within the unaudited condensed consolidated statements of comprehensive income (loss).
 
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
 
Amount Recognized in OCI on Derivative
 
Unaudited Condensed Consolidated Statements of Operations (1)
 
Amount Reclassified from AOCI into Earnings
(in millions)
Pre-Tax Gain (Loss)
Tax Benefit (Expense)
Gain (Loss) Net of Tax
 
Location of Amount Reclassified
Total Amount of Line Item Presented
 
Pre-Tax (Gain) Loss
Tax (Benefit) Expense
(Gain) Loss Net of Tax
Three Months Ended September 30, 2019
Forward currency contracts
 
 
 
 
 
 
 
 
Cash flow hedges
$
101

$
(23
)
$
78

 
Cost of products sold
$
777

 
$
(22
)
$
5

$
(17
)
Net investment hedges (2)
64

(14
)
50

 
Interest expense
95

 
(12
)
3

(9
)
Interest rate derivative contracts
 
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
95

 
1

—

1

Three Months Ended September 30, 2018
Forward currency contracts
 
 
 
 
 
 
 
 
Cash flow hedges
$
58

$
(13
)
$
45

 
Cost of products sold
$
672

 
$
2

$
—

$
2

Net investment hedges (2)
4

(1
)
3

 
Interest expense
58

 
(10
)
2

(8
)
Nine Months Ended September 30, 2019
Forward currency contracts
 
 
 
 
 
 
 
 
Cash flow hedges
$
176

$
(40
)
$
136

 
Cost of products sold
$
2,265

 
$
(47
)
$
10

$
(36
)
Net investment hedges (2)
92

(21
)
71

 
Interest expense
294

 
(33
)
7

(25
)
Interest rate derivative contracts
 
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
294

 
3

(1
)
2

Nine Months Ended September 30, 2018
Forward currency contracts
 
 
 
 
 
 
 
 
Cash flow hedges
$
135

$
(30
)
$
105

 
Cost of products sold
$
2,084

 
$
27

$
(6
)
$
21

Net investment hedges (2)
25

(6
)
19

 
Interest expense
177

 
(17
)
4

(13
)
Interest rate derivative contracts
 
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
177

 
(1
)
—

(1
)

(1)
In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from AOCI to earnings represent the effect of the hedging relationships on earnings. All other amounts included in earnings related to hedging relationships were immaterial.
(2)
For our outstanding net investment hedges, the net gain or loss reclassified from AOCI to earnings as a reduction of Interest expense represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with FASB ASC Topic 815. In the current period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in AOCI or earnings.

As of September 30, 2019, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
Designated Derivative Instrument
 
FASB ASC Topic 815 Designation
 
Location on Unaudited Condensed Consolidated Statements of Operations
 
Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Forward currency contracts
 
Cash flow hedge
 
Cost of products sold
 
$
104

Forward currency contracts
 
Net investment hedge
 
Interest expense
 
48

Interest rate derivative contracts
 
Cash flow hedge
 
Interest expense
 
(5
)

Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
 
 
Location on Unaudited Condensed Consolidated Statements of Operations
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions)
 
 
2019
 
2018
 
2019
 
2018
Net gain (loss) on currency hedge contracts
 
Other, net
 
$
(202
)
 
$
16

 
$
(334
)
 
$
25

Net gain (loss) on currency transaction exposures
 
Other, net
 
(4
)
 
(23
)
 
—

 
(40
)
Net currency exchange gain (loss)
 
 
 
$
(207
)
 
$
(6
)
 
$
(334
)
 
$
(15
)


Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the purchase price of the BTG Acquisition. As of September 30, 2019, we settled all outstanding contracts. We recognized a $207 million loss in the third quarter of 2019 and a $323 million loss in the first nine months of 2019 in Net gain (loss) on currency hedge contracts due to changes in fair value of the contracts.

Fair Value Measurements

FASB ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures (FASB ASC Topic 820) and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date given the applicable current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative assets and liabilities:
 
 
Location on Unaudited Condensed Consolidated Balance Sheets (1)
 
As of
(in millions)
 
 
September 30, 2019
 
December 31, 2018
Derivative Assets:
 
 
 
 
 
 
Designated Derivative Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current assets
 
$
98

 
$
55

Forward currency contracts
 
Other long-term assets
 
358

 
183

 
 
 
 
456

 
237

Non-Designated Derivative Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current assets
 
48

 
67

Total Derivative Assets
 
 
 
$
504

 
$
304

 
 
 
 
 
 
 
Derivative Liabilities:
 
 
 
 
 
 
Designated Derivative Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current liabilities
 
$
3

 
$
2

Forward currency contracts
 
Other long-term liabilities
 
5

 
3

Interest rate contracts
 
Other current liabilities
 
—

 
44

 
 
 
 
8

 
49

Non-Designated Derivative Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current liabilities
 
40

 
31

Total Derivative Liabilities
 
 
 
$
48

 
$
80

(1)
We classify derivative assets and liabilities as current when the settlement date of the derivative contract is one year or less.
Recurring Fair Value Measurements
On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
•
Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.
•
Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
•
Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Assets and liabilities measured at fair value on a recurring basis consist of the following:
 
As of
 
September 30, 2019
 
December 31, 2018
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets
 
 
 

 
 
 
 
 
 
 
 

 
 
 
 
Money market and government funds
$
26

 
$
—

 
$
—

 
$
26

 
$
13

 
$
—

 
$
—

 
$
13

Derivative instruments
—

 
504

 
—

 
504

 
—

 
304

 
—

 
304

Licensing arrangements
—

 
—

 
633

 
633

 
—

 
—

 
—

 
—

 
$
26

 
$
504

 
$
633

 
$
1,163

 
$
14

 
$
304

 
$
—

 
$
318

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Derivative instruments
$
—

 
$
48

 
$
—

 
$
48

 
$
—

 
$
80

 
$
—

 
$
80

Contingent consideration
—

 
—

 
380

 
380

 
—

 
—

 
347

 
347

Licensing arrangements
—

 
—

 
341

 
341

 
—

 
—

 
—

 
—

 
$
—

 
$
48

 
$
720

 
$
768

 
$
—

 
$
80

 
$
347

 
$
427



Our investments in money market and government funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as Cash and cash equivalents within our accompanying unaudited condensed consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $26 million invested in money market and government funds as of September 30, 2019, we had $249 million in interest bearing and non-interest-bearing bank accounts. In addition to $13 million invested in money market and government funds as of December 31, 2018, we had $133 million in interest bearing and non-interest-bearing bank accounts.

Our recurring fair value measurements using Level 3 inputs relates to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability.

In addition, our recurring fair value measurements using Level 3 inputs relate to our licensing arrangements. In the third quarter of 2019, we acquired intellectual property and related licensing arrangements as of the result of the BTG Acquisition that provides the contractual right to receive future royalty payments. As part of the licensing arrangements we acquired, we also have the contractual obligation to remit a portion of the cash flows received to the inventors associated with the intellectual property. We have elected the fair value option to account for the licensing arrangements financial asset and financial liability in accordance with FASB ASC Topic 825, Financial Instruments.

As of September 30, 2019, we have recorded the preliminary fair values of the financial asset and financial liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The preliminary fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. As discussed in Note B – Acquisitions and Strategic Investments, given the size and breadth of the BTG Acquisition, we anticipate that the purchase price allocation will take longer than prior acquisitions and potentially up to the one year allowed under FASB ASC Topic 805 to adequately analyze all the factors used in establishing the fair value of assets acquired and liabilities assumed as of the acquisition date, including the licensing arrangements financial asset and liability and the related tax and foreign currency effects of any changes made.

The recurring Level 3 fair value measurements of our licensing arrangements include the following significant unobservable inputs:
Licensing Arrangements
Fair Value as of September 30, 2019
Valuation Technique
Unobservable Input
Range
Weighted Average (1)
Financial Asset
$633 million
Discounted Cash Flow
Discount Rate
9%
9%
Projected Year of Payment
2019
-
2027
2023
Financial Liability
$341 million
Discounted Cash Flow
Discount Rate
9%
9%
Projected Year of Payment
2019
-
2027
2023
(1)
Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements financial assets and liability as of September 30, 2019.
Non-Recurring Fair Value Measurements

We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments.

Refer to Note C – Goodwill and Other Intangible Assets for a discussion of the fair values.

The fair value of our outstanding debt obligations was $11.990 billion as of September 30, 2019 and $7.239 billion as of December 31, 2018. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, amortized cost for commercial paper and face value for term loans and credit facility borrowings outstanding. Refer to Note E – Borrowings and Credit Arrangements for a discussion of our debt obligations.
XML 35 R16.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes
 9 Months Ended
Sep. 30, 2019
Income Tax Disclosure [Abstract]  
INCOME TAXES
NOTE H – INCOME TAXES

Our effective tax rate from continuing operations is presented below:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
2019
 
2018
 
2019
 
2018
Effective tax rate from continuing operations
(38.7
)%
 
5.3
%
 
(1.6
)%
 
(14.1
)%


The change in our reported tax rates for the third quarter and first nine months of 2019, as compared to the same periods in 2018, relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These receipts and charges include intangible asset impairment charges, acquisition-related items, restructuring items, litigation-related items as well as certain discrete tax items primarily related to share-based payments and the 2018 settlement of our transfer pricing dispute with the Internal Revenue Service (IRS) for the 2001 through 2010 tax years.

As of September 30, 2019, we had $405 million of gross unrecognized tax benefits, of which a net $320 million, if recognized, would affect our effective tax rate. As of December 31, 2018, we had $427 million of gross unrecognized tax benefits, of which a net $332 million, if recognized, would affect our effective tax rate.

It is reasonably possible that within the next 12 months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to $99 million.
XML 36 R35.htm IDEA: XBRL DOCUMENT v3.19.3
Supplemental Balance Sheet Information (Tables)
 9 Months Ended
Sep. 30, 2019
Supplemental Balance Sheet Information [Abstract]  
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Cash and cash equivalents
$
277

 
$
146

Restricted cash and restricted cash equivalents included in Other current assets
357

 
655

Restricted cash equivalents in Other long-term assets
43

 
27

 
$
676

 
$
829
Trade accounts receivable, net [Table Text Block]
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Accounts receivable
$
1,871

 
$
1,676

Allowance for doubtful accounts
(75
)
 
(68
)
 
$
1,796

 
$
1,608


 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions)
2019
 
2018
 
2019
 
2018
Beginning balance
$
73

 
$
63

 
$
68

 
$
68

Net charges to expenses
8

 
6

 
19

 
15

Utilization of allowances
(5
)
 
(4
)
 
(11
)
 
(17
)
Ending balance
$
75

 
$
66

 
$
75

 
$
66
Inventory Disclosure [Table Text Block]
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Finished goods
$
940

 
$
760

Work-in-process
206

 
100

Raw materials
420

 
306

 
$
1,566

 
$
1,166
Property, plant and equipment, net [Table Text Block]
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Land
$
112

 
$
97

Buildings and improvements
1,160

 
1,100

Equipment, furniture and fixtures
3,368

 
3,224

Capital in progress
357

 
319

 
4,996

 
4,740

Less: accumulated depreciation
3,055

 
2,958

 
$
1,942

 
$
1,782
Schedule of Accrued Liabilities [Table Text Block]
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Legal reserves
$
328

 
$
712

Payroll and related liabilities
693

 
630

Rebates
280

 
229

Contingent consideration
112

 
138

Other
518

 
538

 
$
1,932

 
$
2,246
Other long-term liabilities [Table Text Block]
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Income taxes
$
671

 
$
739

Legal reserves
240

 
217

Contingent consideration
268

 
209

Other
1,227

 
717

 
$
2,406

 
$
1,882
XML 37 R31.htm IDEA: XBRL DOCUMENT v3.19.3
Strategic Investments (Tables)
 9 Months Ended
Sep. 30, 2019
Investments [Abstract]  
Investment [Table Text Block]
The aggregate carrying amount of our strategic investments was comprised of the following:


As of
(in millions)
September 30, 2019
 
December 31, 2018
Equity method investments
$
270

 
$
303

Measurement alternative investments (1)
173

 
94

Notes receivable
23

 
26

 
$
468

 
$
424


(1)
Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.
XML 38 R39.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]
A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows (in millions, except percentages):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Net sales
2019
 
2018
 
2019
 
2018
MedSurg
$
845

 
$
746

 
$
2,429

 
$
2,207

Rhythm and Neuro
780

 
740

 
2,323

 
2,252

Cardiovascular
1,011

 
908

 
3,009

 
2,806

Reportable segment net sales
2,636

 
2,393

 
7,760

 
7,262

BTG Acquisition(1)
71

 
n/a

 
71

 
n/a

Net sales
$
2,707

 
$
2,393

 
$
7,831

 
$
7,262

 
 
 
 
 
 
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Income (loss) before income taxes
2019
 
2018
 
2019
 
2018
MedSurg
$
319

 
$
274

 
$
870

 
$
807

Rhythm and Neuro
166

 
168

 
488

 
481

Cardiovascular
281

 
268

 
857

 
858

Operating income of reportable segments
766

 
710

 
2,216

 
2,146

BTG Acquisition(1)
16

 
n/a

 
16

 
n/a

Corporate expenses, including hedging activities
(75
)
 
(97
)
 
(215
)
 
(297
)
Intangible asset impairment charges, acquisition/divestiture-related, restructuring- and restructuring-related, litigation-related net (charges) credits and medical device regulation charges
(146
)
 
(77
)
 
(210
)
 
(225
)
Amortization expense
(178
)
 
(148
)
 
(498
)
 
(437
)
Operating income (loss)
383

 
388

 
1,308

 
1,187

Other expense, net
(292
)
 
68

 
(615
)
 
(61
)
Income (loss) before income taxes
$
91

 
$
456

 
$
693

 
$
1,126

 
 
 
 
 
 
 
 
Reportable segment operating income as a percentage of reportable segment net sales
Three Months Ended September 30,
 
Nine Months Ended September 30,
2019
 
2018
 
2019
 
2018
MedSurg
37.8
%
 
36.8
%
 
35.8
%
 
36.6
%
Rhythm and Neuro
21.3
%
 
22.7
%
 
21.0
%
 
21.4
%
Cardiovascular
27.8
%
 
29.5
%
 
28.5
%
 
30.6
%
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.19.3
New Accounting Pronouncements (Policies)
 9 Months Ended
Sep. 30, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
ASC Update No. 2016-13 [Policy Text Block]
ASC Update No. 2016-13

In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (Update No. 2016-13). The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018. We plan to adopt Update No. 2016-13 in the first quarter of 2020, and we are in the process of determining the effect that the adoption will have on our financial position and results of operations.
ASC Update No. 2018-15, Internal-Use Software [Policy Text Block]
ASC Update No. 2018-15

In August 2018, the FASB issued ASC Update No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (Update No. 2018-15). The purpose of Update No. 2018-15 is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Update No. 2018-15 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period. We plan to adopt Update No. 2018-15 in the first quarter of 2020, and we are in the process of determining the effect that the adoption will have on our financial position and results of operations.
XML 40 R20.htm IDEA: XBRL DOCUMENT v3.19.3
Revenue
 9 Months Ended
Sep. 30, 2019
Revenue from Contract with Customer [Abstract]  
Revenue from Contract with Customer [Text Block]
NOTE L – REVENUE

We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our unaudited condensed consolidated statements of operations. The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Businesses
2019
 
2018
 
2019
 
2018
Endoscopy
 
 
 
 
 
 
 
U.S.
$
277

 
$
247

 
$
800

 
$
724

International
209

 
196

 
596

 
580

Worldwide
486

 
443

 
1,396

 
1,304

 
 
 
 
 
 
 
 
Urology and Pelvic Health
 
 
 
 
 
 
 
U.S.
257

 
214

 
737

 
623

International
102

 
89

 
297

 
280

Worldwide
359

 
303

 
1,033

 
904

 
 
 
 
 
 
 
 
Cardiac Rhythm Management
 
 
 
 
 
 
 
U.S.
284

 
289

 
860

 
869

International
194

 
186

 
607

 
594

Worldwide
478

 
475

 
1,467

 
1,462

 
 
 
 
 
 
 
 
Electrophysiology
 
 
 
 
 
 
 
U.S.
38

 
37

 
113

 
111

International
43

 
39

 
132

 
119

Worldwide
81

 
76

 
245

 
230

 
 
 
 
 
 
 
 
Neuromodulation
 
 
 
 
 
 
 
U.S.
183

 
155

 
487

 
446

International
39

 
34

 
125

 
113

Worldwide
222

 
189

 
612

 
559

 
 
 
 
 
 
 
 
Interventional Cardiology
 
 
 
 
 
 
 
U.S.
327

 
283

 
942

 
859

International
373

 
332

 
1,126

 
1,062

Worldwide
700

 
615

 
2,067

 
1,922

 
 
 
 
 
 
 
 
Peripheral Interventions
 
 
 
 
 
 
 
U.S.
155

 
152

 
466

 
449

International
156

 
142

 
475

 
436

Worldwide
311

 
293

 
942

 
885

 
 
 
 
 
 
 
 
BTG Acquisition(1)
 
 
 
 
 
 
 
Interventional Medicine
48

 
 n/a

 
48

 
 n/a

Specialty Pharmaceuticals
23

 
 n/a

 
23

 
 n/a

Worldwide
71

 
n/a

 
71

 
n/a

 
 
 
 
 
 
 
 
Net Sales
$
2,707

 
$
2,393

 
$
7,831

 
$
7,262

(1)
For the first nine months of 2019, there have been no changes to our internal reporting structure, and accordingly, we have not revised our segment reporting or geographic presentation. We will continue to integrate the BTG Acquisition into our operations in the fourth quarter and will reassess our operating and reportable segments as well as geographic presentation for any changes related to our internal reporting structure as well as to the information regularly reviewed by the CODM. To the extent any changes in our operating and reportable segments are identified, these will be reflected in our segment reporting information in the period in which the change occurs. Our results of operations include the results of BTG following the acquisition date of August 19, 2019. BTG net sales are substantially U.S. based.

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Geographic Regions (Excluding BTG Acquisition)
2019
 
2018
 
2019
 
2018
U.S.
$
1,521

 
$
1,375

 
$
4,402

 
$
4,078

EMEA (Europe, Middle East and Africa)
530

 
498

 
1,662

 
1,619

APAC (Asia-Pacific)
484

 
425

 
1,402

 
1,282

Latin America and Canada
101

 
94

 
293

 
282

BTG Acquisition(1) (Worldwide)
71

 
n/a

 
71

 
n/a

Net Sales
$
2,707

 
$
2,393

 
$
7,831

 
$
7,262

 
 
 
 
 
 
 
 
Emerging Markets(2) (Excluding BTG Acquisition)
$
310

 
$
267

 
$
925

 
$
812


(1)
Our results of operations include the results of BTG following the acquisition date of August 19, 2019. BTG net sales are substantially U.S. based.
(2)
We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries. Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam. We have revised prior year amounts to the current year’s presentation. The revision had an immaterial impact on prior year Emerging Markets sales.

Deferred Revenue

Contract liabilities are classified within Other current liabilities and Other long-term liabilities on our accompanying unaudited condensed consolidated balance sheets. Our deferred revenue balance was $398 million as of September 30, 2019 and $373 million as of December 31, 2018. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We recognized revenue of $35 million in the third quarter of 2019 and $107 million in the first nine months of 2019 that was included in the above December 31, 2018 contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.

Variable Consideration

We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit and record the amount for estimated sales returns as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer.

We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.19.3
Fair Value Measurements Hedging Activities and Fair Value Measurements (Policies)
 9 Months Ended
Sep. 30, 2019
Fair Value Disclosures [Abstract]  
Fair Value Measurement, Policy [Policy Text Block] FASB ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures
Derivatives, Policy [Policy Text Block] Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.

We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.
XML 42 R45.htm IDEA: XBRL DOCUMENT v3.19.3
Strategic Investments (Details) - USD ($)
$ in Millions
Sep. 30, 2019
Dec. 31, 2018
Schedule of Investments [Line Items]    
Equity Method Investment, Difference Between Carrying Amount and Underlying Equity $ 308  
Equity method investments 270 $ 303
Measurement alternative investments (1) 173 94
Notes receivable 23 26
Investments $ 468 $ 424
XML 43 R41.htm IDEA: XBRL DOCUMENT v3.19.3
Changes in Other Comprehensive Income (Tables)
 9 Months Ended
Sep. 30, 2019
Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]  
Changes in Other Comprehensive Income [Table Text Block]
The following tables provide the reclassifications out of Other comprehensive income (loss), net of tax:
(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of June 30, 2019
$
(46
)
 
$
150

 
$
—

 
$
(26
)
 
$
78

Other comprehensive income (loss) before reclassifications
7

 
78

 
—

 
—

 
86

(Income) loss amounts reclassified from accumulated other comprehensive income
(9
)
 
(16
)
 
—

 
—

 
(26
)
Total other comprehensive income (loss)
(2
)
 
62

 
—

 
—

 
60

Balance as of September 30, 2019
$
(48
)
 
$
213

 
$
—

 
$
(26
)
 
$
138



(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of June 30, 2018
$
(68
)
 
$
79

 
$
—

 
$
(27
)
 
$
(16
)
Other comprehensive income (loss) before reclassifications
2

 
45

 
—

 
—

 
47

(Income) loss amounts reclassified from accumulated other comprehensive income
(8
)
 
1

 
—

 
—

 
(7
)
Total other comprehensive income (loss)
(6
)
 
47

 
—

 
—

 
40

Balance as of September 30, 2018
$
(74
)
 
$
126

 
$
—

 
$
(27
)
 
$
25



(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of December 31, 2018
$
(53
)
 
$
111

 
$
—

 
$
(25
)
 
$
33

Other comprehensive income (loss) before reclassifications
30

 
136

 
—

 
(1
)
 
165

(Income) loss amounts reclassified from accumulated other comprehensive income
(25
)
 
(34
)
 
—

 
—

 
(59
)
Total other comprehensive income (loss)
4

 
102

 
—

 
(1
)
 
105

Balance as of September 30, 2019
$
(48
)
 
$
213

 
$
—

 
$
(26
)
 
$
138


(in millions)
Foreign Currency Translation Adjustments
 
Net Change in Derivative Financial Instruments
 
Net Change in Available-for-Sale Securities
 
Net Change in Defined Benefit Pensions and Other Items
 
Total
Balance as of December 31, 2017
$
(32
)
 
$
1

 
$
(1
)
 
$
(27
)
 
$
(59
)
Other comprehensive income (loss) before reclassifications
(29
)
 
105

 
—

 
—

 
76

(Income) loss amounts reclassified from accumulated other comprehensive income
(13
)
 
20

 
1

 
—

 
8

Total other comprehensive income (loss)
(42
)
 
125

 
—

 
—

 
82

Balance as of September 30, 2018
$
(74
)
 
$
126

 
$
—

 
$
(27
)
 
$
25
XML 44 R49.htm IDEA: XBRL DOCUMENT v3.19.3
Supplemental Balance Sheet Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Dec. 31, 2017
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]            
Cash and Cash Equivalents $ 277 $ 168 $ 277 $ 168 $ 146  
Restricted Cash and Cash Equivalents in Other current assets 357 781 357 781 655  
Restricted Cash Equivalents in Other long-term assets 43 31 43 31 27  
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 676 980 676 980 829 $ 1,017
Trade accounts receivable, net            
Accounts receivable 1,871   1,871   1,676  
Less: allowance for doubtful accounts (75)   (75)   (68)  
Trade accounts receivable, net 1,796   1,796   1,608  
Allowance for doubtful accounts            
Beginning balance 73 63 68 68    
Charges to expenses 8 6 19 15    
Utilization of allowances (5) (4) (11) (17)    
Ending balance 75 66 75 66    
Inventories            
Inventory, Finished Goods, Net of Reserves 940   940   760  
Inventory, Work in Process, Net of Reserves 206   206   100  
Inventory, Raw Materials, Net of Reserves 420   420   306  
Inventories 1,566   1,566   1,166  
Property, plant and equipment, net            
Land 112   112   97  
Buildings and improvements 1,160   1,160   1,100  
Equipment, furniture and fixtures 3,368   3,368   3,224  
Capital in progress 357   357   319  
Property, plant and equipment 4,996   4,996   4,740  
Less: accumulated depreciation 3,055   3,055   2,958  
Property, plant and equipment, net 1,942   1,942   1,782  
Supplemental Balance Sheet Information            
Depreciation expense 79 $ 74 220 $ 212    
Accrued expenses            
Legal reserves, current 328   328   712  
Payroll and related liabilities 693   693   630  
Accrued Rebates, Current 280   280   229  
Business Combination, Contingent Consideration, Liability, Current 112   112   138  
Other 518   518   538  
Accrued expenses 1,932   1,932   2,246  
Other long-term liabilities            
Accrued income taxes 671   671   739  
Legal reserves, noncurrent 240   240   217  
Business Combination, Contingent Consideration, Liability, Noncurrent 268   268   209  
Other Accrued Liabilities, Noncurrent 1,227   1,227   717  
Other long-term liabilities 2,406   2,406   $ 1,882  
Non Acquisition Related [Member]            
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]            
Restricted Cash and Cash Equivalents in Other current assets $ 357   $ 357      
XML 45 R3.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Net income (loss) $ 126 $ 432 $ 704 $ 1,285
Other comprehensive income (loss), net of tax:        
Foreign currency translation adjustment (2) (6) 4 (42)
Net change in derivative financial instruments 62 47 102 125
Net change in defined benefit pensions and other items 0 0 (1) 0
Total other comprehensive income (loss) 60 40 105 82
Total comprehensive income (loss) $ 186 $ 472 $ 809 $ 1,367
XML 46 R7.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Cash provided by (used for) operating activities    
Cash provided by (used for) operating activities $ 1,144 $ 291
Investing activities:    
Purchases of property, plant and equipment (275) (210)
Proceeds from sale of property, plant and equipment 5 0
Payments for acquisitions of businesses, net of cash acquired (4,382) (968)
Payments for investments and acquisitions of certain technologies (137) (148)
Proceeds from divestiture of certain businesses 90 0
Payments for settlements of hedge contracts (294) 0
Cash provided by (used for) investing activities (4,992) (1,326)
Financing activities:    
Payment of contingent consideration amounts and royalty rights previously established in purchase accounting (135) (16)
Payments on short-term borrowings (1,000) 0
Proceeds from short-term borrowings, net of debt issuance costs 0 999
Net increase (decrease) in commercial paper 13 (403)
Payments on borrowings from credit facilities 0 (569)
Proceeds from borrowings on credit facilities 0 569
Payments on long-term borrowings and debt extinguishment costs (1,472) (602)
Proceeds from long-term borrowings, net of debt issuance costs 6,243 989
Cash used to net share settle employee equity awards (64) (54)
Proceeds from issuances of shares of common stock 113 94
Cash provided by (used for) financing activities 3,697 1,007
Effect of foreign exchange rates on cash (2) (9)
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents (153) (37)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period 829 1,017
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period 676 980
Supplemental Information    
Stock-based compensation expense 116 104
Fair value of contingent consideration recorded in purchase accounting $ 127 $ 190
XML 47 R52.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Contingencies (Details)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Oct. 16, 2019
claims
Dec. 31, 2018
USD ($)
Sep. 12, 2018
USD ($)
Loss Contingencies [Line Items]                
Accrual for legal matters that are probable and estimable | $ $ 568     $ 568     $ 929  
Restricted Cash and Cash Equivalents in Other current assets | $ 357   $ 781 357 $ 781   $ 655  
Litigation-related net charges (credits) | $ (25) $ (148) $ (18) 108 $ (18)      
Litigation Settlement Received, Gain | $   $ 180            
Subsequent Event [Member]                
Loss Contingencies [Line Items]                
Product liability cases or claims related to mesh product           53,000    
Putative class actions in the U.S., Mesh           8    
Product liability cases or claims related to mesh product - Canada           25    
Certified class actions in Canada, Mesh           1    
Putative class actions in Canada, Mesh           3    
Product liability cases or claims related to mesh product - United Kingdom           25    
Assigned to one judge in MA [Member] | Subsequent Event [Member]                
Loss Contingencies [Line Items]                
Product liability cases or claims related to mesh product           3,100    
Settled Litigation [Member] | Subsequent Event [Member]                
Loss Contingencies [Line Items]                
Product liability cases or claims related to mesh product           52,000    
Total Product liability cases and claims settled related to Mesh product           43,500    
Non Acquisition Related [Member]                
Loss Contingencies [Line Items]                
Restricted Cash and Cash Equivalents in Other current assets | $ $ 357     $ 357        
Upfront Cash [Member]                
Loss Contingencies [Line Items]                
Alleged Breach of Purchase Agreement, Amount | $               $ 145
Maximum Contingent Payment [Member]                
Loss Contingencies [Line Items]                
Alleged Breach of Purchase Agreement, Amount | $               $ 130
XML 48 R56.htm IDEA: XBRL DOCUMENT v3.19.3
Changes in Other Comprehensive Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Jun. 30, 2019
Dec. 31, 2018
Jun. 30, 2018
Dec. 31, 2017
Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]                
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax $ 86 $ 47 $ 165 $ 76        
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax (26) (7) (59) 8        
Total other comprehensive income (loss) 60 40 105 82        
Accumulated Other Comprehensive Income (Loss), Net of Tax 138 25 138 25 $ 78 $ 33 $ (16) $ (59)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax 7 2 30 (29)        
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax (9) (8) (25) (13)        
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax (2) (6) 4 (42)        
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax (48) (74) (48) (74) (46) (53) (68) (32)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 78 45 136 105        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (16) 1 (34) 20        
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax 0 0 0 1        
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax 62 47 102 125        
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments and Tax 0 0 0 0        
AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax 213 126 213 126 150 111 79 1
Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax 0 0 0 0        
Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax 0 0 0 0 0 0 0 (1)
Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax 0 0 1 0        
Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax 0 0 0 0        
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax 0 0 1 0        
Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax $ (26) $ (27) $ (26) $ (27) $ (26) $ (25) $ (27) $ (27)
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.19.3
Income Taxes (Tables)
 9 Months Ended
Sep. 30, 2019
Schedule of Income Tax Rate Reconciliation [Line Items]  
Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block]
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
2019
 
2018
 
2019
 
2018
Effective tax rate from continuing operations
(38.7
)%
 
5.3
%
 
(1.6
)%
 
(14.1
)%
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.19.3
Hedging Activities and Fair Value Measurements (Tables)
 9 Months Ended
Sep. 30, 2019
Derivative [Line Items]  
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]
The following table presents the contractual amounts of our derivative instruments outstanding:
(in millions)
 
FASB ASC Topic 815 Designation
 
As of
 
September 30, 2019
 
December 31, 2018
Forward currency contracts
 
Cash flow hedge
 
$
4,030

 
$
3,962

Forward currency contracts
 
Net investment hedge
 
1,935

 
1,483

Forward currency contracts
 
Non-designated
 
3,522

 
5,880

Interest rate derivative contracts
 
Cash flow hedge
 
—

 
1,000

Total Notional Outstanding
 
 
 
$
9,487

 
$
12,326
Derivative Instruments, Gain (Loss) [Table Text Block]
 
Effect of Hedging Relationships on Accumulated Other Comprehensive Income
 
Amount Recognized in OCI on Derivative
 
Unaudited Condensed Consolidated Statements of Operations (1)
 
Amount Reclassified from AOCI into Earnings
(in millions)
Pre-Tax Gain (Loss)
Tax Benefit (Expense)
Gain (Loss) Net of Tax
 
Location of Amount Reclassified
Total Amount of Line Item Presented
 
Pre-Tax (Gain) Loss
Tax (Benefit) Expense
(Gain) Loss Net of Tax
Three Months Ended September 30, 2019
Forward currency contracts
 
 
 
 
 
 
 
 
Cash flow hedges
$
101

$
(23
)
$
78

 
Cost of products sold
$
777

 
$
(22
)
$
5

$
(17
)
Net investment hedges (2)
64

(14
)
50

 
Interest expense
95

 
(12
)
3

(9
)
Interest rate derivative contracts
 
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
95

 
1

—

1

Three Months Ended September 30, 2018
Forward currency contracts
 
 
 
 
 
 
 
 
Cash flow hedges
$
58

$
(13
)
$
45

 
Cost of products sold
$
672

 
$
2

$
—

$
2

Net investment hedges (2)
4

(1
)
3

 
Interest expense
58

 
(10
)
2

(8
)
Nine Months Ended September 30, 2019
Forward currency contracts
 
 
 
 
 
 
 
 
Cash flow hedges
$
176

$
(40
)
$
136

 
Cost of products sold
$
2,265

 
$
(47
)
$
10

$
(36
)
Net investment hedges (2)
92

(21
)
71

 
Interest expense
294

 
(33
)
7

(25
)
Interest rate derivative contracts
 
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
294

 
3

(1
)
2

Nine Months Ended September 30, 2018
Forward currency contracts
 
 
 
 
 
 
 
 
Cash flow hedges
$
135

$
(30
)
$
105

 
Cost of products sold
$
2,084

 
$
27

$
(6
)
$
21

Net investment hedges (2)
25

(6
)
19

 
Interest expense
177

 
(17
)
4

(13
)
Interest rate derivative contracts
 
 
 
 
 
 
 
 
Cash flow hedges
—

—

—

 
Interest expense
177

 
(1
)
—

(1
)
Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]
As of September 30, 2019, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under FASB ASC Topic 815 that may be reclassified from AOCI to earnings within the next twelve months are presented below (in millions):
Designated Derivative Instrument
 
FASB ASC Topic 815 Designation
 
Location on Unaudited Condensed Consolidated Statements of Operations
 
Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings
Forward currency contracts
 
Cash flow hedge
 
Cost of products sold
 
$
104

Forward currency contracts
 
Net investment hedge
 
Interest expense
 
48

Interest rate derivative contracts
 
Cash flow hedge
 
Interest expense
 
(5
)
Derivatives Not Designated as Hedging Instruments [Table Text Block]
Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:
 
 
Location on Unaudited Condensed Consolidated Statements of Operations
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions)
 
 
2019
 
2018
 
2019
 
2018
Net gain (loss) on currency hedge contracts
 
Other, net
 
$
(202
)
 
$
16

 
$
(334
)
 
$
25

Net gain (loss) on currency transaction exposures
 
Other, net
 
(4
)
 
(23
)
 
—

 
(40
)
Net currency exchange gain (loss)
 
 
 
$
(207
)
 
$
(6
)
 
$
(334
)
 
$
(15
)


Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the purchase price of the BTG Acquisition. As of September 30, 2019, we settled all outstanding contracts. We recognized a $207 million loss in the third quarter of 2019 and a $323 million loss in the first nine months of 2019 in Net gain (loss) on currency hedge contracts due to changes in fair value of the contracts.

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] The following are the balances of our derivative assets and liabilities:
 
 
Location on Unaudited Condensed Consolidated Balance Sheets (1)
 
As of
(in millions)
 
 
September 30, 2019
 
December 31, 2018
Derivative Assets:
 
 
 
 
 
 
Designated Derivative Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current assets
 
$
98

 
$
55

Forward currency contracts
 
Other long-term assets
 
358

 
183

 
 
 
 
456

 
237

Non-Designated Derivative Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current assets
 
48

 
67

Total Derivative Assets
 
 
 
$
504

 
$
304

 
 
 
 
 
 
 
Derivative Liabilities:
 
 
 
 
 
 
Designated Derivative Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current liabilities
 
$
3

 
$
2

Forward currency contracts
 
Other long-term liabilities
 
5

 
3

Interest rate contracts
 
Other current liabilities
 
—

 
44

 
 
 
 
8

 
49

Non-Designated Derivative Instruments
 
 
 
 
 
 
Forward currency contracts
 
Other current liabilities
 
40

 
31

Total Derivative Liabilities
 
 
 
$
48

 
$
80

(1)
We classify derivative assets and liabilities as current when the settlement date of the derivative contract is one year or less.
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Assets and liabilities measured at fair value on a recurring basis consist of the following:
 
As of
 
September 30, 2019
 
December 31, 2018
(in millions)
Level 1
 
Level 2
 
Level 3
 
Total
 
Level 1
 
Level 2
 
Level 3
 
Total
Assets
 
 
 

 
 
 
 
 
 
 
 

 
 
 
 
Money market and government funds
$
26

 
$
—

 
$
—

 
$
26

 
$
13

 
$
—

 
$
—

 
$
13

Derivative instruments
—

 
504

 
—

 
504

 
—

 
304

 
—

 
304

Licensing arrangements
—

 
—

 
633

 
633

 
—

 
—

 
—

 
—

 
$
26

 
$
504

 
$
633

 
$
1,163

 
$
14

 
$
304

 
$
—

 
$
318

Liabilities
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Derivative instruments
$
—

 
$
48

 
$
—

 
$
48

 
$
—

 
$
80

 
$
—

 
$
80

Contingent consideration
—

 
—

 
380

 
380

 
—

 
—

 
347

 
347

Licensing arrangements
—

 
—

 
341

 
341

 
—

 
—

 
—

 
—

 
$
—

 
$
48

 
$
720

 
$
768

 
$
—

 
$
80

 
$
347

 
$
427


The recurring Level 3 fair value measurements of our licensing arrangements include the following significant unobservable inputs:
Licensing Arrangements
Fair Value as of September 30, 2019
Valuation Technique
Unobservable Input
Range
Weighted Average (1)
Financial Asset
$633 million
Discounted Cash Flow
Discount Rate
9%
9%
Projected Year of Payment
2019
-
2027
2023
Financial Liability
$341 million
Discounted Cash Flow
Discount Rate
9%
9%
Projected Year of Payment
2019
-
2027
2023
(1)
Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.
XML 51 R10.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions and Strategic Investments
 9 Months Ended
Sep. 30, 2019
Business Combinations [Abstract]  
ACQUISITIONS AND STRATEGIC INVESTMENTS
NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS

Our unaudited condensed consolidated financial statements include the operating results for acquired entities from the respective date of acquisition. With the exception of the acquisition of BTG, which was completed on August 19, 2019, we have not presented supplemental pro forma financial information for acquisitions given their results are not material to our unaudited condensed consolidated financial statements. Transaction costs for all acquisitions in 2019 and 2018 were immaterial to our unaudited condensed consolidated financial statements and were expensed as incurred.

2019 Acquisitions

We recorded immaterial purchase price adjustments to the preliminary purchase price allocations of previous acquisitions during the measurement period in the first nine months of 2019.

BTG plc

On August 19, 2019, we announced the closing of our acquisition of BTG, a public company organized under the laws of England and Wales. BTG has three key portfolios, the largest of which is its interventional medicine portfolio (Interventional Medicine) that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease. In addition to the Interventional Medicine product lines, the BTG portfolio also includes a specialty pharmaceutical business (Specialty Pharmaceuticals) comprised of acute care antidotes to treat overexposure to certain medications and toxins and a licensing portfolio (Licensing) that generates net royalties related to BTG intellectual property and product license agreements.

The transaction price consisted of upfront cash in the aggregate amount of £3.312 billion for the entire issued ordinary share capital of BTG (or $4.023 billion based on the exchange rate of U.S. $1.21: £1.00 at closing on August 19, 2019), whereby BTG shareholders received 840 pence in cash for each BTG share. The transaction price of $4.023 billion included $404 million of cash and cash equivalents acquired. We implemented the BTG Acquisition by way of a court-sanctioned scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006, as amended.

After closing the BTG Acquisition, we terminated the £150 million BTG revolving credit facility, which contained an option to increase the facility by £150 million and was scheduled to expire in November 2020. The termination was effective on August 27, 2019, and there were no amounts outstanding at the time of close of the BTG Acquisition.

Purchase Price Allocation

We accounted for the BTG Acquisition as a business combination, and in accordance with FASB ASC Topic 805, Business Combinations (FASB ASC Topic 805), we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The preliminary BTG Acquisition purchase price was comprised of the amounts presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed from the BTG Acquisition. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period as required by FASB ASC Topic 805. As of September 30, 2019, the valuation studies necessary to determine the fair market value of the assets acquired and liabilities assumed are preliminary, including the projection of the underlying cash flows used to determine the fair value of the identified tangible, intangible and financial assets and liabilities. Given the size and breadth of the BTG Acquisition, we anticipate that the purchase price allocation will take longer than prior acquisitions and potentially up to the one year allowed under FASB ASC Topic 805 to adequately analyze all the factors used in establishing the fair value of assets acquired and liabilities assumed as of the acquisition date, including, but not limited to, intangible assets, inventories, financial assets, real and personal property, leases, certain assumed liabilities, including reserves and deferred revenues, tax-related items, and the related tax and foreign currency effects of any changes made.

Any potential adjustments made could be material in relation to the preliminary values presented below:
(in millions)
 
Payment for acquisition, net of cash acquired
$
3,619



The following summarizes the BTG Acquisition preliminary purchase price allocation as of September 30, 2019:
(in millions)
 
Goodwill
$
1,549

Trade accounts receivable, net
107

Inventories
205

Other current assets
259

Other intangible assets, net
1,869

Other long-term assets
604

Accrued expenses and other current liabilities
(305
)
Other long-term liabilities
(289
)
Deferred tax liability
(380
)
 
$
3,619



As a result of the BTG Acquisition, we recognized goodwill of $1.549 billion, which is attributable to the synergies expected to arise from the BTG Acquisition and revenue and cash flow projections associated with future technologies. The goodwill is not deductible for tax purposes. As of September 30, 2019, given the preliminary nature of the purchase price allocation, we have not yet allocated goodwill to the relevant reporting units.

We acquired certain intellectual property and related licensing arrangements, principally relating to Zytiga™, as part of the BTG Acquisition that provides the contractual right to receive future royalty payments. The licensing arrangements were accounted for as financial assets as part of acquisition accounting and were recognized at fair value based upon a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. Additionally, as part of the intellectual property related to the licensing arrangements that we acquired we also have the contractual obligation to remit a portion of the cash flows received to the inventors associated with the intellectual property. As such, as part of acquisition accounting we have recorded a financial liability related to the future cash flows we are required to remit to the inventors when we collect the royalty payments. The amount recognized for the financial asset was $633 million in aggregate, comprised of $200 million included in Other current assets and $432 million included in Other long-term assets. The amount recognized for the financial liability was $395 million, comprised of $153 million included in Accrued expenses and other current liabilities and $241 million included in Other long-term liabilities.

We allocated a portion of the BTG Acquisition preliminary purchase price to specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
 
 
 
 
Technology-related
$
1,794

 
10
-
17
 
10
%
-
12%
Other intangible assets
75

 
2
-
11
 
11%
 
$
1,869

 
 
 
 
 
 
 
 


As a result of the BTG Acquisition, we assumed a benefit obligation related to a defined benefit pension plan sponsored by BTG for eligible United Kingdom (U.K.) employees (U.K. Plan). The U.K. Plan was closed to new entrants as of June 1, 2004. Prior to the acquisition close date of August 19, 2019, the Trustees of the U.K. Plan executed buy-in arrangements (Buy-in Contracts), under which the benefit obligation of the pension plan is not transferred to the insurers, and we remain responsible for paying pension benefits. Effectively, the Buy-in Contracts are intended to provide payments designed to equal all future designated contractual benefit payments to covered participants. We do not anticipate any additional material contributions or payments to the U.K. Plan or the insurer.

The following assumptions were used to measure the fair value of the benefit obligation and associated plan assets:
 
Discount Rate
 
Expected Return on Plan Assets
 
Rate of Compensation Increase
U.K. Plan
0.4%
 
0.4%
 
3.4%


As of the measurement date of August 19, 2019, the funded status recognized in our unaudited condensed consolidated balance sheets was as follows:
(in millions)
 
Fair value of plan assets
$
213

Benefit obligation
(216
)
Funded status
$
(3
)

BTG Pro Forma Financial Information (unaudited)
BTG contributed $71 million to our Net sales and immaterial amounts to our Net income (loss) for the period from August 19, 2019 through September 30, 2019.

The unaudited estimated pro forma results presented below include the effects of the BTG Acquisition as if it was consummated on January 1, 2018. In the third quarter and first nine months of 2019, we incurred nonrecurring charges that we attributed to the BTG Acquisition, which are presented in our unaudited condensed consolidated statements of operations for these periods. These nonrecurring charges that are attributable to the BTG Acquisition include immaterial amounts of acquisition-related costs, stock-based compensation expenses as a result of the change in control and retention bonuses and severance payments, adjusted for the related tax effects. We have reflected these nonrecurring charges as adjustments to the pro forma earnings presented below for the third quarter and first nine months of 2019 and 2018.

Additionally, these pro forma amounts have been calculated after applying our accounting policies and adjusting the results of BTG to reflect the additional costs associated with fair value adjustments relating to inventories, property, plant, and equipment, and intangible assets as if the BTG Acquisition had occurred on January 1, 2018, with the consequential tax effects. Additionally, the pro forma amounts have been adjusted to reflect the amortization of deferred financing costs and interest expense associated with additional financing entered into as part of the BTG Acquisition. The pro forma results exclude BTG’s historical licensing revenue and related cost of sales, as these arrangements are accounted for as part of the BTG Acquisition as a financial asset and liability and are not accounted for within the scope of FASB ASC Topic 606, Revenue from Contracts with Customers.

The supplemental pro forma information presented below is for informational purposes only and should be read in conjunction with our historical financial statements. The pro forma results do not include any anticipated synergies or other expected benefits of the BTG Acquisition. Accordingly, the unaudited estimated pro forma financial information below is not necessarily indicative of what the actual results of operations of the combined companies would have been had the BTG Acquisition occurred as of January 1, 2018, nor are they indicative of future results of operations. We believe that the pro forma assumptions and adjustments are reasonable and appropriate under the circumstances and are factually supported based on information currently available.

 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions, except per share data)
2019
 
2018
 
2019
 
2018
Net sales
$
2,795

 
$
2,561

 
$
8,237

 
$
7,740

Net income (loss)
152

 
332

 
599

 
950

Net income (loss) per common share — basic
$
0.11

 
$
0.24

 
$
0.43

 
$
0.69

Net income (loss) per common share — assuming dilution
$
0.11

 
$
0.24

 
$
0.42

 
$
0.68


Transaction with Varian Medical Systems, Inc.

On August 21, 2019, we completed the sale of our drug-eluting and bland embolic microsphere portfolio to Varian Medical Systems, Inc. (Varian) in connection with the BTG Acquisition. The transaction price consisted of an upfront cash payment of $90 million, a portion of which is allocated to the fair value of the services to be rendered under the Transition Services Agreement and Transition Manufacturing Agreement entered into with Varian as part of this transaction. Additionally, we transferred certain contingent consideration arrangements arising from our initial acquisition of the portfolio to Varian and agreed to indemnify Varian for any payments ultimately arising under the terms of the contingent consideration arrangement. Accordingly, as part of the disposal, we recorded a liability of $16 million to recognize the fair value of this guarantee based on our potential obligation resulting from the indemnifications. The maximum amount payable under this guarantee is $200 million in accordance with FASB ASC Topic 460, Guarantees, which is consistent with the contingent consideration arrangement executed with our initial acquisition of the portfolio in accordance with FASB ASC Topic 805.

Vertiflex, Inc.

On June 11, 2019, we announced the closing of our acquisition of Vertiflex, Inc. (Vertiflex), a privately-held company which has developed and commercialized the Superion™ Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS). The transaction price consisted of an upfront cash payment of $465 million and contingent payments that are based on a percentage of Vertiflex sales growth in the first three years following the acquisition close. We estimate the sales-based contingent payments to be in a range of zero to $100 million; however, the payments are uncapped over the three year term. Vertiflex is part of our Neuromodulation business.

Millipede, Inc.

On January 29, 2019, we announced the closing of our acquisition of Millipede, Inc. (Millipede), a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation. We have been an investor in Millipede since the first quarter of 2018 as part of an investment and acquisition option agreement, whereby we purchased a portion of the outstanding shares of Millipede, along with newly issued shares of the company, for an upfront cash payment of $90 million. We held an interest of approximately 20 percent immediately prior to the acquisition date. In the fourth quarter of 2018, upon the recent successful completion of a first-in-human clinical study, we exercised our option to acquire the remaining shares of Millipede. We remeasured the fair value of our previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests. The transaction price for the remaining stake consisted of an upfront cash payment of $325 million and up to an additional $125 million payment upon achievement of a commercial milestone. Millipede is part of our Interventional Cardiology business.

Purchase Price Allocation

We accounted for our 2019 acquisitions of Vertiflex and Millipede as business combinations, and in accordance with FASB ASC Topic 805, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components:
(in millions)
 
Payments for acquisitions, net of cash acquired
$
763

Fair value of contingent consideration
127

Fair value of prior interests
102

 
$
992



The preliminary purchase price allocations of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of September 30, 2019:
(in millions)
 
Goodwill
$
575

Amortizable intangible assets
220

Indefinite-lived intangible assets
240

Other assets acquired
24

Liabilities assumed
(12
)
Net deferred tax liabilities
(56
)
 
$
992



We allocated a portion of the preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, to the specific intangible asset categories as follows:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
Technology-related
$
210

 
12
 
15%
Other intangible assets
10

 
12
 
15%
Indefinite-lived intangible assets:
 
 
 
 
 
In-process research and development (IPR&D)
240

 
N/A
 
19%
 
$
461

 
 
 
 


2018 Acquisitions

We recorded immaterial purchase price adjustments to the preliminary purchase price allocations of previous acquisitions during the measurement period in the first nine months of 2019.

Claret Medical, Inc.

On August 2, 2018, we announced the closing of our acquisition of Claret Medical, Inc. (Claret), a privately-held company that has developed and commercialized the Sentinel™ Cerebral Embolic Protection System. The device is used to protect the brain during certain interventional procedures, predominately in patients undergoing transcatheter aortic valve replacement (TAVR). The transaction price consisted of an upfront cash payment of $220 million and an additional $50 million payment for reaching a reimbursement-based milestone that was achieved in the third quarter of 2018. Claret is part of our Interventional Cardiology business.

Cryterion Medical, Inc.

On July 5, 2018, we announced the closing of our acquisition of Cryterion Medical, Inc. (Cryterion), a privately-held company developing a single-shot cryoablation platform for the treatment of atrial fibrillation. We have been an investor in Cryterion since 2016 and held an interest of approximately 35 percent immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of $202 million. Cryterion is part of our Electrophysiology business.

NxThera, Inc.

On April 30, 2018, we announced the closing of our acquisition of NxThera, Inc. (NxThera), a privately-held company that developed the Rezūm™ System, a minimally invasive therapy in a growing category of treatment options for patients with benign prostatic hyperplasia (BPH). We held a minority interest immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of approximately $240 million and up to approximately $85 million in payments contingent upon commercial milestones over the four years following the date of acquisition. NxThera is part of our Urology and Pelvic Health business.

nVision Medical Corporation

On April 16, 2018, we announced the closing of our acquisition of nVision Medical Corporation (nVision), a privately-held company focused on women’s health. nVision developed the first and only device cleared by the U.S. Food and Drug Administration (FDA) to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. The transaction price consisted of an upfront cash payment of $150 million and up to an additional $125 million in payments contingent upon clinical and commercial milestones over the four years following the date of acquisition. nVision is part of our Urology and Pelvic Health business.

In addition, we completed other individually immaterial acquisitions in the first nine months of 2018 for total consideration of $158 million in cash at closing plus aggregate contingent consideration of up to $62 million.

We recorded gains of $142 million in the third quarter of 2018 and $182 million in the first nine months of 2018 within Other, net on our unaudited condensed consolidated statements of operations based on the difference between the book values and the fair values of our previously-held investments immediately prior to the acquisition dates. The aggregate fair value of our previously-held investments immediately prior to the acquisition dates was $251 million. We remeasured the fair value of each previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests.

Purchase Price Allocation

We accounted for our 2018 acquisitions as business combinations, and in accordance with FASB ASC Topic 805, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The components of the aggregate purchase prices are as follows for our 2018 acquisitions as of September 30, 2019:
(in millions)
 
Payments for acquisitions, net of cash acquired
$
969

Fair value of contingent consideration
190

Fair value of prior interests
251

 
$
1,410



The following summarizes the aggregate purchase price allocations for our 2018 acquisitions as of September 30, 2019:
(in millions)
 
Goodwill
$
618

Amortizable intangible assets
707

Indefinite-lived intangible assets
213

Other assets acquired
19

Liabilities assumed
(14
)
Net deferred tax liabilities
(134
)
 
$
1,410



We allocated a portion of the aggregate purchase prices to specific intangible asset categories as follows for our 2018 acquisitions as of September 30, 2019:
 
Amount Assigned
(in millions)
 
Amortization Period
(in years)
 
Risk-Adjusted Discount
Rates used in Purchase Price Allocation
Amortizable intangible assets:
 
 
 
 
 
 
 
 
 
Technology-related
$
697

 
10
-
14
 
17
%
-
23%
Other intangible assets
10

 
6
-
13
 
13
%
-
15%
Indefinite-lived intangible assets:
 
 
 
 
 
 
 
 
 
IPR&D
213

 
N/A
 
15%
 
$
920

 
 
 
 
 
 
 
 


Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.

Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations as well as revenue and cash flow projections associated with future technologies and has been allocated to our reportable segments based on the relative expected benefit. Based on preliminary estimates updated for applicable regulatory changes, the goodwill recorded relating to our 2019 and 2018 acquisitions is not deductible for tax purposes.

Contingent Consideration

Changes in the fair value of our contingent consideration liability were as follows:
(in millions)
 
Balance as of December 31, 2018
$
347

Amount recorded related to current year acquisitions
127

Contingent consideration arrangements transferred to Varian
(16
)
Contingent consideration expense (benefit)
(9
)
Contingent consideration payments
(68
)
Balance as of September 30, 2019
$
380



As of September 30, 2019, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay was $747 million, which includes our estimate of maximum contingent payments of $100 million associated with the Vertiflex acquisition described above. The maximum decreased $126 million compared to the amount as of December 31, 2018 primarily due to the contingent consideration arrangement which is now accounted for as a guarantee in connection with our transaction with Varian as discussed in the BTG section above.

The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:
Contingent Consideration Liability
Fair Value as of September 30, 2019
Valuation Technique
Unobservable Input
Range
Weighted Average (1)
R&D, Regulatory and Commercialization-based Milestones
$220 million
Discounted Cash Flow
Discount Rate
2
%
-
3%
3%
Probability of Payment
50
%
-
90%
84%
Projected Year of Payment
2019

-
2027
2020
Revenue-based Payments
$160 million
Discounted Cash Flow
Discount Rate
11
%
-
15%
13%
Probability of Payment
60
%
-
100%
99%
Projected Year of Payment
2019

-
2026
2021

(1)
Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.

Projected contingent payment amounts related to some of our research and development (R&D), commercialization-based and revenue-based milestones are discounted back to the current period using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of September 30, 2019.

Strategic Investments

The aggregate carrying amount of our strategic investments was comprised of the following:


As of
(in millions)
September 30, 2019
 
December 31, 2018
Equity method investments
$
270

 
$
303

Measurement alternative investments (1)
173

 
94

Notes receivable
23

 
26

 
$
468

 
$
424


(1)
Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

These investments are classified as Other long-term assets within our accompanying unaudited condensed consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies.

As of September 30, 2019, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by $308 million, which represents amortizable intangible assets, IPR&D, goodwill and deferred tax liabilities.
XML 52 R14.htm IDEA: XBRL DOCUMENT v3.19.3
Supplemental Balance Sheet Information
 9 Months Ended
Sep. 30, 2019
Supplemental Balance Sheet Information [Abstract]  
SUPPLEMENTAL BALANCE SHEET INFORMATION
NOTE F – SUPPLEMENTAL BALANCE SHEET INFORMATION

Components of selected captions in our accompanying unaudited condensed consolidated balance sheets are as follows:

Cash, cash equivalents, restricted cash and restricted cash equivalents
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Cash and cash equivalents
$
277

 
$
146

Restricted cash and restricted cash equivalents included in Other current assets
357

 
655

Restricted cash equivalents in Other long-term assets
43

 
27

 
$
676

 
$
829



Trade accounts receivable, net
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Accounts receivable
$
1,871

 
$
1,676

Allowance for doubtful accounts
(75
)
 
(68
)
 
$
1,796

 
$
1,608



The following is a rollforward of our allowance for doubtful accounts:
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions)
2019
 
2018
 
2019
 
2018
Beginning balance
$
73

 
$
63

 
$
68

 
$
68

Net charges to expenses
8

 
6

 
19

 
15

Utilization of allowances
(5
)
 
(4
)
 
(11
)
 
(17
)
Ending balance
$
75

 
$
66

 
$
75

 
$
66



Inventories
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Finished goods
$
940

 
$
760

Work-in-process
206

 
100

Raw materials
420

 
306

 
$
1,566

 
$
1,166



Property, plant and equipment, net
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Land
$
112

 
$
97

Buildings and improvements
1,160

 
1,100

Equipment, furniture and fixtures
3,368

 
3,224

Capital in progress
357

 
319

 
4,996

 
4,740

Less: accumulated depreciation
3,055

 
2,958

 
$
1,942

 
$
1,782



Depreciation expense was $79 million for the third quarter of 2019, $74 million for the third quarter of 2018, $220 million for the
first nine months of 2019 and $212 million for the first nine months of 2018.

Accrued expenses
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Legal reserves
$
328

 
$
712

Payroll and related liabilities
693

 
630

Rebates
280

 
229

Contingent consideration
112

 
138

Other
518

 
538

 
$
1,932

 
$
2,246



Other long-term liabilities
 
As of
(in millions)
September 30, 2019
 
December 31, 2018
Income taxes
$
671

 
$
739

Legal reserves
240

 
217

Contingent consideration
268

 
209

Other
1,227

 
717

 
$
2,406

 
$
1,882
XML 53 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 54 R18.htm IDEA: XBRL DOCUMENT v3.19.3
Weighted Average Shares Outstanding
 9 Months Ended
Sep. 30, 2019
Earnings Per Share [Abstract]  
Weighted Average Number Of Shares Outstanding [Text Block]
NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
(in millions)
2019

2018
 
2019
 
2018
Weighted average shares outstanding - basic
1,393.1

 
1,382.8

 
1,390.6

 
1,380.0

Net effect of common stock equivalents
19.0

 
21.0

 
19.1

 
19.9

Weighted average shares outstanding - assuming dilution
1,412.2

 
1,403.9

 
1,409.7

 
1,399.8


The impact of stock options outstanding with exercise prices greater than the average fair market value of our common stock was immaterial for all periods presented.

We issued approximately two million shares of our common stock in the third quarter of 2019, approximately two million shares of our common stock in the third quarter of 2018, approximately nine million shares of our common stock in the first nine months of 2019 and approximately 10 million shares of our common stock in the first nine months of 2018, following the exercise of stock options, vesting of deferred stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock in the first nine months of 2019 or 2018.
XML 55 R22.htm IDEA: XBRL DOCUMENT v3.19.3
New Accounting Pronouncements
 9 Months Ended
Sep. 30, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]  
Description of New Accounting Pronouncements Not yet Adopted [Text Block]
NOTE N – NEW ACCOUNTING PRONOUNCEMENTS

Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our unaudited condensed consolidated financial statements.

Standards to be Implemented

ASC Update No. 2016-13

In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (Update No. 2016-13). The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018. We plan to adopt Update No. 2016-13 in the first quarter of 2020, and we are in the process of determining the effect that the adoption will have on our financial position and results of operations.

ASC Update No. 2018-15

In August 2018, the FASB issued ASC Update No. 2018-15, Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (Update No. 2018-15). The purpose of Update No. 2018-15 is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Update No. 2018-15 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period. We plan to adopt Update No. 2018-15 in the first quarter of 2020, and we are in the process of determining the effect that the adoption will have on our financial position and results of operations.

No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our unaudited condensed consolidated financial statements.
XML 56 R26.htm IDEA: XBRL DOCUMENT v3.19.3
Commitments and Contingencies Commitments and Contingencies (Policies)
 9 Months Ended
Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]  
Legal Costs, Policy [Policy Text Block]
In accordance with FASB ASC Topic 450, Contingencies, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.19.3
Hedging Activities and Fair Value Measurements (Details)
£ in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
Rate
Sep. 30, 2018
USD ($)
Sep. 30, 2019
GBP (£)
units
Sep. 30, 2019
USD ($)
units
Dec. 31, 2018
USD ($)
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Payments for Hedge, Investing Activities     $ 294 $ 0      
Derivative, Notional Amount           $ 9,487 $ 12,326
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax $ 78 $ 45 136 105      
Cost of Goods and Services Sold 777 672 2,265 2,084      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 16 (1) 34 (20)      
Interest Expense 95 58 294 177      
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax (9) (8) $ (25) (13)      
Derivative Asset, Fair Value, Gross Asset           504 304
Cash           249 133
Derivative Liability, Fair Value, Gross Liability           48 80
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Debt Instrument, Fair Value Disclosure           11,990 7,239
Business Combination, Contingent Consideration, Liability           380 347
Fair Value, Inputs, Level 3 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Discount Rate, Fair Value Input     9.00%        
Fair Value, Measurements, Recurring [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Money Market Funds, at Carrying Value           26 13
Derivative Asset           504 304
Licensing arrangements, asset           633 0
Derivative Liability           48 80
Business Combination, Contingent Consideration, Liability           380 347
Licensing arrangements, liability           341 0
Financial and Nonfinancial Liabilities, Fair Value Disclosure           768 427
Assets, Fair Value Disclosure           1,163 318
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Money Market Funds, at Carrying Value           26 13
Derivative Asset           0 0
Licensing arrangements, asset           0 0
Derivative Liability           0 0
Business Combination, Contingent Consideration, Liability           0 0
Licensing arrangements, liability           0 0
Financial and Nonfinancial Liabilities, Fair Value Disclosure           0 0
Assets, Fair Value Disclosure           26 14
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Money Market Funds, at Carrying Value           0 0
Derivative Asset           504 304
Licensing arrangements, asset           0 0
Derivative Liability           48 80
Business Combination, Contingent Consideration, Liability           0 0
Licensing arrangements, liability           0 0
Financial and Nonfinancial Liabilities, Fair Value Disclosure           48 80
Assets, Fair Value Disclosure           504 304
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Money Market Funds, at Carrying Value           0 0
Derivative Asset           0 0
Licensing arrangements, asset           633 0
Derivative Liability           0 0
Business Combination, Contingent Consideration, Liability           380 347
Licensing arrangements, liability           341 0
Financial and Nonfinancial Liabilities, Fair Value Disclosure           720 347
Assets, Fair Value Disclosure           633 0
Designated as Hedging Instrument [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative Instruments in Hedges, Assets, at Fair Value           456 237
Derivative Instruments in Hedges, Liabilities, at Fair Value           $ 8 49
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Forward Currency Contracts, Time to Maturity | units         60 60  
Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative, Notional Amount           $ 3,522 5,880
Not Designated as Hedging Instrument [Member] | BTG Acquisition [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Cash         £ 3,312 4,303  
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative, Notional Amount           4,030 3,962
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Interest Rate Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative, Notional Amount           0 1,000
Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative, Notional Amount           1,935 1,483
Weighted Average [Member] | Fair Value, Inputs, Level 3 [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Discount Rate, Fair Value Input     9.00%        
Cost of Sales [Member] | Cash Flow Hedging [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months           104  
Cost of Sales [Member] | Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 101 58 $ 176 135      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax (23) (13) (40) (30)      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 78 45 136 105      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax (22) 2 (47) 27      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax 5 0 10 (6)      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax (17) 2 (36) 21      
Interest Expense [Member] | Cash Flow Hedging [Member] | Interest Rate Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net           (5)  
Interest Expense [Member] | Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Interest Rate Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax 0   0 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax 0   0 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 0   0 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax 1   (3) (1)      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax 0   (1) 0      
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 1   2 (1)      
Interest Expense [Member] | Net Investment Hedging [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net           48  
Interest Expense [Member] | Net Investment Hedging [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax 64 4 92 25      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax (14) (1) (21) (6)      
Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax 50 3 71 19      
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax (12) (10) (33) (17)      
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax 3 2 7 4      
Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax 9 8 (25) 13      
Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments (202) 16 (334) 25      
Foreign Currency Transaction Gain (Loss), before Tax (4) (23) 0 (40)      
Net currency exchange gain (loss) (207) $ (6) (334) $ (15)      
Other Nonoperating Income (Expense) [Member] | Not Designated as Hedging Instrument [Member] | BTG Acquisition [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments $ (207)   $ (323)        
R&D, Regulatory and Commercialization-based Milestone [Member] | Valuation Technique, Discounted Cash Flow [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Business Combination, Contingent Consideration, Liability           220  
R&D, Regulatory and Commercialization-based Milestone [Member] | Weighted Average [Member] | Valuation Technique, Discounted Cash Flow [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Discount Rate, Fair Value Input     3.00%        
R&D, Regulatory and Commercialization-based Milestone [Member] | Minimum [Member] | Valuation Technique, Discounted Cash Flow [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Discount Rate, Fair Value Input     2.00%        
R&D, Regulatory and Commercialization-based Milestone [Member] | Maximum [Member] | Valuation Technique, Discounted Cash Flow [Member]              
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]              
Discount Rate, Fair Value Input | Rate     3.00%        
Prepaid Expenses and Other Current Assets [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative Instruments in Hedges, Assets, at Fair Value           98 55
Prepaid Expenses and Other Current Assets [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value           48 67
Other Noncurrent Assets [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative Instruments in Hedges, Assets, at Fair Value           358 183
Other Current Liabilities [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative Instruments in Hedges, Liabilities, at Fair Value           3 2
Other Current Liabilities [Member] | Designated as Hedging Instrument [Member] | Interest Rate Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative Instruments in Hedges, Liabilities, at Fair Value           0 44
Other Current Liabilities [Member] | Not Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value           40 31
Other Noncurrent Liabilities [Member] | Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member]              
Derivative Instruments and Hedging Activities Disclosures [Line Items]              
Derivative Instruments in Hedges, Liabilities, at Fair Value           $ 5 $ 3
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions (Details)
£ / shares in Units, $ / shares in Units, £ in Millions
 3 Months Ended 9 Months Ended
Aug. 21, 2019
USD ($)
Aug. 19, 2019
GBP (£)
Jun. 11, 2019
USD ($)
Jan. 29, 2019
USD ($)
Aug. 02, 2018
USD ($)
Jul. 05, 2018
USD ($)
Apr. 30, 2018
USD ($)
Apr. 16, 2018
USD ($)
Sep. 30, 2019
USD ($)
$ / shares
Sep. 30, 2018
USD ($)
$ / shares
Sep. 30, 2019
USD ($)
$ / shares
Sep. 30, 2018
USD ($)
$ / shares
Sep. 30, 2019
GBP (£)
Sep. 30, 2019
USD ($)
Aug. 19, 2019
USD ($)
Aug. 19, 2019
£ / shares
Dec. 31, 2018
USD ($)
Business Acquisition [Line Items]                                  
Revenue from Contract with Customer, Excluding Assessed Tax                 $ 2,707,000,000 $ 2,393,000,000 $ 7,831,000,000 $ 7,262,000,000          
Proceeds from Divestiture of Businesses $ 90,000,000                   90,000,000 0          
Business Acquisition, Pro Forma Revenue                 2,795,000,000 2,561,000,000 8,237,000,000 7,740,000,000          
Assets for Plan Benefits, Defined Benefit Plan                           $ 213,000,000      
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate                         0.40% 0.40%      
Operating Lease, Payments                     55,000,000            
Interest Expense                 95,000,000 58,000,000 294,000,000 177,000,000          
Payments to Acquire Businesses, Net of Cash Acquired                     4,382,000,000 968,000,000          
Accounts, Notes, Loans and Financing Receivable, Net, Current                           $ 1,796,000,000     $ 1,608,000,000
Inventory, Net                           1,566,000,000     1,166,000,000
Other Assets, Current                           1,020,000,000     921,000,000
Other Intangible Assets, Net                           8,074,000,000     6,372,000,000
Other Assets, Noncurrent                           1,879,000,000     932,000,000
Accrued Liabilities, Current                           (1,932,000,000)     (2,246,000,000)
Other Liabilities, Noncurrent                           2,406,000,000     1,882,000,000
Deferred Tax Liabilities, Net, Noncurrent                           (807,000,000)     (328,000,000)
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High                           747,000,000      
Other Nonoperating Income (Expense)                   142,000,000   182,000,000          
Business Combination, Contingent Consideration, Liability                           380,000,000     347,000,000
Goodwill                           $ 10,015,000,000     $ 7,911,000,000
Goodwill, Acquired During Period                     $ 2,124,000,000            
Defined Benefit Plan, Expected Return (Loss) on Plan Assets                     0.40%            
Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase                         3.40% 3.40%      
Defined Benefit Plan, Benefit Obligation                           $ (216,000,000)      
Defined Benefit Plan, Funded (Unfunded) Status of Plan                           (3,000,000)      
Business Acquisition, Pro Forma Net Income (Loss)                 $ 152,000,000 $ 332,000,000 $ 599,000,000 $ 950,000,000          
Business Acquisition, Pro Forma Earnings Per Share, Basic | $ / shares                 $ 0.11 $ 0.24 $ 0.43 $ 0.69          
Business Acquisition, Pro Forma Earnings Per Share, Diluted | $ / shares                 $ 0.11 $ 0.24 $ 0.42 $ 0.68          
BTG intellectual property [Member]                                  
Business Acquisition [Line Items]                                  
Other Assets, Current                           200,000,000      
Other Assets, Noncurrent                           432,000,000      
Other Liabilities, Noncurrent                           241,000,000      
Other Assets                           633,000,000      
Other Liabilities                           395,000,000      
Accrued Liabilities and Other Liabilities                           153,000,000      
BTG Acquisition [Member]                                  
Business Acquisition [Line Items]                                  
Revenue from Contract with Customer, Excluding Assessed Tax                 $ 71,000,000   $ 71,000,000            
Business Acquisition, Share Price | £ / shares                               £ 8.40  
Payments to Acquire Businesses, Net of Cash Acquired   £ 3,312             4,023,000,000.000   3,619,000,000            
Accounts, Notes, Loans and Financing Receivable, Net, Current                           107,000,000      
Inventory, Net                           205,000,000      
Other Assets, Current                           259,000,000      
Other Intangible Assets, Net                           1,869,000,000      
Other Assets, Noncurrent                           604,000,000      
Accrued Liabilities, Current                           (305,000,000)      
Other Liabilities, Noncurrent                           (289,000,000)      
Deferred Tax Liabilities, Net, Noncurrent                           (380,000,000)      
Cash Acquired from Acquisition                 $ 404,000,000                
Termination Loans | £                         £ 150        
Goodwill                           $ 1,549,000,000      
Exchange Rate, USD                             $ 1.21    
Intangible Assets Acquired, Finite and Indefinite-lived                     1,869,000,000            
BTG Acquisition [Member] | Technology-Based Intangible Assets [Member]                                  
Business Acquisition [Line Items]                                  
Finite-lived Intangible Assets Acquired                     $ 1,794,000,000            
BTG Acquisition [Member] | Technology-Based Intangible Assets [Member] | Minimum [Member]                                  
Business Acquisition [Line Items]                                  
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life                     10 years            
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                         10.00% 10.00%      
BTG Acquisition [Member] | Technology-Based Intangible Assets [Member] | Maximum [Member]                                  
Business Acquisition [Line Items]                                  
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life                     17 years            
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                         12.00% 12.00%      
BTG Acquisition [Member] | Other Intangible Assets [Member]                                  
Business Acquisition [Line Items]                                  
Finite-lived Intangible Assets Acquired                     $ 75,000,000            
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                         11.00% 11.00%      
BTG Acquisition [Member] | Other Intangible Assets [Member] | Minimum [Member]                                  
Business Acquisition [Line Items]                                  
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life                     2 years            
BTG Acquisition [Member] | Other Intangible Assets [Member] | Maximum [Member]                                  
Business Acquisition [Line Items]                                  
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life                     11 years            
Vertiflex, Inc. [Member]                                  
Business Acquisition [Line Items]                                  
Payments to Acquire Businesses, Gross     $ 465,000,000                            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low     0                            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High     $ 100,000,000                            
Millipede, Inc. [Member]                                  
Business Acquisition [Line Items]                                  
Business Combination, Consideration Transferred       $ 90,000,000                          
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage       20.00%                          
Payments to Acquire Businesses, Gross       $ 325,000,000                          
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High       $ 125,000,000                          
2018 Acquisitions [Member]                                  
Business Acquisition [Line Items]                                  
Payments to Acquire Businesses, Net of Cash Acquired                     $ 969,000,000            
Business Combination, Contingent Consideration, Liability                           $ 190,000,000      
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value                     251,000,000            
Goodwill                           618,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                           707,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets                           213,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets                           19,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities                           (14,000,000)      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities                           $ (134,000,000)      
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination                     1,410,000,000            
Intangible Assets Acquired, Finite and Indefinite-lived                     920,000,000            
2018 Acquisitions [Member] | Purchased research and development [Member]                                  
Business Acquisition [Line Items]                                  
Indefinite-lived Intangible Assets Acquired                     213,000,000            
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                         15.00% 15.00%      
2018 Acquisitions [Member] | Technology-Based Intangible Assets [Member]                                  
Business Acquisition [Line Items]                                  
Finite-lived Intangible Assets Acquired                     $ 697,000,000            
2018 Acquisitions [Member] | Technology-Based Intangible Assets [Member] | Minimum [Member]                                  
Business Acquisition [Line Items]                                  
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life                     10 years            
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                         17.00% 17.00%      
2018 Acquisitions [Member] | Technology-Based Intangible Assets [Member] | Maximum [Member]                                  
Business Acquisition [Line Items]                                  
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life                     14 years            
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                         23.00% 23.00%      
2018 Acquisitions [Member] | Other Intangible Assets [Member]                                  
Business Acquisition [Line Items]                                  
Finite-lived Intangible Assets Acquired                     $ 10,000,000            
2018 Acquisitions [Member] | Other Intangible Assets [Member] | Minimum [Member]                                  
Business Acquisition [Line Items]                                  
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life                     6 years            
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                         13.00% 13.00%      
2018 Acquisitions [Member] | Other Intangible Assets [Member] | Maximum [Member]                                  
Business Acquisition [Line Items]                                  
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life                     13 years            
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                         15.00% 15.00%      
Claret [Member]                                  
Business Acquisition [Line Items]                                  
Payments to Acquire Businesses, Gross         $ 220,000,000         $ 50,000,000              
Cryterion [Member]                                  
Business Acquisition [Line Items]                                  
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage           35.00%                      
Payments to Acquire Businesses, Gross           $ 202,000,000                      
NxThera [Member]                                  
Business Acquisition [Line Items]                                  
Payments to Acquire Businesses, Gross             $ 240,000,000                    
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High             $ 85,000,000                    
nVision [Member]                                  
Business Acquisition [Line Items]                                  
Payments to Acquire Businesses, Gross               $ 150,000,000                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High               $ 125,000,000                  
Other 2018 Acquisitions [Member]                                  
Business Acquisition [Line Items]                                  
Payments to Acquire Businesses, Gross                       $ 158,000,000          
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High                   $ 62,000,000   $ 62,000,000          
2019 Acquisitions [Member]                                  
Business Acquisition [Line Items]                                  
Payments to Acquire Businesses, Net of Cash Acquired                     $ 763,000,000            
Business Combination, Contingent Consideration, Liability                           $ 127,000,000      
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value                     102,000,000            
Goodwill                           575,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles                           220,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets                           240,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets                           24,000,000      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities                           (12,000,000)      
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities                           $ (56,000,000)      
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination                     992,000,000            
Intangible Assets Acquired, Finite and Indefinite-lived                     461,000,000            
2019 Acquisitions [Member] | Purchased research and development [Member]                                  
Business Acquisition [Line Items]                                  
Indefinite-lived Intangible Assets Acquired                     240,000,000            
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                         19.00% 19.00%      
2019 Acquisitions [Member] | Technology-Based Intangible Assets [Member]                                  
Business Acquisition [Line Items]                                  
Finite-lived Intangible Assets Acquired                     $ 210,000,000            
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life                     12 years            
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                         15.00% 15.00%      
2019 Acquisitions [Member] | Other Intangible Assets [Member]                                  
Business Acquisition [Line Items]                                  
Finite-lived Intangible Assets Acquired                     $ 10,000,000            
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life                     12 years            
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation                         15.00% 15.00%      
divested business due to BTG acquisition [Member]                                  
Business Acquisition [Line Items]                                  
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 200,000,000                                
Business Combination, Contingent Consideration, Liability $ 16,000,000                                
XML 59 R23.htm IDEA: XBRL DOCUMENT v3.19.3
Basis of Presentation Basis of Presentation (Policies)
 9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
Lessee, Leases [Policy Text Block] Operating lease right-of-use assets are presented within Other long-term assets and corresponding liabilities are presented within Other current liabilities and Other long-term liabilities on our unaudited condensed consolidated balance sheets. Finance leases are immaterial to our unaudited condensed consolidated financial statements. Refer to Note E – Borrowings and Credit Arrangements for additional information. There was no material impact to our unaudited condensed consolidated statements of operations or unaudited condensed consolidated statements of cash flows. Please refer to Note G – Leases for information regarding our lease portfolio as of September 30, 2019 as accounted for under FASB ASC Topic 842.
Subsequent Events, Policy [Policy Text Block]
Subsequent Events

We evaluate events occurring after the date of our most recent accompanying unaudited condensed consolidated balance sheet for potential recognition or disclosure in our financial statements. Those items requiring disclosure (nonrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note E – Borrowings and Credit Arrangements and Note I – Commitments and Contingencies for more information.
XML 60 R27.htm IDEA: XBRL DOCUMENT v3.19.3
Changes in Other Comprehensive Income Changes in Other Comprehensive Income (Policies)
 9 Months Ended
Sep. 30, 2019
Accounting Policies [Abstract]  
ASC Update No. 2016-01, Financial Instruments [Policy Text Block]
As a result of adopting ASC Update No. 2016-01 in the first quarter of 2018, we recorded a cumulative effect adjustment to retained earnings to reclassify unrealized gains and losses from our equity investments previously recorded to Accumulated other comprehensive income (loss), net of tax. These equity investments were classified as available-for-sale securities under the former accounting guidance, and we now refer to these investments as publicly-held equity securities. Please refer to Note A – Significant Accounting Policies included in Item 8 of our most recent Annual Report on Form 10-K for more information.
XML 61 q32019form10-q_htm.xml IDEA: XBRL DOCUMENT 0000885725 2019-01-01 2019-09-30 0000885725 bsx:A2018AcquisitionsMember 2019-01-01 2019-09-30 0000885725 bsx:A2019AcquisitionsMember 2019-01-01 2019-09-30 0000885725 bsx:BTGAcquisitionMember 2019-01-01 2019-09-30 0000885725 2019-10-22 0000885725 2019-07-01 2019-09-30 0000885725 2018-01-01 2018-09-30 0000885725 2018-07-01 2018-09-30 0000885725 2019-09-30 0000885725 2018-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000885725 us-gaap:TreasuryStockMember 2018-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000885725 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000885725 us-gaap:TreasuryStockMember 2018-03-31 0000885725 us-gaap:CommonStockMember 2018-09-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000885725 us-gaap:CommonStockMember 2018-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000885725 us-gaap:RetainedEarningsMember 2019-06-30 0000885725 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000885725 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0000885725 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000885725 us-gaap:CommonStockMember 2019-06-30 0000885725 us-gaap:RetainedEarningsMember 2017-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000885725 us-gaap:TreasuryStockMember 2018-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0000885725 us-gaap:CommonStockMember 2017-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000885725 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000885725 us-gaap:TreasuryStockMember 2019-06-30 0000885725 us-gaap:RetainedEarningsMember 2018-09-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000885725 us-gaap:TreasuryStockMember 2019-09-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0000885725 us-gaap:RetainedEarningsMember 2019-09-30 0000885725 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000885725 us-gaap:CommonStockMember 2018-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000885725 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000885725 us-gaap:TreasuryStockMember 2017-12-31 0000885725 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000885725 us-gaap:CommonStockMember 2018-03-31 0000885725 us-gaap:CommonStockMember 2019-03-31 0000885725 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000885725 us-gaap:CommonStockMember 2019-09-30 0000885725 us-gaap:TreasuryStockMember 2018-09-30 0000885725 us-gaap:RetainedEarningsMember 2019-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000885725 us-gaap:RetainedEarningsMember 2018-12-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000885725 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000885725 us-gaap:RetainedEarningsMember 2018-06-30 0000885725 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000885725 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000885725 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000885725 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0000885725 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-10-01 2018-12-31 0000885725 us-gaap:RetainedEarningsMember 2018-03-31 0000885725 us-gaap:TreasuryStockMember 2019-03-31 0000885725 us-gaap:NewAccountingPronouncementMember us-gaap:RetainedEarningsMember 2017-12-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000885725 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000885725 2018-09-30 0000885725 2017-12-31 0000885725 us-gaap:AccountingStandardsUpdate201602Member bsx:OperatingleaseliabilityotherlongtermliabilitiesMember 2019-01-01 2019-01-01 0000885725 us-gaap:AccountingStandardsUpdate201602Member bsx:OperatingleaserightofuseassetsotherlongtermassetsMember 2019-01-01 2019-01-01 0000885725 srt:MinimumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 srt:MaximumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MinimumMember bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MaximumMember bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-09-30 0000885725 bsx:BTGAcquisitionMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MaximumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MinimumMember bsx:BTGAcquisitionMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:A2019AcquisitionsMember 2019-09-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-09-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-09-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 bsx:A2019AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-09-30 0000885725 bsx:A2018AcquisitionsMember 2019-09-30 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-09-30 0000885725 bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:A2018AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-09-30 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:OtherIntangibleAssetsMember 2019-09-30 0000885725 srt:MaximumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 bsx:A2018AcquisitionsMember us-gaap:InProcessResearchAndDevelopmentMember 2019-01-01 2019-09-30 0000885725 srt:MinimumMember bsx:A2018AcquisitionsMember us-gaap:TechnologyBasedIntangibleAssetsMember 2019-01-01 2019-09-30 0000885725 bsx:BTGAcquisitionMember 2019-09-30 0000885725 bsx:BTGAcquisitionMember 2019-07-01 2019-09-30 0000885725 bsx:BTGintellectualpropertyMember 2019-09-30 0000885725 bsx:DivestedbusinessduetoBTGacquisitionMember 2019-08-21 0000885725 bsx:VertiflexInc.Member 2019-06-11 0000885725 bsx:Other2018AcquisitionsMember 2018-09-30 0000885725 bsx:Other2018AcquisitionsMember 2018-01-01 2018-09-30 0000885725 bsx:MillipedeInc.Member 2019-01-29 0000885725 2019-08-21 2019-08-21 0000885725 bsx:BTGAcquisitionMember 2019-08-19 0000885725 bsx:NxTheraMember 2018-04-30 0000885725 bsx:NVisionMember 2018-04-16 2018-04-16 0000885725 bsx:MillipedeInc.Member 2019-01-29 2019-01-29 0000885725 bsx:ClaretMember 2018-07-01 2018-09-30 0000885725 srt:MaximumMember 2019-01-01 2019-09-30 0000885725 bsx:ClaretMember 2018-08-02 2018-08-02 0000885725 bsx:CryterionMember 2018-07-05 0000885725 bsx:BTGAcquisitionMember 2019-08-19 2019-08-19 0000885725 bsx:NVisionMember 2018-04-16 0000885725 bsx:VertiflexInc.Member 2019-06-11 2019-06-11 0000885725 bsx:CryterionMember 2018-07-05 2018-07-05 0000885725 bsx:BTGAcquisitionMember 2019-01-01 2019-09-30 0000885725 bsx:NxTheraMember 2018-04-30 2018-04-30 0000885725 srt:MaximumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-09-30 0000885725 srt:MaximumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 srt:WeightedAverageMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 srt:MinimumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-09-30 0000885725 srt:WeightedAverageMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-09-30 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 srt:MaximumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-09-30 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 srt:MinimumMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-09-30 0000885725 srt:MinimumMember bsx:RDRegulatoryandCommercializationbasedMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-09-30 0000885725 srt:WeightedAverageMember bsx:RevenueBasedPaymentsMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2019-01-01 2019-09-30 0000885725 bsx:BTGAcquisitionMember 2018-12-31 0000885725 bsx:MedsurgMember 2019-09-30 0000885725 bsx:CardiovascularMember 2018-12-31 0000885725 bsx:RhythmandNeuroMember 2019-01-01 2019-09-30 0000885725 bsx:CardiovascularMember 2019-01-01 2019-09-30 0000885725 bsx:RhythmandNeuroMember 2019-09-30 0000885725 bsx:MedsurgMember 2019-01-01 2019-09-30 0000885725 bsx:RhythmandNeuroMember 2018-12-31 0000885725 bsx:CardiovascularMember 2019-09-30 0000885725 bsx:BTGAcquisitionMember 2019-09-30 0000885725 bsx:MedsurgMember 2018-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 us-gaap:OtherIntangibleAssetsMember 2019-09-30 0000885725 us-gaap:OtherIntangibleAssetsMember 2018-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2018-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-12-31 0000885725 us-gaap:InProcessResearchAndDevelopmentMember 2019-09-30 0000885725 us-gaap:GoodwillMember 2019-09-30 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2018-12-31 0000885725 us-gaap:PatentsMember 2019-09-30 0000885725 us-gaap:PatentsMember 2018-12-31 0000885725 us-gaap:TechnologyBasedIntangibleAssetsMember 2019-09-30 0000885725 us-gaap:GoodwillMember 2018-12-31 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000885725 us-gaap:FairValueInputsLevel3Member 2019-01-01 2019-09-30 0000885725 srt:WeightedAverageMember us-gaap:FairValueInputsLevel3Member 2019-01-01 2019-09-30 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000885725 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000885725 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000885725 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:OtherNoncurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-09-30 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-09-30 0000885725 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-09-30 0000885725 us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-07-01 2018-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:CostOfSalesMember 2019-09-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:InterestExpenseMember 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-01-01 2018-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2018-07-01 2018-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2018-07-01 2018-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:InterestRateContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-09-30 0000885725 bsx:BTGAcquisitionMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000885725 bsx:BTGAcquisitionMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-09-30 0000885725 us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000885725 bsx:BTGAcquisitionMember us-gaap:NondesignatedMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000885725 bsx:AggregateSeniorUnsecuredDelayedDrawTermLoanMember us-gaap:UnsecuredDebtMember 2018-12-19 0000885725 bsx:RequirementfirsttwoquartersfollowingqualifiedacquisitionMember 2019-09-30 0000885725 us-gaap:CommercialPaperMember 2019-01-01 2019-09-30 0000885725 bsx:CurrentRequirementMember 2019-09-30 0000885725 bsx:August2019TermLoanMember 2019-01-01 2019-09-30 0000885725 bsx:TenderOfferMember us-gaap:SubsequentEventMember 2019-10-22 0000885725 bsx:TwoYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2018-12-19 0000885725 bsx:January2020NotesMember 2019-09-30 0000885725 bsx:RequirementsixthquarterandthereafterfollowingqualifiedacquisitionMember 2019-09-30 0000885725 us-gaap:SeniorNotesMember 2019-09-30 0000885725 bsx:February2019AggregateOfferingMember 2019-02-25 0000885725 bsx:CovenantRequirementDomain 2019-09-30 0000885725 bsx:RequirementfourthquarterfollowingqualifiedacquisitionMember 2019-09-30 0000885725 bsx:March2039NotesMember 2019-09-30 0000885725 bsx:TwoYearDelayedDrawTermLoanMember 2019-01-01 2019-09-30 0000885725 bsx:March2029NotesMember 2019-09-30 0000885725 bsx:March2049NotesMember 2019-09-30 0000885725 bsx:March2028NotesMember 2019-09-30 0000885725 bsx:May2020NotesMember 2019-09-30 0000885725 bsx:January2020NotesMember 2019-02-25 2019-02-25 0000885725 bsx:March2024NotesMember 2019-09-30 0000885725 bsx:ThreeYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2019-08-19 0000885725 bsx:March2026NotesMember 2019-09-30 0000885725 bsx:ThreeYearDelayedDrawTermLoanMember 2019-01-01 2019-09-30 0000885725 bsx:May2025NotesMember 2019-09-30 0000885725 us-gaap:SeniorNotesMember 2018-12-31 0000885725 bsx:May2022NotesMember 2019-09-30 0000885725 bsx:October2023NotesMember 2019-09-30 0000885725 bsx:ThreeYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2018-12-19 0000885725 bsx:RequirementthirdquarterfollowingqualifiedacquisitionMember 2019-09-30 0000885725 us-gaap:RevolvingCreditFacilityMember bsx:The2018FacilityDomain 2019-09-30 0000885725 bsx:August2019TermLoanMember 2018-12-31 0000885725 bsx:RequirementfifthquarterfollowingqualifiedacquisitionMember 2019-09-30 0000885725 bsx:May2020NotesMember 2019-02-25 2019-02-25 0000885725 bsx:TwoYearDelayedDrawTermLoanMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2019-08-19 0000885725 us-gaap:CommercialPaperMember 2018-12-31 0000885725 us-gaap:CommercialPaperMember 2019-09-30 0000885725 us-gaap:CommercialPaperMember 2018-01-01 2018-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2019-01-01 2019-09-30 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2018-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2019-01-01 2019-09-30 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2019-09-30 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2019-09-30 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2018-01-01 2018-12-31 0000885725 bsx:EuroDenominatedFactoringArrangementsMember 2018-12-31 0000885725 bsx:YenDenominatedFactoringArrangementsMember 2018-01-01 2018-12-31 0000885725 bsx:November2035NotesMember 2019-09-30 0000885725 bsx:March2024NotesMember 2018-12-31 0000885725 bsx:May2022NotesMember 2018-12-31 0000885725 bsx:May2020NotesMember 2018-12-31 0000885725 bsx:January2040NotesMember 2019-09-30 0000885725 bsx:January2040NotesMember 2018-12-31 0000885725 us-gaap:CapitalLeaseObligationsMember 2019-09-30 0000885725 bsx:August2021TermLoanMember 2019-09-30 0000885725 bsx:March2028NotesMember 2018-12-31 0000885725 us-gaap:InterestRateSwapMember 2018-12-31 0000885725 bsx:March2026NotesMember 2018-12-31 0000885725 bsx:May2025NotesMember 2018-12-31 0000885725 bsx:January2020NotesMember 2018-12-31 0000885725 bsx:March2049NotesMember 2018-12-31 0000885725 bsx:March2029NotesMember 2018-12-31 0000885725 bsx:August2021TermLoanMember 2018-12-31 0000885725 bsx:November2035NotesMember 2018-12-31 0000885725 us-gaap:InterestRateSwapMember 2019-09-30 0000885725 us-gaap:CapitalLeaseObligationsMember 2018-12-31 0000885725 bsx:August2022TermLoanMember 2019-09-30 0000885725 bsx:August2022TermLoanMember 2018-12-31 0000885725 bsx:March2039NotesMember 2018-12-31 0000885725 bsx:October2023NotesMember 2018-12-31 0000885725 bsx:ActualCovenantMember 2019-09-30 0000885725 us-gaap:RevolvingCreditFacilityMember bsx:The2018FacilityDomain 2018-12-31 0000885725 2019-06-30 0000885725 2018-06-30 0000885725 srt:MaximumMember 2019-09-30 0000885725 srt:MinimumMember 2019-09-30 0000885725 us-gaap:SettledLitigationMember us-gaap:SubsequentEventMember 2019-10-16 0000885725 us-gaap:SubsequentEventMember 2019-10-16 0000885725 bsx:MaximumContingentPaymentMember 2018-09-12 0000885725 bsx:NonAcquisitionRelatedMember 2019-09-30 0000885725 bsx:AssignedtoonejudgeinMAMember us-gaap:SubsequentEventMember 2019-10-16 0000885725 2019-03-31 0000885725 bsx:UpfrontCashMember 2018-09-12 0000885725 2019-01-01 2019-03-31 0000885725 bsx:MedsurgMember 2019-07-01 2019-09-30 0000885725 bsx:SpecialChargesMember 2018-07-01 2018-09-30 0000885725 bsx:RhythmandNeuroMember 2018-01-01 2018-09-30 0000885725 bsx:RhythmandNeuroMember 2018-07-01 2018-09-30 0000885725 bsx:RhythmandNeuroMember 2019-07-01 2019-09-30 0000885725 bsx:ExcludesBTGAcquisitionMember 2019-01-01 2019-09-30 0000885725 bsx:MedsurgMember 2018-01-01 2018-09-30 0000885725 bsx:CardiovascularMember 2019-07-01 2019-09-30 0000885725 bsx:SpecialChargesMember 2018-01-01 2018-09-30 0000885725 bsx:SpecialChargesMember 2019-07-01 2019-09-30 0000885725 bsx:MedsurgMember 2018-07-01 2018-09-30 0000885725 bsx:CardiovascularMember 2018-01-01 2018-09-30 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2018-01-01 2018-09-30 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2019-07-01 2019-09-30 0000885725 bsx:BTGAcquisitionMember 2019-07-01 2019-09-30 0000885725 bsx:CardiovascularMember 2018-07-01 2018-09-30 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2019-01-01 2019-09-30 0000885725 bsx:CorporateExpensesincludinghedgingactivitiesMember 2018-07-01 2018-09-30 0000885725 bsx:SpecialChargesMember 2019-01-01 2019-09-30 0000885725 bsx:ExcludesBTGAcquisitionMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:BTGSpecPharmaMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalCrmReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalCrmReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:BTGInterventionalMedicineMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember country:US 2019-07-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:BTGSpecPharmaMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember country:US 2019-01-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalElectrophysiologyEpReportingUnitMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember country:US 2018-07-01 2018-09-30 0000885725 bsx:GlobalEndoscopyEndoReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalNeuromodulationNmReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalInterventionalCardiologyIcReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember 2018-01-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember country:US 2018-01-01 2018-09-30 0000885725 bsx:BTGInterventionalMedicineMember 2019-01-01 2019-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalUrologyandPelvicHealthReportingUnitMember us-gaap:NonUsMember 2019-07-01 2019-09-30 0000885725 bsx:GlobalCrmReportingUnitMember us-gaap:NonUsMember 2018-07-01 2018-09-30 0000885725 bsx:GlobalPeripheralInterventionsPiReportingUnitMember us-gaap:NonUsMember 2018-01-01 2018-09-30 0000885725 srt:AsiaPacificMember 2018-01-01 2018-09-30 0000885725 bsx:LatinAmericaandCanadaMember 2018-07-01 2018-09-30 0000885725 srt:AsiaPacificMember 2019-07-01 2019-09-30 0000885725 country:US 2018-01-01 2018-09-30 0000885725 bsx:EmergingMarketsMember 2019-07-01 2019-09-30 0000885725 bsx:EmergingMarketsMember 2018-07-01 2018-09-30 0000885725 bsx:EmergingMarketsMember 2018-01-01 2018-09-30 0000885725 us-gaap:EMEAMember 2018-01-01 2018-09-30 0000885725 bsx:LatinAmericaandCanadaMember 2019-01-01 2019-09-30 0000885725 bsx:LatinAmericaandCanadaMember 2019-07-01 2019-09-30 0000885725 country:US 2019-07-01 2019-09-30 0000885725 country:US 2018-07-01 2018-09-30 0000885725 country:US 2019-01-01 2019-09-30 0000885725 srt:AsiaPacificMember 2019-01-01 2019-09-30 0000885725 bsx:EmergingMarketsMember 2019-01-01 2019-09-30 0000885725 us-gaap:EMEAMember 2019-01-01 2019-09-30 0000885725 us-gaap:EMEAMember 2019-07-01 2019-09-30 0000885725 srt:AsiaPacificMember 2018-07-01 2018-09-30 0000885725 bsx:LatinAmericaandCanadaMember 2018-01-01 2018-09-30 0000885725 us-gaap:EMEAMember 2018-07-01 2018-09-30 iso4217:GBP bsx:units pure iso4217:USD iso4217:GBP shares iso4217:USD shares utreg:Rate shares bsx:claims bsx:reportablesegments false --12-31 Q3 2019 0000885725 0.01 0.01 2000000000 2000000000 1632148030 1384581760 1393776239 0.06 0.07375 0.04 0.0285 0.03375 0.0385 0.0700 0.04125 true 2750000000 0.01 0.01 50000000 50000000 0 0 0 0 247566270 247566270 10-Q true 2019-09-30 false 1-11083 BOSTON SCIENTIFIC CORPORATION DE 04-2695240 300 Boston Scientific Way Marlborough MA 01752-1234 508 683-4000 Common Stock, $0.01 par value BSX NYSE Yes Yes Large Accelerated Filer false false false 0.01 1393823592 2707000000 2393000000 7831000000 7262000000 777000000 672000000 2265000000 2084000000 1930000000 1720000000 5566000000 5179000000 1012000000 870000000 2849000000 2616000000 306000000 289000000 866000000 825000000 15000000 17000000 48000000 52000000 178000000 148000000 498000000 437000000 0 0 105000000 35000000 8000000 -13000000 -9000000 -12000000 3000000 3000000 10000000 20000000 25000000 18000000 -108000000 18000000 1547000000 1333000000 4258000000 3992000000 383000000 388000000 1308000000 1187000000 95000000 58000000 294000000 177000000 -197000000 126000000 -322000000 116000000 91000000 456000000 693000000 1126000000 -35000000 24000000 -11000000 -159000000 126000000 432000000 704000000 1285000000 0.09 0.31 0.51 0.93 0.09 0.31 0.50 0.92 1393100000 1382800000 1390600000 1380000000.0 1412200000 1403900000 1409700000 1399800000 126000000 432000000 704000000 1285000000 -2000000 -6000000 4000000 -42000000 62000000 47000000 102000000 125000000 0 0 1000000 0 60000000 40000000 105000000 82000000 186000000 472000000 809000000 1367000000 277000000 146000000 1796000000 1608000000 1566000000 1166000000 189000000 161000000 1020000000 921000000 4847000000 4003000000 1942000000 1782000000 10015000000 7911000000 8074000000 6372000000 1879000000 932000000 26756000000 20999000000 1297000000 2253000000 512000000 349000000 1932000000 2246000000 513000000 412000000 4254000000 5260000000 9590000000 4803000000 807000000 328000000 2406000000 1882000000 16000000 16000000 1717000000 1717000000 17510000000 17346000000 -6249000000 -6953000000 138000000 33000000 9699000000 8726000000 26756000000 20999000000 1621062898 16000000 -1717000000 17161000000 -8390000000 -59000000 298000000 -233000000 -69000000 6125111 23000000 1627188009 16000000 -1717000000 17184000000 -8326000000 -128000000 555000000 112000000 1688243 47000000 1628876252 16000000 -1717000000 17231000000 -7770000000 -16000000 432000000 40000000 2395031 73000000 1631271283 16000000 -1717000000 17304000000 -7339000000 25000000 386000000 8000000 876747 42000000 1632148030 16000000 -1717000000 17346000000 -6953000000 33000000 424000000 54000000 6001343 28000000 1638149373 16000000 -1717000000 17374000000 -6528000000 87000000 154000000 -9000000 949557 48000000 1639098930 16000000 -1717000000 17422000000 -6375000000 78000000 126000000 60000000 2243579 89000000 1641342509 16000000 -1717000000 17510000000 -6249000000 138000000 1144000000 291000000 275000000 210000000 5000000 0 4382000000 968000000 137000000 148000000 90000000 0 294000000 0 -4992000000 -1326000000 135000000 16000000 1000000000 0 0 999000000 13000000 -403000000 0 569000000 0 569000000 1472000000 602000000 6243000000 989000000 64000000 54000000 113000000 94000000 3697000000 1007000000 -2000000 -9000000 -153000000 -37000000 829000000 1017000000 676000000 980000000 116000000 104000000 127000000 190000000 277000000 168000000 357000000 781000000 43000000 31000000 676000000 980000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE A – BASIS OF PRESENTATION</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The accompanying </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. When used in this report, the terms, "we," "us," "our," and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the </span><span style="font-family:inherit;font-size:10pt;">three and nine</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">. For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts reported in millions within this report are computed based on the amounts in thousands. As a result, the sum of the components reported in millions may not equal the total amount reported in millions due to rounding. Certain columns and rows within tables may not add due to the use of rounded numbers. Percentages presented are calculated from the underlying numbers in dollars.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">August 19, 2019</span><span style="font-family:inherit;font-size:10pt;">, we announced the closing of our acquisition of BTG plc (</span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;">)</span><span style="font-family:inherit;font-size:10pt;">. Refer to </span><span style="font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:10pt;"> for more information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Subsequent Events</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We evaluate events occurring after the date of our most recent accompanying </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheet</span><span style="font-family:inherit;font-size:10pt;"> for potential recognition or disclosure in our financial statements. Those items requiring disclosure (nonrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to </span><span style="font-style:italic;">Note E – Borrowings and Credit Arrangements</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-style:italic;">Note I – Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;"> for more information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting Standards Implemented Since December 31, 2018</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-02</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (FASB) issued ASC Update No. 2016-02, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> (</span><span>FASB ASC Topic 842, </span><span style="font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">). We adopted the standard as of January 1, 2019, using the modified retrospective approach and the transition method provided by ASC Update No. 2018-11, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(Topic 842): Targeted Improvements</span><span style="font-family:inherit;font-size:10pt;">. Under this method, we applied the new leasing rules on the date of adoption and recognized the cumulative effect of initially applying the standard as an adjustment to our opening balance sheet, rather than at the earliest comparative period presented in the financial statements. Prior periods presented are in accordance with the previous lease guidance under </span><span>FASB ASC Topic 840, </span><span style="font-style:italic;">Leases</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we applied the package of practical expedients permitted under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;"> transition guidance to our entire lease portfolio at January 1, 2019. As a result, we were not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases and (iii) the treatment of initial direct costs for any existing leases. Furthermore, we elected not to separate lease and non-lease components for the majority of our leases. Instead, for all applicable classes of underlying assets, we accounted for each separate lease component and the non-lease components associated with that lease component, as a single lease component.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of adopting </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;"> on January 1, 2019, we recognized right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$271 million</span></span><span style="font-family:inherit;font-size:10pt;"> and corresponding liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$278 million</span></span><span style="font-family:inherit;font-size:10pt;"> for our existing operating lease portfolio on our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheet</span><span style="font-family:inherit;font-size:10pt;">. Operating lease right-of-use assets are presented within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span><span style="font-family:inherit;font-size:10pt;"> and corresponding liabilities are presented within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">. Finance leases are immaterial to our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-style:italic;">Note E – Borrowings and Credit Arrangements</span><span style="font-family:inherit;font-size:10pt;"> for additional information. There was no material impact to our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of cash flows</span><span style="font-family:inherit;font-size:10pt;">. Please refer to </span><span style="font-style:italic;">Note G – Leases</span><span style="font-family:inherit;font-size:10pt;"> for information regarding our lease portfolio as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> as accounted for under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">To meet the reporting and disclosure requirements of </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;">, we implemented a new lease administration and lease accounting system in 2018 that tracks all of our material leasing arrangements. In addition, we designed and implemented new processes and internal controls during the first quarter of 2019 to ensure the completeness and accuracy of the transition adjustment </span></div><span style="font-family:inherit;font-size:10pt;">and subsequent financial reporting under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span>. We also established monitoring controls to ensure we have appropriate mechanisms in place to identify material leases in a timely manner, particularly contracts that may contain embedded lease features. <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Subsequent Events</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We evaluate events occurring after the date of our most recent accompanying </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheet</span><span style="font-family:inherit;font-size:10pt;"> for potential recognition or disclosure in our financial statements. Those items requiring disclosure (nonrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to </span><span style="font-style:italic;">Note E – Borrowings and Credit Arrangements</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-style:italic;">Note I – Commitments and Contingencies</span><span style="font-family:inherit;font-size:10pt;"> for more information.</span></div> 271000000 278000000 Operating lease right-of-use assets are presented within <span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span><span style="font-family:inherit;font-size:10pt;"> and corresponding liabilities are presented within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">. Finance leases are immaterial to our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-style:italic;">Note E – Borrowings and Credit Arrangements</span><span style="font-family:inherit;font-size:10pt;"> for additional information. There was no material impact to our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of cash flows</span><span style="font-family:inherit;font-size:10pt;">. Please refer to </span><span style="font-style:italic;">Note G – Leases</span><span style="font-family:inherit;font-size:10pt;"> for information regarding our lease portfolio as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> as accounted for under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:10pt;">. </span> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> include the operating results for acquired entities from the respective date of acquisition. With the exception of the acquisition of </span><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;">, which was completed on </span><span style="font-family:inherit;font-size:10pt;">August 19, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have not presented supplemental pro forma financial information for acquisitions given their results are not material to our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">. Transaction costs for all acquisitions in </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> were immaterial to our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;"> and were expensed as incurred. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2019 Acquisitions</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recorded immaterial purchase price adjustments to the preliminary purchase price allocations of previous acquisitions during the measurement period in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">BTG plc</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">August 19, 2019</span><span style="font-family:inherit;font-size:10pt;">, we announced the closing of our acquisition of </span><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;">, a public company organized under the laws of England and Wales. </span><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;"> has three key portfolios, the largest of which is its interventional medicine portfolio (Interventional Medicine) that encompasses interventional oncology therapeutic technologies for patients with liver and kidney cancers, as well as a vascular portfolio for treatment of deep vein thrombosis, pulmonary embolism, deep venous obstruction and superficial venous disease. In addition to the Interventional Medicine product lines, the </span><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;"> portfolio</span><span style="font-family:inherit;font-size:10pt;"> also includes a specialty pharmaceutical business (</span><span style="font-family:inherit;font-size:10pt;">Specialty Pharmaceuticals</span><span style="font-family:inherit;font-size:10pt;">) comprised of acute care antidotes to treat overexposure to certain medications and toxins and a licensing portfolio (Licensing) that generates net royalties related to </span><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;"> intellectual property and product license agreements.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The transaction price consisted of upfront cash in the aggregate amount of </span><span style="font-family:inherit;font-size:10pt;"><span>£3.312 billion</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">for the entire issued ordinary share capital of BTG (or </span><span style="font-family:inherit;font-size:10pt;"><span>$4.023 billion</span></span><span style="font-family:inherit;font-size:10pt;"> based on the exchange rate of U.S. </span><span style="font-family:inherit;font-size:10pt;"><span>$1.21</span></span><span style="font-family:inherit;font-size:10pt;">: £1.00 at closing on </span><span style="font-family:inherit;font-size:10pt;">August 19, 2019</span><span style="font-family:inherit;font-size:10pt;">)</span><span style="font-family:inherit;font-size:10pt;">, whereby BTG shareholders received </span><span style="font-family:inherit;font-size:10pt;"><span>840 pence</span></span><span style="font-family:inherit;font-size:10pt;"> in cash for each BTG share.</span><span style="font-family:inherit;font-size:10pt;"> The transaction price of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.023 billion</span></span><span style="font-family:inherit;font-size:10pt;"> included </span><span style="font-family:inherit;font-size:10pt;"><span>$404 million</span></span><span style="font-family:inherit;font-size:10pt;"> of cash and cash equivalents acquired. We implemented the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> by way of a court-sanctioned scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006, as amended.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">After closing the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">, we terminated the </span><span style="font-family:inherit;font-size:10pt;"><span>£150 million</span></span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;"> revolving credit facility, which contained an option to increase the facility by </span><span style="font-family:inherit;font-size:10pt;"><span>£150 million</span></span><span style="font-family:inherit;font-size:10pt;"> and was scheduled to expire in November 2020. The termination was effective on August 27, 2019, and there were no amounts outstanding at the time of close of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Price Allocation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accounted for the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> as a business combination, and in accordance with </span><span>FASB ASC Topic 805</span><span style="font-style:italic;">, Business Combinations</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">), we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The preliminary </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> purchase price was comprised of the amounts presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed from the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period as required by </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">. As of September 30, 2019, the valuation studies necessary to determine the fair market value of the assets acquired and liabilities assumed are preliminary, including the projection of the underlying cash flows used to determine the fair value of the identified tangible, intangible and financial assets and liabilities. Given the size and breadth of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">, we anticipate that the purchase price allocation will take longer than prior acquisitions and potentially up to the one year allowed under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;"> to adequately analyze all the factors used in establishing the fair value of assets acquired and liabilities assumed as of the acquisition date, including, but not limited to, intangible assets, inventories, financial assets, real and personal property, leases, certain assumed liabilities, including reserves and deferred revenues, tax-related items, and the related tax and foreign currency effects of any changes made.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any potential adjustments made could be material in relation to the preliminary values presented below:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment for acquisition, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,619</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following summarizes the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> preliminary purchase price allocation as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,549</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,869</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(289</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,619</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">, we recognized goodwill of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.549 billion</span></span><span style="font-family:inherit;font-size:10pt;">, which is attributable to the synergies expected to arise from the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> and revenue and cash flow projections associated with future technologies. The goodwill is not deductible for tax purposes. As of September 30, 2019, given the preliminary nature of the purchase price allocation, we have not yet allocated goodwill to the relevant reporting units.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We acquired certain intellectual property and related licensing arrangements, principally relating to Zytiga™, as part of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> that provides the contractual right to receive future royalty payments. The licensing arrangements were accounted for as financial assets as part of acquisition accounting and were recognized at fair value based upon a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. Additionally, as part of the intellectual property related to the licensing arrangements that we acquired we also have the contractual obligation to remit a portion of the cash flows received to the inventors associated with the intellectual property. As such, as part of acquisition accounting we have recorded a financial liability related to the future cash flows we are required to remit to the inventors when we collect the royalty payments. The amount recognized for the financial asset was </span><span style="font-family:inherit;font-size:10pt;"><span>$633 million</span></span><span style="font-family:inherit;font-size:10pt;"> in aggregate, comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$200 million</span></span><span style="font-family:inherit;font-size:10pt;"> included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$432 million</span></span><span style="font-family:inherit;font-size:10pt;"> included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span><span style="font-family:inherit;font-size:10pt;">. The amount recognized for the financial liability was </span><span style="font-family:inherit;font-size:10pt;"><span>$395 million</span></span><span style="font-family:inherit;font-size:10pt;">, comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$153 million</span></span><span style="font-family:inherit;font-size:10pt;"> included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued expenses and other current liabilities </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;"><span>$241 million</span></span><span style="font-family:inherit;font-size:10pt;"> included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocated a portion of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> preliminary purchase price to specific intangible asset categories as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,794</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,869</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">, we assumed a benefit obligation related to a defined benefit pension plan sponsored by </span><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;"> for eligible United Kingdom (U.K.) employees (U.K. Plan). The U.K. Plan was closed to new entrants as of June 1, 2004. Prior to the acquisition close date of </span><span style="font-family:inherit;font-size:10pt;">August 19, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Trustees of the U.K. Plan executed buy-in arrangements (Buy-in Contracts), under which the benefit obligation of the pension plan is not transferred to the insurers, and we remain responsible for paying pension benefits. Effectively, the Buy-in Contracts are intended to provide payments designed to equal all future designated contractual benefit payments to covered participants. We do not anticipate any additional material contributions or payments to the U.K. Plan or the insurer.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following assumptions were used to measure the fair value of the benefit obligation and associated plan assets:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:38%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Return on Plan Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rate of Compensation Increase</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.K. Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.4%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the measurement date of </span><span style="font-family:inherit;font-size:10pt;">August 19, 2019</span><span style="font-family:inherit;font-size:10pt;">, the funded status recognized in our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(216</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Funded status</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">BTG Pro Forma Financial Information (unaudited)</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;"> contributed </span><span style="font-family:inherit;font-size:10pt;"><span>$71 million</span></span><span style="font-family:inherit;font-size:10pt;"> to our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net sales</span><span style="font-family:inherit;font-size:10pt;"> and immaterial amounts to our </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net income (loss)</span><span style="font-family:inherit;font-size:10pt;"> for the period from </span><span style="font-family:inherit;font-size:10pt;">August 19, 2019</span><span style="font-family:inherit;font-size:10pt;"> through </span><span style="font-family:Times New Roman;font-size:10pt;color:#000000;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The unaudited estimated pro forma results presented below include the effects of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> as if it was consummated on January 1, 2018. In the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter and </span><span style="font-family:inherit;font-size:10pt;">first nine months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we incurred nonrecurring charges that we attributed to the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">, which are presented in our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> for these periods. These nonrecurring charges that are attributable to the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> include immaterial amounts of acquisition-related costs, stock-based compensation expenses as a result of the change in control and retention bonuses and severance payments, adjusted for the related tax effects. We have reflected these nonrecurring charges as adjustments to the pro forma earnings presented below for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter and </span><span style="font-family:inherit;font-size:10pt;">first nine months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Additionally, these pro forma amounts have been calculated after applying our accounting policies and adjusting the results of </span><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;"> to reflect the additional costs associated with fair value adjustments relating to inventories, property, plant, and equipment, and intangible assets as if the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> had occurred on January 1, 2018, with the consequential tax effects. Additionally, the pro forma amounts have been adjusted to reflect the amortization of deferred financing costs and interest expense associated with additional financing entered into as part of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">. The pro forma results exclude </span><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;">’s historical licensing revenue and related cost of sales, as these arrangements are accounted for as part of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> as a financial asset and liability and are not accounted for within the scope of </span><span>FASB ASC Topic 606, </span><span style="font-style:italic;">Revenue from Contracts with Customers</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The supplemental pro forma information presented below is for informational purposes only and should be read in conjunction with our historical financial statements. The pro forma results do not include any anticipated synergies or other expected benefits of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">. Accordingly, the unaudited estimated pro forma financial information below is not necessarily indicative of what the actual results of operations of the combined companies would have been had the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> occurred as of January 1, 2018, nor are they indicative of future results of operations. We believe that the pro forma assumptions and adjustments are reasonable and appropriate under the circumstances and are factually supported based on information currently available.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except per share data)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,795</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,561</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>599</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>950</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per common share — basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per common share — assuming dilution</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Transaction with Varian Medical Systems, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 21, 2019, we completed the sale of our drug-eluting and bland embolic microsphere portfolio to Varian Medical Systems, Inc. (Varian) in connection with the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">. The transaction price consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;">, a portion of which is allocated to the fair value of the services to be rendered under the Transition Services Agreement and Transition Manufacturing Agreement entered into with Varian as part of this transaction. Additionally, we transferred certain contingent consideration arrangements arising from our initial acquisition of the portfolio to Varian and agreed to indemnify Varian for any payments ultimately arising under the terms of the contingent consideration arrangement. Accordingly, as part of the disposal, we recorded a liability of </span><span style="font-family:inherit;font-size:10pt;"><span>$16 million</span></span><span style="font-family:inherit;font-size:10pt;"> to recognize the fair value of this guarantee based on our potential obligation resulting from the indemnifications. The maximum amount payable under this guarantee is </span><span style="font-family:inherit;font-size:10pt;"><span>$200 million</span></span><span style="font-family:inherit;font-size:10pt;"> in accordance with </span><span>FASB ASC Topic 460, </span><span style="font-style:italic;">Guarantees</span><span style="font-family:inherit;font-size:10pt;">, which is consistent with the contingent consideration arrangement executed with our initial acquisition of the portfolio in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Vertiflex, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 11, 2019, we announced the closing of our acquisition of Vertiflex, Inc. (Vertiflex), a privately-held company which has developed and commercialized the Superion™ Indirect Decompression System, a minimally-invasive device used to improve physical function and reduce pain in patients with lumbar spinal stenosis (LSS). The transaction price consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$465 million</span></span><span style="font-family:inherit;font-size:10pt;"> and contingent payments that are based on a percentage of Vertiflex sales growth in the first three years following the acquisition close. We estimate the sales-based contingent payments to be in a range of </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;">; however, the payments are uncapped over the three year term. Vertiflex is part of our Neuromodulation business.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Millipede, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 29, 2019, we announced the closing of our acquisition of Millipede, Inc. (Millipede), a privately-held company that has developed the IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation. We have been an investor in Millipede since the first quarter of 2018 as part of an investment and acquisition option agreement, whereby we purchased a portion of the outstanding shares of Millipede, along with newly issued shares of the company, for an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$90 million</span></span><span style="font-family:inherit;font-size:10pt;">. We held an interest of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>20 percent</span></span><span style="font-family:inherit;font-size:10pt;"> immediately prior to the acquisition date. In the fourth quarter of 2018, upon the recent successful completion of a first-in-human clinical study, we exercised our option to acquire the remaining shares of Millipede. We remeasured the fair value of our previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests. The transaction price for the remaining stake consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$325 million</span></span><span style="font-family:inherit;font-size:10pt;"> and up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$125 million</span></span><span style="font-family:inherit;font-size:10pt;"> payment upon achievement of a commercial milestone. Millipede is part of our Interventional Cardiology business. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Price Allocation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accounted for our 2019 acquisitions of Vertiflex and Millipede as business combinations, and in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments for acquisitions, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of prior interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preliminary purchase price allocations of our acquisitions of Vertiflex and Millipede, presented in aggregate, were comprised of the following components as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocated a portion of the preliminary purchase prices of our acquisitions of Vertiflex and Millipede, presented in aggregate, to the specific intangible asset categories as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development (IPR&amp;D)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>461</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">2018 Acquisitions</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recorded immaterial purchase price adjustments to the preliminary purchase price allocations of previous acquisitions during the measurement period in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Claret Medical, Inc.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 2, 2018, we announced the closing of our acquisition of Claret Medical, Inc. (Claret), a privately-held company that has developed and commercialized the Sentinel™ Cerebral Embolic Protection System. The device is used to protect the brain during certain interventional procedures, predominately in patients undergoing transcatheter aortic valve replacement (TAVR). The transaction price consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$220 million</span></span><span style="font-family:inherit;font-size:10pt;"> and an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$50 million</span></span><span style="font-family:inherit;font-size:10pt;"> payment for reaching a reimbursement-based milestone that was achieved in the third quarter of 2018. Claret is part of our Interventional Cardiology business. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">Cryterion Medical, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On July 5, 2018, we announced the closing of our acquisition of Cryterion Medical, Inc. (Cryterion), a privately-held company developing a single-shot cryoablation platform for the treatment of atrial fibrillation. We have been an investor in Cryterion since 2016 and held an interest of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>35 percent</span></span><span style="font-family:inherit;font-size:10pt;"> immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$202 million</span></span><span style="font-family:inherit;font-size:10pt;">. Cryterion is part of our Electrophysiology business.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">NxThera, Inc.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 30, 2018, we announced the closing of our acquisition of NxThera, Inc. (NxThera), a privately-held company that developed the Rezūm™ System, a minimally invasive therapy in a growing category of treatment options for patients with benign prostatic hyperplasia (BPH). We held a minority interest immediately prior to the acquisition date. The transaction price to acquire the remaining stake consisted of an upfront cash payment of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$240 million</span></span><span style="font-family:inherit;font-size:10pt;"> and up to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$85 million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments contingent upon commercial milestones over the four years following the date of acquisition. NxThera is part of our Urology and Pelvic Health business. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;text-decoration:underline;">nVision Medical Corporation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 16, 2018, we announced the closing of our acquisition of nVision Medical Corporation (nVision), a privately-held company focused on women’s health. nVision developed the first and only device cleared by the U.S. Food and Drug Administration (FDA) to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. The transaction price consisted of an upfront cash payment of </span><span style="font-family:inherit;font-size:10pt;"><span>$150 million</span></span><span style="font-family:inherit;font-size:10pt;"> and up to an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$125 million</span></span><span style="font-family:inherit;font-size:10pt;"> in payments contingent upon clinical and commercial milestones over the four years following the date of acquisition. nVision is part of our Urology and Pelvic Health business.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, we completed other individually immaterial acquisitions in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> for total consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$158 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash at closing plus aggregate contingent consideration of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$62 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recorded gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$142 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$182 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other, net</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> based on the difference between the book values and the fair values of our previously-held investments immediately prior to the acquisition dates. The aggregate fair value of our previously-held investments immediately prior to the acquisition dates was </span><span style="font-family:inherit;font-size:10pt;"><span>$251 million</span></span><span style="font-family:inherit;font-size:10pt;">. We remeasured the fair value of each previously-held investment based on the implied enterprise value and allocation of purchase price consideration according to priority of equity interests.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Purchase Price Allocation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We accounted for our 2018 acquisitions as business combinations, and in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">, we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition dates. The components of the aggregate purchase prices are as follows for our 2018 acquisitions as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments for acquisitions, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>969</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of prior interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,410</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following summarizes the aggregate purchase price allocations for our 2018 acquisitions as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>618</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>707</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(134</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,410</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocated a portion of the aggregate purchase prices to specific intangible asset categories as follows for our 2018 acquisitions as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>697</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>920</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our technology-related intangible assets consist of technical processes, intellectual property and institutional understanding with respect to products and processes that we intend to leverage in future products or processes and will carry forward from one product generation to the next. We used the multi-period excess earnings method, a form of the income approach, to derive the fair value of the technology-related intangible assets and are amortizing them on a straight-line basis over their assigned estimated useful lives.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill was primarily established due to synergies expected to be gained from leveraging our existing operations as well as revenue and cash flow projections associated with future technologies and has been allocated to our reportable segments based on the relative expected benefit. Based on preliminary estimates updated for applicable regulatory changes, the goodwill recorded relating to our </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;"> acquisitions is not deductible for tax purposes.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Contingent Consideration</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the fair value of our contingent consideration liability were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount recorded related to current year acquisitions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration arrangements transferred to Varian</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration expense (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>380</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the maximum amount of future contingent consideration (undiscounted) that we could be required to pay was </span><span style="font-family:inherit;font-size:10pt;"><span>$747 million</span></span><span style="font-family:inherit;font-size:10pt;">, which includes our estimate of maximum contingent payments of </span><span style="font-family:inherit;font-size:10pt;"><span>$100 million</span></span><span style="font-family:inherit;font-size:10pt;"> associated with the Vertiflex acquisition described above. The maximum decreased </span><span style="font-family:inherit;font-size:10pt;"><span>$126 million</span></span><span style="font-family:inherit;font-size:10pt;"> compared to the amount as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> primarily due to the contingent consideration arrangement which is now accounted for as a guarantee in connection with our transaction with Varian as discussed in the </span><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;"> section above. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:20%;"/><td style="width:18%;"/><td style="width:10%;"/><td style="width:23%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:8%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingent Consideration Liability</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value as of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average (1)</span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">R&amp;D, Regulatory and Commercialization-based Milestones</span></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$220 million</span></span></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of Payment</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90%</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84%</span></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue-based Payments</span></div></td><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$160 million</span></span></div></td><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of Payment</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2026</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:30px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected contingent payment amounts related to some of our research and development (R&amp;D), commercialization-based and revenue-based milestones are discounted back to the current period using a discounted cash flow model. Significant increases or decreases in projected revenues, probabilities of payment, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Strategic Investments</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate carrying amount of our strategic investments was comprised of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Measurement alternative investments (1)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notes receivable</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>468</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">These investments are classified as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span><span style="font-family:inherit;font-size:10pt;"> within our accompanying </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">, in accordance with U.S. GAAP and our accounting policies. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the cost of our aggregated equity method investments exceeded our share of the underlying equity in net assets by </span><span style="font-family:inherit;font-size:10pt;"><span>$308 million</span></span><span style="font-family:inherit;font-size:10pt;">, which represents amortizable intangible assets, IPR&amp;D, goodwill and deferred tax liabilities.</span></div> 3312000000 4023000000.000 1.21 8.40 4023000000.000 404000000 150000000 150000000 The preliminary <span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> purchase price was comprised of the amounts presented below, which represent the preliminary determination of the fair value of identifiable assets acquired and liabilities assumed from the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">. The final determination of the fair value of certain assets and liabilities will be completed within the measurement period as required by </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;">. As of September 30, 2019, the valuation studies necessary to determine the fair market value of the assets acquired and liabilities assumed are preliminary, including the projection of the underlying cash flows used to determine the fair value of the identified tangible, intangible and financial assets and liabilities. Given the size and breadth of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">, we anticipate that the purchase price allocation will take longer than prior acquisitions and potentially up to the one year allowed under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;"> to adequately analyze all the factors used in establishing the fair value of assets acquired and liabilities assumed as of the acquisition date, including, but not limited to, intangible assets, inventories, financial assets, real and personal property, leases, certain assumed liabilities, including reserves and deferred revenues, tax-related items, and the related tax and foreign currency effects of any changes made.</span><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any potential adjustments made could be material in relation to the preliminary values presented below:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payment for acquisition, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,619</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3619000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following summarizes the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> preliminary purchase price allocation as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,549</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade accounts receivable, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventories</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>205</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,869</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses and other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(305</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(289</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred tax liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(380</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,619</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1549000000 107000000 205000000 259000000 1869000000 604000000 305000000 -289000000 380000000 3619000000 1549000000 633000000 200000000 432000000 395000000 153000000 241000000 <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We allocated a portion of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> preliminary purchase price to specific intangible asset categories as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,794</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,869</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1794000000 P10Y P17Y 0.10 0.12 75000000 P2Y P11Y 0.11 1869000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following assumptions were used to measure the fair value of the benefit obligation and associated plan assets:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:38%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:20%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Discount Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Return on Plan Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rate of Compensation Increase</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.K. Plan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.4%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.004 0.004 0.034 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of the measurement date of </span><span style="font-family:inherit;font-size:10pt;">August 19, 2019</span><span style="font-family:inherit;font-size:10pt;">, the funded status recognized in our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> was as follows:</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Benefit obligation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(216</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Funded status</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 213000000 216000000 -3000000 71000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except per share data)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,795</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,561</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8,237</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>599</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>950</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per common share — basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.69</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net income (loss) per common share — assuming dilution</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2795000000 2561000000 8237000000 7740000000 152000000 332000000 599000000 950000000 0.11 0.24 0.43 0.69 0.11 0.24 0.42 0.68 90000000 16000000 200000000 465000000 0 100000000 90000000 0.20 325000000 125000000 <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments for acquisitions, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of prior interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 763000000 127000000 102000000 992000000 <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>575</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>220</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(56</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 575000000 220000000 240000000 24000000 12000000 56000000 992000000 <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In-process research and development (IPR&amp;D)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>461</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 210000000 P12Y 0.15 10000000 P12Y 0.15 240000000 0.19 461000000 220000000 50000000 0.35 202000000 240000000 85000000 150000000 125000000 158000000 62000000 142000000 182000000 251000000 The components of the aggregate purchase prices are as follows for our 2018 acquisitions as of <span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">:</span><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payments for acquisitions, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>969</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fair value of prior interests</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>251</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,410</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 969000000 190000000 251000000 1410000000 <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>618</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortizable intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>707</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Indefinite-lived intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets acquired</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities assumed</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(134</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,410</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 618000000 707000000 213000000 19000000 14000000 134000000 1410000000 <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:2%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:6%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Assigned</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortization Period</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Adjusted Discount </span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rates used in Purchase Price Allocation</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>697</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">N/A</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>920</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 697000000 P10Y P14Y 0.17 0.23 10000000 P6Y P13Y 0.13 0.15 213000000 0.15 920000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Changes in the fair value of our contingent consideration liability were as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:86%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>347</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount recorded related to current year acquisitions</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration arrangements transferred to Varian</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration expense (benefit)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>380</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 347000000 127000000 -16000000 -9000000 68000000 380000000 747000000 100000000 -126000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our contingent consideration liability include the following significant unobservable inputs:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:20%;"/><td style="width:18%;"/><td style="width:10%;"/><td style="width:23%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:8%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Contingent Consideration Liability</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value as of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average (1)</span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">R&amp;D, Regulatory and Commercialization-based Milestones</span></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$220 million</span></span></div></td><td rowspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of Payment</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90%</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84%</span></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td></tr><tr><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue-based Payments</span></div></td><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$160 million</span></span></div></td><td rowspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15%</span></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13%</span></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Probability of Payment</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99%</span></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2026</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;padding-left:30px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unobservable inputs were weighted by the relative fair value of the contingent consideration liability. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div> 220000000 0.02 0.03 0.03 0.50 0.90 0.84 160000000 0.11 0.15 0.13 0.60 1 0.99 <div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate carrying amount of our strategic investments was comprised of the following:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equity method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Measurement alternative investments (1)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>173</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Notes receivable</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>468</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>424</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Measurement alternative investments are privately-held equity securities without readily determinable fair values that are measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div> 270000000 303000000 173000000 94000000 23000000 26000000 468000000 424000000 308000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization/ Write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization/ Write-offs</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,018</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,545</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,266</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(393</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,748</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,047</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(958</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>14,290</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(6,996</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12,383</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(6,617</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,915</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>661</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>486</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>20,695</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>18,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following represents our goodwill balance allocated to our global reportable segments and unallocated amounts:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MedSurg</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rhythm and Neuro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cardiovascular</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,063</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,925</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,911</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of foreign currency fluctuations and other changes in carrying amount</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>307</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,549</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,124</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill divested</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,060</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,191</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>4,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,550</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,015</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As a result of the </span><span style="font-family:inherit;font-size:9pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:9pt;">, we recognized goodwill attributable to the synergies expected to arise from the </span><span style="font-family:inherit;font-size:9pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:9pt;"> and revenue and cash flow projections associated with future technologies. The goodwill is not deductible for tax purposes. As of September 30, 2019, given the preliminary nature of the </span><span style="font-family:inherit;font-size:9pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:9pt;"> purchase price allocation, we have not yet allocated goodwill to the relevant reporting units and/or reportable segments.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Goodwill and Indefinite-Lived Intangible Asset Impairment Testing</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not have any goodwill impairments in the third quarter and first nine months of 2019 or 2018. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We test our goodwill balances in the second quarter of each year for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist. In the second quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we performed our annual goodwill impairment test for all of our reporting units and concluded that the fair value of each reporting unit exceeded its carrying value.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In performing the goodwill impairment assessment, we utilized both the optional qualitative assessment and the quantitative approach prescribed under </span><span>FASB ASC Topic 350, </span><span style="font-style:italic;">Intangibles - Goodwill and Other</span><span style="font-family:inherit;font-size:10pt;">. In 2019, we performed a qualitative assessment for our Urology and Pelvic Health, Neuromodulation and Endoscopy reporting units since their fair values have exceeded carrying value by greater than 100 percent. The remaining reporting units were quantitatively tested for impairment. For the reporting units subject to a qualitative assessment, if it is determined that it is more likely than not that the fair value of the reporting unit is less than its carrying value, the quantitative approach of the goodwill impairment test is necessary. In 2019, for all reporting units tested using the qualitative assessment, we concluded that it was unnecessary to perform the quantitative impairment test. For all reporting units tested using the quantitative approach, we concluded that the fair value of each reporting unit exceeded its carrying value.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We did not have any </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible asset impairment charges</span><span style="font-family:inherit;font-size:10pt;"> in the third quarter of 2019 or 2018. We recorded immaterial </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangible asset impairment charges</span><span style="font-family:inherit;font-size:10pt;"> in the first nine months of 2019 and 2018.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the third quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we performed our annual impairment test of all IPR&amp;D projects and our indefinite-lived core technology assets using the optional qualitative assessment approach and determined that the assets were not impaired. We also verified that the classification of IPR&amp;D projects and our indefinite-lived core technology assets we continue to recognize on our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> as indefinite-lived assets continues to be appropriate.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Critical Accounting Policies and Estimates</span><span style="font-family:inherit;font-size:10pt;"> within Part II, Item 7. </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="font-family:inherit;font-size:10pt;"> contained in our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization/ Write-offs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Accumulated Amortization/ Write-offs</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortizable intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12,018</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,545</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10,197</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5,266</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Patents</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>524</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(404</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>520</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(393</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other intangible assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,748</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1,047</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,666</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(958</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>14,290</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(6,996</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12,383</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(6,617</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Indefinite-lived intangible assets</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19,915</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17,811</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">IPR&amp;D</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>661</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>486</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Technology-related</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>20,695</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>18,417</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(9,900</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 12018000000 5545000000 10197000000 5266000000 524000000 404000000 520000000 393000000 1748000000 1047000000 1666000000 958000000 14290000000 6996000000 12383000000 6617000000 19915000000 9900000000 17811000000 9900000000 661000000 486000000 120000000 120000000 20695000000 9900000000 18417000000 9900000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following represents our goodwill balance allocated to our global reportable segments and unallocated amounts:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:26%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">MedSurg</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Rhythm and Neuro</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cardiovascular</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,063</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,924</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>3,925</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,911</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Impact of foreign currency fluctuations and other changes in carrying amount</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill acquired</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>307</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,549</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,124</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill divested</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,060</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,191</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>4,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,550</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>10,015</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">As a result of the </span><span style="font-family:inherit;font-size:9pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:9pt;">, we recognized goodwill attributable to the synergies expected to arise from the </span><span style="font-family:inherit;font-size:9pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:9pt;"> and revenue and cash flow projections associated with future technologies. The goodwill is not deductible for tax purposes. As of September 30, 2019, given the preliminary nature of the </span><span style="font-family:inherit;font-size:9pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:9pt;"> purchase price allocation, we have not yet allocated goodwill to the relevant reporting units and/or reportable segments.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2063000000 1924000000 3925000000 0 7911000000 -3000000 0 2000000 1000000 -1000000 0 268000000 307000000 1549000000 2124000000 19000000 19000000 2060000000 2191000000 4214000000 1550000000 10015000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Derivative Instruments and Hedging Activities</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Currency Derivative Instruments</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk Management Strategy</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our risk from changes in currency exchange rates consists primarily of monetary assets and liabilities, forecast intercompany and third-party transactions, net investments in certain subsidiaries and the purchase price of any acquisition that is denominated in a currency other than the U.S. dollar. We manage currency exchange rate risk at a consolidated level to reduce the cost of hedging by taking advantage of offsetting transactions. We employ derivative instruments, primarily forward currency contracts, to reduce the risk to our earnings and cash flows associated with changes in currency exchange rates. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The success of our currency risk management program depends, in part, on forecast transactions denominated primarily in Euro, Japanese yen, Chinese renminbi and British pound sterling. We may experience unanticipated currency exchange gains or losses to the extent the actual activity is different than forecast. In addition, changes in currency exchange rates related to any unhedged transactions may impact our earnings and cash flows.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Designations and Hedging Relationships</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our currency derivative instruments are designated as cash flow hedges under </span><span>FASB ASC Topic 815</span><span style="font-style:italic;">, Derivatives and Hedging</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;">), and are intended to protect the U.S. dollar value of forecasted transactions. The gain or loss on a derivative instrument designated as a cash flow hedge is recorded in the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net change in derivative financial instruments</span><span style="font-family:inherit;font-size:10pt;"> component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income (loss), net of tax (OCI)</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;"> until the underlying third-party transaction occurs. When the underlying third-party transaction occurs, we recognize the gain or loss in earnings within the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cost of products sold</span><span style="font-family:inherit;font-size:10pt;"> caption of our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. In the event the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the gains or losses within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax (AOCI)</span><span style="font-family:inherit;font-size:10pt;"> to earnings at that time.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also designate certain forward currency contracts as net investment hedges to hedge a portion of our net investments in certain of our entities with functional currencies denominated in the Euro, Swiss franc, Japanese yen, British pound sterling, South Korean won and Taiwan dollar. We elected to use the spot method to assess effectiveness for our derivatives that are designated as net investment hedges. Under the spot method, the change in fair value attributable to changes in the spot rate is recorded in the</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Foreign currency translation adjustment (CTA)</span><span style="font-family:inherit;font-size:10pt;"> component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;">. We have elected to exclude the spot-forward difference from the assessment of hedge effectiveness and are amortizing this amount separately, as calculated at the date of designation, on a straight-line basis over the term of the currency forward contracts. Amortization of the spot-forward difference is then reclassified from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> to current period earnings as a reduction to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also use forward currency contracts that are not part of designated hedging relationships under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> as a part of our strategy to manage our exposure to currency exchange rate risk related to monetary assets and liabilities and related forecast transactions. These non-designated currency forward contracts have an original time to maturity consistent with the hedged currency transaction exposures, generally less than one year, and are marked-to-market with changes in fair value recorded to earnings within the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other, net</span><span style="font-family:inherit;font-size:10pt;"> caption of our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the purchase price of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;"> As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we settled all outstanding contracts</span><span style="font-family:inherit;font-size:10pt;">, resulting in a cumulative loss on the contracts of </span><span style="font-family:inherit;font-size:10pt;"><span>$294 million</span></span><span style="font-family:inherit;font-size:10pt;"> that was recognized over time in earnings as we adjusted for changes in fair value until the final fair value was determined at maturity. We received </span><span style="font-family:inherit;font-size:10pt;"><span>£3.312 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of cash to fund the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">, which translated into </span><span style="font-family:inherit;font-size:10pt;font-style:normal;"><span>$4.303 billion</span></span><span style="font-family:inherit;font-size:10pt;"> based on hedged currency exchange rates. </span><span style="font-family:inherit;font-size:10pt;">We recognized a </span><span style="font-family:inherit;font-size:10pt;"><span>$207 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and a </span><span style="font-family:inherit;font-size:10pt;"><span>$323 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span> in </span><span style="font-style:italic;">Other, net</span><span style="font-style:italic;"> </span><span>due to changes in fair value of the contracts.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Interest Rate Derivative Instruments</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Risk Management Strategy</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our interest rate risk relates primarily to U.S. dollar borrowings partially offset by U.S. dollar cash investments. We use interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates. Under these agreements we and the counterparty, at specified intervals, exchange the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. We designate these derivative instruments either as fair value or cash flow hedges in accordance with </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Derivative Designations and Hedging Relationships</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had no interest rate derivative instruments designated as cash flow hedges outstanding as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, which were intended to manage our earnings and cash flow exposure to changes in the benchmark interest rate in connection with the forecasted issuance of fixed-rate debt. For outstanding designated cash flow hedges, we record the changes in the fair value of the derivatives within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;"> until the underlying hedged transaction occurs, at which time we recognize the gain or loss within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> over the same period that the hedged items affect earnings, so long as the hedge relationship remains effective. If we determine the hedging relationship is no longer effective, or if the occurrence of the hedged forecast transaction becomes no longer probable, we reclassify the amount of gains or losses from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> to earnings at that time.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the fourth quarter of 2018, we entered into interest rate derivative contracts designated as cash flow hedges having a notional amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> to hedge interest rate risk. In the first quarter of 2019, we terminated these instruments in connection with our senior notes issuance in the same period as discussed in </span><span style="font-style:italic;">Note E – Borrowings and Credit Arrangements</span><span style="font-family:inherit;font-size:10pt;">. We recognized an immaterial loss within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">OCI</span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and are reclassifying the amortization of the loss from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> into earnings as a component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> over the same period that the hedged item affects earnings, so long as the hedge relationship remains effective. We are also continuing to reclassify in a similar manner the amortization of the gains or losses of our other previously terminated interest rate derivative instruments that were designated as cash flow hedges. The balance of the deferred loss on our terminated cash flow hedges within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> was immaterial as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;color:#ff0000;font-weight:bold;"> </span><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. We recognized immaterial gains and losses in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> relating to the amortization of our terminated cash flow hedges in the current and prior periods.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had no interest rate derivative instruments designated as fair value hedges outstanding as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Prior to 2018, we terminated interest rate derivative instruments that were designated as fair value hedges and are continuing to recognize the amortization of the gains or losses originally recorded within the </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term debt</span><span style="font-family:inherit;font-size:10pt;"> caption on our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> into earnings as a component of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> over the same period that the discount or premium associated with the hedged items affects earnings. In the event that we designate outstanding interest rate derivative instruments as fair value hedges, we record the changes in the fair values of interest rate derivatives designated as fair value hedges and of the underlying hedged debt instruments in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;">, which generally offset. The balance of the deferred gains on our terminated fair value hedges within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Long-term debt</span><span style="font-family:inherit;font-size:10pt;"> was immaterial as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. We recognized immaterial gains in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:10pt;"> relating to the amortization of the terminated fair value hedges in the current and prior periods.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the contractual amounts of our derivative instruments outstanding:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FASB ASC Topic 815 Designation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,030</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,935</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,483</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-designated</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,522</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Notional Outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,487</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12,326</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The remaining time to maturity as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> is within </span><span style="font-family:inherit;font-size:10pt;"><span>60</span></span><span style="font-family:inherit;font-size:10pt;"> months for all designated forward currency contracts and generally less than one year for all non-designated forward currency contracts.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following presents the effect of our derivative instruments designated as cash flow and net investment hedges under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> on our accompanying </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. Refer to </span><span style="font-style:italic;">Note M – Changes in Other Comprehensive Income</span><span style="font-family:inherit;font-size:10pt;"> for the total amounts relating to derivative instruments presented within the </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of comprehensive income (loss)</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:12%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="24" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Recognized in OCI on Derivative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unaudited Condensed Consolidated Statements of Operations (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Reclassified from AOCI into Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pre-Tax Gain (Loss)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Tax Benefit (Expense)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gain (Loss) Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location of Amount Reclassified</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Amount of Line Item Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pre-Tax (Gain) Loss</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Tax (Benefit) Expense</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Gain) Loss Net of Tax</span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>777</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate derivative contracts</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2018</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,265</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>294</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate derivative contracts</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>294</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2018</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,084</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate derivative contracts</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">In all periods presented in the table above, the pre-tax (gain) loss amounts reclassified from </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:9pt;"> to earnings represent the effect of the hedging relationships on earnings. All other amounts included in earnings related to hedging relationships were immaterial.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For our outstanding net investment hedges, the net gain or loss reclassified from </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:9pt;"> to earnings as a reduction of </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">Interest expense</span><span style="font-family:inherit;font-size:9pt;"> represents the straight-line amortization of the excluded component as calculated at the date of designation. This initial value of the excluded component has been excluded from the assessment of effectiveness in accordance with </span><span style="font-family:inherit;font-size:9pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:9pt;">. In the current period, we did not recognize any gains or losses on the components included in the assessment of hedge effectiveness in </span><span style="font-family:inherit;font-size:9pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:9pt;"> or earnings.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> that may be reclassified from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> to earnings within the next twelve months are presented below (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Designated Derivative Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FASB ASC Topic 815 Designation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Unaudited Condensed Consolidated Statements of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Unaudited Condensed Consolidated Statements of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gain (loss) on currency hedge contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(202</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gain (loss) on currency transaction exposures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net currency exchange gain (loss)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(207</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(334</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the purchase price of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;"> As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we settled all outstanding contracts</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;">We recognized a </span><span style="font-family:inherit;font-size:10pt;"><span>$207 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and a </span><span style="font-family:inherit;font-size:10pt;"><span>$323 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net gain (loss) on currency hedge contracts</span><span style="font-style:italic;"> </span><span>due to changes in fair value of the contracts.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by </span><span>FASB ASC Topic 820, </span><span style="font-style:italic;">Fair Value Measurements and Disclosures</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 820</span><span style="font-family:inherit;font-size:10pt;">) and considering the estimated amount we would receive or pay to transfer these instruments at the reporting date given the applicable current currency exchange rates, interest rates, the creditworthiness of the counterparty for unrealized gain positions and our own creditworthiness for unrealized loss positions. In certain instances, we may utilize financial models to measure fair value of our derivative instruments. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability and inputs derived principally from, or corroborated by, observable market data by correlation or other means. The following are the balances of our derivative assets and liabilities:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Unaudited Condensed Consolidated Balance Sheets (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Designated Derivative Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>456</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Designated Derivative Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Derivative Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>504</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Designated Derivative Instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Designated Derivative Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Derivative Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">We classify derivative assets and liabilities as current when the settlement date of the derivative contract is one year or less.</span></div></td></tr></table><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Recurring Fair Value Measurements</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 820</span><span style="font-family:inherit;font-size:10pt;"> establishes a three-level valuation hierarchy for disclosure of fair value measurements. The category of a financial asset or a financial liability within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market and government funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>633</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>633</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>504</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,163</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>318</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>768</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>347</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>427</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our investments in money market and government funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</span><span style="font-family:inherit;font-size:10pt;"> within our accompanying </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">, in accordance with U.S. GAAP and our accounting policies. In addition to </span><span style="font-family:inherit;font-size:10pt;"><span>$26 million</span></span><span style="font-family:inherit;font-size:10pt;"> invested in money market and government funds as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$249 million</span></span><span style="font-family:inherit;font-size:10pt;"> in interest bearing and non-interest-bearing bank accounts. In addition to </span><span style="font-family:inherit;font-size:10pt;"><span>$13 million</span></span><span style="font-family:inherit;font-size:10pt;"> invested in money market and government funds as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$133 million</span></span><span style="font-family:inherit;font-size:10pt;"> in interest bearing and non-interest-bearing bank accounts.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our recurring fair value measurements using Level 3 inputs relates to our contingent consideration liability. Refer to </span><span style="font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span><span style="font-family:inherit;font-size:10pt;">for a discussion of the changes in the fair value of our contingent consideration liability.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, our recurring fair value measurements using Level 3 inputs relate to our licensing arrangements. In the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we acquired intellectual property and related licensing arrangements as of the result of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> that provides the contractual right to receive future royalty payments. As part of the licensing arrangements we acquired, we also have the contractual obligation to remit a portion of the cash flows received to the inventors associated with the intellectual property. We have elected the fair value option to account for the licensing arrangements financial asset and financial liability in accordance with </span><span>FASB ASC Topic 825, </span><span style="font-style:italic;">Financial Instruments</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of September 30, 2019, we have recorded the preliminary fair values of the financial asset and financial liability using a discounted cash flow approach considering the probability-weighted expected future cash flows to be generated by the royalty stream. The preliminary fair value of the financial liability also considers the related contractual provisions that govern our payment obligations. As discussed in </span><span style="font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:10pt;">, given the size and breadth of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">, we anticipate that the purchase price allocation will take longer than prior acquisitions and potentially up to the one year allowed under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 805</span><span style="font-family:inherit;font-size:10pt;"> to adequately analyze all the factors used in establishing the fair value of assets acquired and liabilities assumed as of the acquisition date, including the licensing arrangements financial asset and liability and the related tax and foreign currency effects of any changes made.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our licensing arrangements include the following significant unobservable inputs:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:20%;"/><td style="width:18%;"/><td style="width:10%;"/><td style="width:23%;"/><td style="width:8%;"/><td style="width:2%;"/><td style="width:8%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Licensing Arrangements</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value as of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average (1)</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Asset</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$633 million</span></span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9%</span></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Liability</span></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$341 million</span></span></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:middle;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9%</span></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:30px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Significant increases or decreases in projected cash flows of the royalty stream and the related contractual provisions that govern our payment obligations, discount rates or the time until payment is made would have resulted in a significantly lower or higher fair value measurement of the licensing arrangements financial assets and liability as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Recurring Fair Value Measurements</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods after initial recognition. The fair value of a measurement alternative investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to </span><span style="font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:10pt;"> for a discussion of our strategic investments. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-style:italic;">Note C – Goodwill and Other Intangible Assets</span><span style="font-family:inherit;font-size:10pt;"> for a discussion of the fair values.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The fair value of our outstanding debt obligations was </span><span style="font-family:inherit;font-size:10pt;"><span>$11.990 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.239 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. We determined fair value by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy, amortized cost for commercial paper and face value for term loans and credit facility borrowings outstanding. Refer to </span><span style="font-style:italic;">Note E – Borrowings and Credit Arrangements</span><span style="font-family:inherit;font-size:10pt;"> for a discussion of our debt obligations.</span></div> Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on the hedged item.<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage concentration of counterparty credit risk by limiting acceptable counterparties to major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to individual counterparties and by actively monitoring counterparty credit ratings and the amount of individual credit exposure. We also employ master netting arrangements that limit the risk of counterparty non-payment on a particular settlement date to the net gain that would have otherwise been received from the counterparty. Although not completely eliminated, we do not consider the risk of counterparty default to be significant as a result of these protections. Further, none of our derivative instruments are subject to collateral or other security arrangements, nor do they contain provisions that are dependent on our credit ratings from any credit rating agency.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 294000000 3312000000 4303000000 -207000000 -323000000 1000000000.000 1000000000.000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the contractual amounts of our derivative instruments outstanding:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FASB ASC Topic 815 Designation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,030</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,962</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,935</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,483</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-designated</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,522</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5,880</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Notional Outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,487</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>12,326</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 4030000000 3962000000 1935000000 1483000000 3522000000 5880000000 0 1000000000 9487000000 12326000000 60 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:12%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="24" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Effect of Hedging Relationships on Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Recognized in OCI on Derivative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unaudited Condensed Consolidated Statements of Operations (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount Reclassified from AOCI into Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pre-Tax Gain (Loss)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Tax Benefit (Expense)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Gain (Loss) Net of Tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location of Amount Reclassified</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Amount of Line Item Presented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Pre-Tax (Gain) Loss</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Tax (Benefit) Expense</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">(Gain) Loss Net of Tax</span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2019</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>777</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate derivative contracts</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2018</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>672</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,265</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(47</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>294</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate derivative contracts</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>294</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2018</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Forward currency contracts</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,084</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedges (2)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest rate derivative contracts</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedges</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>177</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 101000000 -23000000 78000000 777000000 -22000000 5000000 -17000000 64000000 -14000000 50000000 95000000 -12000000 3000000 9000000 0 0 0 95000000 1000000 0 1000000 58000000 -13000000 45000000 672000000 2000000 0 2000000 4000000 -1000000 3000000 58000000 -10000000 2000000 8000000 176000000 -40000000 136000000 2265000000 -47000000 10000000 -36000000 92000000 -21000000 71000000 294000000 -33000000 7000000 -25000000 0 0 0 294000000 -3000000 -1000000 2000000 135000000 -30000000 105000000 2084000000 27000000 -6000000 21000000 25000000 -6000000 19000000 177000000 -17000000 4000000 13000000 0 0 0 177000000 -1000000 0 -1000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, pre-tax net gains or losses for our derivative instruments designated, or previously designated, as cash flow and net investment hedges under </span><span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> that may be reclassified from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">AOCI</span><span style="font-family:inherit;font-size:10pt;"> to earnings within the next twelve months are presented below (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Designated Derivative Instrument</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">FASB ASC Topic 815 Designation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Unaudited Condensed Consolidated Statements of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount of Pre-Tax Gain (Loss) that may be Reclassified to Earnings</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of products sold</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>104</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net investment hedge</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate derivative contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash flow hedge</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 104000000 48000000 -5000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gains and losses on currency hedge contracts not designated as hedging instruments offset by net gains and losses from currency transaction exposures are presented below:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Unaudited Condensed Consolidated Statements of Operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gain (loss) on currency hedge contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(202</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net gain (loss) on currency transaction exposures</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(40</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net currency exchange gain (loss)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(207</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(334</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(15</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain of our non-designated forward currency contracts were entered into for the purpose of managing our exposure to currency exchange rate risk related to the purchase price of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;"> As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we settled all outstanding contracts</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;">We recognized a </span><span style="font-family:inherit;font-size:10pt;"><span>$207 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and a </span><span style="font-family:inherit;font-size:10pt;"><span>$323 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net gain (loss) on currency hedge contracts</span><span style="font-style:italic;"> </span><span>due to changes in fair value of the contracts.</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -202000000 16000000 -334000000 25000000 -4000000 -23000000 0 -40000000 -207000000 -6000000 -334000000 -15000000 -207000000 -323000000 <span style="font-family:inherit;font-size:10pt;">FASB ASC Topic 815</span><span style="font-family:inherit;font-size:10pt;"> requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by </span><span>FASB ASC Topic 820, </span><span style="font-style:italic;">Fair Value Measurements and Disclosures</span> The following are the balances of our derivative assets and liabilities:<div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Location on Unaudited Condensed Consolidated Balance Sheets (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Designated Derivative Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>98</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>456</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>237</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Designated Derivative Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Derivative Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>504</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Derivative Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Designated Derivative Instruments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Non-Designated Derivative Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward currency contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Derivative Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">We classify derivative assets and liabilities as current when the settlement date of the derivative contract is one year or less.</span></div> 98000000 55000000 358000000 183000000 456000000 237000000 48000000 67000000 504000000 304000000 3000000 2000000 5000000 3000000 0 44000000 8000000 49000000 40000000 31000000 48000000 80000000 <div style="line-height:120%;padding-left:4px;padding-top:12px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets and liabilities measured at fair value on a recurring basis consist of the following:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:37%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Money market and government funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>304</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>633</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>633</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>504</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>633</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,163</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>318</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;text-decoration:underline;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>380</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>347</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Licensing arrangements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>341</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>48</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>720</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>768</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>347</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>427</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The recurring Level 3 fair value measurements of our licensing arrangements include the following significant unobservable inputs:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:20%;"/><td style="width:18%;"/><td style="width:10%;"/><td style="width:23%;"/><td style="width:8%;"/><td style="width:2%;"/><td style="width:8%;"/><td style="width:11%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Licensing Arrangements</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value as of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Valuation Technique</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable Input</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Range</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average (1)</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Asset</span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$633 million</span></span></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9%</span></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td></tr><tr><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Liability</span></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>$341 million</span></span></div></td><td rowspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discounted Cash Flow</span></div></td><td style="vertical-align:middle;background-color:#bfe4ff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Discount Rate</span></div></td><td colspan="3" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9%</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9%</span></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Projected Year of Payment</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">-</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2027</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:30px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Unobservable inputs relate to a single financial asset and liability. As such, unobservable inputs were not weighted by the relative fair value of the instruments. For projected year of payment, the amount represents the median of the inputs and is not a weighted average.</span></div> 26000000 0 0 26000000 13000000 0 0 13000000 0 504000000 0 504000000 0 304000000 0 304000000 0 0 633000000 633000000 0 0 0 0 26000000 504000000 633000000 1163000000 14000000 304000000 0 318000000 0 48000000 0 48000000 0 80000000 0 80000000 0 0 380000000 380000000 0 0 347000000 347000000 0 0 341000000 341000000 0 0 0 0 0 48000000 720000000 768000000 0 80000000 347000000 427000000 26000000 249000000 13000000 133000000 633000000 0.09 0.09 341000000 0.09 0.09 11990000000 7239000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE E – BORROWINGS AND CREDIT ARRANGEMENTS</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had total debt of </span><span style="font-family:inherit;font-size:10pt;"><span>$10.888 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$7.056 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. The debt maturity schedule for our long-term debt obligations is presented below: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except interest rates)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Issuance Date</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Semi-annual Coupon Rate</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2020 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2009</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2020 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.850%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2021 Term Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2022 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.375%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2022 Term Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2023 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.125%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2024 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.450%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2025 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.850%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2026 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2026</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.750%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2028 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2028</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2029 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2029</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2035 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2005</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2035</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2039 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2039</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.550%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2040 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2009</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2040</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.375%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2049 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2049</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.700%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized Debt Issuance Discount<br/>and Deferred Financing Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2049</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(79</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized Gain on Fair Value Hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance Lease Obligation (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>4,803</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Note:</span><span style="font-family:inherit;font-size:9pt;"> The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges. </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Effective January 1, 2019, we adopted </span><span style="font-family:inherit;font-size:9pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:9pt;">, which requires that we recognize finance lease obligations in our </span><span style="font-family:inherit;font-size:9pt;">unaudited condensed consolidated balance sheet</span><span style="font-family:inherit;font-size:9pt;">. As of December 31, 2018, these leases were referred to as capital lease obligations in accordance with </span><span style="font-family:inherit;font-size:9pt;">FASB ASC Topic 840</span><span style="font-family:inherit;font-size:9pt;">. Please refer to </span><span style="font-size:9pt;font-style:italic;">Note A – Basis of Presentation</span><span style="font-family:inherit;font-size:9pt;"> for additional information.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revolving Credit Facility </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we maintained a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.750 billion</span></span><span style="font-family:inherit;font-size:10pt;"> revolving credit facility (2018 Facility) with a global syndicate of commercial banks that matures on December 19, 2023 with one-year extension options subject to certain conditions.</span><span style="font-family:inherit;font-size:10pt;"> This facility provides backing for the commercial paper program. The 2018 Credit Agreement for the 2018 Facility requires that we comply with certain covenants, including financial covenants as described within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt Covenants</span><span style="font-family:inherit;font-size:10pt;"> below. </span><span style="font-family:inherit;font-size:10pt;">There were no amounts outstanding under our revolving credit facility as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Term Loans </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 25, 2019, upon the closing of our senior notes offering in aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.300 billion</span></span><span style="font-family:inherit;font-size:10pt;"> described below, we terminated the </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> Term Loan Credit Agreement, entered into on August 20, 2018 and amended on December 19, 2018 (</span><span style="font-family:inherit;font-size:10pt;">August 2019 Term Loan</span><span style="font-family:inherit;font-size:10pt;">). The </span><span style="font-family:inherit;font-size:10pt;">August 2019 Term Loan</span><span style="font-family:inherit;font-size:10pt;"> was scheduled to mature on August 19, 2019. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> outstanding under our </span><span style="font-family:inherit;font-size:10pt;">August 2019 Term Loan</span><span style="font-family:inherit;font-size:10pt;">, which was presented within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Current debt obligations</span><span style="font-family:inherit;font-size:10pt;"> on our accompanying </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 19, 2018, we entered into a </span><span style="font-family:inherit;font-size:10pt;"><span>$2.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> senior unsecured delayed-draw term loan facility consisting of a </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> two-year delayed draw term loan credit facility maturing in two years from the date of the closing of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> (Two-Year Delayed Draw Term Loan) and a </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> three-year delayed draw term loan credit facility maturing in three years from the date of the closing of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> (Three-Year Delayed Draw Term Loan).</span><span style="font-family:inherit;font-size:10pt;"> Borrowings are available in U.S. dollars and bear interest at LIBOR or a base rate, in each case plus an applicable margin based on our public debt ratings. We are required to pay customary ticking fees on the average daily unused commitments based on our public debt ratings. The facilities contain customary representations and covenants, as described within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt Covenants</span><span style="font-family:inherit;font-size:10pt;"> below. The facilities contain customary events of default, which may result in the acceleration of any outstanding commitments, and also contain customary U.K. certain funds provisions. Any proceeds from the facilities will be available to finance the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"> and pay related transaction costs, as defined by the facilities. </span><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">August 19, 2019</span><span style="font-family:inherit;font-size:10pt;">, for the purpose of funding the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">, we borrowed </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> under the Two-Year Delayed Draw Term Loan</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> under the Three-Year Delayed Draw Term Loan</span><span style="font-family:inherit;font-size:10pt;">.</span><span style="font-family:inherit;font-size:10pt;"> As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, our average interest rates on the borrowings were </span><span style="font-family:inherit;font-size:10pt;"><span>3.37 percent</span></span><span style="font-family:inherit;font-size:10pt;"> for the Two-Year Delayed Draw Term Loan and </span><span style="font-family:inherit;font-size:10pt;"><span>3.47 percent</span></span><span style="font-family:inherit;font-size:10pt;"> for the Three-Year Delayed Draw Term Loan. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt Covenants</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of and through </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we were in compliance with all the required covenants related to our debt obligations.</span><span style="font-family:inherit;font-size:10pt;"> For additional information regarding the terms of our debt agreements, refer to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note E – Borrowings and Credit Arrangements</span><span style="font-family:inherit;font-size:10pt;"> to our consolidated financial statements in our most recent Annual Report on Form 10-K. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">All existing credit arrangements described above require that we maintain certain financial covenants, as follows: </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:32%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Covenant Requirement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Actual</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">as of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">as of September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maximum leverage ratio (1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.75 times</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.27 times</span></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, for the preceding four consecutive fiscal quarters.</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our covenants require that we maintain a maximum leverage ratio of </span><span style="font-family:inherit;font-size:10pt;"><span>3.75 times</span></span><span style="font-family:inherit;font-size:10pt;">, provided, however, that for the two consecutive fiscal quarters ended immediately following the consummation of a Qualified Acquisition, as defined by each agreement, the maximum leverage ratio shall be </span><span style="font-family:inherit;font-size:10pt;"><span>4.75 times</span></span><span style="font-family:inherit;font-size:10pt;">, and then subject to a step-down for each succeeding fiscal quarter end to </span><span style="font-family:inherit;font-size:10pt;"><span>4.50 times</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>4.25 times</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>4.00 times</span></span><span style="font-family:inherit;font-size:10pt;"> and then back to </span><span style="font-family:inherit;font-size:10pt;"><span>3.75 times</span></span><span style="font-family:inherit;font-size:10pt;"> for each fiscal quarter end thereafter. </span><span style="font-family:inherit;font-size:10pt;">On </span><span style="font-family:inherit;font-size:10pt;">August 19, 2019</span><span style="font-family:inherit;font-size:10pt;">, we announced the closing of our acquisition of </span><span style="font-family:inherit;font-size:10pt;">BTG</span><span style="font-family:inherit;font-size:10pt;">, a Qualified Acquisition, and our maximum leverage ratio was </span><span style="font-family:inherit;font-size:10pt;"><span>4.75 times</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. Refer to </span><span style="font-style:italic;">Note B – Acquisitions and Strategic Investments</span><span style="font-family:inherit;font-size:10pt;"> for more information. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our covenants provide for an exclusion from the calculation of consolidated EBITDA, as defined by the agreements, through maturity, of any non-cash charges and up to </span><span style="font-family:inherit;font-size:10pt;"><span>$500 million</span></span><span style="font-family:inherit;font-size:10pt;"> in restructuring charges and restructuring-related expenses related to our current or future restructuring plans. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$314 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the restructuring charge exclusion remaining. In addition, any cash litigation payments (net of any cash litigation receipts), as defined by the agreements, are excluded from the calculation of consolidated EBITDA, as defined by the agreements, provided that the sum of any excluded net cash litigation payments do not exceed </span><span style="font-family:inherit;font-size:10pt;"><span>$2.624 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in the aggregate. As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$1.262 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of the litigation exclusion remaining.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Any inability to maintain compliance with these covenants could require us to seek to renegotiate the terms of our credit facility or seek waivers from compliance with these covenants, both of which could result in additional borrowing costs. Further, there can be no assurance that our lenders would agree to such new terms or grant such waivers on terms acceptable to us. In this case, all credit facility commitments would terminate, and any amounts borrowed under the facility would become immediately due and payable. Furthermore, any termination of our credit facility may negatively impact the credit ratings assigned to our commercial paper program which may impact our ability to refinance any then outstanding commercial paper as it becomes due and payable</span><span style="font-family:inherit;font-size:10pt;color:#4f81bd;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commercial Paper </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except maturity and yield)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper outstanding (at par)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,248</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maximum borrowing capacity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Borrowing capacity available </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,457</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,502</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average maturity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40 days</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27 days</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average yield</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Senior Notes </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We had senior notes outstanding of </span><span style="font-family:inherit;font-size:10pt;"><span>$7.650 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.800 billion</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2019, we completed an offering of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.300 billion</span></span><span style="font-family:inherit;font-size:10pt;"> in aggregate principal amount of senior notes</span><span style="font-family:inherit;font-size:10pt;"> comprised of </span><span style="font-family:inherit;font-size:10pt;"><span>$850 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>3.450%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due </span><span style="font-family:inherit;font-size:10pt;">March 2024</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$850 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>3.750%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due </span><span style="font-family:inherit;font-size:10pt;">March 2026</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$850 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due </span><span style="font-family:inherit;font-size:10pt;">March 2029</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$750 million</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>4.550%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due </span><span style="font-family:inherit;font-size:10pt;">March 2039</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of </span><span style="font-family:inherit;font-size:10pt;"><span>4.700%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due </span><span style="font-family:inherit;font-size:10pt;">March 2049</span><span style="font-family:inherit;font-size:10pt;">. We used a portion of the net proceeds from the offering to repay the </span><span style="font-family:inherit;font-size:10pt;"><span>$850 million</span></span><span style="font-family:inherit;font-size:10pt;"> plus accrued interest and premium of our </span><span style="font-family:inherit;font-size:10pt;"><span>6.000%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due in </span><span style="font-family:inherit;font-size:10pt;">January 2020</span><span style="font-family:inherit;font-size:10pt;">, the </span><span style="font-family:inherit;font-size:10pt;"><span>$600 million</span></span><span style="font-family:inherit;font-size:10pt;"> plus accrued interest and premium of our </span><span style="font-family:inherit;font-size:10pt;"><span>2.850%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due in </span><span style="font-family:inherit;font-size:10pt;">May 2020</span><span style="font-family:inherit;font-size:10pt;"> and the </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> plus accrued interest of our </span><span style="font-family:inherit;font-size:10pt;">August 2019 Term Loan</span><span style="font-family:inherit;font-size:10pt;">. In the third quarter of 2019</span><span style="font-family:inherit;font-size:10pt;">, the remaining proceeds were used to finance a portion of the </span><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to liabilities of our subsidiaries (see </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Arrangements</span><span style="font-family:inherit;font-size:10pt;"> below).</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 22, 2019, we announced the commencement of a cash tender offer (Tender Offer) for up to </span><span style="font-family:inherit;font-size:10pt;"><span>$1.000 billion</span></span><span style="font-family:inherit;font-size:10pt;"> combined aggregate principal amount (Aggregate Maximum Principal Amount) of our outstanding </span><span style="font-family:inherit;font-size:10pt;"><span>4.125%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due </span><span style="font-family:inherit;font-size:10pt;">October 2023</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due </span><span style="font-family:inherit;font-size:10pt;">March 2028</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>3.850%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due </span><span style="font-family:inherit;font-size:10pt;">May 2025</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>3.375%</span></span><span style="font-family:inherit;font-size:10pt;"> senior notes due </span><span style="font-family:inherit;font-size:10pt;">May 2022</span><span style="font-family:inherit;font-size:10pt;"> (collectively, Tender Offer Notes). The Tender Offer is being made exclusively pursuant to an offer to purchase dated October 22, 2019, which sets forth the terms and conditions of the Tender Offer. Consummation of the Tender Offer is subject to satisfaction or waiver of the conditions described in the offer to purchase, including the financing condition that we shall have closed one or more debt financings resulting in net proceeds in an amount, together with cash on hand, not less than the amount required, upon the terms and subject to the conditions of the Tender Offer, to purchase all the securities validly tendered and accepted for purchase in the Tender Offer and to pay accrued interest thereon and fees and expenses associated therewith.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Tender Offer will expire at midnight, Eastern Standard Time, on November 19, 2019, unless extended or terminated by us. However, because the aggregate principal amount of Tender Offer Notes validly tendered and not validly withdrawn as of the early tender date at 5:00 p.m. Eastern Standard Time, on November 4, 2019, would cause the Aggregate Maximum Principal Amount to be exceeded and we do not expect to increase the Aggregate Maximum Principal Amount, we do not expect to accept any further tenders of Tender Offer Notes.</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Bridge Facility </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 25, 2019, upon the closing of our senior notes offering in aggregate principal amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$4.300 billion</span></span><span style="font-family:inherit;font-size:10pt;"> described above, we terminated the Bridge Facility entered into on November 20, 2018. The termination was pursuant to the terms of the Bridge Facility, which required full termination upon the refinancing of the </span><span style="font-family:inherit;font-size:10pt;">January 2020 Notes</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">May 2020 Notes</span><span style="font-family:inherit;font-size:10pt;"> discussed above. There were no amounts borrowed under the Bridge Facility as of December 31, 2018. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Arrangements </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have accounts receivable factoring programs in certain European countries and with commercial banks in Japan which include promissory notes discounting programs. We account for our factoring programs as sales under </span><span>FASB ASC Topic 860, </span><span style="font-style:italic;">Transfers and Servicing</span><span style="font-family:inherit;font-size:10pt;">. We have no retained interest in the transferred receivables, other than collection and administration, and once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. Amounts de-recognized for accounts and notes receivable, which are excluded from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Trade accounts receivable, net </span><span style="font-family:inherit;font-size:10pt;">in the accompanying </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">, are aggregated by contract denominated currency below (in millions): </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Factoring Arrangements</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">De-recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">De-recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest Rate</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Euro denominated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Yen denominated</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note E – Borrowing and Credit Arrangements</span><span style="font-family:inherit;font-size:10pt;"> to our audited financial statements contained in Item 8 of our most recent Annual Report on Form 10-K for additional information on our borrowings and credit agreements.</span></div> 10888000000 7056000000.000 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except interest rates)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Issuance Date</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Semi-annual Coupon Rate</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2020 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2009</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2020</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2020 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.850%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2021 Term Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2021</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2022 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.375%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2022 Term Loan</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2023 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">August 2013</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">October 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>450</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.125%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2024 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.450%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2025 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">May 2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.850%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2026 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2026</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.750%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2028 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2028</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2029 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2029</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>850</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2035 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2005</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">November 2035</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.000%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2039 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2039</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.550%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2040 Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">December 2009</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">January 2040</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.375%</span></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2049 Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">February 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 2049</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.700%</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized Debt Issuance Discount<br/>and Deferred Financing Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2049</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(79</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Unamortized Gain on Fair Value Hedges</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 - 2023</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance Lease Obligation (1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Long-term debt</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>9,590</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>4,803</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Note:</span><span style="font-family:inherit;font-size:9pt;"> The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges. </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Effective January 1, 2019, we adopted </span><span style="font-family:inherit;font-size:9pt;">FASB ASC Topic 842</span><span style="font-family:inherit;font-size:9pt;">, which requires that we recognize finance lease obligations in our </span><span style="font-family:inherit;font-size:9pt;">unaudited condensed consolidated balance sheet</span><span style="font-family:inherit;font-size:9pt;">. As of December 31, 2018, these leases were referred to as capital lease obligations in accordance with </span><span style="font-family:inherit;font-size:9pt;">FASB ASC Topic 840</span><span style="font-family:inherit;font-size:9pt;">. Please refer to </span><span style="font-size:9pt;font-style:italic;">Note A – Basis of Presentation</span><span style="font-family:inherit;font-size:9pt;"> for additional information.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 850000000 0.06000 0 600000000 0.02850 1000000000 0 500000000 500000000 0.03375 1000000000 0 450000000 450000000 0.04125 850000000 0 0.03450 750000000 750000000 0.03850 850000000 0 0.03750 1000000000 1000000000 0.04000 850000000 0 0.04000 350000000 350000000 0.07000 750000000 0 0.04550 300000000 300000000 0.07375 1000000000 0 0.04700 -79000000 -29000000 14000000 26000000 6000000 6000000 9590000000 4803000000 2750000000 4300000000 1000000000.000 1000000000.000 2000000000.000 1000000000.000 1000000000.000 1000000000.000 1000000000.000 0.0337 0.0347 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:32%;"/><td style="width:1%;"/><td style="width:32%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Covenant Requirement</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Actual</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">as of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">as of September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maximum leverage ratio (1)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.75 times</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.27 times</span></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Ratio of total debt to consolidated EBITDA, as defined by the credit agreements, for the preceding four consecutive fiscal quarters.</span><span style="font-family:inherit;font-size:10pt;"> </span></div> 4.75 4.27 3.75 4.75 4.50 4.25 4.00 3.75 4.75 500000000 314000000 2624000000 1262000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Commercial Paper </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions, except maturity and yield)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Commercial paper outstanding (at par)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,293</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,248</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Maximum borrowing capacity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Borrowing capacity available </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,457</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,502</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average maturity</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40 days</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27 days</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average yield</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.04</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:12px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1293000000 1248000000 2750000000 2750000000 1457000000 1502000000 P40D P27D 0.0243 0.0304 7650000000 4800000000 4300000000 850000000 0.03450 850000000 0.03750 850000000 0.04000 750000000 0.04550 1000000000.000 0.04700 850000000 0.06000 600000000 0.02850 1000000000.000 1000000000.000 0.04125 0.04000 0.03850 0.03375 4300000000 <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Factoring Arrangements</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31, 2018</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">De-recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Amount</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">De-recognized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Average</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interest Rate</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Euro denominated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Yen denominated</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 146000000 0.017 165000000 0.027 210000000 0.006 195000000 0.009 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE F – SUPPLEMENTAL BALANCE SHEET INFORMATION</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Components of selected captions in our accompanying </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;"> are as follows:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Cash, cash equivalents, restricted cash and restricted cash equivalents</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash and restricted cash equivalents included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>357</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash equivalents in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>676</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Trade accounts receivable, net</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,871</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,676</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following is a rollforward of our allowance for doubtful accounts:</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net charges to expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Utilization of allowances</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>66</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>66</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Inventories</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>940</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>760</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,566</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,166</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Property, plant and equipment, net</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Buildings and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment, furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,368</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>357</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,996</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,958</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,942</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,782</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation expense was </span><span style="font-family:inherit;font-size:10pt;"><span>$79 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$74 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$220 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$212 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Accrued expenses</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>328</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payroll and related liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>693</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rebates</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,932</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,246</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Other long-term liabilities</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>671</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>739</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal reserves</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>717</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,406</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,882</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash and restricted cash equivalents included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>357</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restricted cash equivalents in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>676</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>829</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 277000000 146000000 357000000 655000000 43000000 27000000 676000000 829000000 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,871</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,676</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Allowance for doubtful accounts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,796</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,608</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Beginning balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net charges to expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Utilization of allowances</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Ending balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>66</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>66</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1871000000 1676000000 75000000 68000000 1796000000 1608000000 73000000 63000000 68000000 68000000 8000000 6000000 19000000 15000000 5000000 4000000 11000000 17000000 75000000 66000000 75000000 66000000 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>940</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>760</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,566</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,166</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 940000000 760000000 206000000 100000000 420000000 306000000 1566000000 1166000000 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Buildings and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment, furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,368</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,224</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>357</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,996</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,958</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,942</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,782</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 112000000 97000000 1160000000 1100000000 3368000000 3224000000 357000000 319000000 4996000000 4740000000 3055000000 2958000000 1942000000 1782000000 79000000 74000000 220000000 212000000 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>328</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>712</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Payroll and related liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>693</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rebates</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>229</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>138</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,932</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,246</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 328000000 712000000 693000000 630000000 280000000 229000000 112000000 138000000 518000000 538000000 1932000000 2246000000 <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>671</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>739</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Legal reserves</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>217</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>717</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,406</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,882</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 671000000 739000000 240000000 217000000 268000000 209000000 1227000000 717000000 2406000000 1882000000 <div style="line-height:120%;font-size:10pt;"><span style="font-weight:bold;">NOTE G – LEASES</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term, and as a result, the remaining lease </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. For leases executed in 2019 and later, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than </span><span style="font-family:inherit;font-size:10pt;"><span>1 year</span></span><span style="font-family:inherit;font-size:10pt;"> to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>60 years</span></span><span style="font-family:inherit;font-size:10pt;">, some of which may include options to extend the leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>10 years</span></span><span style="font-family:inherit;font-size:10pt;">. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to our operating leases:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:77%;"/><td style="width:23%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.6 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our operating lease cost was </span><span style="font-family:inherit;font-size:10pt;"><span>$21 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$57 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental cash flow information related to our operating leases: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash paid for amounts included in the measurement of operating lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets obtained in exchange for operating lease obligations totaled </span><span style="font-family:inherit;font-size:10pt;"><span>$84 million</span></span><span style="font-family:inherit;font-size:10pt;"> for</span><span style="font-family:inherit;font-size:10pt;"> the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the maturities of our operating lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal year</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases<br/></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (excluding the first nine months of 2019)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total future minimum operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>314</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have additional leases for office space and R&amp;D space, that have not yet commenced, of </span><span style="font-family:inherit;font-size:10pt;"><span>$68 million</span></span><span style="font-family:inherit;font-size:10pt;">. These leases will commence during the fourth quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2020</span><span style="font-family:inherit;font-size:10pt;">, with lease terms of </span><span style="font-family:inherit;font-size:10pt;"><span>1 month</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div> Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). For leases executed in 2019 and later, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. P1Y P60Y P10Y <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to our operating leases:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease right-of-use assets in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 306000000 62000000 251000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:77%;"/><td style="width:23%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">As of September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.6 years</span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7%</span></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P5Y7M6D 0.037 21000000 57000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental cash flow information related to our operating leases: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:21%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash paid for amounts included in the measurement of operating lease liabilities</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 55000000 84000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the maturities of our operating lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:82%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal year</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases<br/></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2019 (excluding the first nine months of 2019)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total future minimum operating lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>350</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Present value of operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>314</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 22000000 76000000 65000000 52000000 41000000 95000000 350000000 37000000 314000000 68000000 P1M P15Y <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE H – INCOME TAXES</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our effective tax rate from continuing operations is presented below:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:37%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective tax rate from continuing operations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The change in our reported tax rates for the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, as compared to the same periods in </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate. These receipts and charges include intangible asset impairment charges, acquisition-related items, restructuring items, litigation-related items as well as certain discrete tax items primarily related to share-based payments and the 2018 settlement of our transfer pricing dispute with the Internal Revenue Service (IRS) for the 2001 through 2010 tax years.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$405 million</span></span><span style="font-family:inherit;font-size:10pt;"> of gross unrecognized tax benefits, of which a net </span><span style="font-family:inherit;font-size:10pt;"><span>$320 million</span></span><span style="font-family:inherit;font-size:10pt;">, if recognized, would affect our effective tax rate. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">, we had </span><span style="font-family:inherit;font-size:10pt;"><span>$427 million</span></span><span style="font-family:inherit;font-size:10pt;"> of gross unrecognized tax benefits, of which a net </span><span style="font-family:inherit;font-size:10pt;"><span>$332 million</span></span><span style="font-family:inherit;font-size:10pt;">, if recognized, would affect our effective tax rate. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">It is reasonably possible that within the next 12 months we will resolve multiple issues with foreign, federal and state taxing authorities, resulting in a reduction in our balance of unrecognized tax benefits of up to </span><span style="font-family:inherit;font-size:10pt;"><span>$99 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:37%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Effective tax rate from continuing operations</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(38.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(14.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -0.387 0.053 -0.016 -0.141 405000000 320000000 427000000 332000000 99000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE I – COMMITMENTS AND CONTINGENCIES</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The medical device market in which we primarily participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding, or in a series of related proceedings, or litigate multiple features of a single class of devices. These dynamics frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters; however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the normal course of business, product liability, securities and commercial claims are asserted against us. Similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our financial position, results of operations and/or liquidity.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with </span><span>FASB ASC Topic 450, </span><span style="font-style:italic;">Contingencies</span><span style="font-family:inherit;font-size:10pt;">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Our accrual for legal matters that are probable and estimable was </span><span style="font-family:inherit;font-size:10pt;"><span>$568 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$929 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> and includes certain estimated costs of settlement, damages and defense. The decrease in our legal accrual was mainly due to settlement payments associated with product liability cases or claims related to transvaginal surgical mesh products. A portion of our legal accrual is already funded through our qualified settlement fund (QSF), which is included in other restricted cash and restricted cash equivalents balance of </span><span style="font-family:inherit;font-size:10pt;"><span>$357 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$655 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Refer to </span><span style="font-style:italic;">Note F – Supplemental Balance Sheet Information</span><span style="font-family:inherit;font-size:10pt;"> for additional information. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We recorded litigation-related net charges of </span><span style="font-family:inherit;font-size:10pt;"><span>$25 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and litigation-related net credits of </span><span style="font-family:inherit;font-size:10pt;"><span>$108 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;">In the first quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, we recorded </span><span style="font-family:inherit;font-size:10pt;"><span>$148 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the total </span><span style="font-family:inherit;font-size:10pt;"><span>$180 million</span></span><span> one-time settlement payment received from Edwards Lifesciences Corporation in January 2019 to </span><span style="font-style:italic;">Litigation-related net charges (credits)</span><span> on our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">. </span><span>We record certain legal and product liability charges, credits and costs of defense, which we consider to be unusual or infrequent and significant as </span><span style="font-style:italic;">Litigation-related net charges (credits)</span><span> in our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">. All other legal and product liability charges, credits and costs are recorded within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;">. </span><span style="font-family:inherit;font-size:10pt;">As such, a portion of the related gain from this settlement was recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Selling, general and administrative expenses</span><span style="font-family:inherit;font-size:10pt;"> on our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the periods ended March 31, 2019 and June 30, 2019 and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be estimated.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Patent Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 20, 2017, The Board of Regents, University of Texas System (UT) and TissueGen.Inc., served a lawsuit against us in the Western District of Texas. The complaint against us alleges patent infringement of two U.S. patents owned by UT, relating to “Drug Releasing Biodegradable Fiber Implant” and “Drug Releasing Biodegradable Fiber for Delivery of Therapeutics,” and affects the manufacture, use and sale of our Synergy™ Stent System. On March 12, 2018, the District Court for the Western District of Texas dismissed the action and transferred it to the United States District Court for the District of Delaware. On September 5, 2019, the Court of Appeals for the Federal Circuit affirmed the dismissal of the District Court for the Western District of Texas. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Liability Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">October 16, 2019</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>53,000</span></span><span style="font-family:inherit;font-size:10pt;"> product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us. As of </span><span style="font-family:inherit;font-size:10pt;">October 16, 2019</span><span style="font-family:inherit;font-size:10pt;">, we have entered into master settlement agreements in principle or are in the final stages of entering one with certain plaintiffs' counsel </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">to resolve an aggregate of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>52,000</span></span><span style="font-family:inherit;font-size:10pt;"> cases and claims. These master settlement agreements provide that the settlement and distribution of settlement funds to participating claimants are conditional upon, among other things, achieving minimum required claimant participation thresholds. Of the approximately </span><span style="font-family:inherit;font-size:10pt;"><span>52,000</span></span><span style="font-family:inherit;font-size:10pt;"> cases and claims, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>43,500</span></span><span style="font-family:inherit;font-size:10pt;"> have met the conditions of the settlement and are final. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. On April 16, 2019, the U.S. Food and Drug Administration (FDA) ordered that all manufacturers of surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse stop selling and distributing their products in the United States immediately, stemming from the FDA’s 2016 reclassification of these devices to class III (high risk) devices, and as a result, the Company ceased global sales and distribution of surgical mesh products indicated for transvaginal pelvic organ prolapse. The pending cases are in various federal and state courts in the U.S. and include </span><span style="font-family:inherit;font-size:10pt;"><span>eight</span></span><span style="font-family:inherit;font-size:10pt;"> putative class actions. Generally, the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products. The plaintiffs assert design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. Over </span><span style="font-family:inherit;font-size:10pt;"><span>3,100</span></span><span style="font-family:inherit;font-size:10pt;"> of the cases have been specially assigned to one judge in state court in Massachusetts. On February 7, 2012, the Judicial Panel on Multi-District Litigation (MDL) established MDL-2326 in the U.S. District Court for the Southern District of West Virginia and transferred the federal court transvaginal surgical mesh cases to MDL-2326 for coordinated pretrial proceedings. During the fourth quarter of 2013, we received written discovery requests from certain state attorneys general offices regarding our transvaginal surgical mesh products. We have responded to those requests. There were also fewer than </span><span style="font-family:inherit;font-size:10pt;"><span>25</span></span><span style="font-family:inherit;font-size:10pt;"> cases in Canada, inclusive of </span><span style="font-family:inherit;font-size:10pt;"><span>one</span></span><span style="font-family:inherit;font-size:10pt;"> certified and </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> putative class actions and fewer than </span><span style="font-family:inherit;font-size:10pt;"><span>25</span></span><span style="font-family:inherit;font-size:10pt;"> claims in the United Kingdom. We have reached a tentative agreement to settle the Canadian class actions. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products. While we believe that our accrual associated with this matter is adequate, changes to this accrual may be required in the future as additional information becomes available. While we continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims and intend to vigorously contest the cases and claims asserted against us that do not settle, the final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Initial trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Other Proceedings</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 1, 2017 we entered into a definitive agreement with Channel Medsystems, Inc. (Channel) pursuant to which we could have been obligated to pay </span><span style="font-family:inherit;font-size:10pt;"><span>$145 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash up-front and a maximum of </span><span style="font-family:inherit;font-size:10pt;"><span>$130 million</span></span><span style="font-family:inherit;font-size:10pt;"> in contingent payments to acquire Channel. The agreement contained a provision allowing Channel to sell the remaining equity interests of the company to us upon achievement of a regulatory milestone and an option allowing us to acquire the remaining equity interests. We sent a notice of termination of that agreement to Channel in the second quarter of 2018. On September 12, 2018, Channel filed a complaint in Delaware Chancery Court against us for alleged breach of the agreement. Channel alleges that we breached the agreement by terminating it. We have answered the complaint, denied the claims by Channel and have counterclaimed to recover part of our investment in Channel, alleging fraud in the inducement. On April 2, 2019, Channel announced its receipt of FDA approval of the Cerene™ Cryotherapy Device. Trial testimony was taken in April 2019, and the post-trial briefing and hearing have been completed. During the third quarter of 2019, Channel notified us that they were exercising their option to sell the remaining equity interests in Channel to us. We responded to the notification that we did not intend to purchase Channel since the previous agreement had been terminated.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On September 6, 2019, Boston Scientific Corporation, Boston Scientific Scimed, Inc., and Fortis Advisors, LLC, as a Securityholder Representative for the former Securityholders of nVision Medical Corp. filed a declaratory judgment action against BioCardia, Inc. in the United States District Court for the Northern District of California to address threats and allegations by BioCardia challenging inventorship and ownership of various patents that Boston Scientific Corporation acquired through an April 13, 2018 merger with nVision as well as related threats and allegations by BioCardia of trade secret misappropriation and unjust enrichment.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 18, 2019, Blue Cross &amp; Blue Shield of Louisiana and HMO Louisiana, Inc. filed a class action complaint against Janssen Biotech, Inc, Janssen Oncology, Inc, Janssen Research &amp; Development, LLC and BTG International Limited in the United States District Court for the Eastern District of Virginia. The complaint alleges that the defendants violated the Sherman Act and the antitrust and consumer protections laws of several states by pursuing patent litigation relating to ZYTIGA™ in order to delay generic entry. On June 21, 2019, the case was transferred to the United States District Court for the District of New Jersey and has been consolidated with similar complaints.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 21, 2017, Janssen Biotech, Inc., Janssen Oncology, Inc, Janssen Research &amp; Development, LLC, and Johnson &amp; Johnson (collectively, Janssen) were served with a </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">qui tam </span><span style="font-family:inherit;font-size:10pt;">complaint filed on behalf of the United States, 28 states, and the District </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">of Columbia. The complaint, which was filed in the United States District Court for the Northern District of California, alleges that Janssen violated the federal False Claims Act and state law when providing pricing information for ZYTIGA to the government in connection with direct government sales and government-funded drug reimbursement programs. The case has been transferred to United States District Court for the District of New Jersey. On June 20, 2019, the complaint was amended to include BTG International Limited as a defendant.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Matters Concluded Since December 31, 2018</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 15, 2019, we announced that we reached an agreement with Edwards Lifesciences Corporation (Edwards) to settle all outstanding patent disputes between us and Edwards in all venues around the world. All pending cases or appeals in courts and patent offices between the two companies have been or will be dismissed, and the parties will not litigate patent disputes related to current portfolios of transcatheter aortic valves, certain mitral valve repair devices, and left atrial appendage closure devices. Any injunctions currently in place will be lifted. Under the terms of the agreement, Edwards made a one-time payment to us of </span><span style="font-family:inherit;font-size:10pt;"><span>$180 million</span></span><span style="font-family:inherit;font-size:10pt;">. No further royalties will be owed by either party under the agreement. All other terms remain confidential. The previously disclosed matters that have been resolved as a result of this settlement include:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 30, 2015, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation and Edwards Lifesciences Services GmbH in Düsseldorf District Court in Germany for patent infringement. We allege that Edwards’ SAPIEN 3™ Heart Valve infringes our patent related to adaptive sealing technology. On February 25, 2016, we extended the action to allege infringement of a second patent related to adaptive sealing technology. The trial began on February 7, 2017. On March 9, 2017, the court found that Edwards infringed both patents and Edwards appealed.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 9, 2015, Edwards Lifesciences, LLC filed an invalidity claim against one of our subsidiaries, Sadra Medical, Inc. (Sadra), in the High Court of Justice, Chancery Division Patents Court in the United Kingdom, alleging that a European patent owned by Sadra relating to a repositionable heart valve is invalid. On January 15, 2016, we filed our defense and counterclaim for a declaration that our European patent is valid and infringed by Edwards. On February 25, 2016, we amended our counterclaim to allege infringement of a second patent related to adaptive sealing technology. A trial was held from January 18 to January 27, 2017. On March 3, 2017, the court found one of our patents valid and infringed and some claims of the second patent invalid and the remaining claims not infringed. Both parties have filed an appeal. On March 28, 2018, the Court of Appeals affirmed the decision of the High Court.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 23, 2015, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '672) owned by Edwards is infringed by our Lotus™ Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we did not infringe the Spenser '672 patent. Edwards filed an appeal.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 23, 2015, Edwards Lifesciences Corporation filed a patent infringement action against us and Boston Scientific Medizintechnik GmbH in the District Court of Düsseldorf, Germany alleging an European patent (Bourang) owned by Edwards is infringed by our Lotus Valve System. The trial began on February 7, 2017. On March 28, 2017, the European Patent Office revoked the Bourang patent and on April 3, 2017, the court suspended the infringement action pending Edwards' appeal of the revocation of the patent at the European Patent Office.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation (Edwards) in the U.S. District Court for the District of Delaware for patent infringement. We allege that Edwards’ SAPIEN 3 Valve infringes a patent related to adaptive sealing technology. On June 9, 2016, Edwards filed a counterclaim alleging that our Lotus Valve System infringes three patents owned by Edwards. On October 12, 2016, Edwards filed a petition for inter partes review of our patent with the U.S. Patent and Trademark Office (USPTO), Patent Trial and Appeal Board. On March 29, 2017, the USPTO granted the inter partes review request. On April 18, 2017, Edwards filed a second petition for inter partes review of our patent with the USPTO. On March 23, 2018, the USPTO found our patent invalid. The Company filed an appeal before the United States Court of Appeals for the Federal Circuit on May 24, 2018.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 19, 2016, a subsidiary of Boston Scientific filed suit against Edwards Lifesciences Corporation in the U.S. District Court for the Central District of California for patent infringement. We allege that Edwards’ aortic valve delivery systems infringe eight of our catheter related patents. On October 13, 2016, Edwards filed a petition for inter partes review of one asserted patent with the USPTO, Patent Trial and Appeal Board. On April 21, 2017, the USPTO denied the petition. On April 19 and 20, 2017, Edwards filed multiple inter partes review petitions against the patents in suit. On September 8, 2017, the court granted a stay of the action pending an inter partes review of the patents in suit.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 26, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Medizintechnik GmbH, in the District Court of Düsseldorf, Germany alleging a European patent (Spenser '550) owned by Edwards is infringed by our Lotus™ Transcatheter Heart Valve System. The trial began on February 7, 2017. On March 9, 2017, the court found that we infringed the Spenser '550 patent. The Company filed an appeal. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 27, 2016, Edwards Lifesciences PVT, Inc. filed a patent infringement action against us and one of our subsidiaries, Boston Scientific, LTD, in the Federal Court of Canada alleging that three Canadian patents (Spenser) owned by Edwards are infringed by our Lotus Transcatheter Heart Valve System.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 22, 2016, Edwards Lifesciences PVT, Inc. and Edwards Lifesciences SA (AG) filed a plenary summons against Boston Scientific Limited and Boston Scientific Group Public Company in the High Court of Ireland alleging that a European patent (Spenser) owned by Edwards is infringed by our Lotus Valve System. On April 13, 2018, the ‘550 patent was revoked by the European Patent Office.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 1, 2018, the Company filed a patent infringement action on the merits in Dusseldorf, Germany against Edwards Lifesciences Corporation and Edwards Lifesciences GmbH (collectively Edwards) alleging that the Sapien 3™ Device and Sapien 3 Ultra Device infringed a patent owned by the Company.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 3, 2018, the Company filed a preliminary injunction request in Dusseldorf, Germany against Edwards Lifesciences Corporation and Edwards Lifesciences GmbH (collectively Edwards) alleging that the Sapien 3 Ultra Device infringed a patent owned by the Company. On October 23, 2018, the court found that the Sapien 3 Ultra Device infringed the patent. Edwards had the right to appeal.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:inherit;font-size:10pt;">•</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 22, 2018, Edwards Lifesciences LLC filed a patent infringement action against Boston Scientific Corporation, in the U. S. District Court of Delaware, alleging that two U.S. patents (Schweich) owned by them are infringed by our Watchman™ Left Atrial Appendage Closure Device, Watchman Delivery System and Watchman Access System.</span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 14, 2016, we learned that the Associacao Brasileira de Medicina de Grupo d/b/a ABRAMGE filed a complaint against us, Arthrex and Zimmer Biomet Holdings, in the U.S. District Court for the District of Delaware. This complaint, which ABRAMGE never served against us, alleges that the defendants or their agents paid kickbacks to health care providers in order to increase sales and prices and are liable under a variety of common law theories. On February 6, 2017, ABRAMGE filed and served an amended complaint on us and the other defendants. The amended complaint does not contain any material changes in the allegations against us. Subsequently, on March 2, 2017, ABRAMGE filed a motion to consolidate this lawsuit with two other similar suits that it had brought against Stryker and Abbott Laboratories, in a multidistrict litigation proceeding. On April 13, 2017, we filed a motion to dismiss the amended complaint, as well as a separate opposition to the multidistrict litigation motion and on May 31, 2017, the Joint Panel on Multi-District Litigation denied ABRAMGE’s motion for the multidistrict litigation. On September 1, 2017, ABRAMGE filed a motion for leave to file a Second Amended Complaint, while our motion to dismiss the Amended Complaint remained pending. On September 15, 2017, we filed an opposition to the motion seeking leave to amend. On November 8, 2018, the Court granted ABRAMGE’s motion for leave to file a Second Amended Complaint, while also granting us leave to renew our motion to dismiss. We filed our motion to dismiss the Second Amended Complaint on January 18, 2019. On February 28, 2019, ABRAMGE dismissed its Second Amended Complaint, concluding the lawsuit.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On or about January 12, 2016, Teresa L. Stevens filed a claim against us and three other defendants asserting, for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the U.S. District Court for the Southern District of West Virginia, before the same Court that is hearing the mesh MDL. The complaint, which alleges Racketeer Influenced and Corrupt Organizations Act (RICO) violations, fraud, misrepresentation, deceptive trade practices and unjust enrichment, seeks both equitable relief and damages under state and federal law. On January 26, 2016, the Court issued an order staying the case and directing the plaintiff to submit information to allow the FDA to issue a determination with respect to her allegations. In addition, we were in contact with the U.S. Attorney’s Office for the Southern District of West Virginia and responded voluntarily to their requests in connection with that office’s review of the allegations concerning the use of mesh resin in the complaint. We reached a settlement on this matter and this case was dismissed on May 13, 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 27, 2017, Carolyn Turner filed a complaint against us and five other defendants asserting for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the U.S. District Court for the Middle District of Florida, Orlando Division and alleges violations of the RICO, negligence, strict liability, breach of an express or implied warranty, intentional and negligent misrepresentation, fraud and unjust enrichment. Ms. Turner served this complaint </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">against us on April 7, 2017. As of April 27, 2017, this case was stayed, pending resolution of the transfer petition to the mesh multidistrict litigation. We reached a settlement on this matter and this case was dismissed on February 25, 2019.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 24, 2019, a class action complaint was filed in the U.S. District Court for the Southern District of New York against Boston Scientific Corporation, Michael F. Mahoney, our Chief Executive Officer, and Daniel J. Brennan, our Chief Financial Officer. The complaint alleges violations of federal securities laws based on false and/or misleading statements and failure to disclose facts related to the Company’s transvaginal surgical mesh products. On September 20, 2019, the case was dismissed with prejudice.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with </span><span>FASB ASC Topic 450, </span><span style="font-style:italic;">Contingencies</span><span style="font-family:inherit;font-size:10pt;">, we accrue anticipated costs of settlement, damages, losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.</span></div> 568000000 929000000 357000000 655000000 25000000 -108000000 148000000 180000000 53000 52000 52000 43500 8 3100 25 1 3 25 145000000 130000000 180000000 <div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:57%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding - basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,393.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,382.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,390.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,380.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net effect of common stock equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted average shares outstanding - assuming dilution</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,412.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,403.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,409.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,399.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The impact of stock options outstanding with exercise prices greater than the average fair market value of our common stock was immaterial for all periods presented.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We issued approximately </span><span style="font-family:inherit;font-size:10pt;"><span>two million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>two million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, approximately </span><span style="font-family:inherit;font-size:10pt;"><span>nine million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and approximately </span><span style="font-family:inherit;font-size:10pt;"><span>10 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of our common stock in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">, following the exercise of stock options, vesting of deferred stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> or </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:57%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding - basic</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,393.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,382.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,390.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,380.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Net effect of common stock equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted average shares outstanding - assuming dilution</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,412.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,403.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,409.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,399.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1393100000 1382800000 1390600000 1380000000.0 19000000.0 21000000.0 19100000 19900000 1412200000 1403900000 1409700000 1399800000 2000000000000 2000000000000 9000000000000 10000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE K – SEGMENT REPORTING</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We have </span><span style="font-family:inherit;font-size:10pt;"><span>three</span></span><span style="font-family:inherit;font-size:10pt;"> reportable segments comprised of MedSurg, Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Each of our reportable segments generates revenues from the sale of medical devices. We measure and evaluate our reportable segments based on reportable segment net sales, operating income of reportable segments, excluding intersegment profits, and reportable segment operating income as a percentage of reportable segment net sales. Reportable segment operating income as a percentage of reportable segment net sales is defined as operating income of reportable segments divided by reportable segment net sales. Our presentation of reportable segment net sales and operating income of reportable segments includes the impact of foreign currency fluctuations, since our chief operating decision maker (CODM) reviews operating results both including and excluding the impact of foreign currency fluctuations, and the following presentation more closely aligns to our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our CODM considers to be non-operational, such as amounts related to amortization expense, intangible asset impairment charges, acquisition-related items, restructuring and restructuring-related items, litigation-related items and medical device regulation charges. Although we exclude these amounts from operating income of reportable segments, they are included in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income (loss) before income taxes</span><span style="font-family:inherit;font-size:10pt;"> on the </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> and are included in the reconciliation below. </span></div><div style="line-height:120%;padding-top:13px;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> is as follows (in millions, except percentages): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net sales</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>845</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,207</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>780</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,011</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>908</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,009</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,806</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reportable segment net sales</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,636</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,393</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,760</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,262</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net sales</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,393</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,262</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income (loss) before income taxes</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>870</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>807</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>857</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income of reportable segments</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>766</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>710</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,146</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate expenses, including hedging activities</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(97</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(215</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(297</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible asset impairment charges, acquisition/divestiture-related, restructuring- and restructuring-related, litigation-related net (charges) credits and medical device regulation charges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(146</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(210</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(225</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization expense</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(178</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(148</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(498</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(437</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>383</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>388</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(292</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(615</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(61</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income (loss) before income taxes</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>456</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>693</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Reportable segment operating income as a percentage of reportable segment net sales</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;">2019</span><span style="font-size:9pt;">, there have been no changes to our internal reporting structure, and accordingly, we have not revised our segment reporting or geographic presentation. We will continue to integrate the </span><span style="font-family:inherit;font-size:9pt;">BTG Acquisition</span><span style="font-size:9pt;"> into our operations in the fourth quarter and will reassess our operating and reportable segments as well as geographic presentation for any changes related to our internal reporting structure as well as to the information regularly reviewed by the </span><span style="font-size:9pt;">CODM</span><span style="font-size:9pt;">. To the extent any changes in our operating and reportable segments are identified, these will be reflected in our segment reporting information in the period in which the change occurs.</span><span style="font-size:9pt;"> Our results of operations include the results of BTG following the acquisition date of August 19, 2019.</span><span style="font-family:inherit;font-size:9pt;"> The </span><span style="font-family:inherit;font-size:9pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:9pt;"> reconciling item above excludes certain adjustments that our CODM considers to be non-operational, such as acquisition-related items.</span></div> 3 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;"> is as follows (in millions, except percentages): </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net sales</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>845</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>746</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,429</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,207</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>780</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>740</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,011</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>908</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,009</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,806</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Reportable segment net sales</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,636</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,393</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,760</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7,262</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net sales</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,393</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,262</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income (loss) before income taxes</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>870</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>807</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>488</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>481</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>268</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>857</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>858</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income of reportable segments</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>766</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>710</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,216</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,146</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate expenses, including hedging activities</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(75</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(97</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(215</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(297</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible asset impairment charges, acquisition/divestiture-related, restructuring- and restructuring-related, litigation-related net (charges) credits and medical device regulation charges</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(146</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(77</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(210</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(225</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amortization expense</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(178</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(148</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(498</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(437</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating income (loss)</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>383</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>388</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,308</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,187</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other expense, net</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(292</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(615</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(61</span></span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Income (loss) before income taxes</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>456</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>693</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Reportable segment operating income as a percentage of reportable segment net sales</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">MedSurg</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rhythm and Neuro</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cardiovascular</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 845000000 746000000 2429000000 2207000000 780000000 740000000 2323000000 2252000000 1011000000 908000000 3009000000 2806000000 2636000000 2393000000 7760000000 7262000000 71000000 71000000 2707000000 2393000000 7831000000 7262000000 319000000 274000000 870000000 807000000 166000000 168000000 488000000 481000000 281000000 268000000 857000000 858000000 766000000 710000000 2216000000 2146000000 16000000 16000000 75000000 97000000 215000000 297000000 146000000 77000000 210000000 225000000 178000000 148000000 498000000 437000000 383000000 388000000 1308000000 1187000000 -292000000 68000000 -615000000 -61000000 91000000 456000000 693000000 1126000000 0.378 0.368 0.358 0.366 0.213 0.227 0.210 0.214 0.278 0.295 0.285 0.306 <div style="line-height:120%;font-size:10pt;"><span style="font-weight:bold;">NOTE L – REVENUE</span><span style="font-family:inherit;font-size:10pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes in our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated statements of operations</span><span style="font-family:inherit;font-size:10pt;">. The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Businesses</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Endoscopy</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>724</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>580</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>486</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>443</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,396</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,304</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Urology and Pelvic Health</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>737</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,033</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>904</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cardiac Rhythm Management</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>869</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>607</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>594</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>475</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,467</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,462</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Electrophysiology</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Neuromodulation</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>487</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>446</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>612</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>559</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interventional Cardiology</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>283</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>859</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,062</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>615</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,067</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Peripheral Interventions</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>449</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>475</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>436</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>885</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interventional Medicine</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> n/a</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> n/a</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Specialty Pharmaceuticals</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,393</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,262</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;">2019</span><span style="font-size:9pt;">, there have been no changes to our internal reporting structure, and accordingly, we have not revised our segment reporting or geographic presentation. We will continue to integrate the </span><span style="font-family:inherit;font-size:9pt;">BTG Acquisition</span><span style="font-size:9pt;"> into our operations in the fourth quarter and will reassess our operating and reportable segments as well as geographic presentation for any changes related to our internal reporting structure as well as to the information regularly reviewed by the </span><span style="font-size:9pt;">CODM</span><span style="font-size:9pt;">. To the extent any changes in our operating and reportable segments are identified, these will be reflected in our segment reporting information in the period in which the change occurs.</span><span style="font-size:9pt;"> Our results of operations include the results of BTG following the acquisition date of August 19, 2019.</span><span style="font-size:9pt;"> BTG net sales are substantially U.S. based.</span><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Geographic Regions (Excluding BTG Acquisition)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,521</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,078</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EMEA (Europe, Middle East and Africa)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>498</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,662</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">APAC (Asia-Pacific)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>484</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,282</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Latin America and Canada</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">(Worldwide)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,393</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,262</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging Markets</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span><span style="font-family:inherit;font-size:9.5pt;"> (Excluding BTG Acquisition)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>310</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>812</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Our results of operations include the results of BTG following the acquisition date of August 19, 2019.</span><span style="font-size:9pt;"> BTG net sales are substantially U.S. based.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-size:9pt;">We define Emerging Markets as the </span><span style="font-family:inherit;font-size:9pt;"><span>20</span></span><span style="font-size:9pt;"> countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities.</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-size:9pt;">Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries.</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-size:9pt;">Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam.</span><span style="font-family:inherit;font-size:9pt;"> We have revised prior year amounts to the current year’s presentation. </span><span style="font-size:9pt;">The revision had an immaterial impact on prior year Emerging Markets sales.</span><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Deferred Revenue</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liabilities are classified within </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other current liabilities</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span><span style="font-family:inherit;font-size:10pt;"> on our accompanying </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated balance sheets</span><span style="font-family:inherit;font-size:10pt;">. Our deferred revenue balance was </span><span style="font-family:inherit;font-size:10pt;"><span>$398 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">September 30, 2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$373 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;">. Our contractual liabilities are primarily composed of deferred revenue related to the LATITUDE™ Patient Management System. Revenue is recognized over the average service period which is based on device and patient longevity. We recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$35 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter of </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$107 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> that was included in the above </span><span style="font-family:inherit;font-size:10pt;">December 31, 2018</span><span style="font-family:inherit;font-size:10pt;"> contract liability balance. We have elected not to disclose the transaction price allocated to unsatisfied performance obligations when the original expected contract duration is one year or less. In addition, we have not identified material unfulfilled performance obligations for which revenue is not currently deferred.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Variable Consideration</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We generally allow our customers to return defective, damaged and, in certain cases, expired products for credit and record the amount for estimated sales returns as a reduction to revenue when we sell the initial product. In addition, we may allow customers to return previously purchased products for next-generation product offerings. For these transactions, we defer recognition of revenue on the sale of the earlier generation product based upon an estimate of the amount of product to be returned when the next-generation products are shipped to the customer. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We also offer sales rebates and discounts to certain customers. We treat sales rebates and discounts as a reduction of revenue and classify the corresponding liability as current. If we are unable to reasonably estimate the expected rebates, we record a liability for the maximum rebate percentage offered. We have entered certain agreements with group purchasing organizations to sell our products to participating hospitals at negotiated prices. We recognize revenue from these agreements following the same revenue recognition criteria discussed above.</span></div> The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Businesses</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Endoscopy</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>277</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>247</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>800</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>724</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>580</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>486</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>443</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,396</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,304</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Urology and Pelvic Health</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>214</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>737</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>623</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>359</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,033</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>904</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Cardiac Rhythm Management</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>289</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>860</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>869</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>607</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>594</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>478</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>475</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,467</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,462</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Electrophysiology</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>132</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>119</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Neuromodulation</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>183</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>487</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>446</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>612</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>559</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Interventional Cardiology</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>327</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>283</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>859</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>373</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,062</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>700</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>615</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,067</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Peripheral Interventions</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>152</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>466</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>449</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">International</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>156</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>475</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>436</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>885</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interventional Medicine</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> n/a</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> n/a</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Specialty Pharmaceuticals</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Worldwide</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,393</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,262</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">For the </span><span style="font-family:inherit;font-size:9pt;">first nine months of</span><span style="font-size:9pt;"> </span><span style="font-family:inherit;font-size:9pt;">2019</span><span style="font-size:9pt;">, there have been no changes to our internal reporting structure, and accordingly, we have not revised our segment reporting or geographic presentation. We will continue to integrate the </span><span style="font-family:inherit;font-size:9pt;">BTG Acquisition</span><span style="font-size:9pt;"> into our operations in the fourth quarter and will reassess our operating and reportable segments as well as geographic presentation for any changes related to our internal reporting structure as well as to the information regularly reviewed by the </span><span style="font-size:9pt;">CODM</span><span style="font-size:9pt;">. To the extent any changes in our operating and reportable segments are identified, these will be reflected in our segment reporting information in the period in which the change occurs.</span><span style="font-size:9pt;"> Our results of operations include the results of BTG following the acquisition date of August 19, 2019.</span><span style="font-size:9pt;"> BTG net sales are substantially U.S. based.</span><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:57%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Geographic Regions (Excluding BTG Acquisition)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,521</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,078</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">EMEA (Europe, Middle East and Africa)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>498</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,662</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,619</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">APAC (Asia-Pacific)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>484</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>425</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,402</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,282</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Latin America and Canada</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">BTG Acquisition</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></span><span style="font-family:inherit;font-size:10pt;">(Worldwide)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">n/a</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Sales</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,707</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>2,393</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>7,262</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Emerging Markets</span><span style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></span><span style="font-family:inherit;font-size:9.5pt;"> (Excluding BTG Acquisition)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>310</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>925</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>812</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;">Our results of operations include the results of BTG following the acquisition date of August 19, 2019.</span><span style="font-size:9pt;"> BTG net sales are substantially U.S. based.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:inherit;font-size:9pt;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-size:9pt;">We define Emerging Markets as the </span><span style="font-family:inherit;font-size:9pt;"><span>20</span></span><span style="font-size:9pt;"> countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities.</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-size:9pt;">Periodically, we assess our list of Emerging Markets; effective January 1, 2019, we updated our list of Emerging Market countries.</span><span style="font-family:inherit;font-size:9pt;"> </span><span style="font-size:9pt;">Our current list is comprised of the following countries: Argentina, Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Thailand, Turkey and Vietnam.</span><span style="font-family:inherit;font-size:9pt;"> We have revised prior year amounts to the current year’s presentation. </span><span style="font-size:9pt;">The revision had an immaterial impact on prior year Emerging Markets sales.</span><span style="font-family:inherit;font-size:9pt;"> </span></div></td></tr></table><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 277000000 247000000 800000000 724000000 209000000 196000000 596000000 580000000 486000000 443000000 1396000000 1304000000 257000000 214000000 737000000 623000000 102000000 89000000 297000000 280000000 359000000 303000000 1033000000 904000000 284000000 289000000 860000000 869000000 194000000 186000000 607000000 594000000 478000000 475000000 1467000000 1462000000 38000000 37000000 113000000 111000000 43000000 39000000 132000000 119000000 81000000 76000000 245000000 230000000 183000000 155000000 487000000 446000000 39000000 34000000 125000000 113000000 222000000 189000000 612000000 559000000 327000000 283000000 942000000 859000000 373000000 332000000 1126000000 1062000000 700000000 615000000 2067000000 1922000000 155000000 152000000 466000000 449000000 156000000 142000000 475000000 436000000 311000000 293000000 942000000 885000000 48000000 48000000 23000000 23000000 71000000 71000000 2707000000 2393000000 7831000000 7262000000 1521000000 1375000000 4402000000 4078000000 530000000 498000000 1662000000 1619000000 484000000 425000000 1402000000 1282000000 101000000 94000000 293000000 282000000 71000000 71000000 2707000000 2393000000 7831000000 7262000000 310000000 267000000 925000000 812000000 20 398000000 373000000 35000000 107000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE M – CHANGES IN OTHER COMPREHENSIVE INCOME</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables provide the reclassifications out of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income (loss), net of tax</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Defined Benefit Pensions and Other Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(48</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>213</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>138</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Defined Benefit Pensions and Other Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Defined Benefit Pensions and Other Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(48</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>213</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>138</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Defined Benefit Pensions and Other Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Refer to </span><span style="font-style:italic;">Note D – Hedging Activities and Fair Value Measurements</span><span style="font-family:inherit;font-size:10pt;"> for further detail on our net investment hedges recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Foreign currency translation adjustments</span><span style="font-family:inherit;font-size:10pt;"> and our cash flow hedges recorded in </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net change in derivative financial instruments</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of adopting ASC Update No. 2016-01 in the first quarter of 2018, we recorded a cumulative effect adjustment to retained earnings to reclassify unrealized gains and losses from our equity investments previously recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax</span><span style="font-family:inherit;font-size:10pt;">. These equity investments were classified as available-for-sale securities under the former accounting guidance, and we now refer to these investments as publicly-held equity securities. Please refer to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note A – Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> included in Item 8 of our most recent Annual Report on Form 10-K for more information.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Net change in defined benefit pensions and other items</span><span style="font-family:inherit;font-size:10pt;"> before reclassifications and reclassified from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax</span><span style="font-family:inherit;font-size:10pt;"> were reduced by immaterial income tax impacts in the </span><span style="font-family:inherit;font-size:10pt;">third</span><span style="font-family:inherit;font-size:10pt;"> quarter and </span><span style="font-family:inherit;font-size:10pt;">first nine months of</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">2019</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">2018</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables provide the reclassifications out of </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other comprehensive income (loss), net of tax</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Defined Benefit Pensions and Other Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of June 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(46</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>150</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(26</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>78</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(26</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>60</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(48</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>213</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>138</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Defined Benefit Pensions and Other Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of June 30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(68</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>79</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(16</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Defined Benefit Pensions and Other Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(53</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>111</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(48</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>213</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(26</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>138</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">(in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Foreign Currency Translation Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Available-for-Sale Securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Change in Defined Benefit Pensions and Other Items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(32</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(59</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(Income) loss amounts reclassified from accumulated other comprehensive income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance as of September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(74</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -46000000 150000000 0 26000000 78000000 7000000 78000000 0 0 86000000 -9000000 16000000 0 0 26000000 -2000000 62000000 0 0 60000000 -48000000 213000000 0 26000000 138000000 -68000000 79000000 0 27000000 -16000000 2000000 45000000 0 0 47000000 -8000000 -1000000 0 0 7000000 -6000000 47000000 0 0 40000000 -74000000 126000000 0 27000000 25000000 -53000000 111000000 0 25000000 33000000 30000000 136000000 0 -1000000 165000000 -25000000 34000000 0 0 59000000 4000000 102000000 0 1000000 105000000 -48000000 213000000 0 26000000 138000000 -32000000 1000000 -1000000 27000000 -59000000 -29000000 105000000 0 0 76000000 -13000000 -20000000 1000000 0 -8000000 -42000000 125000000 0 0 82000000 -74000000 126000000 0 27000000 25000000 <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of adopting ASC Update No. 2016-01 in the first quarter of 2018, we recorded a cumulative effect adjustment to retained earnings to reclassify unrealized gains and losses from our equity investments previously recorded to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accumulated other comprehensive income (loss), net of tax</span><span style="font-family:inherit;font-size:10pt;">. These equity investments were classified as available-for-sale securities under the former accounting guidance, and we now refer to these investments as publicly-held equity securities. Please refer to </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Note A – Significant Accounting Policies</span><span style="font-family:inherit;font-size:10pt;"> included in Item 8 of our most recent Annual Report on Form 10-K for more information.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-weight:bold;">NOTE N – NEW ACCOUNTING PRONOUNCEMENTS</span><span style="font-family:inherit;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Periodically, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;text-decoration:underline;">Standards to be Implemented</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-13</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASC Update No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments – Credit Losses </span><span style="font-family:inherit;font-size:10pt;">(Topic 326)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Measurement of Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;"> (Update No. 2016-13). The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018. We plan to adopt Update No. 2016-13 in the first quarter of 2020, and we are in the process of determining the effect that the adoption will have on our financial position and results of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2018-15</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASC Update No. 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40)</span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;">Update No. 2018-15). The purpose of Update No. 2018-15 is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Update No. 2018-15 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period. We plan to adopt Update No. 2018-15 in the first quarter of 2020, and we are in the process of determining the effect that the adoption will have on our financial position and results of operations.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">No other new accounting pronouncements issued or effective in the period had or are expected to have a material impact on our </span><span style="font-family:inherit;font-size:10pt;">unaudited condensed consolidated financial statements</span><span style="font-family:inherit;font-size:10pt;">.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2016-13</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASC Update No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments – Credit Losses </span><span style="font-family:inherit;font-size:10pt;">(Topic 326)</span><span style="font-family:inherit;font-size:10pt;font-style:italic;">: Measurement of Credit Losses on Financial Instruments</span><span style="font-family:inherit;font-size:10pt;"> (Update No. 2016-13). The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted for annual periods beginning after December 15, 2018. We plan to adopt Update No. 2016-13 in the first quarter of 2020, and we are in the process of determining the effect that the adoption will have on our financial position and results of operations.</span></div> <div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">ASC Update No. 2018-15</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASC Update No. 2018-15, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles – Goodwill and Other – Internal-Use Software (Subtopic 350-40)</span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:inherit;font-size:10pt;"> (</span><span style="font-family:inherit;font-size:10pt;">Update No. 2018-15). The purpose of Update No. 2018-15 is to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Update No. 2018-15 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early adoption is permitted, including adoption in any interim period. We plan to adopt Update No. 2018-15 in the first quarter of 2020, and we are in the process of determining the effect that the adoption will have on our financial position and results of operations.</span></div> XML 62 R46.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Intangible Assets and Goodwill [Line Items]          
Impairment of Intangible Assets (Excluding Goodwill) $ 0 $ 0 $ 105 $ 35  
Finite-Lived Intangible Assets, Gross 14,290   14,290   $ 12,383
Finite-Lived Intangible Assets, Accumulated Amortization (6,996)   (6,996)   (6,617)
Indefinite-lived intangible assets, including goodwill 20,695   20,695   18,417
Indefinite-lived intangible assets and goodwill, accumulated write-offs 9,900   9,900   9,900
Goodwill [Roll Forward]          
Goodwill Beginning Balance     7,911    
Goodwill, Translation and Purchase Accounting Adjustments     (1)    
Goodwill, Acquired During Period     2,124    
Goodwill Ending Balance 10,015   10,015    
Goodwill, Written off Related to Sale of Business Unit     (19)    
MedSurg [Member]          
Goodwill [Roll Forward]          
Goodwill Beginning Balance     2,063    
Goodwill, Translation and Purchase Accounting Adjustments     (3)    
Goodwill, Acquired During Period     0    
Goodwill Ending Balance 2,060   2,060    
Rhythm and Neuro [Member]          
Goodwill [Roll Forward]          
Goodwill Beginning Balance     1,924    
Goodwill, Translation and Purchase Accounting Adjustments     0    
Goodwill, Acquired During Period     268    
Goodwill Ending Balance 2,191   2,191    
Cardiovascular [Member]          
Goodwill [Roll Forward]          
Goodwill Beginning Balance     3,925    
Goodwill, Translation and Purchase Accounting Adjustments     2    
Goodwill, Acquired During Period     307    
Goodwill Ending Balance 4,214   4,214    
Goodwill, Written off Related to Sale of Business Unit     (19)    
BTG Acquisition [Member]          
Goodwill [Roll Forward]          
Goodwill Beginning Balance     0    
Goodwill, Translation and Purchase Accounting Adjustments     1    
Goodwill, Acquired During Period     1,549    
Goodwill Ending Balance 1,550   1,550    
Goodwill [Member]          
Intangible Assets and Goodwill [Line Items]          
Goodwill, Gross 19,915   19,915   17,811
Goodwill, Impaired, Accumulated Impairment Loss (9,900)   (9,900)   (9,900)
In Process Research and Development [Member]          
Intangible Assets and Goodwill [Line Items]          
Indefinite-lived Intangible Assets (Excluding Goodwill) 661   661   486
Technology-Based Intangible Assets [Member]          
Intangible Assets and Goodwill [Line Items]          
Indefinite-lived Intangible Assets (Excluding Goodwill) 120   120   120
Technology-Based Intangible Assets [Member]          
Intangible Assets and Goodwill [Line Items]          
Finite-Lived Intangible Assets, Gross 12,018   12,018   10,197
Finite-Lived Intangible Assets, Accumulated Amortization (5,545)   (5,545)   (5,266)
Patents [Member]          
Intangible Assets and Goodwill [Line Items]          
Finite-Lived Intangible Assets, Gross 524   524   520
Finite-Lived Intangible Assets, Accumulated Amortization (404)   (404)   (393)
Other Intangible Assets [Member]          
Intangible Assets and Goodwill [Line Items]          
Finite-Lived Intangible Assets, Gross 1,748   1,748   1,666
Finite-Lived Intangible Assets, Accumulated Amortization $ (1,047)   $ (1,047)   $ (958)
XML 63 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 64 R42.htm IDEA: XBRL DOCUMENT v3.19.3
Basis of Presentation ASUs Implemented (Details) - USD ($)
$ in Millions
 9 Months Ended
Jan. 01, 2019
Sep. 30, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Lease, Practical Expedients, Package [true false]   true
Operating lease, right-of-use assets, other long-term assets [Member] | Accounting Standards Update 2016-02 [Member]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification $ 271  
Operating lease, liability, other long-term liabilities [Member] | Accounting Standards Update 2016-02 [Member]    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification $ 278  
XML 65 R2.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Net sales $ 2,707 $ 2,393 $ 7,831 $ 7,262
Cost of products sold 777 672 2,265 2,084
Gross profit 1,930 1,720 5,566 5,179
Operating expenses:        
Selling, general and administrative expenses 1,012 870 2,849 2,616
Research and development expenses 306 289 866 825
Royalty expense 15 17 48 52
Amortization expense 178 148 498 437
Intangible asset impairment charges 0 0 105 35
Contingent consideration expense (benefit) 8 (13) (9) (12)
Restructuring charges (credits) 3 3 10 20
Litigation-related net charges (credits) 25 18 (108) 18
Operating expenses 1,547 1,333 4,258 3,992
Operating income (loss) 383 388 1,308 1,187
Other income (expense):        
Interest expense (95) (58) (294) (177)
Other, net (197) 126 (322) 116
Income (loss) before income taxes 91 456 693 1,126
Income tax expense (benefit) (35) 24 (11) (159)
Net income (loss) $ 126 $ 432 $ 704 $ 1,285
Net income (loss) per common share — basic $ 0.09 $ 0.31 $ 0.51 $ 0.93
Net income (loss) per common share — assuming dilution $ 0.09 $ 0.31 $ 0.50 $ 0.92
Weighted-average shares outstanding        
Basic 1,393.1 1,382.8 1,390.6 1,380.0
Assuming dilution 1,412.2 1,403.9 1,409.7 1,399.8
XML 66 R6.htm IDEA: XBRL DOCUMENT v3.19.3
Condensed Consolidated Statements of Stockholders' Equity Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Millions
Total
Common Stock [Member]
Treasury Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Cumulative Effect of New Accounting Principle in Period of Adoption | Adjustments for New Accounting Pronouncement [Member]         $ (233)  
Beginning Balance at Dec. 31, 2017   $ 16 $ (1,717) $ 17,161 (8,390) $ (59)
Beginning Balance (Shares) at Dec. 31, 2017   1,621,062,898        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss)         298  
Total other comprehensive income (loss)           (69)
Impact of stock-based compensation plans, net of tax (Shares)   6,125,111        
Impact of stock-based compensation plans, net of tax       23    
Ending Balance at Mar. 31, 2018   $ 16 (1,717) 17,184 (8,326) (128)
Ending Balance (Shares) at Mar. 31, 2018   1,627,188,009        
Beginning Balance at Dec. 31, 2017   $ 16 (1,717) 17,161 (8,390) (59)
Beginning Balance (Shares) at Dec. 31, 2017   1,621,062,898        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) $ 1,285          
Total other comprehensive income (loss) 82          
Ending Balance at Sep. 30, 2018   $ 16 (1,717) 17,304 (7,339) 25
Ending Balance (Shares) at Sep. 30, 2018   1,631,271,283        
Beginning Balance at Mar. 31, 2018   $ 16 (1,717) 17,184 (8,326) (128)
Beginning Balance (Shares) at Mar. 31, 2018   1,627,188,009        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss)         555  
Total other comprehensive income (loss)           112
Impact of stock-based compensation plans, net of tax (Shares)   1,688,243        
Impact of stock-based compensation plans, net of tax       47    
Ending Balance at Jun. 30, 2018   $ 16 (1,717) 17,231 (7,770) (16)
Ending Balance (Shares) at Jun. 30, 2018   1,628,876,252        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) 432       432  
Total other comprehensive income (loss) 40         40
Impact of stock-based compensation plans, net of tax (Shares)   2,395,031        
Impact of stock-based compensation plans, net of tax       73    
Ending Balance at Sep. 30, 2018   $ 16 (1,717) 17,304 (7,339) 25
Ending Balance (Shares) at Sep. 30, 2018   1,631,271,283        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss)         386  
Total other comprehensive income (loss)           8
Impact of stock-based compensation plans, net of tax (Shares)   876,747        
Impact of stock-based compensation plans, net of tax       42    
Ending Balance at Dec. 31, 2018 $ 8,726 $ 16 (1,717) 17,346 (6,953) 33
Ending Balance (Shares) at Dec. 31, 2018 1,632,148,030 1,632,148,030        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss)         424  
Total other comprehensive income (loss)           54
Impact of stock-based compensation plans, net of tax (Shares)   6,001,343        
Impact of stock-based compensation plans, net of tax       28    
Ending Balance at Mar. 31, 2019   $ 16 (1,717) 17,374 (6,528) 87
Ending Balance (Shares) at Mar. 31, 2019   1,638,149,373        
Beginning Balance at Dec. 31, 2018 $ 8,726 $ 16 (1,717) 17,346 (6,953) 33
Beginning Balance (Shares) at Dec. 31, 2018 1,632,148,030 1,632,148,030        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) $ 704          
Total other comprehensive income (loss) 105          
Ending Balance at Sep. 30, 2019 $ 9,699 $ 16 (1,717) 17,510 (6,249) 138
Ending Balance (Shares) at Sep. 30, 2019 1,641,342,509          
Beginning Balance at Mar. 31, 2019   $ 16 (1,717) 17,374 (6,528) 87
Beginning Balance (Shares) at Mar. 31, 2019   1,638,149,373        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss)         154  
Total other comprehensive income (loss)           (9)
Impact of stock-based compensation plans, net of tax (Shares)   949,557        
Impact of stock-based compensation plans, net of tax       48    
Ending Balance at Jun. 30, 2019   $ 16 (1,717) 17,422 (6,375) 78
Ending Balance (Shares) at Jun. 30, 2019   1,639,098,930        
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net income (loss) $ 126       126  
Total other comprehensive income (loss) 60         60
Impact of stock-based compensation plans, net of tax (Shares)   2,243,579        
Impact of stock-based compensation plans, net of tax       89    
Ending Balance at Sep. 30, 2019 $ 9,699 $ 16 $ (1,717) $ 17,510 $ (6,249) $ 138
Ending Balance (Shares) at Sep. 30, 2019 1,641,342,509          
JSON 67 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "q32019form10-q.htm": { "axisCustom": 3, "axisStandard": 27, "contextCount": 439, "dts": { "calculationLink": { "local": [ "bsx-20190930_cal.xml" ] }, "definitionLink": { "local": [ "bsx-20190930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "q32019form10-q.htm" ] }, "labelLink": { "local": [ "bsx-20190930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-doc-2018-01-31.xml", "http://xbrl.sec.gov/invest/2013/invest-doc-2013-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bsx-20190930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.sec.gov/invest/2013/invest-ref-2013-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-ref-2018-01-31.xml" ] }, "schema": { "local": [ "bsx-20190930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-parts-codification-2018-01-31.xsd" ] } }, "elementCount": 674, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2018-01-31": 27, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 32 }, "keyCustom": 52, "keyStandard": 395, "memberCustom": 69, "memberStandard": 47, "nsprefix": "bsx", "nsuri": "http://www.bostonscientific.com/20190930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0002000 - Document - Cover Document", "role": "http://www.bostonscientific.com/role/CoverDocument", "shortName": "Cover Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Acquisitions and Strategic Investments", "role": "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestments", "shortName": "Acquisitions and Strategic Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Goodwill and Other Intangible Assets", "role": "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssets", "shortName": "Goodwill and Other Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Hedging Activities and Fair Value Measurements", "role": "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurements", "shortName": "Hedging Activities and Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2106100 - Disclosure - Borrowings and Credit Arrangements", "role": "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangements", "shortName": "Borrowings and Credit Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108100 - Disclosure - Supplemental Balance Sheet Information", "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation", "shortName": "Supplemental Balance Sheet Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109100 - Disclosure - Leases Leases", "role": "http://www.bostonscientific.com/role/LeasesLeases", "shortName": "Leases Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Income Taxes", "role": "http://www.bostonscientific.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Commitments and Contingencies", "role": "http://www.bostonscientific.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Weighted Average Shares Outstanding", "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding", "shortName": "Weighted Average Shares Outstanding", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Segment Reporting", "role": "http://www.bostonscientific.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-6", "lang": null, "name": "us-gaap:GrossProfit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Revenue", "role": "http://www.bostonscientific.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115100 - Disclosure - Changes in Other Comprehensive Income", "role": "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncome", "shortName": "Changes in Other Comprehensive Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - New Accounting Pronouncements", "role": "http://www.bostonscientific.com/role/NewAccountingPronouncements", "shortName": "New Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeLeasesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2201201 - Disclosure - Basis of Presentation Basis of Presentation (Policies)", "role": "http://www.bostonscientific.com/role/BasisOfPresentationBasisOfPresentationPolicies", "shortName": "Basis of Presentation Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeLeasesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2205201 - Disclosure - Fair Value Measurements Hedging Activities and Fair Value Measurements (Policies)", "role": "http://www.bostonscientific.com/role/FairValueMeasurementsHedgingActivitiesAndFairValueMeasurementsPolicies", "shortName": "Fair Value Measurements Hedging Activities and Fair Value Measurements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermLeasesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2209201 - Disclosure - Leases Leases (Policies)", "role": "http://www.bostonscientific.com/role/LeasesLeasesPolicies", "shortName": "Leases Leases (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:LeasesOfLesseeDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShortTermLeasesPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalCostsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2211201 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Policies)", "role": "http://www.bostonscientific.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesPolicies", "shortName": "Commitments and Contingencies Commitments and Contingencies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LegalCostsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:ASCUpdateNo.201601FinancialInstrumentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2215201 - Disclosure - Changes in Other Comprehensive Income Changes in Other Comprehensive Income (Policies)", "role": "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeChangesInOtherComprehensiveIncomePolicies", "shortName": "Changes in Other Comprehensive Income Changes in Other Comprehensive Income (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:ASCUpdateNo.201601FinancialInstrumentsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:ASCUpdateNo.201613PolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2216201 - Disclosure - New Accounting Pronouncements (Policies)", "role": "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies", "shortName": "New Accounting Pronouncements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:ASCUpdateNo.201613PolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_bsx_A2019AcquisitionsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Acquisitions (Tables)", "role": "http://www.bostonscientific.com/role/AcquisitionsTables", "shortName": "Acquisitions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD_us-gaap_BusinessAcquisitionAxis_bsx_A2019AcquisitionsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)", "role": "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-6", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302302 - Disclosure - Contingent Consideration (Tables)", "role": "http://www.bostonscientific.com/role/ContingentConsiderationTables", "shortName": "Contingent Consideration (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "invest:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302303 - Disclosure - Strategic Investments (Tables)", "role": "http://www.bostonscientific.com/role/StrategicInvestmentsTables", "shortName": "Strategic Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "invest:InvestmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304302 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables)", "role": "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillTables", "shortName": "Goodwill and Other Intangible Assets Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305302 - Disclosure - Hedging Activities and Fair Value Measurements (Tables)", "role": "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables", "shortName": "Hedging Activities and Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Borrowings and Credit Arrangements (Tables)", "role": "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables", "shortName": "Borrowings and Credit Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308301 - Disclosure - Supplemental Balance Sheet Information (Tables)", "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables", "shortName": "Supplemental Balance Sheet Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:LesseeSupplementalBalanceSheetInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - Leases Leases (Tables)", "role": "http://www.bostonscientific.com/role/LeasesLeasesTables", "shortName": "Leases Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:LesseeSupplementalBalanceSheetInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Income Taxes (Tables)", "role": "http://www.bostonscientific.com/role/IncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "bsx:ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312301 - Disclosure - Weighted Average Shares Outstanding (Tables)", "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables", "shortName": "Weighted Average Shares Outstanding (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Segment Reporting (Tables)", "role": "http://www.bostonscientific.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "bsx:CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "-6", "lang": null, "name": "us-gaap:DeferredTaxAssetsNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Revenue (Tables)", "role": "http://www.bostonscientific.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2315302 - Disclosure - Changes in Other Comprehensive Income (Tables)", "role": "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeTables", "shortName": "Changes in Other Comprehensive Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "D2019Q1SD_bsx_OperatingleaserightofuseassetAxis_bsx_OperatingleaserightofuseassetsotherlongtermassetsMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401402 - Disclosure - Basis of Presentation ASUs Implemented (Details)", "role": "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails", "shortName": "Basis of Presentation ASUs Implemented (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "D2019Q1SD_bsx_OperatingleaserightofuseassetAxis_bsx_OperatingleaserightofuseassetsotherlongtermassetsMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - Acquisitions (Details)", "role": "http://www.bostonscientific.com/role/AcquisitionsDetails", "shortName": "Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "D2019Q3Varian", "decimals": "-6", "lang": null, "name": "us-gaap:ProceedsFromDivestitureOfBusinesses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2018Q4", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - Contingent Consideration (Details)", "role": "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "shortName": "Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-6", "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402406 - Disclosure - Strategic Investments (Details)", "role": "http://www.bostonscientific.com/role/StrategicInvestmentsDetails", "shortName": "Strategic Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Goodwill and Other Intangible Assets (Details)", "role": "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "shortName": "Goodwill and Other Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2018Q4", "decimals": "-6", "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:PaymentsForHedgeInvestingActivities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Hedging Activities and Fair Value Measurements (Details)", "role": "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "shortName": "Hedging Activities and Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "-6", "lang": null, "name": "invest:DerivativeNotionalAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Borrowings and Credit Arrangements (Details)", "role": "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "shortName": "Borrowings and Credit Arrangements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:DebtAndCapitalLeaseObligations", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "bsx:CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408402 - Disclosure - Supplemental Balance Sheet Information (Details)", "role": "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails", "shortName": "Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2018Q4", "decimals": "-6", "lang": null, "name": "us-gaap:AccountsReceivableGrossCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "bsx:LesseeSupplementalBalanceSheetInformationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Leases Leases (Details)", "role": "http://www.bostonscientific.com/role/LeasesLeasesDetails", "shortName": "Leases Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-6", "lang": null, "name": "us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Income Taxes (Details)", "role": "http://www.bostonscientific.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2018Q4", "decimals": "-6", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2018Q4", "decimals": "-6", "lang": null, "name": "us-gaap:LossContingencyAccrualAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412402 - Disclosure - Weighted Average Shares Outstanding (Details)", "role": "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails", "shortName": "Weighted Average Shares Outstanding (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-5", "lang": null, "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "reportablesegments", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Segment Reporting (Details)", "role": "http://www.bostonscientific.com/role/SegmentReportingDetails", "shortName": "Segment Reporting (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "reportablesegments", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "0", "first": true, "lang": null, "name": "bsx:EmergingMarketstotalnumberofcountries", "reportCount": 1, "unitRef": "units", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Revenue (Details)", "role": "http://www.bostonscientific.com/role/RevenueDetails", "shortName": "Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2018Q4", "decimals": "-6", "lang": null, "name": "us-gaap:ContractWithCustomerLiability", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415403 - Disclosure - Changes in Other Comprehensive Income (Details)", "role": "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "shortName": "Changes in Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomeNoteTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3QTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2017Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2017Q4_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_NewAccountingPronouncementMember_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "bsx:CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FI2019Q3", "decimals": "-6", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005001 - Statement - Condensed Consolidated Statements of Cash Flows Condensed Consolidated Statement of Cash Flows (Supplemental Disclosure)", "role": "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure", "shortName": "Condensed Consolidated Statements of Cash Flows Condensed Consolidated Statement of Cash Flows (Supplemental Disclosure)", "subGroupType": "", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Basis of Presentation", "role": "http://www.bostonscientific.com/role/BasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "q32019form10-q.htm", "contextRef": "FD2019Q3YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 118, "tag": { "bsx_A2018AcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2018 Acquisitions [Member]", "label": "2018 Acquisitions [Member]", "terseLabel": "2018 Acquisitions [Member]" } } }, "localname": "A2018AcquisitionsMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "domainItemType" }, "bsx_A2019AcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2019 Acquisitions [Member]", "label": "2019 Acquisitions [Member]", "terseLabel": "2019 Acquisitions [Member]" } } }, "localname": "A2019AcquisitionsMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "domainItemType" }, "bsx_ASCUpdateNo.201601FinancialInstrumentsPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ASC Update No. 2016-01, Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities [Policy Text Block]", "label": "ASC Update No. 2016-01, Financial Instruments [Policy Text Block]", "terseLabel": "ASC Update No. 2016-01, Financial Instruments [Policy Text Block]" } } }, "localname": "ASCUpdateNo.201601FinancialInstrumentsPolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeChangesInOtherComprehensiveIncomePolicies" ], "xbrltype": "textBlockItemType" }, "bsx_ASCUpdateNo.201613PolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ASC Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments [Policy Text Block]", "label": "ASC Update No. 2016-13 [Policy Text Block]", "terseLabel": "ASC Update No. 2016-13 [Policy Text Block]" } } }, "localname": "ASCUpdateNo.201613PolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_ASCUpdateNo.201815InternalUseSoftwarePolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ASC Update No. 2018-15, Internal-Use Software [Policy Text Block]", "label": "ASC Update No. 2018-15, Internal-Use Software [Policy Text Block]", "terseLabel": "ASC Update No. 2018-15, Internal-Use Software [Policy Text Block]" } } }, "localname": "ASCUpdateNo.201815InternalUseSoftwarePolicyTextBlock", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "bsx_AccruedRebatesCurrent": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accrued Rebates, Current", "label": "Accrued Rebates, Current", "terseLabel": "Accrued Rebates, Current" } } }, "localname": "AccruedRebatesCurrent", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_AccumulatedOtherComprehensiveIncomeLossSecuritiesAvailableforsaleAdjustmentafterTax": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax", "label": "Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossSecuritiesAvailableforsaleAdjustmentafterTax", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "bsx_ActualCovenantMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Actual Covenant.", "label": "Actual, Covenant [Member]", "terseLabel": "Actual, Covenant [Member]" } } }, "localname": "ActualCovenantMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_AggregateSeniorUnsecuredDelayedDrawTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Aggregate Senior Unsecured Delayed Draw Term Loan [Member]", "label": "Aggregate Senior Unsecured Delayed Draw Term Loan [Member]", "terseLabel": "Aggregate Senior Unsecured Delayed Draw Term Loan [Member]" } } }, "localname": "AggregateSeniorUnsecuredDelayedDrawTermLoanMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_AllegedBreachofPurchaseAgreementAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Alleged Breach of Purchase Agreement, Amount", "label": "Alleged Breach of Purchase Agreement, Amount", "terseLabel": "Alleged Breach of Purchase Agreement, Amount" } } }, "localname": "AllegedBreachofPurchaseAgreementAmount", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_AssignedtoonejudgeinMAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assigned to one judge in MA [Member]", "label": "Assigned to one judge in MA [Member]", "terseLabel": "Assigned to one judge in MA [Member]" } } }, "localname": "AssignedtoonejudgeinMAMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "bsx_August2019TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "August 2019 Term Loan [Member]", "label": "August 2019 Term Loan [Member]", "terseLabel": "August 2019 Term Loan [Member]" } } }, "localname": "August2019TermLoanMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_August2021TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "August 2021 Term Loan [Member]", "label": "August 2021 Term Loan [Member]", "terseLabel": "August 2021 Term Loan [Member]" } } }, "localname": "August2021TermLoanMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_August2022TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "August 2022 Term Loan [Member]", "label": "August 2022 Term Loan [Member]", "terseLabel": "August 2022 Term Loan [Member]" } } }, "localname": "August2022TermLoanMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_BTGAcquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BTG Acquisition [Member]", "label": "BTG Acquisition [Member]", "terseLabel": "BTG Acquisition [Member]", "verboseLabel": "BTG Acquisition [Member]" } } }, "localname": "BTGAcquisitionMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/AcquisitionsTables", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_BTGInterventionalMedicineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BTG Interventional Medicine [Member]", "label": "BTG Interventional Medicine [Member]", "terseLabel": "BTG Interventional Medicine [Member]" } } }, "localname": "BTGInterventionalMedicineMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_BTGSpecPharmaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BTG Spec Pharma [Member]", "label": "BTG Spec Pharma [Member]", "terseLabel": "BTG Spec Pharma [Member]" } } }, "localname": "BTGSpecPharmaMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_BTGintellectualpropertyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "BTG intellectual property [Member]", "label": "BTG intellectual property [Member]", "terseLabel": "BTG intellectual property [Member]" } } }, "localname": "BTGintellectualpropertyMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "bsx_BusinessAcquisitionContingentConsiderationCashPayment": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Acquisition Contingent Consideration Cash Payment", "label": "Business Acquisition Contingent Consideration Cash Payment", "negatedTerseLabel": "Payment of contingent consideration amounts and royalty rights previously established in purchase accounting" } } }, "localname": "BusinessAcquisitionContingentConsiderationCashPayment", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bsx_CardiovascularMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cardiovascular [Member]", "label": "Cardiovascular [Member]", "terseLabel": "Cardiovascular [Member]" } } }, "localname": "CardiovascularMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]", "verboseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Line Items]" } } }, "localname": "CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsLineItems", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "bsx_CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]", "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]" } } }, "localname": "CashCashEquivalentsRestrictedCashandRestrictedCashEquivalentsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "bsx_CertifiedclassactionsinCanadaMesh": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Certified class actions in Canada, Mesh", "label": "Certified class actions in Canada, Mesh", "terseLabel": "Certified class actions in Canada, Mesh" } } }, "localname": "CertifiedclassactionsinCanadaMesh", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_ClaretMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Claret [Member]", "label": "Claret [Member]", "terseLabel": "Claret [Member]" } } }, "localname": "ClaretMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "bsx_CondensedConsolidatedBalanceSheetParentheticalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]", "label": "Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]" } } }, "localname": "CondensedConsolidatedBalanceSheetParentheticalAbstract", "nsuri": "http://www.bostonscientific.com/20190930", "xbrltype": "stringItemType" }, "bsx_CondensedConsolidatedCashFlowSupplementalDIsclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Condensed Consolidated Cash Flow Supplemental DIsclosure [Abstract]", "label": "Condensed Consolidated Cash Flow Supplemental DIsclosure [Abstract]" } } }, "localname": "CondensedConsolidatedCashFlowSupplementalDIsclosureAbstract", "nsuri": "http://www.bostonscientific.com/20190930", "xbrltype": "stringItemType" }, "bsx_ContingentConsiderationLiabilityProbabilityOfPayment": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "contingent consideration liability, probability of payment", "label": "contingent consideration liability, probability of payment", "terseLabel": "contingent consideration liability, probability of payment" } } }, "localname": "ContingentConsiderationLiabilityProbabilityOfPayment", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "percentItemType" }, "bsx_ContingentConsiderationRecognizedInPeriod": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Contingent consideration recognized in the period", "label": "Contingent consideration recognized in the period", "terseLabel": "Fair value of contingent consideration recorded in purchase accounting" } } }, "localname": "ContingentConsiderationRecognizedInPeriod", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bsx_CorporateExpensesincludinghedgingactivitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Corporate Expenses including hedging activities [Member]", "label": "Corporate Expenses including hedging activities [Member]", "verboseLabel": "Corporate expenses and currency exchange [Member]" } } }, "localname": "CorporateExpensesincludinghedgingactivitiesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_CovenantAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Covenant.", "label": "Covenant [Axis]", "terseLabel": "Covenant [Axis]" } } }, "localname": "CovenantAxis", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "bsx_CovenantDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Covenant.", "label": "Covenant [Domain]", "terseLabel": "Covenant [Domain]" } } }, "localname": "CovenantDomain", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_CovenantRequirementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Covenant Requirement [Domain]", "label": "Covenant Requirement [Domain]", "terseLabel": "Current Requirement [Member]" } } }, "localname": "CovenantRequirementDomain", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_CryterionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cryterion [Member]", "label": "Cryterion [Member]", "terseLabel": "Cryterion [Member]" } } }, "localname": "CryterionMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "bsx_CurrentRequirementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Current Requirement.", "label": "Current Requirement [Member]", "terseLabel": "Current Requirement [Member]" } } }, "localname": "CurrentRequirementMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]", "label": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]", "terseLabel": "Derivative Instruments, Gain (Loss) that may be Reclassified from AOCI to Earnings within Twelve Months [Table Text Block]" } } }, "localname": "DerivativeInstrumentsGainLossthatmaybeReclassifiedfromAOCItoEarningswithinTwelveMonthsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "bsx_DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "label": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Derivative Used in Net Investment Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "localname": "DerivativeUsedinNetInvestmentHedgeGainLosstobeReclassifiedDuringNext12MonthsNet", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_DiscountRateFairValueInput": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Discount Rate, Fair Value Input", "label": "Discount Rate, Fair Value Input", "terseLabel": "Discount Rate, Fair Value Input" } } }, "localname": "DiscountRateFairValueInput", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "percentItemType" }, "bsx_DivestedbusinessduetoBTGacquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "divested business due to BTG acquisition [Member]", "label": "divested business due to BTG acquisition [Member]", "terseLabel": "divested business due to BTG acquisition [Member]" } } }, "localname": "DivestedbusinessduetoBTGacquisitionMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "bsx_EmergingMarketsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Emerging Markets [Member]", "label": "Emerging Markets [Member]", "terseLabel": "Emerging Markets [Member]" } } }, "localname": "EmergingMarketsMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_EmergingMarketstotalnumberofcountries": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Emerging Markets total number of countries", "label": "Emerging Markets total number of countries", "terseLabel": "Emerging Markets total countries" } } }, "localname": "EmergingMarketstotalnumberofcountries", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "integerItemType" }, "bsx_EntityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Entity [Abstract]", "label": "Entity [Abstract]" } } }, "localname": "EntityAbstract", "nsuri": "http://www.bostonscientific.com/20190930", "xbrltype": "stringItemType" }, "bsx_EquipmentFurnitureAndFixturesGross": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equipment, furniture and fixtures Gross.", "label": "Equipment, furniture and fixtures Gross", "terseLabel": "Equipment, furniture and fixtures" } } }, "localname": "EquipmentFurnitureAndFixturesGross", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_EuroDenominatedFactoringArrangementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Euro Denominated Factoring Arrangements [Member]", "label": "Euro Denominated Factoring Arrangements [Member]", "terseLabel": "Euro Denominated Factoring Arrangements [Member]" } } }, "localname": "EuroDenominatedFactoringArrangementsMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_ExchangeRateUSD": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Exchange Rate, USD", "label": "Exchange Rate, USD", "terseLabel": "Exchange Rate, USD" } } }, "localname": "ExchangeRateUSD", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_ExcludesBTGAcquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excludes BTG Acquisition [Member]", "label": "Excludes BTG Acquisition [Member]", "terseLabel": "Excludes BTG Acquisition [Member]" } } }, "localname": "ExcludesBTGAcquisitionMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_ExclusionFromEbitdaForRestructuringCharges": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Exclusion from EBITDA for Restructuring Charges", "label": "Exclusion from EBITDA for Restructuring Charges", "terseLabel": "Exclusion from EBITDA for Restructuring Charges" } } }, "localname": "ExclusionFromEbitdaForRestructuringCharges", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_February2019AggregateOfferingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "February2019AggregateOffering [Member]", "label": "February2019AggregateOffering [Member]", "terseLabel": "February2019AggregateOffering [Member]" } } }, "localname": "February2019AggregateOfferingMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_ForwardCurrencyContractsTimetoMaturity": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Forward Currency Contracts, Time to Maturity in Months", "label": "Forward Currency Contracts, Time to Maturity", "terseLabel": "Forward Currency Contracts, Time to Maturity" } } }, "localname": "ForwardCurrencyContractsTimetoMaturity", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "integerItemType" }, "bsx_GlobalCrmReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global CRM Reporting Unit [Member]", "label": "Global CRM Reporting Unit [Member]", "terseLabel": "Global CRM Reporting Unit [Member]" } } }, "localname": "GlobalCrmReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalElectrophysiologyEpReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Electrophysiology (EP) Reporting Unit [Member]", "label": "Global Electrophysiology (EP) Reporting Unit [Member]", "terseLabel": "Global Electrophysiology (EP) Reporting Unit [Member]" } } }, "localname": "GlobalElectrophysiologyEpReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalEndoscopyEndoReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Endoscopy (Endo) Reporting Unit [Member]", "label": "Global Endoscopy (Endo) Reporting Unit [Member]", "terseLabel": "Global Endoscopy (Endo) Reporting Unit [Member]" } } }, "localname": "GlobalEndoscopyEndoReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalInterventionalCardiologyIcReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Interventional Cardiology (IC) Reporting Unit [Member]", "label": "Global Interventional Cardiology (IC) Reporting Unit [Member]", "terseLabel": "Global Interventional Cardiology (IC) Reporting Unit [Member]" } } }, "localname": "GlobalInterventionalCardiologyIcReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalNeuromodulationNmReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Neuromodulation (NM) Reporting Unit [Member]", "label": "Global Neuromodulation (NM) Reporting Unit [Member]", "terseLabel": "Global Neuromodulation (NM) Reporting Unit [Member]", "verboseLabel": "Global Neuromodulation (NM) Reporting Unit [Member]" } } }, "localname": "GlobalNeuromodulationNmReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalPeripheralInterventionsPiReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Peripheral Interventions (PI) Reporting Unit [Member]", "label": "Global Peripheral Interventions (PI) Reporting Unit [Member]", "terseLabel": "Global Peripheral Interventions (PI) Reporting Unit [Member]" } } }, "localname": "GlobalPeripheralInterventionsPiReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_GlobalUrologyandPelvicHealthReportingUnitMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Global Urology and Pelvic Health Reporting Unit [Member]", "label": "Global Urology and Pelvic Health Reporting Unit [Member]", "terseLabel": "Global Urology (Uro) Reporting Unit [Member]" } } }, "localname": "GlobalUrologyandPelvicHealthReportingUnitMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_IndefiniteLivedIntangibleAssetsAccumulatedWriteOffs": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Indefinite-lived intangible assets, accumulated write-offs", "label": "Indefinite-lived intangible assets, accumulated write-offs", "terseLabel": "Indefinite-lived intangible assets and goodwill, accumulated write-offs" } } }, "localname": "IndefiniteLivedIntangibleAssetsAccumulatedWriteOffs", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_IndefiniteLivedIntangibleAssetsIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "indefinite-lived intangible assets including goodwill", "label": "Indefinite-lived intangible assets, including goodwill", "totalLabel": "Indefinite-lived intangible assets, including goodwill" } } }, "localname": "IndefiniteLivedIntangibleAssetsIncludingGoodwill", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_IntangibleAssetsAcquiredFiniteandIndefinitelived": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Intangible Assets Acquired, Finite and Indefinite-lived", "label": "Intangible Assets Acquired, Finite and Indefinite-lived", "terseLabel": "Intangible Assets Acquired, Finite and Indefinite-lived" } } }, "localname": "IntangibleAssetsAcquiredFiniteandIndefinitelived", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_IntangibleAssetsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible Assets [Axis]", "label": "Intangible Assets [Axis]", "terseLabel": "Intangible Assets [Axis]" } } }, "localname": "IntangibleAssetsAxis", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "bsx_IntangibleAssetsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Intangible Assets [Axis]", "label": "Intangible Assets [Domain]", "terseLabel": "Intangible Assets [Domain]" } } }, "localname": "IntangibleAssetsDomain", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "bsx_IntangibleAssetsandGoodwillLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule of Intangible Assets and Goodwill [Table]", "label": "Intangible Assets and Goodwill [Line Items]", "terseLabel": "Intangible Assets and Goodwill [Line Items]" } } }, "localname": "IntangibleAssetsandGoodwillLineItems", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "bsx_January2020NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "January 2020 Notes [Member]", "label": "January 2020 Notes [Member]", "terseLabel": "January 2020 Notes [Member]" } } }, "localname": "January2020NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_January2040NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "January 2040 Notes [Member]", "label": "January 2040 Notes [Member]", "terseLabel": "January 2040 Notes [Member]" } } }, "localname": "January2040NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_LatinAmericaandCanadaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Latin America and Canada [Member]", "label": "Latin America and Canada [Member]", "terseLabel": "Latin America and Canada [Member]" } } }, "localname": "LatinAmericaandCanadaMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "bsx_LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "label": "Legal payments remaining to be excluded from calculation of consolidated EBITDA", "terseLabel": "Legal payments remaining to be excluded from calculation of consolidated EBITDA" } } }, "localname": "LegalPaymentsRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LesseeOperatingandFinanceLeasesOptiontoExtend": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating and Finance Leases, Option to Extend", "label": "Lessee, Operating and Finance Leases, Option to Extend", "terseLabel": "Lessee, Operating and Finance Leases, Option to Extend" } } }, "localname": "LesseeOperatingandFinanceLeasesOptiontoExtend", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "durationStringItemType" }, "bsx_LesseeSupplementalBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee Supplemental Balance Sheet Information [Table Text Block]", "label": "Lessee Supplemental Balance Sheet Information [Table Text Block]", "terseLabel": "Lessee Supplemental Balance Sheet Information [Table Text Block]" } } }, "localname": "LesseeSupplementalBalanceSheetInformationTableTextBlock", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesTables" ], "xbrltype": "textBlockItemType" }, "bsx_Lesseeleasesnotyetcommencedamount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Lessee, leases not yet commenced, amount", "label": "Lessee, leases not yet commenced, amount", "terseLabel": "Lessee, leases not yet commenced, amount" } } }, "localname": "Lesseeleasesnotyetcommencedamount", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Licensingarrangementsasset": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Licensing arrangements, asset", "label": "Licensing arrangements, asset", "terseLabel": "Licensing arrangements, asset" } } }, "localname": "Licensingarrangementsasset", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Licensingarrangementsliability": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Licensing arrangements, liability", "label": "Licensing arrangements, liability", "terseLabel": "Licensing arrangements, liability" } } }, "localname": "Licensingarrangementsliability", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LitigationAndDebtExclusionFromEbitda": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Exclusion of litigation payments and any debt Issued to fund tax deficiency payments", "label": "Litigation and Debt Exclusion from EBITDA", "terseLabel": "Litigation and Debt Exclusion from EBITDA" } } }, "localname": "LitigationAndDebtExclusionFromEbitda", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_LitigationSettlementReceivedGain": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Litigation Settlement Received, Gain", "label": "Litigation Settlement Received, Gain", "terseLabel": "Litigation Settlement Received, Gain" } } }, "localname": "LitigationSettlementReceivedGain", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "bsx_March2024NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2024 Notes [Member]", "label": "March 2024 Notes [Member]", "terseLabel": "March 2024 Notes [Member]" } } }, "localname": "March2024NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2026NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2026 Notes [Member]", "label": "March 2026 Notes [Member]", "terseLabel": "March 2026 Notes [Member]" } } }, "localname": "March2026NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2028NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2028 Notes [Member]", "label": "March 2028 Notes [Member]", "terseLabel": "March 2028 Notes [Member]" } } }, "localname": "March2028NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2029NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2029 Notes [Member]", "label": "March 2029 Notes [Member]", "terseLabel": "March 2029 Notes [Member]" } } }, "localname": "March2029NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2039NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2039 Notes [Member]", "label": "March 2039 Notes [Member]", "terseLabel": "March 2039 Notes [Member]" } } }, "localname": "March2039NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_March2049NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "March 2049 Notes [Member]", "label": "March 2049 Notes [Member]", "terseLabel": "March 2049 Notes [Member]" } } }, "localname": "March2049NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_MaturitiesofLeaseLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maturities of Lease Liabilities [Table Text Block]", "label": "Maturities of Lease Liabilities [Table Text Block]", "terseLabel": "Maturities of Lease Liabilities [Table Text Block]" } } }, "localname": "MaturitiesofLeaseLiabilitiesTableTextBlock", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesTables" ], "xbrltype": "textBlockItemType" }, "bsx_MaximumCommercialPaperOutstandingwith2018Facility": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum Commercial Paper Outstanding with 2018 Facility", "label": "Maximum Commercial Paper Outstanding with 2018 Facility", "terseLabel": "Maximum Commercial Paper Outstanding with 2017 Facility" } } }, "localname": "MaximumCommercialPaperOutstandingwith2018Facility", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_MaximumContingentPaymentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum Contingent Payment [Member]", "label": "Maximum Contingent Payment [Member]", "terseLabel": "Maximum Contingent Payment [Member]" } } }, "localname": "MaximumContingentPaymentMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "bsx_MaximumLeverageRatio": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum leverage ratio permitted by revolving credit facility agreement.", "label": "Maximum Leverage Ratio", "terseLabel": "Maximum Leverage Ratio" } } }, "localname": "MaximumLeverageRatio", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "pureItemType" }, "bsx_May2020NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "May 2020 Notes [Member]", "label": "May 2020 Notes [Member]", "terseLabel": "May 2020 Notes [Member]" } } }, "localname": "May2020NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_May2022NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "May 2022 Notes [Member]", "label": "May 2022 Notes [Member]", "terseLabel": "May 2022 Notes [Member]" } } }, "localname": "May2022NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_May2025NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "May 2025 Notes [Member]", "label": "May 2025 Notes [Member]", "terseLabel": "May 2025 Notes [Member]" } } }, "localname": "May2025NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_MedsurgMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "MedSurg [Member]", "label": "MedSurg [Member]", "terseLabel": "MedSurg [Member]" } } }, "localname": "MedsurgMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_MillipedeInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Millipede, Inc. [Member]", "label": "Millipede, Inc. [Member]", "terseLabel": "Millipede, Inc. [Member]" } } }, "localname": "MillipedeInc.Member", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "domainItemType" }, "bsx_NVisionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "nVision [Member]", "label": "nVision [Member]", "terseLabel": "nVision [Member]" } } }, "localname": "NVisionMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "bsx_Netcurrencyexchangegainloss": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net currency exchange gain (loss)", "label": "Net currency exchange gain (loss)", "terseLabel": "Net currency exchange gain (loss)" } } }, "localname": "Netcurrencyexchangegainloss", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_NonAcquisitionRelatedMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Non Acquisition Related [Member]", "label": "Non Acquisition Related [Member]", "terseLabel": "Non Acquisition Related [Member]" } } }, "localname": "NonAcquisitionRelatedMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "bsx_November2035NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "November 2035 Notes [Member]", "label": "November 2035 Notes [Member]", "terseLabel": "November 2035 Notes [Member]" } } }, "localname": "November2035NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_NxTheraMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NxThera [Member]", "label": "NxThera [Member]", "terseLabel": "NxThera [Member]" } } }, "localname": "NxTheraMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "bsx_October2023NotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "October 2023 Notes [Member]", "label": "October 2023 Notes [Member]", "terseLabel": "October 2023 Notes [Member]" } } }, "localname": "October2023NotesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_OperatingIncomeAllocatedToReportableSegments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating Income Allocated to Reportable Segments", "label": "Operating Income Allocated to Reportable Segments", "terseLabel": "Operating Income Allocated to Reportable Segments" } } }, "localname": "OperatingIncomeAllocatedToReportableSegments", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "bsx_OperatingIncomeUnallocatedToSegment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating Income Unallocated to Segment", "label": "Operating Income Unallocated to Segment", "negatedTerseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated" } } }, "localname": "OperatingIncomeUnallocatedToSegment", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "bsx_OperatingleaseLiabilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating lease, Liability [Axis]", "label": "Operating lease, Liability [Axis]", "terseLabel": "Operating lease, Liability [Axis]" } } }, "localname": "OperatingleaseLiabilityAxis", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails" ], "xbrltype": "stringItemType" }, "bsx_OperatingleaseLiabilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Operating lease, Liability [Axis]", "label": "Operating lease, Liability [Domain]", "terseLabel": "Operating lease, Liability [Domain]" } } }, "localname": "OperatingleaseLiabilityDomain", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails" ], "xbrltype": "domainItemType" }, "bsx_OperatingleaseliabilityotherlongtermliabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating lease, liability, other long-term liabilities [Member]", "label": "Operating lease, liability, other long-term liabilities [Member]", "terseLabel": "Operating lease, liability, other long-term liabilities [Member]" } } }, "localname": "OperatingleaseliabilityotherlongtermliabilitiesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails" ], "xbrltype": "domainItemType" }, "bsx_OperatingleaserightofuseassetAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating lease, right-of-use asset [Axis]", "label": "Operating lease, right-of-use asset [Axis]", "terseLabel": "Operating lease, right-of-use asset [Axis]" } } }, "localname": "OperatingleaserightofuseassetAxis", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails" ], "xbrltype": "stringItemType" }, "bsx_OperatingleaserightofuseassetDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for Operating lease, right-of-use asset [Axis]", "label": "Operating lease, right-of-use asset [Domain]", "terseLabel": "Operating lease, right-of-use asset [Domain]" } } }, "localname": "OperatingleaserightofuseassetDomain", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails" ], "xbrltype": "domainItemType" }, "bsx_OperatingleaserightofuseassetsotherlongtermassetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Operating lease, right-of-use assets, other long-term assets [Member]", "label": "Operating lease, right-of-use assets, other long-term assets [Member]", "terseLabel": "Operating lease, right-of-use assets, other long-term assets [Member]" } } }, "localname": "OperatingleaserightofuseassetsotherlongtermassetsMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails" ], "xbrltype": "domainItemType" }, "bsx_Other2018AcquisitionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other 2018 Acquisitions - immaterial in the aggregate [Member]", "label": "Other 2018 Acquisitions [Member]", "terseLabel": "Other 2018 Acquisitions [Member]" } } }, "localname": "Other2018AcquisitionsMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "bsx_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), after Reclassification, Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossafterReclassificationTax", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_PaymentOfContingentConsideration": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payment of contingent consideration", "label": "Payment of contingent consideration", "negatedLabel": "Payment of contingent consideration" } } }, "localname": "PaymentOfContingentConsideration", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "bsx_Paymenttonetsharesettleemployeeequityawards": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payment to net share settle employee equity awards", "label": "Payment to net share settle employee equity awards", "negatedTerseLabel": "Cash used to net share settle employee equity awards" } } }, "localname": "Paymenttonetsharesettleemployeeequityawards", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bsx_Productliabilitycasesorclaimsrelatedtomeshproduct": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product liability cases or claims asserted related to mesh products", "label": "Product liability cases or claims related to mesh product", "terseLabel": "Product liability cases or claims related to mesh product" } } }, "localname": "Productliabilitycasesorclaimsrelatedtomeshproduct", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_ProductliabilitycasesorclaimsrelatedtomeshproductCanada": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product liability cases or claims related to mesh product - Canada", "label": "Product liability cases or claims related to mesh product - Canada", "terseLabel": "Product liability cases or claims related to mesh product - Canada" } } }, "localname": "ProductliabilitycasesorclaimsrelatedtomeshproductCanada", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_ProductliabilitycasesorclaimsrelatedtomeshproductUnitedKingdom": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Product liability cases or claims related to mesh product - United Kingdom", "label": "Product liability cases or claims related to mesh product - United Kingdom", "terseLabel": "Product liability cases or claims related to mesh product - United Kingdom" } } }, "localname": "ProductliabilitycasesorclaimsrelatedtomeshproductUnitedKingdom", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_PutativeclassactionsinCanadaMesh": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Putative class actions in Canada, Mesh", "label": "Putative class actions in Canada, Mesh", "terseLabel": "Putative class actions in Canada, Mesh" } } }, "localname": "PutativeclassactionsinCanadaMesh", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_PutativeclassactionsintheU.S.Mesh": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Putative class actions in the U.S., Mesh", "label": "Putative class actions in the U.S., Mesh", "terseLabel": "Putative class actions in the U.S., Mesh" } } }, "localname": "PutativeclassactionsintheU.S.Mesh", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_RDRegulatoryandCommercializationbasedMilestoneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "R&D, Regulatory and Commercialization-based Milestone [Member]", "label": "R&D, Regulatory and Commercialization-based Milestone [Member]", "terseLabel": "R&D, Regulatory and Commercialization-based Milestone [Member]" } } }, "localname": "RDRegulatoryandCommercializationbasedMilestoneMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "bsx_RangeofRiskAdjustedDiscountRatesusedinPurchasePriceAllocation": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Range of Risk Adjusted Discount Rates used in Purchase Price Allocation", "label": "Range of Risk Adjusted Discount Rates used in Purchase Price Allocation", "terseLabel": "Range of Risk Adjusted Discount Rates used in Purchase Price Allocation" } } }, "localname": "RangeofRiskAdjustedDiscountRatesusedinPurchasePriceAllocation", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "percentItemType" }, "bsx_RequirementfifthquarterfollowingqualifiedacquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Requirement, fifth quarter following qualified acquisition [Member]", "label": "Requirement, fifth quarter following qualified acquisition [Member]", "terseLabel": "Requirement, fifth quarter following qualified acquisition [Member]" } } }, "localname": "RequirementfifthquarterfollowingqualifiedacquisitionMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementfirsttwoquartersfollowingqualifiedacquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Requirement, first two quarters following qualified acquisition [Member]", "label": "Requirement, first two quarters following qualified acquisition [Member]", "terseLabel": "Requirement, first two quarters following qualified acquisition [Member]" } } }, "localname": "RequirementfirsttwoquartersfollowingqualifiedacquisitionMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementfourthquarterfollowingqualifiedacquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Requirement, fourth quarter following qualified acquisition [Member]", "label": "Requirement, fourth quarter following qualified acquisition [Member]", "terseLabel": "Requirement, fourth quarter following qualified acquisition [Member]" } } }, "localname": "RequirementfourthquarterfollowingqualifiedacquisitionMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementsixthquarterandthereafterfollowingqualifiedacquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Requirement, sixth quarter and thereafter following qualified acquisition [Member]", "label": "Requirement, sixth quarter and thereafter following qualified acquisition [Member]", "terseLabel": "Requirement, sixth quarter and thereafter following qualified acquisition [Member]" } } }, "localname": "RequirementsixthquarterandthereafterfollowingqualifiedacquisitionMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_RequirementthirdquarterfollowingqualifiedacquisitionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Requirement, third quarter following qualified acquisition [Member]", "label": "Requirement, third quarter following qualified acquisition [Member]", "terseLabel": "Requirement, third quarter following qualified acquisition [Member]" } } }, "localname": "RequirementthirdquarterfollowingqualifiedacquisitionMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA.", "label": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA", "terseLabel": "Restructuring charges remaining to be excluded from calculation of consolidated EBITDA" } } }, "localname": "RestructuringChargesRemainingToBeExcludedFromCalculationOfConsolidatedEbitda", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "bsx_RevenueBasedPaymentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "revenue-based payments [Member]", "label": "revenue-based payments [Member]", "terseLabel": "revenue-based payments [Member]" } } }, "localname": "RevenueBasedPaymentsMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bsx_RhythmandNeuroMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rhythm and Neuro [Member]", "label": "Rhythm and Neuro [Member]", "terseLabel": "Rhythm and Neuro [Member]" } } }, "localname": "RhythmandNeuroMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block]", "label": "Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block]", "terseLabel": "Schedule of Effective Income Tax Rate from Continuing Operations [Table Text Block]" } } }, "localname": "ScheduleofEffectiveIncomeTaxRatefromContinuingOperationsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "bsx_ScheduleofIncomeTaxRateReconciliationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Schedule of Income Tax Rate Reconciliation [Table]", "label": "Schedule of Income Tax Rate Reconciliation [Line Items]", "terseLabel": "Schedule of Income Tax Rate Reconciliation [Line Items]" } } }, "localname": "ScheduleofIncomeTaxRateReconciliationLineItems", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "bsx_ScheduleofIncomeTaxRateReconciliationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Income Tax Rate Reconciliation [Table]", "label": "Schedule of Income Tax Rate Reconciliation [Table]", "terseLabel": "Schedule of Income Tax Rate Reconciliation [Table]" } } }, "localname": "ScheduleofIncomeTaxRateReconciliationTable", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "bsx_ScheduleofIntangibleAssetsandGoodwillTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of Intangible Assets and Goodwill [Table]", "label": "Schedule of Intangible Assets and Goodwill [Table]", "terseLabel": "Schedule of Intangible Assets and Goodwill [Table]" } } }, "localname": "ScheduleofIntangibleAssetsandGoodwillTable", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "bsx_SegmentOperatingIncomeasaPercentageofNetSales": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Segment Operating Income as a Percentage of Net Sales", "label": "Segment Operating Income as a Percentage of Net Sales", "terseLabel": "Segment Operating Income as a Percentage of Net Sales" } } }, "localname": "SegmentOperatingIncomeasaPercentageofNetSales", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "percentItemType" }, "bsx_SpecialChargesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Special Charges [Member]", "label": "Special Charges [Member]" } } }, "localname": "SpecialChargesMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "bsx_StatementAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "statement [Axis]", "label": "statement [Axis]", "terseLabel": "statement [Axis]" } } }, "localname": "StatementAxis", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure" ], "xbrltype": "stringItemType" }, "bsx_StatementDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Domain] for statement [Axis]", "label": "statement [Domain]", "terseLabel": "statement [Domain]" } } }, "localname": "StatementDomain", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure" ], "xbrltype": "domainItemType" }, "bsx_SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summary of term loan and revolving credit facility agreement compliance with debt covenants.", "label": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]", "terseLabel": "Summary Of Term Loan And Revolving Credit Facility Agreement Compliance With Debt Covenants [Table Text Block]" } } }, "localname": "SummaryOfTermLoanAndRevolvingCreditFacilityAgreementComplianceWithDebtCovenantsTableTextBlock", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "bsx_SupplementalBalanceSheetInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplemental Balance Sheet Information.", "label": "Supplemental Balance Sheet Information [Abstract]" } } }, "localname": "SupplementalBalanceSheetInformationAbstract", "nsuri": "http://www.bostonscientific.com/20190930", "xbrltype": "stringItemType" }, "bsx_SupplementalBalanceSheetInformationTextualsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplemental Balance Sheet Information.", "label": "Supplemental Balance Sheet Information (Textuals) [Abstract]", "verboseLabel": "Supplemental Balance Sheet Information" } } }, "localname": "SupplementalBalanceSheetInformationTextualsAbstract", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "bsx_SupplementalCashFlowInformationRelatedtoLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Supplemental Cash Flow Information Related to Leases [Table Text Block]", "label": "Supplemental Cash Flow Information Related to Leases [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information Related to Leases [Table Text Block]" } } }, "localname": "SupplementalCashFlowInformationRelatedtoLeasesTableTextBlock", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesTables" ], "xbrltype": "textBlockItemType" }, "bsx_TenderOfferMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash Tender Offer [Member]", "label": "Tender Offer [Member]", "terseLabel": "Tender Offer [Member]" } } }, "localname": "TenderOfferMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_The2018FacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "the 2018 Facility", "label": "the 2018 Facility [Domain]", "terseLabel": "the 2018 Facility [Member]" } } }, "localname": "The2018FacilityDomain", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_ThreeYearDelayedDrawTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Three-Year Delayed Draw Term Loan [Member]", "label": "Three-Year Delayed Draw Term Loan [Member]", "terseLabel": "Three-Year Delayed Draw Term Loan [Member]" } } }, "localname": "ThreeYearDelayedDrawTermLoanMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_TotalProductliabilitycasesandclaimssettledrelatedtoMeshproduct": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total Product liability cases and claims settled related to Mesh product", "label": "Total Product liability cases and claims settled related to Mesh product", "terseLabel": "Total Product liability cases and claims settled related to Mesh product" } } }, "localname": "TotalProductliabilitycasesandclaimssettledrelatedtoMeshproduct", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "integerItemType" }, "bsx_TwoYearDelayedDrawTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-Year Delayed Draw Term Loan [Member]", "label": "Two-Year Delayed Draw Term Loan [Member]", "terseLabel": "Two-Year Delayed Draw Term Loan [Member]" } } }, "localname": "TwoYearDelayedDrawTermLoanMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "bsx_UpfrontCashMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Upfront Cash [Member]", "label": "Upfront Cash [Member]", "terseLabel": "Upfront Cash [Member]" } } }, "localname": "UpfrontCashMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "bsx_VertiflexInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vertiflex, Inc.", "label": "Vertiflex, Inc. [Member]", "terseLabel": "Vertiflex, Inc. [Member]" } } }, "localname": "VertiflexInc.Member", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "bsx_WeightedAverageMaturityDays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted Average Maturity, Days", "label": "Weighted Average Maturity, Days", "terseLabel": "Weighted Average Maturity, Days" } } }, "localname": "WeightedAverageMaturityDays", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "durationStringItemType" }, "bsx_YenDenominatedFactoringArrangementsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Yen denominated factoring arrangements.", "label": "Yen Denominated Factoring Arrangements [Member]", "terseLabel": "Yen Denominated Factoring Arrangements [Member]" } } }, "localname": "YenDenominatedFactoringArrangementsMember", "nsuri": "http://www.bostonscientific.com/20190930", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]", "terseLabel": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r435" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]", "terseLabel": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "verboseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r438" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "yesNoItemType" }, "dei_EntityListingParValuePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.", "label": "Entity Listing, Par Value Per Share", "terseLabel": "Entity Listing, Par Value Per Share" } } }, "localname": "EntityListingParValuePerShare", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "perShareItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r437" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r433" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r434" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.bostonscientific.com/role/CoverDocument" ], "xbrltype": "tradingSymbolItemType" }, "invest_DerivativeNotionalAmount": { "auth_ref": [ "r439" ], "lang": { "en-US": { "role": { "documentation": "Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative, Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "invest_InvestmentTableTextBlock": { "auth_ref": [ "r440" ], "lang": { "en-US": { "role": { "documentation": "A table of investments, shown as a text block.", "label": "Investment [Table Text Block]", "terseLabel": "Investment [Table Text Block]" } } }, "localname": "InvestmentTableTextBlock", "nsuri": "http://xbrl.sec.gov/invest/2013-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsTables" ], "xbrltype": "textBlockItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "APAC [Member]" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]", "verboseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]", "verboseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r152", "r230", "r233", "r428" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r153", "r230", "r234", "r430", "r432" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_WeightedAverageMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average [Member]" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]", "terseLabel": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": { "auth_ref": [ "r57" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate of amounts due from customers or clients, within one year of the balance sheet date (or one operating cycle, if longer), for goods or services that have been delivered or sold in the normal course of business and an amount representing an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date within one year of the balance sheet, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection and net of any write-downs taken for collection uncertainty on the part of the holder, respectively.", "label": "Accounts, Notes, Loans and Financing Receivable, Net, Current", "terseLabel": "Accounts, Notes, Loans and Financing Receivable, Net, Current", "totalLabel": "Trade accounts receivable, net", "verboseLabel": "Trade accounts receivable, net" } } }, "localname": "AccountsNotesAndLoansReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounts, Notes, Loans and Financing Receivable, Net, Current [Abstract]", "verboseLabel": "Trade accounts receivable, net" } } }, "localname": "AccountsNotesAndLoansReceivableNetCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableGrossCurrent": { "auth_ref": [ "r27", "r414" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.", "label": "Accounts Receivable, Gross, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableGrossCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesNoncurrent": { "auth_ref": [ "r23", "r402", "r417" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.", "label": "Accrued Income Taxes, Noncurrent", "terseLabel": "Accrued income taxes" } } }, "localname": "AccruedIncomeTaxesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued Liabilities and Other Liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "negatedTerseLabel": "Accrued Liabilities, Current", "totalLabel": "Accrued expenses", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accrued Liabilities, Current [Abstract]", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r42", "r191" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax": { "auth_ref": [ "r72", "r77" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax", "negatedTerseLabel": "Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossDefinedBenefitPensionAndOtherPostretirementPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": { "auth_ref": [ "r66", "r74", "r76", "r77", "r354", "r358" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.", "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax", "terseLabel": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r74", "r76", "r77" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "verboseLabel": "Accumulated other comprehensive income (loss), net of tax" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r73", "r77", "r80", "r298" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r178" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r28" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r126" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r58", "r155" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsNotesAndLoansReceivableNetCurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.", "label": "Allowance for Doubtful Accounts Receivable, Current", "negatedLabel": "Less: allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r112", "r175", "r184" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization expense", "terseLabel": "Amortization expense" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": { "auth_ref": [ "r74" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax", "terseLabel": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax" } } }, "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r145", "r399", "r416" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets and Liabilities, Lessee [Abstract]", "terseLabel": "Assets and Liabilities, Lessee [Abstract]" } } }, "localname": "AssetsAndLiabilitiesLesseeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r60" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "verboseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r339" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets, Fair Value Disclosure" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r156", "r157" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Notes receivable" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r311", "r317" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r8", "r190" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Buildings and improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/AcquisitionsTables", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r273", "r274" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/AcquisitionsTables", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "auth_ref": [ "r271", "r272" ], "lang": { "en-US": { "role": { "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic", "terseLabel": "Business Acquisition, Pro Forma Earnings Per Share, Basic" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "auth_ref": [ "r271", "r272" ], "lang": { "en-US": { "role": { "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted", "terseLabel": "Business Acquisition, Pro Forma Earnings Per Share, Diluted" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r271", "r272" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Business Acquisition, Pro Forma Information [Table Text Block]" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Business Acquisition, Share Price" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r271", "r272" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Business Acquisition, Pro Forma Net Income (Loss)" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r271", "r272" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Business Acquisition, Pro Forma Revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r282", "r283", "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Business Combination, Consideration Transferred", "verboseLabel": "Business Combination, Consideration Transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1": { "auth_ref": [ "r268", "r286" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value at acquisition-date of the assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interests issued by the acquirer, including but not limited to, instruments or interests issued or issuable in consideration for the business combination.", "label": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination", "terseLabel": "Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination" } } }, "localname": "BusinessCombinationConsiderationTransferredIncludingEquityInterestInAcquireeHeldPriorToCombination1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Contingent Consideration Arrangements [Abstract]", "terseLabel": "Business Combination, Contingent Consideration Arrangements [Abstract]" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration [Abstract]" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r111", "r291" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "verboseLabel": "Contingent consideration expense (benefit)" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow": { "auth_ref": [ "r289" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements and indemnification assets recognized in connection with a business combination, this element represents an estimate of the low-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, Low" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r281", "r284", "r288" ], "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Business Combination, Contingent Consideration, Liability Ending Balance", "periodStartLabel": "Business Combination, Contingent Consideration, Liability Beginning Balance", "terseLabel": "Business Combination, Contingent Consideration, Liability", "verboseLabel": "Business Combination, Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r281", "r285" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Business Combination, Contingent Consideration, Liability, Current" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "auth_ref": [ "r281", "r285" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Business Combination, Contingent Consideration, Liability, Noncurrent" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r292" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "verboseLabel": "ACQUISITIONS AND STRATEGIC INVESTMENTS" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred": { "auth_ref": [ "r278" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete.", "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred", "terseLabel": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Consideration Transferred" } } }, "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r255", "r276" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r275", "r276" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r276" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTerseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r276" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": { "auth_ref": [ "r269" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "terseLabel": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "auth_ref": [ "r270" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "terseLabel": "Other Nonoperating Income (Expense)" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalLeaseObligationsMember": { "auth_ref": [ "r364" ], "lang": { "en-US": { "role": { "documentation": "A borrowing recorded for a lease meeting the criteria for capitalization. A lease is defined as an agreement conveying the right to use property, plant, or equipment (land or depreciable assets) usually for a stated period of time.", "label": "Capital Lease Obligations [Member]", "terseLabel": "Finance Lease Obligation (1)" } } }, "localname": "CapitalLeaseObligationsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAcquiredFromAcquisition": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).", "label": "Cash Acquired from Acquisition", "terseLabel": "Cash Acquired from Acquisition" } } }, "localname": "CashAcquiredFromAcquisition", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r39", "r114" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r108", "r114", "r116" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period", "periodStartLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period", "totalLabel": "Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period", "verboseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r108", "r353" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgingMember": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.", "label": "Cash Flow Hedging [Member]" } } }, "localname": "CashFlowHedgingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Change in Contract with Customer, Liability [Abstract]" } } }, "localname": "ChangeInContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsTables", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommercialPaper": { "auth_ref": [ "r18", "r400", "r419" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.", "label": "Commercial Paper", "terseLabel": "Commercial Paper" } } }, "localname": "CommercialPaper", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r54", "r201", "r407", "r423" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r200", "r210" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Ending Balance (Shares)", "periodStartLabel": "Beginning Balance (Shares)", "terseLabel": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r26", "r218" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,641,342,509 shares as of September 30, 2019 and 1,632,148,030 shares as of December 31, 2018" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r83", "r85", "r295", "r301" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r97" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Comprehensive Income (Loss) Note [Text Block]" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressGross": { "auth_ref": [ "r190" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress, Gross", "terseLabel": "Capital in progress" } } }, "localname": "ConstructionInProgressGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r226", "r227", "r231" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "terseLabel": "Contract with Customer, Liability" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Contract with Customer, Liability [Abstract]", "terseLabel": "Contract with Customer, Liability [Abstract]" } } }, "localname": "ContractWithCustomerLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r232" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract with Customer, Liability, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r92" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold", "verboseLabel": "Cost of Goods and Services Sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "terseLabel": "Cumulative Effect of New Accounting Principle in Period of Adoption" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtAndCapitalLeaseObligations": { "auth_ref": [ "r405", "r425" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of all debt, including all short-term borrowings, long-term debt, and capital lease obligations.", "label": "Debt and Capital Lease Obligations", "terseLabel": "Total debt" } } }, "localname": "DebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r48" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "terseLabel": "Debt, Current", "verboseLabel": "Current debt obligations" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r217" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "BORROWINGS AND CREDIT ARRANGEMENTS" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r20", "r21", "r22", "r401", "r403", "r413" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r349" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Debt Instrument, Fair Value Disclosure" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r51", "r361" ], "lang": { "en-US": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Debt Instrument, Interest Rate During Period" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r51" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Three [Member]", "terseLabel": "Debt Instrument, Redemption, Period Three [Member]" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Debt Instrument, Redemption, Period Two [Member]" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r52", "r120", "r219", "r220", "r221", "r222", "r360", "r361", "r363", "r412" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Debt Instrument [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r215", "r362" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "terseLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": { "auth_ref": [ "r261" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.", "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible", "terseLabel": "Decrease in Unrecognized Tax Benefits is Reasonably Possible" } } }, "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetCurrent": { "auth_ref": [ "r255", "r256", "r257", "r258", "r264" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards classified as current.", "label": "Deferred Tax Assets, Net of Valuation Allowance, Current", "verboseLabel": "Prepaid income taxes" } } }, "localname": "DeferredTaxAssetsNetCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesNoncurrent": { "auth_ref": [ "r255", "r257", "r258" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.", "label": "Deferred Tax Liabilities, Net, Noncurrent", "negatedTerseLabel": "Deferred Tax Liabilities, Net, Noncurrent", "verboseLabel": "Deferred income taxes" } } }, "localname": "DeferredTaxLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": { "auth_ref": [ "r17", "r236", "r237", "r239", "r398", "r415" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.", "label": "Assets for Plan Benefits, Defined Benefit Plan", "terseLabel": "Assets for Plan Benefits, Defined Benefit Plan" } } }, "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase", "terseLabel": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanBenefitObligation": { "auth_ref": [ "r238" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Benefit Obligation", "negatedTerseLabel": "Defined Benefit Plan, Benefit Obligation" } } }, "localname": "DefinedBenefitPlanBenefitObligation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": { "auth_ref": [ "r236", "r239" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.", "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan", "terseLabel": "Defined Benefit Plan, Funded (Unfunded) Status of Plan" } } }, "localname": "DefinedBenefitPlanFundedStatusOfPlan", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r112", "r189" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r62", "r63", "r349" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative Asset" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r61", "r64", "r314", "r393" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Derivative Asset, Fair Value, Gross Asset" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r61", "r64", "r314", "r393" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Derivative Liability, Fair Value, Gross Liability", "terseLabel": "Derivative Liability, Fair Value, Gross Liability" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r312", "r315", "r323", "r330" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "auth_ref": [ "r309", "r312", "r323" ], "lang": { "en-US": { "role": { "documentation": "Information by type of hedging relationship.", "label": "Hedging Relationship [Axis]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.", "label": "Derivative Instruments in Hedges, Assets, at Fair Value", "terseLabel": "Derivative Instruments in Hedges, Assets, at Fair Value" } } }, "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.", "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value", "terseLabel": "Derivative Instruments in Hedges, Liabilities, at Fair Value" } } }, "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": { "auth_ref": [ "r316" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as an asset.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value", "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": { "auth_ref": [ "r316" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of derivative instrument not designated as hedging instrument and classified as a liability.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value", "terseLabel": "Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r62", "r63", "r349" ], "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r122", "r303", "r305", "r306", "r309", "r310", "r318", "r323", "r332", "r334", "r336" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r118", "r123", "r303", "r305", "r309", "r310", "r333" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Derivatives, Policy [Policy Text Block]" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsHedgingActivitiesAndFairValueMeasurementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted": { "auth_ref": [ "r130" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.", "label": "Description of New Accounting Pronouncements Not yet Adopted [Text Block]", "terseLabel": "Description of New Accounting Pronouncements Not yet Adopted [Text Block]" } } }, "localname": "DescriptionOfNewAccountingPronouncementsNotYetAdopted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/NewAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disaggregation of Revenue [Abstract]", "terseLabel": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/RevenueTables" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue [Table Text Block]" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfQuantitativeInformationAboutSecuritizedAssetsAndAnyOtherFinancialAssetsManagedTogetherAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Securitized or Asset-backed Financing Arrangement Assets and Other Financial Assets Managed Together [Abstract]", "terseLabel": "Disclosure of Securitized or Asset-backed Financing Arrangement Assets and Other Financial Assets Managed Together [Abstract]" } } }, "localname": "DisclosureOfQuantitativeInformationAboutSecuritizedAssetsAndAnyOtherFinancialAssetsManagedTogetherAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "EMEA [Member]" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r89", "r127", "r133", "r134", "r135", "r136", "r139", "r409", "r426" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net income (loss) per common share \u2014 basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r89", "r127", "r133", "r134", "r135", "r136", "r139", "r409", "r426" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net income (loss) per common share \u2014 assuming dilution" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r140" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Weighted Average Number Of Shares Outstanding [Text Block]" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r353" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of foreign exchange rates on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r121", "r259", "r260" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate from continuing operations" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r49" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related liabilities" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r218" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": { "auth_ref": [ "r160" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.", "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity", "terseLabel": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity" } } }, "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r40", "r146", "r159" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity method investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r158" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Measurement alternative investments (1)" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ExtinguishmentOfDebtAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount of debt extinguished.", "label": "Extinguishment of Debt, Amount", "terseLabel": "Extinguishment of Debt, Amount" } } }, "localname": "ExtinguishmentOfDebtAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r338", "r339", "r340", "r341", "r346", "r347" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r240", "r241", "r250", "r340", "r388" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r338" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurements", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Disclosures [Text Block]" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r240", "r241", "r250", "r340", "r389" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r240", "r241", "r250", "r340", "r390" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r240", "r241", "r250", "r340", "r391" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r343", "r347" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [ "r338", "r345" ], "lang": { "en-US": { "role": { "documentation": "Provides the general categories used to describe the frequency with which financial assets and liabilities (as defined) are measured at fair value (on a recurring or nonrecurring basis).", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/FairValueMeasurementsHedgingActivitiesAndFairValueMeasurementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "auth_ref": [ "r344" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "terseLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r338", "r345" ], "lang": { "en-US": { "role": { "documentation": "This item represents a description of the frequency with which certain items are measured at fair value. Items measured at fair value on a recurring basis generally include those items for which measurement inputs are readily available and which are measured at fair value at successive reporting periods.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r381", "r385" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Finance Lease, Weighted Average Discount Rate, Percent" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r183" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedTerseLabel": "Finite-Lived Intangible Assets, Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r176", "r180", "r183", "r186", "r396" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "verboseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r183", "r396" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Finite-Lived Intangible Assets, Gross" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r176", "r182" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r177" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Finite-lived Intangible Assets Acquired" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": { "auth_ref": [ "r337" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months", "terseLabel": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months" } } }, "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r350", "r351", "r352" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign Currency Transaction Gain (Loss), before Tax" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r240", "r328" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign Exchange Contract [Member]" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r312", "r322" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "terseLabel": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r164", "r165" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill Ending Balance", "periodStartLabel": "Goodwill Beginning Balance", "terseLabel": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r167" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Goodwill, Acquired During Period" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r188" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "verboseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillGross": { "auth_ref": [ "r166", "r171" ], "calculation": { "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails": { "order": 1.0, "parentTag": "bsx_IndefiniteLivedIntangibleAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Gross", "terseLabel": "Goodwill, Gross" } } }, "localname": "GoodwillGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": { "auth_ref": [ "r166", "r171" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impaired, Accumulated Impairment Loss", "negatedTerseLabel": "Goodwill, Impaired, Accumulated Impairment Loss" } } }, "localname": "GoodwillImpairedAccumulatedImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill [Member]", "terseLabel": "Goodwill [Member]" } } }, "localname": "GoodwillMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillTranslationAndPurchaseAccountingAdjustments": { "auth_ref": [ "r169", "r170", "r267" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from foreign currency translation adjustments and purchase accounting adjustments of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Translation and Purchase Accounting Adjustments", "terseLabel": "Goodwill, Translation and Purchase Accounting Adjustments" } } }, "localname": "GoodwillTranslationAndPurchaseAccountingAdjustments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "auth_ref": [ "r168" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Written off Related to Sale of Business Unit", "negatedTerseLabel": "Goodwill, Written off Related to Sale of Business Unit" } } }, "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r91" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r309", "r331" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_HedgingRelationshipDomain": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Nature or intent of a hedge.", "label": "Hedging Relationship [Domain]" } } }, "localname": "HedgingRelationshipDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r112", "r187" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.", "label": "Impairment of Intangible Assets (Excluding Goodwill)", "terseLabel": "Intangible asset impairment charges", "verboseLabel": "Impairment of Intangible Assets (Excluding Goodwill)" } } }, "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "Purchased research and development [Member]", "verboseLabel": "In Process Research and Development [Member]" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r88", "r127", "r397", "r408", "r427" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsTables", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsTables", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "verboseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r119", "r144", "r265" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r179", "r185" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]", "verboseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "auth_ref": [ "r185" ], "calculation": { "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails": { "order": 2.0, "parentTag": "bsx_IndefiniteLivedIntangibleAssetsIncludingGoodwill", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)" } } }, "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r179", "r185" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "verboseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.", "label": "Indefinite-lived Intangible Assets Acquired", "terseLabel": "Indefinite-lived Intangible Assets Acquired" } } }, "localname": "IndefinitelivedIntangibleAssetsAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r174", "r181" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other Intangible Assets, Net", "verboseLabel": "Other intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r87", "r143", "r359", "r362", "r410" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest Expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseMember": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing interest expense.", "label": "Interest Expense [Member]", "terseLabel": "Interest Expense [Member]" } } }, "localname": "InterestExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "auth_ref": [ "r337" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months.", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "terseLabel": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net" } } }, "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r240", "r327" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest Rate Contract [Member]" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r327" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Unamortized Gain on Fair Value Hedges" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r31", "r163" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Inventory, Finished Goods, Net of Reserves" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r59", "r162" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory, Net", "totalLabel": "Inventories", "verboseLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory, Net [Abstract]", "verboseLabel": "Inventories" } } }, "localname": "InventoryNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r33", "r163" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Inventory, Raw Materials, Net of Reserves" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r32", "r163" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Inventory, Work in Process, Net of Reserves" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Investments": { "auth_ref": [ "r424" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "terseLabel": "Investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments [Abstract]" } } }, "localname": "InvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_Land": { "auth_ref": [ "r7", "r41" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Weighted average remaining lease term and discount rate [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeasePracticalExpedientsPackage": { "auth_ref": [ "r366", "r367" ], "lang": { "en-US": { "role": { "documentation": "Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.", "label": "Lease, Practical Expedients, Package [true false]", "terseLabel": "Lease, Practical Expedients, Package [true false]" } } }, "localname": "LeasePracticalExpedientsPackage", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r365", "r386" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalCostsPolicyTextBlock": { "auth_ref": [ "r117", "r118", "r209" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.", "label": "Legal Costs, Policy [Policy Text Block]", "terseLabel": "Legal Costs, Policy [Policy Text Block]" } } }, "localname": "LegalCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Lessee Disclosure [Abstract]", "terseLabel": "Lessee Disclosure [Abstract]" } } }, "localname": "LesseeDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails", "http://www.bostonscientific.com/role/LeasesLeasesTables" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r373" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Lessee, Leases [Policy Text Block]" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": { "auth_ref": [ "r375" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract", "terseLabel": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract" } } }, "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r383" ], "calculation": { "http://www.bostonscientific.com/role/LeasesLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bostonscientific.com/role/LeasesLeasesDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Lessee, Operating Lease, Liability, Payments, Due" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r383" ], "calculation": { "http://www.bostonscientific.com/role/LeasesLeasesDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r383" ], "calculation": { "http://www.bostonscientific.com/role/LeasesLeasesDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Five" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r383" ], "calculation": { "http://www.bostonscientific.com/role/LeasesLeasesDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r383" ], "calculation": { "http://www.bostonscientific.com/role/LeasesLeasesDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r383" ], "calculation": { "http://www.bostonscientific.com/role/LeasesLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r383" ], "calculation": { "http://www.bostonscientific.com/role/LeasesLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r383" ], "calculation": { "http://www.bostonscientific.com/role/LeasesLeasesDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r374" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lessee, Operating Lease, Term of Contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r30", "r404", "r421" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r339" ], "calculation": { "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Financial and Nonfinancial Liabilities, Fair Value Disclosure" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r22", "r403", "r413" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Long-term Line of Credit" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityAxis": { "auth_ref": [ "r46", "r120" ], "lang": { "en-US": { "role": { "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.", "label": "Lender Name [Axis]", "terseLabel": "Lender Name [Axis]" } } }, "localname": "LineOfCreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLenderDomain": { "auth_ref": [ "r46" ], "lang": { "en-US": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.", "label": "Line of Credit Facility, Lender [Domain]", "terseLabel": "Line of Credit Facility, Lender [Domain]" } } }, "localname": "LineOfCreditFacilityLenderDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Line of Credit Facility, Remaining Borrowing Capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserveCurrent": { "auth_ref": [ "r54", "r201", "r208" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.", "label": "Estimated Litigation Liability, Current", "terseLabel": "Legal reserves, current" } } }, "localname": "LitigationReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserveNoncurrent": { "auth_ref": [ "r54", "r201" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.", "label": "Estimated Litigation Liability, Noncurrent", "terseLabel": "Legal reserves, noncurrent" } } }, "localname": "LitigationReserveNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation Settlement, Expense", "negatedLabel": "Litigation-related net charges (credits)", "terseLabel": "Litigation-related net charges (credits)" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationStatusAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by status of pending, threatened, or settled litigation.", "label": "Litigation Status [Axis]", "terseLabel": "Litigation Status [Axis]" } } }, "localname": "LitigationStatusAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationStatusDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Status of pending, threatened, or settled litigation.", "label": "Litigation Status [Domain]", "terseLabel": "Litigation Status [Domain]" } } }, "localname": "LitigationStatusDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r22", "r216", "r403", "r419" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "auth_ref": [ "r22" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt and capital lease obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt and Capital Lease Obligations", "terseLabel": "Long-term Debt and Capital Lease Obligations", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtAndCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r52" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r52", "r214" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r211", "r212" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "auth_ref": [ "r201" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of loss contingency liability.", "label": "Loss Contingency Accrual", "verboseLabel": "Accrual for legal matters that are probable and estimable" } } }, "localname": "LossContingencyAccrualAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Money Market Funds, at Carrying Value" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "verboseLabel": "Allowance for doubtful accounts" } } }, "localname": "MovementInValuationAllowancesAndReservesRollForward", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r108" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Cash provided by (used for) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r108" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Cash provided by (used for) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "verboseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r108", "r109", "r113" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "terseLabel": "Cash provided by (used for) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash provided by (used for) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetInvestmentHedgingMember": { "auth_ref": [ "r308" ], "lang": { "en-US": { "role": { "documentation": "Hedges of a net investment in a foreign operation.", "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedging [Member]" } } }, "localname": "NetInvestmentHedgingMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues \"Accounting Standards Updates\" to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Adjustments for New Accounting Pronouncement [Member]", "terseLabel": "Adjustments for New Accounting Pronouncement [Member]" } } }, "localname": "NewAccountingPronouncementMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the quantification of the effect of adopting the new accounting standard or change in accounting principle expected by the entity to have a significant effect on the entity's financial statements.", "label": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification", "terseLabel": "New Accounting Pronouncement or Change in Accounting Principle, Effect of Adoption, Quantification" } } }, "localname": "NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r126", "r128", "r129" ], "lang": { "en-US": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]", "terseLabel": "International [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r309" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r95" ], "calculation": { "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "terseLabel": "Other expense, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "verboseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 }, "http://www.bostonscientific.com/role/SegmentReportingDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "terseLabel": "Operating income (loss)", "totalLabel": "Operating income (loss)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r377", "r385" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r371" ], "calculation": { "http://www.bostonscientific.com/role/LeasesLeasesDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating Lease, Liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r371" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating Lease, Liability, Current" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r371" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating Lease, Liability, Noncurrent" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r372", "r378" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r370" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Lease, Right-of-Use Asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r380", "r385" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r302" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "verboseLabel": "BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r10", "r11", "r12", "r49" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 4.0, "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Noncurrent", "terseLabel": "Other Accrued Liabilities, Noncurrent" } } }, "localname": "OtherAccruedLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r17", "r398", "r415" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other Assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets", "verboseLabel": "Other Assets, Noncurrent" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "auth_ref": [ "r67", "r74", "r354", "r355", "r357", "r358" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "terseLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r71" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax", "negatedLabel": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments and Tax" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "auth_ref": [ "r77", "r86" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "totalLabel": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r69", "r74" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "totalLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "verboseLabel": "Net change in derivative financial instruments" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": { "auth_ref": [ "r69", "r74" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r69", "r74", "r313", "r319", "r335" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": { "auth_ref": [ "r75" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r74", "r78" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "negatedTerseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r74", "r78", "r321" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": { "auth_ref": [ "r75" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax", "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": { "auth_ref": [ "r70", "r74", "r320", "r335" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax": { "auth_ref": [ "r70", "r74", "r320", "r335" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before adjustments, of tax expense (benefit) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.", "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax", "terseLabel": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, Tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r66", "r356" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "totalLabel": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r325" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r326" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r82", "r85", "r86", "r218" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Total other comprehensive income (loss)", "totalLabel": "Total other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss) Net of Tax, Period Change [Abstract]" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodChangeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income (loss), net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "auth_ref": [ "r72", "r74" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, before reclassification adjustment, of (increase) decrease in accumulated other comprehensive income of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax", "negatedTerseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, before Reclassification Adjustment, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "auth_ref": [ "r72", "r74" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "negatedLabel": "Net change in defined benefit pensions and other items", "totalLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax": { "auth_ref": [ "r74", "r78", "r79" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized loss realized upon the write-down of available-for-sale securities.", "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax", "terseLabel": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI for Write-down of Securities, Net of Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForWritedownOfSecuritiesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax": { "auth_ref": [ "r74", "r78", "r79", "r242" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive (income) loss for net periodic benefit cost (credit) of defined benefit plan.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax", "terseLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Reclassification Adjustment from AOCI, after Tax" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r71", "r74" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax", "terseLabel": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current liabilities.", "label": "Other Current Liabilities [Member]", "terseLabel": "Other Current Liabilities [Member]" } } }, "localname": "OtherCurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other Intangible Assets [Member]" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r406" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "terseLabel": "Other Liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r49" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other Liabilities, Noncurrent", "totalLabel": "Other long-term liabilities", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Liabilities, Noncurrent [Abstract]", "verboseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Noncurrent Assets [Member]" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities [Member]" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Table Text Block]", "verboseLabel": "Other long-term liabilities [Table Text Block]" } } }, "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r96" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "verboseLabel": "Other income (expense):" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r280" ], "lang": { "en-US": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForHedgeInvestingActivities": { "auth_ref": [ "r102", "r110" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation.", "label": "Payments for Hedge, Investing Activities", "negatedTerseLabel": "Payments for settlements of hedge contracts", "terseLabel": "Payments for Hedge, Investing Activities" } } }, "localname": "PaymentsForHedgeInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r100", "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payments to Acquire Businesses, Gross" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r100" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Payments for acquisitions of businesses, net of cash acquired", "terseLabel": "Payments to Acquire Businesses, Net of Cash Acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r102" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Payments for investments and acquisitions of certain technologies" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r101" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred Stock, Par or Stated Value Per Share" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r25" ], "lang": { "en-US": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r25" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value - authorized 50,000,000 shares, none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r37", "r38" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Other Assets, Current", "verboseLabel": "Other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets [Member]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r98" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from Divestiture of Businesses", "verboseLabel": "Proceeds from divestiture of certain businesses" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r103" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuances of shares of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet": { "auth_ref": [ "r104" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with security instrument that either represents a creditor or an ownership relationship with the holder of the investment security with a maturity of beyond one year or normal operating cycle, if longer. Includes proceeds from (a) debt, (b) capital lease obligations, (c) mandatory redeemable capital securities, and (d) any combination of (a), (b), or (c).", "label": "Proceeds from Issuance of Long-term Debt and Capital Securities, Net", "terseLabel": "Proceeds from long-term borrowings, net of debt issuance costs" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLongTermLinesOfCredit": { "auth_ref": [ "r105" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Proceeds from Long-term Lines of Credit", "terseLabel": "Proceeds from borrowings on credit facilities" } } }, "localname": "ProceedsFromLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfCommercialPaper": { "auth_ref": [ "r105", "r106", "r115" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or cash outflow from issuing (borrowing) and repaying commercial paper.", "label": "Proceeds from (Repayments of) Commercial Paper", "terseLabel": "Net increase (decrease) in commercial paper" } } }, "localname": "ProceedsFromRepaymentsOfCommercialPaper", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r99" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property, plant and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromShortTermDebt": { "auth_ref": [ "r105" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from Short-term Debt", "terseLabel": "Proceeds from short-term borrowings, net of debt issuance costs" } } }, "localname": "ProceedsFromShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r81", "r84", "r107", "r145", "r151", "r295", "r296", "r297", "r300", "r301" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r41", "r190" ], "calculation": { "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r15", "r16", "r192", "r422" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment, Net [Abstract]", "verboseLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNetAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r15", "r192" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "verboseLabel": "Property, plant and equipment, net [Table Text Block]" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReceivableWithImputedInterestEffectiveYieldInterestRate": { "auth_ref": [ "r361" ], "lang": { "en-US": { "role": { "documentation": "Yield on the receivable, on which interest has been imputed, as calculated from its issuance value or purchase price. The calculated effective interest rate considers factors such as the issued face value or price paid for the receivable, the time period between payments, and the time until maturity [full receipt] of the receivable.", "label": "Receivable with Imputed Interest, Effective Yield (Interest Rate)", "verboseLabel": "Average interest rate of de-recognized receivables" } } }, "localname": "ReceivableWithImputedInterestEffectiveYieldInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r77", "r80", "r86" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTotalLabel": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]", "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Abstract]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r148", "r149" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "verboseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": { "auth_ref": [ "r147", "r149" ], "lang": { "en-US": { "role": { "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table]", "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r106" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Payments on long-term borrowings and debt extinguishment costs" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermLinesOfCredit": { "auth_ref": [ "r106" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.", "label": "Repayments of Long-term Lines of Credit", "negatedTerseLabel": "Payments on borrowings from credit facilities" } } }, "localname": "RepaymentsOfLongTermLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r106" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-term Debt", "negatedTerseLabel": "Payments on short-term borrowings" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "auth_ref": [ "r253" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r14", "r114", "r116" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Restricted Cash and Cash Equivalents in Other current assets", "verboseLabel": "Restricted cash and restricted cash equivalents included in Other current assets" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashEquivalentsNoncurrent": { "auth_ref": [ "r6", "r17", "r116", "r431" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash Equivalents, Noncurrent", "terseLabel": "Restricted cash equivalents included in Other long-term assets", "verboseLabel": "Restricted Cash Equivalents in Other long-term assets" } } }, "localname": "RestrictedCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r112", "r195", "r197", "r198" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "verboseLabel": "Restructuring charges (credits)" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r223", "r420" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r228", "r229", "r230" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales", "verboseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r125", "r235" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue from Contract with Customer [Text Block]" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r90", "r141", "r142", "r150" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/RevenueDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility [Member]" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r379", "r385" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r93" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Any scenario, that is, the particular reporting scenario is left unspecified. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario, Unspecified [Domain]", "terseLabel": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r57" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "verboseLabel": "Trade accounts receivable, net [Table Text Block]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "verboseLabel": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r77" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Changes in Other Comprehensive Income [Table Text Block]" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r137" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r273", "r274" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "verboseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r273", "r274" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r52", "r120", "r219", "r220", "r221", "r222", "r360", "r361", "r363", "r412" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-term Debt Instruments [Table Text Block]", "verboseLabel": "Schedule of Long-term Debt Instruments [Table Text Block]" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": { "auth_ref": [ "r246", "r247", "r248", "r249", "r250" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.", "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r312", "r323", "r331" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "verboseLabel": "Derivative Instruments, Gain (Loss) [Table Text Block]" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r318" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "verboseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r338" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "verboseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r172", "r173" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "auth_ref": [ "r172" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.", "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of Intangible Assets and Goodwill [Table Text Block]" } } }, "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r13", "r34", "r35", "r36" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventory Disclosure [Table Text Block]" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]", "terseLabel": "Schedule of Investments [Line Items]" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsTable": { "auth_ref": [ "r429" ], "lang": { "en-US": { "role": { "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.", "label": "Schedule of Investments [Table]", "terseLabel": "Schedule of Investments [Table]" } } }, "localname": "ScheduleOfInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.", "label": "Schedule of Net Funded Status [Table Text Block]", "terseLabel": "Schedule of Net Funded Status [Table Text Block]" } } }, "localname": "ScheduleOfNetFundedStatusTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]" } } }, "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r322", "r324" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Derivatives Not Designated as Hedging Instruments [Table Text Block]" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table]", "terseLabel": "Schedule of Short-term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-term Debt [Table Text Block]", "terseLabel": "Schedule of Short-term Debt [Table Text Block]" } } }, "localname": "ScheduleOfShortTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of Weighted Average Number of Shares [Table Text Block]" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segment [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r154" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "verboseLabel": "SEGMENT REPORTING" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting, Revenue Reconciling Item [Line Items]", "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]" } } }, "localname": "SegmentReportingRevenueReconcilingItemLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r94", "r161" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes [Member]" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock": { "auth_ref": [ "r384" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy election of practical expedient not to separate lease component from nonlease component.", "label": "Separation of Lease and Nonlease Components [Policy Text Block]", "terseLabel": "Separation of Lease and Nonlease Components [Policy Text Block]" } } }, "localname": "SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SettledLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.", "label": "Settled Litigation [Member]", "terseLabel": "Settled Litigation [Member]" } } }, "localname": "SettledLitigationMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r111" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.", "label": "Share-based Compensation", "verboseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r19", "r401", "r418" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-term Debt", "terseLabel": "Short-term Debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-term Debt [Line Items]", "terseLabel": "Short-term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r44" ], "lang": { "en-US": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtWeightedAverageInterestRate": { "auth_ref": [ "r45" ], "lang": { "en-US": { "role": { "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.", "label": "Short-term Debt, Weighted Average Interest Rate, at Point in Time", "terseLabel": "Short-term Debt, Weighted Average Interest Rate, at Point in Time" } } }, "localname": "ShortTermDebtWeightedAverageInterestRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermLeasesPolicyTextBlock": { "auth_ref": [ "r369" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy election for short-term lease to recognize lease payments on straight-line basis over lease term and variable lease payments as incurred.", "label": "Short-term Leases [Policy Text Block]", "terseLabel": "Short-term Leases [Policy Text Block]" } } }, "localname": "ShortTermLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/LeasesLeasesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r145", "r172", "r194", "r196", "r199", "r428" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]", "verboseLabel": "Statement, Business Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails", "http://www.bostonscientific.com/role/SegmentReportingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r24", "r25", "r26", "r218" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsTables", "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r56", "r218" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Statement, Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by scenario to be reported. Scenarios distinguish among different kinds of business reporting facts, as for example actual versus budgeted figures.", "label": "Scenario [Axis]", "verboseLabel": "Statement, Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "auth_ref": [ "r251", "r252" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after forfeitures, of stock or other type of equity granted of any equity-based compensation plan other than an employee stock ownership plan (ESOP).", "label": "Stock Granted, Value, Share-based Compensation, Net of Forfeitures", "terseLabel": "Impact of stock-based compensation plans, net of tax" } } }, "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r25", "r26", "r218", "r223" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Stock Issued During Period, Shares, New Issues" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r25", "r26", "r218", "r223" ], "lang": { "en-US": { "role": { "documentation": "Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.", "label": "Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures", "terseLabel": "Impact of stock-based compensation plans, net of tax (Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r293", "r294", "r299" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationMaterialSubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationMaterialSubsequentEventDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/BasisOfPresentationMaterialSubsequentEventDetails", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r387" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/BasisOfPresentationMaterialSubsequentEventDetails", "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails", "http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails", "http://www.bostonscientific.com/role/StrategicInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "auth_ref": [ "r118" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for reporting subsequent events.", "label": "Subsequent Events, Policy [Policy Text Block]", "terseLabel": "Subsequent Events, Policy [Policy Text Block]" } } }, "localname": "SubsequentEventsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationBasisOfPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "verboseLabel": "SUPPLEMENTAL BALANCE SHEET INFORMATION" } } }, "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "verboseLabel": "Supplemental Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.", "label": "Technology-Based Intangible Assets [Member]", "terseLabel": "Technology-Based Intangible Assets [Member]" } } }, "localname": "TechnologyBasedIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails", "http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TerminationLoans": { "auth_ref": [ "r395" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Definite liabilities to third parties under a termination loan agreement, whether or not guaranteed in whole or in part by the government.", "label": "Termination Loans", "terseLabel": "Termination Loans" } } }, "localname": "TerminationLoans", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/AcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized": { "auth_ref": [ "r392" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction, at the date of derecognition.", "label": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized", "verboseLabel": "Transfer of Financial Assets Accounted for as Sales, Amount Derecognized" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognized", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Transfer of Financial Assets Accounted for as Sales [Line Items]", "terseLabel": "Transfer of Financial Assets Accounted for as Sales [Line Items]" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesLineItems", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTable": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction.", "label": "Transfer of Financial Assets Accounted for as Sales [Table]", "terseLabel": "Transfer of Financial Assets Accounted for as Sales [Table]" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesTable", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock": { "auth_ref": [ "r394" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derecognized financial assets from transactions which comprise an initial transfer and an agreement entered into in contemplation of the initial transfer resulting in retention of substantially all of the exposure to the economic return throughout the term of the transaction.", "label": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]", "terseLabel": "Transfer of Financial Assets Accounted for as Sales [Table Text Block]" } } }, "localname": "TransferOfFinancialAssetsAccountedForAsSalesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialAssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Transfers and Servicing of Financial Assets [Abstract]", "terseLabel": "Transfers and Servicing of Financial Assets [Abstract]" } } }, "localname": "TransfersAndServicingOfFinancialAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax": { "auth_ref": [ "r68", "r326" ], "calculation": { "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification from accumulated other comprehensive income (AOCI) of gain (loss) from increase (decrease) in fair value of net investment hedge.", "label": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax", "terseLabel": "Gain (Loss) on Derivative Used in Net Investment Hedge, after Tax" } } }, "localname": "TranslationAdjustmentForNetInvestmentHedgeIncreaseDecreaseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r55", "r224" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r55", "r224" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r55", "r224", "r225" ], "calculation": { "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost - 247,566,270 shares as of September 30, 2019 and December 31, 2018" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails", "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r254", "r262" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "auth_ref": [ "r263" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate" } } }, "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured Debt [Member]" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesBalance": { "auth_ref": [ "r124" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "ValuationAllowancesAndReservesBalance", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "auth_ref": [ "r124" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "terseLabel": "Charges to expenses" } } }, "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDeductions": { "auth_ref": [ "r124" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction", "negatedLabel": "Utilization of allowances" } } }, "localname": "ValuationAllowancesAndReservesDeductions", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Valuation Technique, Discounted Cash Flow [Member]" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/ContingentConsiderationDetails", "http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/IncomeTaxesTables" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r136" ], "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Weighted Average Number Diluted Shares Outstanding Adjustment" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r132", "r136" ], "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted", "verboseLabel": "Assuming dilution" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "verboseLabel": "Weighted-average shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r131", "r136" ], "calculation": { "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted Average Number of Shares Outstanding, Basic", "verboseLabel": "Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2018-01-31", "presentation": [ "http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6911-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3255-108585" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3291-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3000-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3536-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3581-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3044-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3098-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e7018-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690" }, "r125": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22580-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1448-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1505-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1252-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=SL5780133-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109260490&loc=d3e1337-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109256448&loc=d3e4984-109258" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84173941&loc=d3e5074-111524" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=109979856&loc=d3e26610-111562" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=82897076&loc=d3e27161-111563" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=84241550&loc=SL75117539-209714" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=68049868&loc=d3e3927-108312" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14615-108349" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14394-108349" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14453-108349" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14472-108349" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=6396582&loc=d3e15243-108350" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=115931803&loc=d3e12053-110248" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r217": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130531-203044" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=82913815&loc=SL49130532-203044" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130539-203045" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130543-203045" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130545-203045" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=109196051&loc=SL49130549-203045" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=108792157&loc=SL49130690-203046-203046" }, "r235": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e1928-114920" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2410-114920" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2417-114920" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=108410482&loc=d3e2439-114920" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=112275985&loc=d3e4179-114921" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=109243414&loc=d3e3913-113898" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=6418191&loc=d3e15009-113911" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=SL37586934-109318" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31917-109318" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31928-109318" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31931-109318" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84176650&loc=d3e31958-109318" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84229725&loc=d3e961-128460" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=108330185&loc=d3e2207-128464" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=84161108&loc=SL65897772-128472" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5227-128473" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r292": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4590271-111686" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591551-111686" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=84234705&loc=SL4591552-111686" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(ii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)(iii)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19190-110258" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19207-110258" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=SL7498348-110258" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=99377789&loc=d3e19279-110258" }, "r348": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=109250915&loc=d3e13433-108611" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30700-110894" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32022-110900" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32157-110900" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b,c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240241&loc=d3e32211-110900" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r365": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=113997351&loc=SL77916155-209984" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888369&loc=SL77918418-209957" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918707-209980" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r386": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=d3e107207-111719" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109247956&loc=SL51823488-111719" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=68073528&loc=d3e56288-109415" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.13,16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=114873765&loc=SL114874048-224260" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1(h))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=114873790&loc=SL114874131-224263" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99384497&loc=SL65671331-158438" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "305", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=84242212&loc=d3e2352-115587" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r433": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r434": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r435": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r436": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r437": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r438": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r439": { "Article": "12", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "13", "Sentence": "Column B" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Article": "6", "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(c)", "Publisher": "SEC", "Section": "10", "Subparagraph": "(1)" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r65": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "210", "URI": "http://asc.fasb.org/topic&trid=2122208" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a-c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(dd)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e640-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e681-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=d3e689-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724391-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6812-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669619-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=114867106&loc=SL7669625-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=82887183&loc=d3e6904-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=115205541&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585" } }, "version": "2.1" } XML 68 R53.htm IDEA: XBRL DOCUMENT v3.19.3
Weighted Average Shares Outstanding (Details) - shares
shares in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Weighted Average Number of Shares Outstanding, Basic 1,393.1 1,382.8 1,390.6 1,380.0
Weighted Average Number Diluted Shares Outstanding Adjustment 19.0 21.0 19.1 19.9
Weighted Average Number of Shares Outstanding, Diluted 1,412.2 1,403.9 1,409.7 1,399.8
Stock Issued During Period, Shares, New Issues 2,000,000.0 2,000,000.0 9,000,000.0 10.0
ZIP 69 0000885725-19-000045-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000885725-19-000045-xbrl.zip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–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�(=9K#=GSHXI8BA8T" @FA$C++*?4"JDL3!$1 MP$$M25.XWBK+::,_.;7@E\&,&.:AC9L(:/SS<)(N]EJ-9Y11NV"S./[/6L/O M@REZ?S)AJ/DP?U,-C;X6@T_!Y<9"'=M9XR?ONT=&EP7M1B;X+3 MRY\K+K_WF3#GE6.XC8'XR^[V2FHMEU&HA;3X2G-?1\7LC.5[L4@2JF?#WGA/ MG2],4$8&A(S4$-%0113<%I/O/FWWKO>'-SM]O?7^,)]Y@V=#*0,E MED(C;GW]WODS0EI".;KN^^GC,)0(+ .1W&8,?%9%?_:0L)!5X-1J,O_2,A:] M$/26CY=$^6@]9MR[K3O^6"Y4Y0J'=VTXJ(TG6#'5HM'HAOO2+.H MGR'E[3KO"G1P1".<0;$PPIW&)H7)= 8R0"V7RC#I?@"$"@HSB^=&>"D*:F5: M?IX!G JHML$I*_Z3[.=;G6LN7G%YQK&ZT=*?^P7TTXQWZJRS] ;O/K:.!F;7 M[6>U;_4F-.;%A1\ 6&\?VMRQ1'-4GQ:=.M'#0/3BX,?-SR;"L7T]I^=@1<++ M^5LGGN]]3,L*9OA(XJ$OMAYX8Q%44TL/ZHU]':7R/#^H!N]G8',[*[=>7\IZ MH,\*T"S2*D;=6ACN8H#K-GH]^+?YD/I7139NS$19S\1<))3X\]KRP,F?T&Y/ M+VE^J@W&0\XC6L<."^=!G8O:KK522HXR0^#M@E)ODG&92S&OYU2&YRYE<92U MJ&NQX.MUJ%N: 5)5[EG-!6E=1&[,YG@>R*>C>0&HNZ&O![12ZU^$K5^*I'I6 M :MB9%Y0O^[S;T$&589214S'5'T(C:K/=:H^BS2C=<_)(M^N/$=8:74Q*\D_ MFN<0E29[W=38H$V$J.1BT!OZD$7OE%GH$_/4FIHH\:%&97W?,KMFUP, 1XA% MDBUJL>K*O>,5)%,6R5*U4ERORU*IG\X/ZKT^CB3 7X7Y%WJD=,!Y[J@NMVNE M_M9R;L(VMDMR!VFSG#YSK"2N$ZB+,VUQ_%IUT>=]C&:Y'[.SC+#/P[K"%D); MQSTW]GSDC:K!;)";*&&MZF@9?%WFX#[Z!C##Z3AT"QM5F96[^(5#"&?Q8A&, MLA[#O,O PC"Z*T*[EWE0KA]2;01K.L81$I)?1'HXY_N M[IP,!N67SQ3QE6)5CM>TH:3[D^Y1$WU9KM$2#DK\W,?!+;#&3 MC/,<13_CQY%75$JDB@627N]MKGEU+MW=W#B#_AIHT='VPO1L2LJL[\II>;VV*51ILX;;.D'W@B;:4N)^ M4?V<5_YXEGS/4?\\J*?)YXZ;\;1?_'*W[#$>_W+W2P7*E6/WUUG?S'$(A]S: M ,4"R;@5F&%&J:12&4VA@88RD"*LZ@U0?-LL#BCF5+C_M-695EI)HS6E66A M=?0.4B^&?X:CAWX_."^3LAB1[R _T^:J8X7IXIQ@X9-X1HC5I-['@^AI%@F\ M/KO:_?/HR'YQ-_D(YM&1O=#"(/Q>?\$L16XIHM)?XQXYZ^]1]/NS;__M'7@7 M?G<#[\Q_W["B7WK^L.[GXGORV_ A'ZR.]B$?.;6T'%X^G0SG'X2@Y?*3[[WN MY-Y=[29_Z_76T?O0U^%Q7'R<_U!?%?^H,.*1^]]K>GZ$@W][!WV+E[],NOZ/ MT>+KV8C+=V#WBOE%J]_!Y[]"]*#;MGTE&W_BJU]67[71\'NYJ&BQYTZ-#'T9 M9[MP.YQ,A@_S#2M_^P@?_TB"VIW\"81_?EPB3^1(K4Y[]=]G3ZA_5)((*NES M! 26 M6L4KYWIB@G@6,@\AB67OXWI0:CURR9^!"YY]U>S?.#7]C5HT^8?,K]G M%^OH#/\OQ]C:0W2^QI*@RP#.+?&;$E35L)02@BF+,<>:9L#]P;',&-"0"R0( M/#Q^LUY/J,&R0)<0PKF]_ANY 7@]A',E=+,):CTZ;VVJ*1"A,T+G&4,GJNJN M00 59,@*2@7%G(N,2.K49T.03)%\R]#W")VS(CLWDJW7([PDZ-S9$+M&>RN* MAY983S]O:*S2DOF>RK_T[+&#FTNSSN,WE(:TDH8,6\ @)Q@;3#,J!:?0?4", M$Y+<6'!IAH0C\4\+"F^Q2(0W$M,&16)KC88(%BT'"UYEC7*J,F(-RE(FJ852 M04()$=9DS*0(LTM3G<\'+(A8+U-YAF 1SROB>45;)WXX$B68(20U@@BM@,F%1-%ENY B M$EPE$B"Y0 (J .8 ,\XIIA)8"7&F)52&& -3)EJG?I\$">B-$)=]#G=ISN1/ M+U94NDZ_PF4XE5\?DG,!6[F[ 'O+>.6WE&.,+.0849 P0(B$5-!,8ZFQYFFF M; HH0=R^H49[)<7'5B3F_Q:C8=>W$_MK*)^%?FQ27+Y P*W5GR/*7 #*"!Q+ M'+8%9=:3NP-*0E?AI.\G\SY)ZDE>D=_1IQXG/AN4(8= ME'6'4Y\6_QIY_.QJSMX6DO#?&C4W@,9!X:@O+=AKXE4/6Y^&M)P-"_2RV@-1 MI?:DF3^,UUAQ@RBQ0@"1,BJ)@2G"EM!7&5<-J 'RAHCU7J9-J0'[D,(I^2"Z M^2-(1I!\6Y D5=]KCJU(>2HM@90"G2FI)4JIDD!:"[5ZE6W8A*V$;MRH(TIN MM['^$FH'S3]OY-E+M:Y:4G_K-#6IRE+;/5^3RC>P" M/1MT%PKQ524K^\4X5-+U)6*+Y*G(1XO'#98"MK8\\L,ZLIQ;4^;5VB+=V)3Y M+9HRX]IT7KO5M M:!_WIH]%V0G[-0UN?O.%>+V,WZO[SM\6W7=,51+Y ME] GP[B%&!7W;O1E^VW?6>WP]?7@&TJK!O_RO AFO1CK,U0UH\-&*I+OO3.= MI37HA35(?O!5T_]\^%8U6IIUZZ'3I\'G^71^N;.]03[H]/+^K\4H"/5!9WN1 M5DX9TY0)B:1'9J="I9I:D:6I@A +72O2RA7$AC,B3"8I%$@;BXS4G(",2:'! M7D5:UZ&L=O62AZ"%-4L;*DB*Z+OGCZ)F[T '5?0439<(;?\#(3[LMN:KJ9[S M*N[VP*LL9HA(FX(UCEBP+EOH@1O[O'LM2G4ZTX=I/PC3EQ6):R^#*:^$<$IG MJZ.6JF& TS/-)T\QE0ISY2%?IT"1$\03;R"/OR_4^[\]T^?5?#LK]2-FLJU#;ITI:J\SN7W#U?)/EU M5+S_DO^1>!,X^>&GNJ5^=6OAUT$7@^*N-TE^R,K&.=>[&C6*2'R5)"='W )= MI_!X@_D==NA\Q/W_:=A9-'G:($M:P1>M6[0R''BV7&[A?O(-Q3_YWL^_SOVR MU\E!5P"8.:]V+<(ZS&3IGY-LN0G=U:U&C2*VB]*ZUEWW;;?! MSFT?UMZ/BB+Y6QG[D U\$]Z=>H5L7.07F^H<-P:U9;&7^]9JVKTWR=6&\L:) M7][$(]G'W;_RW8^+$!?AXMS%:Q58+B;C@J*G]8 MZ2I3@ZZSZ]YMC$K[SR]I"\O]'KN(0JT>A%_/Q;'DW+FX/)CA>/++W>>\7XR; M*\$ X"54"8Y@\_9@\\-6M)%5C7"E%4EQ"C'.),V UE1 0ZC0!E*H #P2VD2H M.0'4^&&XS[9B#FJR,/FZ\M,&UGZK()*(4896 M(PY5EDJ2IQA_=AO_K"1H MAXDU5V(K*=$;)%1G^%+2MI5:B8 RFM1=8""6F666DP M0P;SC&B:4;/&Z7LKBJLJ8JDX1AVQK;9LDQU&HBT;,>I 9815/4&491IJ)61* M.!5(*^R4$ 6981D'@(#&(2J"4[L,V-@D-"+,$;0@46E!(D-IFBIKI$UI)J1( M+1,\ U8Q;P>MU9=X-<1$1UF;E2#8I%UY/DK0E51UW]P$?IS\@%Y*_KJVUFP( M@.I(04*829T"(:B@J8-%0CE@'-F4R P8O ]&KG4=OKA BS?IJ[P78LX[=,R2 M,QK3SABYZ$YT%\__VY0DQV&5DH0YYR05! $,*&920>#0@"B(E=.EZ%YV6,5= MC@W[TV[1]1<.!XYXW46C(A\7:5'^72*"ZOI*?H$)(Q*<$@EVTI_>!!+.1[&Z M> S9"B&U]JY2F)1#7R9/.0A10"E--$=2.6CAM"I*?FP(.4?SZ\)P9)N_Y[)[ MV[;*NFK30>"IS,KF8A\6;7Z+G3*@KT\6U$X>#< *(480S"A5%DKN_E),0,*VAPSL$ VZ7&. -0F +ILWMMNR_&JA1;C %.2&0*!H"DC&NI,(2NA MA21#>B^']_/.G(LX^[\PO6LG^ZW)((!HO[4?-[;"AA!5GIVA(L, T:Y^U=H MA@06W, T2S/)5+TKS&&0$=ILG/F!_(4AQA:@:#+QI95ZTF6S_59U 8)*75 M8"0-S: D3DO/!%* &, Y%M1H:U?5A2^C?# NN:/RNCC>6^?[55>-N^*7N\CO M+>5W&?6"5U>6.HLS\O#K";:Z*_.47T"D*=&S/F_K<8#;MN9AYS!(+HQZ-U7]^# MJ<[#NW-UD,'8 C*@T% :D:68"JI0*D$J,J 9(B*#J1"M+W<4\2+B1<2+X^*% MJ!(%K,72EQ\R3 N*!)&22B-AYK!#&T[0>=0>BJ 102.&VL18OQCK=Z!(P(#& M6+\(0&WP%$9U;94W4:T"D+/C#),6&R,H1)E$&A D-#!:$JA>7SO[V%& 45-K MIG+VM2MJ$2Z>A0M@CAZ@5L)%U"MBA\_#0@QW MZ? I8H?/0Y8V=O@\:P]FG'C+@LLN>1&N=N)Q]^,BQ$6('3YCB=Y6.!-8K2,) MS5)!2,I1"A65"/NN!1G)C,H P88<*PCMV;A5T=9DQ%;Y%(Y2#3RVLXI8TWRZ M,R-5F3I@A$ ID2PS*16"*X.X!1DETJ%0*E_?<6"?B->(-*>O!QX;?$:,:H$^ MQ&K5TSACG#)C)6746*ZM9#PSF68IA28]%D1M.6*).'4JC8C$!BEG8%#'!I]1 M?)Q6?(A*PS6*&0Q39%/F^_Q9C3'@$#(C&4).I+RJP:=H*C:7\28+T45D.R-D MBXQ^.*-S4(7K492EVDA",RTH4%J*%+/,9CP5&:+\;:-[HXIX*A4QXFC$F>9Q M!E5U)5BFN6:<"V$D32%3-@,*4(*AT9BSYCOH180Y,<(<,RHX0DR$F!)B,*\@ M!G,#H!46<$4)XE)G2&16"<8RJ2Q]RWCBB#-1DVDH*K@]X26QT^8)@:Y6HPM M)TY-QC.49A1(9[EQF7'-F14FHW*MVO*;=-IL+>)=3_7EV&CSK-E_:_@!KQ7< M(DI+WUD!91I2"5*%LPPQC7%J,P787IUVFV^T&8'@;8!@I\"$6(_]JB!D*X(( M6'E]%48$*$F\DY=(J*R@-LT@)4 #!O;2(([49S/"R,GUB8OOWM(>TZI-QW&Q M]-:EBP(!*F72G_,1C7B*4TX)9PH2:H14F4;$9'*MY?++I;<:.]YO-)([ E"; M .BR>6^K)2=0E;5B4V,!Y0I(BZ@V2G"KH)(B@X"25.Q5;;V9-IM1[6J1]?8F M?@%L8;6'H6>?NX-7BJA)6,)K4-6-I;0.FM/9)QX+)T3=S_N?ER$N BQA-9! MB;^QA-:9Q<]C6(N?I]H2K#!0!".*0:I2JX52D$F22@6.5C)B2^O7_VZEH^'B M8^@A9Y<011_!IEV^3 QI%8+F9&(F,YYB05,JD94ITI*F&J;$R@R_;0VM"#4G MKZ%%FCSL/!_?9<2HEBE$M3C[+"48P\QP;B@5' B5$99EUA LM96O3R@\I%%M MQ*G3J$0XJD1G8%+'(EI1?IQ6?LA*Q57,*JP5@$!IFEJF19I9+(@0@AILUE3< MO8IHE:*@B>"1&\1B@< KQ;;(ZJ\P9Q&L0O*T+[+*J= (4@HSIG%*&+!&,>6+ M1+]YE]RH)I[8G.71G(T8=7)U!-63#:1D,C,6 ,4H$)E 0C%.,(&I@0SOE6SP MNLZ\$9Q.8\,VZ6*[*#4O0LQKU*!:9H)WY-,L-9P!3"5@DM(4.AO(.E,H);9Y M-2@ZR]JL!37J-#L?+2B6[[K&-(ZM&$FK8P7&!81$4@, I)D2BA!E?.%E *U3 MR_A)RG>U%BRO)ZM#QC2NL^;_[4H2KY0DJ(6R' -$J*;: "6PX$@:)KD67)^X M?E=$@O9D@*-8P.NZ,&0KA(C*EZ.4L0S85&E,*!!: HXPI-I] A7%L@4%O"*. MG%RCX&\"'ZWU!%ULXD"K)AXK>)U %N#:T2,B*12$I4Z/U!0)IJ#%5"O&4Z4( M -G^%;R:BRV0%U^3N#V,&$MXO94QAY&L>7/\"1HGG$I%.7&:&$-&6,ZPELZZ MVZOQ?#,EO*+BU1X##K])#=5HP+4&-[;"!JGZ,UN$N:38L2L&E"@'%I(H1A"T MU'UEQ9N6\(J(<7I3[=+UI,MF^^WJ JTUUJ5:(VMIQB"B*&/"6 Y2)2151 FP MEE-RE!)>D=_;HR&@)F.O+T!#.*C0U%D#CHSFS--8Z:@+ ML#/C_,Y[?I%6+V=^U[27<:X7.-?=(_->J YZ[I%[N]5JNFRC;9O-1H&H#MN% M1WXG=-@2]7A1';((+5 M\EE2I+"/HE=8*4H-U1P)9;'%0'*FY>M],=$+TQJE6?M1(P3;UE\U"4OPM5./.Y^7(2X"+%G92PXVPI?@:BUV.!0I4)**#&E M5,!,4"4RIA%%E@'\]CTK15LSZUKE,CA.@Z;8Q"2"3?.'%Q)45='UBQ=R!KQ*G3]?N(*M$9F-2Q9V64'Z>5'Z12<8F AG&F MG0&-J#588R()MHA1AE&JUA*?]NI9*9KK60E$DR&R$=O."-LBJ[^"U5D5BDQ;#X4;UL,;M023Z4EHB9+SUT4D$:@>8W?C(M: MT"\V&D.I( <42R!99HV1D$'N<$:9-PKZC1AS*]SR2&TG(XR<7*& \M(5BO885VTZ MS(OULRY>%M2.#Q$#4&?09LZ:I%IR23G64$@#!81ZO8OYR_6S&@L/@/SBVRFU MAQ%C_:PWL^4$KIPY&:,6 PJ1R*@F0!LDF*%88L($%'L5R6BF[614O-ICO\$W MP;]HP+4&-[;"AJQ.XBEE7&>8$:Q]G6.N&4BQ,MA*)B7AZDW;3D;$.+FI=O%U M1B^;[;>J"Q#BFNN7( TLI98QBIVZ#C5A-!6*$>5^6'/<'*7M9.3WD_,[C/VH MGSTQC]TF8[?).+\SGU^DU$,IH)J#-+<&I3!0"FZAQ*%L42Q['15'2_;&=Y7G67HTJEFA%#D,14(*N0 M0(1KRI'A(F6H]76#(K]'?H_\OIW?915ICV0J@1",IRFE3$HI2,8L-D187R^, MG$<1GLCTD>EC+$J,AHO1<,] /H8T1L-%!&J%*^TBF6_K\3;&52PJT,I@AH!! M5E":*L&@38T!@C,",[%7:N-)2ME$72OVEHOQ;T<2TZ1*8 +6,JO=Y\B)::"= MF98YRTU3PHC 4C1?[2%"1#3'H@_FS72"6GZ*@,KIW3P#6',*A=8TTU9;P#,A MA-*O=[I&]TMK^#VJ!(=%OOUEDM_VB_GGC8!0N<8_.S(8]3IN)?T+DD[1[\\F M_F_OP+OPN[NK,_]]PTN_]!Z*=W'\DHES0 MV3;N?!#OMF=Y&_J]0?'^OHR?@PC\:VWVTKU^&2))^=+=%U"&&?P ]ZH6YL;X MXPN#?)YXY+ZT(V<^H"3O]Y-']^6P.TX<.(Z]?ZF;] :) \RDW-_\UMF]-^$# M=\7[2?Y'\L-7AT-_3OH.B9+\P;'*9)R,%HCI'G W&CXD\^GO-ZSR-W_UQ][$ MS;;C!JI^,9\.>]J[OR:385+DHX';4#_(V23#=!Q3%YU0U=K_=E\"G;NF@M1Q MXH30_.X/B7*K-?2B9#'KWJ!,;_=+5GM+WV.G?_/FAWYW:)CT'AR:N2'G_0\O ML7!DM&V,]EQEJ/8PFAV.DN'4_S\93_*!GW,RV%3FJF0S_Y7GL,3=%GCL+'@K M=_^YD?KJ\%YU % (S#2CN=)O?[_M[3@&=J1RK_F\_''S!B M5K_"Z7VS A9^HHZ<.M.2R?,22[H^[-K=TZU4J@_)E_N>AXC>Q#%Y\BWO3XLM MC[UWS[TMBD'U7=AI?[7;^V(\#G3B[B]ARRF& _>A!YZ\TQF.NOF@4R3?>Y/[ M ]?=D:GZK!/UV21?AH^]3B(@/?1)'Y)/I0@I>P]/9C+FQB%?TNUUD\%PXHEZ M^'7@[DGRP5.@]_&_YT]B+N?O1;'Z[B:[Y&/-]!IC58W<65;0X&]Q>W.Y^+ M?A%P_'U&-4.4*9EE*=6$: (HSS3CU"*=(O6>E#:Q>X0S%R=[WT[?S1U\,[MB MW<*6L].R*GUUJW$\N<\G#_G3;2V&HNAZ+/4L/!EF,T;T4-D;?/E>]+\59?_Y ML(I^^+H_[/S^;L-B"*@IQP0@P3,J,R E14)#FG&,,Y.9]Z!>@=_*-#-:$D(5 MH=*Z/;=66&E3J2E]EQ3.QGWT[#.:%KLS3(-\K\:'2>G9[9^+QTFPY,M#+ QN M$K]9!S_O9F%?S!6@ND"XF^E0M=2F7K7W"[E;."'CKG1/^M8;3L?]IZ5O@NB> MAS,[16RS%I8XV]_I^ =/I DY.D H\E^:BH69JWA=^)']SE[@5];R#]^>,RC._(%L]&1M3N7S(W M@+,VPOT]M]F#\O?Z"P;>V]1?1]5/W\<%Q_G/ZR9+Y61M_ >RW?/VW3E*Y#XUYH%N/P= MW/*5/.@VQ ][VY8G[G;;[ED_Q)^"E,-R+$X_0D*Y2_.V"^=G==),3NG0%XN]:C@'O?$\*M3Z;\XE=X; M9\D/WCS[\Y).6[?1O!8YM\ZN.>/2#D??\U%WYCSK/+U4PZ$]B]$J;#[[&.V5 MS-NVKT'<_#8VW+U:$CAD?J>+^3JD(]>+6]N"D*YM$5V45CD6@EE+B.)684ZY M2#6Q)M.6^,KS-B-KO8EGM%[ASI MWN: ]JW:CZRT'R,SQ3+ B** LM1GL9 4,@$@PP@(L?GL^^_CPDWL^7+-D^'M M"_J/N_=L5* ="KF>M-JRB%U&S\C'=FB]U/8L2IMDZP6X6Z*O[7HWOP&-ZY)W M_XJ3#AFI(OJ$5(0##(F$B%(&A4)( YQ2C#*3J;5"!$M)?H?YIQK2STZ=;MB* M',$WZ81\UCF">P7<'3_^O)YJN%>$\)P!/W><+)_VBU_N0OYO1>+CGX>3K3FN MXRJBX9<[VQOD@TXO[__J4-?3UZ!3J$&W^G@X[GEZFI/URV'$6OC ;PD@-H3B M5&K)&,FD9-P*8!&JA1$+A F6ED*C&*50"Z(QLA3+--4IMJP%8<0_+Z)U?41M ME;^Q\#*6N1D+Q3ID?U11N3XH=YXF5X_H'=[=C=V3;Y]JX<"U%X3XU\4K)KZG MR0R_G1 ?CJ<.2S;%FNX177K6L:0-!8K"ER-%\6&1HCL&:.[Q5>,QI/%=KXV: MO0#E]]+G-QI^WU&YO]AHM1CK^'K3\*6^2L>@GE/0RI?[45$DI7669 .?C[K( M@THPN(ED?7/K\6A;Z/GM+L+?67G$* MV*CGQ[XY9>RQ&I%LVD8V(@)*"RCCZC C;O[)-W\3YU]-F,;"9!NQ5%_SQ-%=]%&,WR2_^B!] M]+1\&I75B,]7@\];X9E7\(PX0C!C'!"&*<=Z)6<&%["+N^?QO664WAL:,Q2 2EIB M)D"&4ZXQ2*EA6B%)4&HXADY<9F;-F%F1D5\J=%BDR6UI''S9CO-&S90=B>_\ MO><14BX!4E -4B" +)50L(Q2:K#&4AL$<(:A%9"99B'E?'W(.YW%X8@I$5,N M%E.V0@H1"TB1R"$)5R#35E%CC8! ,\$L=UJ+M60MY_G56LH%V.M'[0K^ LVU M]G0J L-Y ,-V98/5#K49<=:*)I101C.-5<93CA7$%'"L[5HYDE*##O9 M+R J&]<;9KPA[MK[!1>.P&)6U[#N*8SG3W'B<>*[02!V$-@=3GVAD]=(X%-% M!&V AX..(5]:DS9'W&U8@QW4%0A$K7J:T5!H11%@- 56$&M3AC,C,XZ%!/42 MMPY]Y^ [QUX/O1YXK\ZUB@ _FFYR"!&V26O90)51,$>8CC"])TRC"J8M]M$C M6# &#=58:ZHTLU!" %)NLU? ]&6[JQL-?8X@'4$Z@G0$Z260)G(!T@P+:R&C M!JN4(JJ$R:0@4@D %).4O4J7OF W7\/QU!&F(TQ'F(XPO033K()IK)G1"K(L MXXRF.%46($AX1JW01B]W]=E;E[Y@F(:-!EA?(TIO*.[>Q$%S;68[5,L^]AN/ M4\W<."KRQSS#NV0X'26."-_7:I7?/=M!,?E>C(HDQ"J[ZWJ#R=!?G#C621ZG MH\?AN/"/?,@'>:AT[I\]#RKW?<_7#YM"8Z)1;_Q[,O)=%\KVZ+/'N4O&OK1Y MKQ.>ZC^=K]O>$]9?_CU1G7].>V45^X.?\^'@.Q,5:ND>?/^B]&8IO#&X2>I% ML_9^WHW;RV1<3"9]7YV^WW>;-1E/\H'G]?5Z0_LOU.$S_8>CB*(S_#IPG[FA M'?Z@4I+]RS9)A@!:2#) ,"%$6F8Y==)+*@M31 2@*2%I"LG)"Y'HZ=C!PWA< M(^0@PIQH_?\<@=<^7I%_%R8Z-YT6S(NNKLC0_=G4*R,.V5X'-Y/[WJA[^!C^ M.O H?0@^+(G =I+:0L P+0C5)3\-Y_QTY M;]VWL"%@N5V<=]<;C2?)P%>N?AB&RM7#N\.'="+N4% MU]ZZ\LBEX?VU.RVUNZ#2A2V\RWNCY%O>GRXTM\4K#M6@M@YC+SWZF$&J*QV= M_.]^YKW!-"]-O'!9>>/JF-?3 =_M/*?&XC,3!%>F%/Z\'\V?\IA_+=[?CHK\ M]_?YG1ODQ[S_/7\:NW?]Y7XTF]]^)E2^SP"3^Y%'LC^-4RLT18KJU*EK"%B% M@*)*$,4LEH*R0R8?FEIYBO7]X[QD6"Q%OKP:<6J13I%Z3TLIY![AA-1D[]O9[K32F!VYSI(;+'?KH>"_ A3\K/[HIA\2/[A>R,[*'OP6H/_?EE\ M>2_&,Z/R:N'7\I:1V^COP]'OH1=;9]2[]JB(6?$[RIRG^&CH*FG MO7&GOY*ZOR*)]M^5'P[>T/5I'ORH/X?Y.>X:]_P6S!:[<$SY4+;5>QA.!Q/O MRO@^G/:[GD *OTENWQ_SI^!,\BD =T5P4HV7=Z\D(7?/XW#DE>?$-S]*OKK[ M2S+)'Q_=VI>]ZX+"M"E%U:UVG:_!YUG5'1[$T<4SASTUD.E"TW] MU8_.R'L*_K/IP,G3?B#KH*@]SIHMEKOKZ6_X?;#^N)5;@_Z\N/5#\LG=,O/S M^5E[BA\'K\^#6YGII.?O2N[F#1Z=NMPM^H'1'DKZVID-PJNZ0[^"XV%XPS2L M]./4,^Z]6^;>H-.?=@MGV []K@6?7CG^<<\10/XROCFQ_SZ'=WP=[L0>6X?.]$WZBQ?,E-,@S8,;P=%Z-O8=]GDY@[.<-3ZP]] M"CLTNRJL3CDVMZ2/#LV>0@?'&W]'9S@:#6^'HT"VMT\W];>48_+DEWO,\)?. M>M#Z.\M!N4WQF_K:)J$;+>1/@X696>\$.B.EA=#:*IU,"BC*I$71OV;BZ 45<%V'J5V] M='![P:T^X;OGTWYFK3[)8:T^F^]@R=ZP)^:.+[NTTDBMJ@<4FV*VNBFFGED- MG[W5,$Y^@-=>NN!:^B"JNA-YK\S1![+4#!2['48I$?M3'<[_2UU/D]BJ M[(I)(2TZ,TJ @1(.ZULV%PN75E"@[N\L#)I-<;Y MG??\=L:PJN)>7LY=-VV!ME4?O_FJ?3=:)NEC[;:^&^SXLXE3*(^Q( <=% M]]CL]"TK1E-:5?!A*=92$LJLYC354",KH=6$*8&U5FL9(\^$O?CTC&)<^JK4 M9!'HLI(0\JF,JZFR0 MFP;X6V_\^])S9]DNV2SVS,R0?K^PHSOWISADKFV0CZS6/B]E*=)"&"L(IIF DL 4 MP(QD*F4( '1:,V.>_=VY(H&(:9.&16OMAP@49P 4B%7^"*XL5- (I"1%RFB. M4L:18 H1]Q4[K2)]C4 !19.]]=JO(5]L!$%TM<0=OYX=;ZS]6Z.+-'M92/3; MO1O@6\IB!JOB!PHS@:%)G924\H19QPRRK011U7:6R'["#U>I?X]*.TP MJCFUZAW1):++*KJ(*GF=$P$5T5H0G5'HX,3@3'+!-.=46;/6_KI13;\5Z.(@ M-:++E7BTM\6[.H/R?8QY;9W;^^3J^07LW]7$2<:]O)R]C#&O,>+Q'/Q',>:U ME19?DXO0!J.-\\HEA!EC0&1&R2F8PR;AF$F@K.=S+:7JPC'JRY:PDC MW5"ZO G/50P;C4AT<4@D*_<1,XH9QHT4AE",E#(4XC13$F )J-HMHJ0))+J< M2,SC(!%KU,G5.B0ZT$_54I,@_+IOPLK(A<*5L4(HI,0(K39#[,?4)'ICRE%L#!67P M>65CH3G4*T8'!-ULU#21Z@#>MF]Q*X^/(I9%+(M8ML"R6CMXY0TG*J!"7%&' M:5JF0'(..4)0&KPEJF\^Q>6UQ,K5;7)]CI61'2M>VW MR+9_.;"K0S9T"LN0"LX72!-5 2H;!-.4LU190J MD6+I<(<(J)'B^]4';[V'OK58LUKYZ7@9DRW"FMC.XYJ])'''KVW'8\']@\0U M@E41$Z"Q3*%25&!% 4F5S;!1!###L"!@OQZU!YD&K9"/C19&O*R:^Q%@(L#L M"S!(U@"&FU1HIK@A5&&M,FBRE ,AJ-2:X>/; ZT &"(CPER)>SUV]3@[-_S) MM?0+V+^K2>F->WDY>WDMZ=DQXO.\W4CM/">^9#)HI^G7!NL.H\I]9*3@P)H, M^ :-FD,!K&44I= H3:34S13 MN7C^VWS=OI,]$*BA"OQOS[6G*K)_;.UAPU1W4"=X[;0+8ZI0*H'(+#5""I5B MG4')M(59IK;DQVVLH[_0&X[6%Z39EH O;7%K#8&(.Q%WS@YWI*C,&$"4P 9@ MB0TE4FDDE7$?1N,(O/RS_=Y/W2]@;3 MO)Q]N"CI%/W^C #_[1UX%WYW3^W,?]\PJ"^]AV*<_%Q\3WX;/N2#'Y/UT2U; M$-][WOGHE^$[7QO4D!1)BWBVHE" M1@1P5(NLAI01*:AZCTKBV1=(NPC&^D MG/KNVRS#.OX _[RRQVN[N)U>W=K]V,SBO33[&HW_SW0\Z=T]K)(/NO7C!/?QXI3A^WTQ2";W1>(NG/0+[X-(NC[S<'@7 M/JX];'XJE?3&R7!0)$]%/DJ&HZ1?C,A). PLG?BGP\'14; D%./I=W?_UED.3):#'LVWS<&]\DWXODH1RU M@ZO1).\-DKO>(!]T>LZTKU%']>$2G4R2.S_];V'Z[I%%-YD^.J[XYW3H8V0> M\M'OQ21Y'/4ZQ?A#\@\WM&+C=YY,AN%T:W@[+D;? I[V!H]3_WIWSV X2?)O M>:_OOPBCSA\?^T_AQ24?3HK._:#WSZE[UF28%&[9'CR55L/[D,RW9/_S5_59 M)^JS2;X,'WN=1"!P\*/\R-P<>N-[OWR.@T9%X8#M6]&OS>6^5XSR4>?^R4OA MI-L;=_K#L$6.YVKK_5 CMP_)%\>,'3?EK\/1D[\P7]U(O\;YAHU\2K[W)O>] MDLLW#<*Q6ZOV> +J%&[@;@D.FNV'?O7^U$\9>(GB)Y;R2>'*9O)LT#.]_ MI3A+KH.AZZ= 9S )J9?PQ^13"0PSVJI(]J&8W ^[P_[P M:TDT&Y'&LU3/V71A9G.(\U*JPK558;4FFB*Q73JQH;V)[1GQ=>/^[O2G?A&? MI\=QSXW)*4L;J3'(W_*>]TX7&0UOO4+BGE.^(!+KU1,KWIM8IX-U/:N4\?[B M?)!_#;(Z/);_Z+[SXGZA5,TE_GA!RKE?CIX;O?OL^W#:=[K"V#\X$+DG?3^< MA192:1[Y9$T]\,9%G6G<7=.'1S\+QPFW0Z=GC'KCWU^D^G4+(UQ8VOJK.OEZ MM-;NN]G8X7>"T,JDPI_WHXHWOQ;O;T=%_OO[_,X-\F/>_YX_C3UGW8]F\]N# M6]Q]^3X#3)R2=O=O[_XT3JW0%"FJ4\LI E8AH*@21#&+G8'+#IG\ET")CK#\ M ?:2_90O+\?J+KYLCV=4,T29DEF64DV()H#R3#-.+=(I4M[OM<69\>+M_-W< MU??S],'-KK/L=TM+?_]_?TE7'7F?._=%=]HO?KE;./)"\]VQ&G27H@("6AHP7XG>P.NSX??ZXP;>A=M?7CU0"L7&')8KHRT%/@1N M'C/';LFFQZY!>R:Y_ M+AXG(9HSP> F\8KH=<97G';G#\OQ/WX(X_,>X-$G=/WWL>5L^.]^[^=]I%.B(MS7SS5XXKU[[_JYZKN/_7M?\X M[O^5[G]( HF[?Z6['Z5_W/\H_:]]_Z/TO];]?T[Z-]V-LL1;R5?4(:WZS3Y8,%,DS@E-+)GZENW_:^K>1-%I,&G'WH]82M99( MGA&$9$C0CFJYF2X3]_UO8?NNW6TU,/AH] MN5GN4E-VD6&AGQ8__L<\PSAXL9>K*LZO*1.JP@5PI:9B[9&UQ'\[*OXY]46Z M-S^O7B)@D<[16,5%Q!JLS-):K>4"Q%-$I3:ADD +5$JMA39E2!HM:98IC0D7 M2KF?.0=XO1C3R5$)M1"5CMDL.:)21*6K0"4'%0M4(A@3)H!R"(0I T+8U%!! MD910&$!AZU )1U2*J!11Z0)1"56H)#*M+%<5_RAV8L1110(3*1IEDF,X0!(KA]J!2=0!&5(BI= M(BK5^I-H("'3[A\B4PHXDX)K095TQI;&4LK6H5)T D54BJATB:A4ZUXBN34< M4^1@R%*48F&8YDYA@M90A>A:%]G&4"F:6TU"R)4D;/G:-XM^%;VJR>=U1;B^ MS.$85H$Z$%%*,XR9TH!:034F%DN6TE0+0\1:6=-JA'B6OS6D24B"C1"I3@M<@2 M)C*8$9@9[5""8BVY09A(8Q'GMDF3(TK^R-.1IX_&T[(Z5+6:,TX!P) K2CA5 M%A*A1(H05(+K0R3_%<1V1,D?4>+248* ZI"34JYX2@6SW%)_WFF54)DP**62 MTS:@Q!FX$7!4)B),7!Y,H HF,&0,>K\BA9(JK@1,+5$4N$^P$?H0;V,,?H@H M$5'B_%&"U&(3+$BMQ4P2)FGJ- D"L\PX($'NJE2 YE B2OZ6A2F<233"3[U. M,1CW?)O;T2@?E%UW7QV-\);=J]Z2M5G%VD(#P3"%2$!L@;0IPPP9PU-DK51X MX2&\'?_Q<;'(]34.S8AC:$+C:L +M-=:;>"JA/ZE H3@54JI,FK4%(-KH3H@ $0'B(@&" K8 "*0P!S(EUE?:,(2E'!"48LN0 M)192VQ: :*,C8<7J8+C)&.B($!$A3H<0J$(("B'FAG I>>;L"VHMD\AHD@'@ ME8G&$2*R(LP4 1A8 %*"I,8RTYI:A93[GP< H#!CF21M 8!KOLL.?7TZPR2.&:IW\.I]K1-,&.D9<3SB.=O MB>>D"F@QW*$XXCZ,55(.I3*I@%8QX4MM"+J6&7-"/&^C ^NX^;81T".@1T"/ M@/XBH+,JO RP2E1Q$)FJ)5.,]=$:Y89BSGB69L O8T.RS<,6HB '@$] GH$ M]$V +FH1I3C-+))&$ 0H(TPQ *31P%))-41KI7 ; /2VH"^\@2SB;\3?B+\1 M?]\4?SFH OR(Q$I8K7G&4LJPEC0%5&#N4%D1;-?ZT>V#OU<0X[<*Z=%!$O$\ MXGG$\[?%!?*$>'X&'N^&2T-$0(^ M'@$] OJ+@$Y(K1X/ BF5&FE+**&II)DVT@(%J2"J"M]K :"WT>/]=DDX$<\C MGD<\CWB^"<]9%8XM42H%P4)::*E.D=:*<2HI@4:Y']?ZY#: YZW1IJ&(Z'LE M9=K6^"2\P9'"<)3[C?_HMJ48]7N#XD=?T2V_[?5[DU[Q4ADW?(2$C7,*=K\ M21OW,NYEW,NXEW$OXU[&O8Q[&?L"A'"EEH%I)(9,C1%0%JF4H4U0@9(G:Z=*)\([\X@/(@T>IX1\2[B M7<2[AO"N5N$N32$26')I+:6$9M(8FPJC) R3?%:B/N)\.[JHF!?Q+N+=87@G8%4_AU*!G#E+)6:^8KQ" MF/A:.LQBJP'(&L:[J(S%7*P#YFG2\@ M85D&M>64<2V$3J'4#!FFM))K#*RGX]Z@&(_-\.&V-PBK6*VNJ2_NG,&?8FS8 MQ;3CN::XYDOE?@BK6*B,8:@-,QH022%6PABHF%*4P"S+TK6SLE9R?QN=-Y'[ M(_>WD_MQ=5*N*5-IJH %**649()1J@E6!*=:2W$>LK^-KHS5P@^-F@N1_2/[ M'\[^M,;^*I7"($%21:F!6&2<@=1J0[7U38/>E/TCKT9>C;RZS*N\.D?-B-/) MAL:D ME38%JIW"4-_B:Y*-1[DAQ2VV9G;E[N03N>BW;1A>M%;! M:S:!49BF)G,V > I@5Q@@%+ 888-XQ+-8>%V_,?'Q>K7%[\?S^??IC+^'H39 M6J7ADL,1(]X\BS>\4D-@JA#'G!E B,%06F*-QQL$,+":P#;AS;6Y&B+>1+RY M"+R1H%:63C($N&*,2<&LX)!D*,56,:NQ@:W"F[-P;L (.!%P(N L 0Z&%> X M94:#C&#LXZ 9R(RQ."@XSK;*=-4*N$G B>@0T>%\T.'BN!_)*A@JPP)A@H$! M*.-8X=2PP/U,(^5PXE7<'^,H+BQ!*N+%5>(%$57>%.(4&YTRB7#& ;1&$*2H$M5831+/RN,4(RS,#CH$7D;G;%?1Q)K$=+>LK M?@7MPX^V#"?L$BY(+>258J ,%JEFCE=*96,8VB!DHI B?5:NDNMF,QNK<)C M@,N1FX^WLL?X%83&1L"-@+LKX-:"C"6QE"MF80HTA5@KS#DA@ @F#33FQ M$+"8KP6(:[ M_F62NY'./V_DV>6Z_CQ]<+=TEB;7[PV*]_].Z>CC3A MMQ_$+]-1TAM\*\:30,/NY^1A."B>DH=\]'LQ2?)!-_GJI<7 ?Y_<30?=<9*/ MBJ33S\?CWEVOZ";?>Y-[=U]0.A*8#.^2R7V1W#D>2;YY)DGNYXI+$"[K)--1V^^=T.'&_S%[]Z/:E&'](OMP7[H[Z(%?>GX^3^3(>@E#A M\H^]B5O;CEL1DX_OP[0[_@?'_3TWQGJUN;W7>+Y 0[?6>:/+S/?B) MTT$^[?;\6CE(<_)[7/X4.#;W']_F_7S0*9+Q?5&\8N0WGA[\D$?=\#@_D>3O M'SY_2/Y=J5_#*LTG-0TE(I-'-X1.SV_;)W>GDT-60 M#E-!E":,()A2DUJ-+$H!X1D2-"-ZK=KMWSRU_RU0G/7$K28F'XW\]@2 O\[8 MWQ4YA-B:&$K]G[^1?OYU_V_>W#:2WP^_%91W\ZN9*EGI M^YA]LE5]3IS,V!/;FZW]*P61D,4,17()TA[GU3_= $B (G61H 112"43BR2. M[O[>Q^<[^7TEA9Y8]#128(YQB"5PECE#H;32*\;"OY30%!G:@NAY!3FP&S0& M\8F('IL-FI('%I)'=%SR2-Y D8>>0X,M@HX" :6BQELK@9)(*[R5W[U%\@0* M;H4JCDH6>TN>Y[;F.^-2S%>"H.D&7#A5*X;!S,USP*[6A7 M1NH9[9B[G*R;4\^30$?9_$XI?\.^?Q]\C$0G188=_B51@V#AYX6NR(MC_K0( M#\F^C 9!C:Q=CA;]B_TY-C!$DB;#43Y8!MU-SD$GW(^W%_,_7.9SH,P.TBI M'6X\IY']YH4.7F3C<398+--Q#8%Z.%ZN_ M]GXO_?GGIE38?X<75VF,8DR_!H;+2TX-OXGZ*JZQ"+)&&@E$EHV^!KY=+@)9 M)?/I]W0$HO+PQWR]L%OVH;&9Y7@3&25?6<:#D M43!Y@N<^7S2%2HQ^Q!1!OGK!8?QU_"K:39/%=![W/I\.1L7I%*&!\ML=!WF> M_#TK7R:+7\5[W9!4L]7[5,HTJO^[EGLYFJ23\.QQ?(G*9JL_6PNV70&,YHG^ MU:M/.E&?3/)Y.@LR7R!Z]F!5XM?/>S?)%_-EVZJBE\KQ"E4P^-IU3U9>>V4" M?XV,'P^X(JI9D!>CZW R\^\- EL+B8?232G82W4;Z3$;UBR1I+- V.G@:JU. MXV_+AT\OJCM4F8]P7?;'K*3YBL,;K!7H_2)+@F:.&CG&[;Z7DJR2 8&HLO2Z M"('>LJ[M9=5+*"3 Z@WS2D26LK0I#@H)E1?V3R&Q2L^G4%V5#&I(C%(<539( MZ3IUT?"*VN5+D%FEBHV?%X^X"-LY#!*@*RJB%-3!.!N,9H7%$/>_H*-E\.+3 M/"N#X.$DQ]-!*;&_!2\G6:2_!\$X#<(PRLCPT/"S:!S>W-)9V/)P]W!Y(.C9 M2GX'5S?Y'OR7XK;?8O1]$@AD_]VX*4(!/4!G!@4PS()M$I1(5/_I^/O_%>NO M%,:@T#O+BO0"E:2!-/.K%?]M,D;!X7EM8\0M&=!D%1O$PZ^;ZV MZZ_#CG11%00'O/0LENDZ=/ Y//Q3H>/#)V^=-DI0B[!5EE@H.-(:U_FX=0^6"W4$Y)7J6-=CF-_!A_ MDH9VN*7R$7%[WVSEWJO'BSN^N^,ZA&__[HY;HKVN M@K#^[HE!I:J3*6ZR ^![KT*$6^G[\+*5>OR8NG?\V"-J,+87]X2[6_[\!6Q^ MS#0D1:JA4M3;KL"S5=6],#J.NUCJZL_9X&HR^N]E$W)VM_5M331NBCX&&5OMYG]Q>SEWU?A"17V+/V2)3_ '^]!FYQ/OY6T>RNTZO5H M.!QGKU,"U-% %9W W63:Q2WL)LD^*$/-49VA1@IS("WQ/)@$AC#+ 8D3OQCR MQ$/J[X6\+7SW'@IG_.:O[.'Y]9Z\]R5O6T>6BYI3'YS_Q^BV:B>?:[1S^QN1 M?$P7MVCW^ZVFI]F-%TUP]S=?<-(8$"VXYMA KQAV7F@+J$264 *$5 !LB-/5 M"<8#W!1Y-\2I+<7I/S[;(TC4AN KZAN:HN_=>[^6?6_1G<)ONZCQ7_9HNNCI ML0UZI+5Z=UZZ0(I*,\B5 HI02Y$5EAFM(=#N4'K,YXO_*?R+@MSB7RL+N3*0 M;U?;+Y!N[X_WM:JHGX":?IM/_[=,L_XCYK:FE\EO9?9R'Z[M0(3CV-UYF]4[ MC]B<%T,1;[M^\K<)YJ/WVB$0.PN[O3G[Z;0G(*NP>;BM0,D+V-$.QUE6_;[? M#W1&^U-H(Q8C&N!$_?3UH\]7;C<>T[/ \\5K+BXSTK9'^.R[U =SGMMY%HCT MP9P^F-,=>L2R#^8\;S#G:;1\'^PYG6#/R5!,'PSJ@T%/' S:!*VJ8:>:1?,M MEDHGV\O95;9,1,EPU2$_6(6$8WO32LT_/*SF']U3\U_O@@R;L$&%N*I.?_@I MRV(?MRNCMD[Q;I8)>_>7=C;OOM7?+A_D8RF\O.!OV^T'C?[F-(F!F_'NMKI& ME[[*DWPYN#K;UIW&]4-E^>)G\YC%UME M$7RO+(*J>>VL;.RY+IS2>3:;9WG1>1$_OF')TPC!%75-^& 4 M6YJ+KO\ODZ)7M^R0O]'\N\%"03($#B^MB1I*=*7GPY^CZT)*C I6"Z^9%C9) M$.*Q@;J &9U^+SE_@]N3=!AD3)Y53;YQ MO=L-RRMTC?+M.@YN%.R$78A$48CFZ\"[E]KB=Y*(E$+^. <46S'K4L\B-]Y]]OP81?G*8Y-DDXKT$TR4+WLDF%/H*AKT"';\-BOTL MAD3FB_"FT37*2[RMP?3Z.IL7OL0L#597"5.2#BJ<]A*3*ZPD."YI95$$YVPX MBI;0%BD3>%X;ZFC%NK/5W?-S[6E(_=U8[?GAES4X+?&_SIBBZ, M\90H'7+,&1/($:V-H0@""8TUFACI*:+*D#?-L,;&1(3;4JN[A$<]8R/&._1X M.OC]S8[P!S%""JJT45)1J*#B-(@E2H@ 0 #!WM;#EC53D@/E"(.$(L\4EQ0) M8"C%B&#N[@PAW_L<^"98_(- X/_V)@B]["A!E\V:Q?-TQD#,2!GF!4920>L]]W@72ZG)T*2S* Q_B<&O M#[40.IY)!LZ%V)[QW16]_'),LHH"9-U+9QG@&BJD*+640J]%D$[26XK"Y\%, M.Y@"VC+, -TQZJ$C!-"Z819=N$(4A/U8SJ/QD@^NLN%RG*V-KXBQ][:P>+:\ MN5&>5+FDF+#*XC"U&Z)V+WWZJ7J%#Y>;9GE^IVJ5Q@D)O!?0:,J=$$Q2H* 0 M@!!'N&JH5B:D1H(H%Y,0@" MG07(<0P!9E"*.U7KO<]YG&K=9JL7A$76$M 8 MI/&[D,;N^(H\Z65W?'4'/MF>=WS*A\G=,&GWU]8_*5[2D>N$=KEH/\3! M&:5R"&YH]L<@J.AZ=D*1*]L%*?.8O3O&WCSQ\,N70B=';-EZE^?+ G_;WMH4 MT%/$JZ*(7UI4L+8 ^#-0P7.<>0'D_CK/NN?XX+]?C]ZFDTFLOS'3 MY2QXR[>TB#TQ%FTWA,!]<)!/6F[=G6;OS?*C(I3XK("O/;%TF%A6$:(D!H=6 MM")>(:T\6((^%WA<6[TK_Y$&?3+_GB" 0!(SAGN! 3 /DJA/_H7>_1-UN_Z!G3IY/=9WZV;=70!_^=C'.T^?G%KS35W-,J7B4.& M<#WOFS*OB)&064&A5HHBA2RFGCL(J$,WLT>_3"=?/F?SZY@[N@@D MN:.>H9Y'S"D3.RS=O[V?:!C8RYAAIQ"VQQ-%@($C,+", "$P\5I%]N:0!H@:6WP''H0Z%QV#D VVQ]$#S.$<,^1Y & MOZ8'!CQ.G?M?#).7)PEI1];8G^$!W-B1-3Y72N(891M=,(UE;1HKZI'U @!G M-562:^0\Z=-L)L%4JWX7BVPUTW[=,=UFG/7EUDK],P0.[G,EQS&<6$6NPU M]HI2Y;%0"OO@+5+DE#5^*Z!\?$_Q3A[SR5,T2H(VOLJ@'X0NT\T2C+P]A"8)UDP /*!9%213 A M0(1$2%MYO-PC:C<[0OOL2,]>W6 O5J=%#,*"<"@1,X8&)THP@9V4QEJ)%*OG MU;:??.S9ZY6RUVE8(/=SF:BY#&$K"0P\A0&FVA%%,>58.T ETXX]6_+Q%A[< M/_F(SS&GIY=\W'P&F6U"LKTM/FDU28'Z!&7GHRE]@K(_^&,D*/=Q:D_YX%]M MND/".D%)F>+8&<6MQPA31@QT2&@EK5/&P*/TPZ[3':A/4/89CYYC'\"QN$Y0 M0FPT-)AK!#$Q6&"K0.!8S;URFFIZU 1E"QS;)RA?"[N^SH6?6H+RPV Q+0&! M$.Z3E"\]O%3[@;NFK/?'^$*.L<0.2E\YY:S14! M"$KGB%;*6^F/X:15%!8)K-V$"FD50J2SAEW/8IUG,0@:W9*((PXHP3@.Y53V/O7H>.PUSY &LUFB9Y(@RZ8(>XPI3Y)U$3&*! MN(?"*VO=TVIY3<@:/1,0FPHX,IS)C1%S$L)L#3 82TLDOI( ME;F!)"-%]G"9?7:C9]9[F+71+FF%<41()I@$5 NBK!0.(L(,%H%UP7'J?-MA MUCX3^5IXM3L+?R;W&X*:98'&E@J@C(CUP@*(P*Z$(>@)APC#+?WZ%$7#=S+T MEO/][KU_>.'PKEC8Z\.VI7WJ]J4'V?K^TE,Y0_1*S_#D$TJPT6 *K#3$ \"= MPM09(H3&E.O@R6H%M#MB@REMUXGE?3*IYZ^.\%>CP]1YA1A'%F)!J4?!JE5& M.X)Q8#0!K3I>AVG/7Z^4OT[#!GD FS5:3*FT0!.@+7"&8LRDQX'QH+,\_#>X MD,_58GH+$Q[28MKCV]Z3KV%]HK;3"^\3M?W1'R51R[J^_*X:VB>7^T&-WE'M M!*!.:4MB0!DZ29AV%",M$0%"/G; Q*-"Q:Q/U/;)GYY9[V'61MNH,@!9&SXB MP7;FVBB-"90. X8%Q^0H8TC;8M8^4?M:>+4["W\FUQLUAI!*QH,GCJC#3E!E MG::62\H@-\BZP(+/EZB]A:$/2]3NBH.]JD1M96R+/E7[TD-L39]9=&2A_4$> MQ)0=6657;><7:R)+4NM;*X$1 BN$!7 :$T8Q:S[/(9AHY4=*$&T\ !J205QBD+A%',&8PRF&]CSV:GGL M-*R1![ :Q@UP8.R\T5@KZRF63AJ,@&6>$\J=!,^2N;V3$0]ILMW%BGWNMF' MRCYWV^F%][G;_NB/XKGVY]ZG@RKC@,G:.+"60(2==IY1YKRTA&B@,*-::XP> M6SWY*/4O^]QMGP_JF?4>9A5UH06AD!,H-80<4PJX@,80( 20'(2/CE3JW ZS M]KG;U\*KW5GX,SG?@27KOGBD"'!.2V((-8%Y(7186T58],3Q%F3CTSG?MS#T M(;G;X[G?+\3+?A]8[;K$8\5]I^V+C[,UCA.\TE;-DSM(_$H/\N2S2X34&5Q! M(<#6PZ!Q<5&1; SWDB*M, Y&]%$JDE2:,H(% Y#((CWB&!M\%$@GWHFZYGL-$R2!_"::"+_>RB@8EXJ3952@BB' ML896,0D,?P:LIOLY\1!/DO>)W'OR.;A/Y'9[X7TBMS_Z8R1R<7_N?6ZHM! H MK!.YBF/CA>K!X[R.LQB=R#F;5/Y+X67NW.PI_) Z>T M9EENA7,.*<&)HEX9*;QBF"!KA-+ *< I<0R M9KT11\GB]CSVZGGL-.R1![!:HQ&7>>5PT&^2.$>)Y#)".ED!O*?:. :?WH6\ MEQ$/R^%B?H(3;S>?0<+OBU^,)H%K%C^]+3YI,=U#^CQOMQ?>YWG[HS]&GI?T MY]ZGCBHCHM&P*PD!DD/#C"44!'O=>8^PDT 2*!@])M@R:3G/VS9P3I\]ZMFU M$^S::-GE7AD+K<0T,"=V*KC7@FDM,.= 4K"5-FHQTWLPN_:9WM?"J]U9^#.Y MZ;S1LBLA(\II@Q2TU!"N,0/,0 V(Q1!;]VR9WML8^K!,+W_!+;M/Y(O_+1SX M-*SQ_[)A$@\G>9?GRW0RR!([R@>!,Q:%4$DG\>O+;#X/O_.C2?A%>+G$3/-% MGS[NU]>O[YG$/P(()&_W=:E/X!A/(J'UPYWZN]'\RQ%5QE#OA#24.Z6YA YX MI;$70EMVM_YNR/J5W*?H0TFC+EO^QY^<3Y6=6\[.R2$0&]HA:*A14F#DJB8' M"J[T/>-/VN#G>[WN)^%GU//SB?+S2:^OS^K>XDG^G(XF29![/AW-D_].Q\LL M^?=L^*5/]?8+[Q?>D84?UQ]%N.OK[ZIA>W(Y(X%@79(IN=: * Z8H XA(8AS MS%*"@]7+P)8#>VB*=_7E1NCZ6SIK+]%+^LQ1S[&GQK$$U"BO4DK@N8.2>4JM MU013HQ5@3#,E6>M%U$?GV#CIO>?8D^38U[GP3J4MVR@0+=*+6?)+EN99\N$B MW#PM1-0/L ^B].OKU_=,OMU_I_/1=/E*T_T/-P:G\V$V7ZT$SOY(\NEX-$S^ M!(K_>;DVH61KF] ;+37U0 H$J")>"AL<.R<)5D8"WCH@T^I+D\Y&BW1<*(9: M+[17M=NJ97@/'7360.R9]>4SJX1TS:Q4< B-E!IY3HDURE%@ #? (RNYI,=R MX'IF[9FUD\91)WVSEXW=6_SY+2L>=S$=#\,MHFQX&X5#X.V+1>^O]POO%]XO MO%_X+H,#!X-C.%U>C+.#+,];=[-Z6KSTR6V;':KAS\?8L'M)Z:Z-VVM_6K+G M=VS0 PQ\7GOCL3F6"PZ$(YA:+Z4QPFOAE(HC@N 6]D;3P%>3X2UV^FX_O06[ M79Y1V6IK[-Z4\9QLT2=P>IG9R\RGE9F-""8U7F/(.(<<4N2D(%9BYB1@1BB_ M/71F;YDI_HNT(#/)F0"XEYF]S.P7W@RL_.LB#42[_KSX;^-]QJ-)]O:JE!(0 M@7_Y2X,B_W>9+T:7WW<41]?O(!_[TG*W:(I-$S^MUO"XN[WY:_+Y*DN*=2;I M1=CAP*E9GDRFBV0T&8R7PRQ(E[KP.OQK.5GDR3P;Q_[L9#$-/RL+:9)Y^*00 M4%%^Y$$,Q%/\'7XU M6/V]8UV?1]?A?=]GWY*/T^MT\I=DFRHVXV/?1L/%U4]$E.154?F#PVF!?-_< M302;&[Q]_H\^\3=_?61A0GC'O]SSDK?+SKV(\LU?W>5E%K1&H)\5T# \*Q"X MSI)O@;*&TUDDA'V)U*M/.E&?3/)Y.AL-$D'0OG<*KW,U&EP% O[G^GI8!"4<_&"WT:+J_8.$^R_U-_*-RV6$==PZYTVY6?QS4]QJ:-! M)4 3E110+? OB4[S4;&%OP4"B? 3<0OVEJ_![$JB$(@W"5L[FI1V6/CK_%Z] M4QID[Y?7X=:#[;^+RTJ3Y:9NVJ[0>+A$:"V1F"!R8XG%?Z_FJ[O,TB_9VXMY MEO[^-KT,+_E3.OZ6?L^C7+Z:5^M[F*Q=O6/ZF!=,KN;1:OY3;KW0%*F(Y\LI M EXAH&B<%,D\EH*R?1;_N=!H@8I,M-DG#1R+=,NBV#C%<,A1BXZ"&%W[&)_# MZ7S*QEEAF+\E1H2W4MHHJ2A44''*$**$" $$.PM+#V%<(MLJ!:/OAR]>;;.UXCS=$S,?LZW3\ M=10Q38*X'2V2X":.QJ/%]QMVT%._Z\XM?/J7*%76XV5L=?FG+)@74=F5]CP& M9QOHGX\77!&/9N^K5YJW>IE*_>Y]N\*"NDZ#G1W^+UK3^[]9&<3X\QU1# 0X MJN$@##36"44$-A0B+;5G049HZ*WC#O.M*$9XOP^7)8&OZ/O7](_1]?):3^?S MZ;= _R:-]OSB^SUU6ILWV2C\6+/2C0<5>U[7CNQXES4J5/!YXI&L/K?3N+T/ MBJ/(NVO_SW<-X$LN1N-QPX38FRKG:R$R*(7(Y4J(_!"7LY8I/Y8&6II\&4^# M39GDWR?#X!\L"G4TF%X'\V$P"I]?I)/?*PLXK&@9S>% #6O#,1KOL=.NO-LT M"(+O63I/PID%VS7233#J"^,P7U[\;U *T0 ;!%?+S_=?[^2K8 M8>LUSN;3KZ/@528QZ! W(5I6P:1MKFB6SL*+AU]^F:?7YX5O6^Q,)735EWF6 M16B#];4;^[;M%81;S\;?RPVHE_8U"Q["(C^K7.3B74K,JO *ZZ^C01U>=S ? M702NC;<(%^^Y&;M42@&G959/VW^7+[+@EI_O+U3")@=/HG G)M-UA&"Z7.2+ M($;CYBR#MS,O7*?;*3CMG@;8_^*NJ(Z;4997:5WLXIT8:T]^F:9!>/4[%*[X M,$EJW'2ZBMPL9T'(%Q)V/,TCTP8.C5R<%U@M,4@8-<9E\+WCES%$\"4(V"]1 MT$5J M:97 ^,7]4).K#8S7J-5&?*AVYQ%EJ7>;&.1\UZ26UDR,6F$5:J&P/>-J1V4D M-Q+#<8^QSJ')8'H&X>><#LZYWJQA97.RA78=JNF H%IU^E![B] M#V'OQD@?QY#T#A*O#:$:" D@#O\61A#JJ=J":EBSZ-J5O"4??M),O=NL[@CY MKY(KD0MF9>S\*)Z/6<[GT8F+E=_-+,4!VUIF=F**XSI<_#UN[]YW>UR>9_^W M/G]NJ[$KINN6>BJ$V8:..V[0#-(:NS*<\VT1EK8;:R-4L(Q;\%>AL$G3.TV3C]'O[?//VV*>4>UE_5N,_% MHC7QB(XK'BO/9+EZ]_"*Q2:\'89=* S99!PMHG78(?+E*%]4SLVQJ:1&RK<0 M.F2AM]IQJG3P%B&'N638;,]G/91*/G^;_B-+YP<2Q>;-/V;#[+J( ?X6 M-F4Z#,]X*7IT\6U:1C,K DEN$,C-\%1AQU5>;K@VB=?FR>5\>EWX1,,JN'K# M63[(7=*??T[4X)_!H1GMEX!>K?6'<"YOX^$GU>DG\?AK??]C:>X?E_99[=AQ M$1P[3Y'%FH;_ 1H8SJ5%068R0]T1:/\J.#['I_[XE!=#__%E]^> >/4+XX%B MP7=QP?Z)BM(%J_V2) TN7_HU'8V+&H"P87\[_W2>#*?C<=RQR&T7\476I7/I M(OGEG?[P,8FU(L$\C"4M83=C@B')TF!1#^)'L_$R7IRDLUFP@XM;7Z?S+^$W M\8KARHB=+8-%/"B-XSC?)+S0>?+WK'BI*L%1N*:S-*B_8(=-KV/4;S&JDBI9 MF06*QY9^S>;IEWBR8?F!I)>E)7M]/5I$!L@?\-SHG%7^,MKT'.@G56-7#>8.ZY^5FQ@594Z3R=YI80&$9N\HJ/+(G]^ M\?W&$@_(?7W8FQI7OG_M1+%K&JB(AWF.,/E/-S@/("H$ZQ62X9XX(!21PF@+ +6>!K+SB6DO-U/'( MJC=E[R"M^VR\PT-MCW^]CI6VG96!SLJRVVC>6-M]%[4E6Y1U',A5=S(5K"-G M@NO@SAG!@<6 ,H.IX,C*P%C 8<.VD(1NGQYH"T^EI.7[DW][2O"[Q@B2APX1 MQ.>8;[/&K)Q[>#!KK&R">V1N&Z+S[D.N U_.:*B@518IQYR70DH:#]DH S$S M_JD/^5YYVM(QDZXYFL+Z M5E47%K67U[/QJ.Y!2H-O&BE_'=>HJR\;+8I1X]W,%1Z@T?VM'3U)3,3,USY7 MM+[R5=%4\0+IJ@0CN*3W-RT]GHZ+3B97=S(U0E+A;%=U(//@'W\I7^. "&*Y MKQN)S;H*-H_S>\L@4=4U=SV-9D86!5ZB)I-E^-'';#:=+XI!/F$'$PC>_FH(S_;!--'RY7ZE--AK>4ZJ\+DN#D*X;4, M+MJG8L.1'D\'O[_9T7^$"(=$!-.!24"ATXI!2!UDR$7L6 C?UD,&-%+2"T$D MTI)JSQ50D +$D,+:2D+O;)>Z]SGP31).(YV%C0CF1?;HKJ?&KS?:A<%L_;F=_#VKS Z^+)GA;OO$K9#O[Y. *,7?VX"/JR$ M9%"@A=2_;CH1_0&__ -6@T6PCVYK#W\0WNL1D*>?859'I\Z^2[3]S.=[1-HO M&\'67F1RTX'LB: G@E<(@?WFKU4G=3+.JN!]$8[<(SK<9E&&XZA<,0K#YGS1D&%)$%*"\D 8TW_OB*_7RKJ^UC&PG/KX)ZF.$ZWP^N+Z,O>"*YWAU)>+8MT@PM(8V@L MH,@Z :6UB/H"R(8;SX7$FAB&1)M<4%KVJX_;Y "T(\%T#P?<"G)X$VCJ9:'S MW0]=])"0WB$10=0%C, M'*0'H0:VL'GWK?[.D/F>^(,%(Q;EQM,(8%R$T^\^6[6K%G 586]D9];E=#%E44)\K-(=V6!9(!U>CB)K)O]NM0'Z&9\G5 M]%M<_EEYF"MVC+TW=_!@4K:LCZZO \\&IA]_KQ)%1%&$G];]\_%6MU!4?I66!=-'I:NZPA5YS2EA3'%I* 9,,\.< M@M9ZZSW1MDVZ:M#3Y6B>+\)IK'9^OQ!?6?^039J 5A%0 M,IN]'4Z_30HB+"@A7T:+N )^:A)@I+\#4OH/.WM9]YI*#I3 6B,A*%9 :^&P M#9]$<];:5BW7QMDOKD;S8;7B)SOW7*VP%:/>!K[B%%(%E [>( URUD&% MG-2M!DIOE\Y;+_0TNJDB:/UD,EU. M!A7JU0T(M,;A'>1#Z,\_'V*PW&J]AB,IBNYVVZ@1H.68?-B8A//Z0LQ[R,AN MM8B<)Q_OQ]/?47>JUW6G#5HL*T\_+6*#R9?1('DW^9KEB\-J3\MU1G%T/2WJ M@FM(_;Y\=#LJ4OG4Y22"29+],1@O"_S>=;MO8(#!7(*&.9DTIQ0A64FF#C MB1/>>$H1WO"0W6IS?-@;=S%:#%,_G7_,8N/(H 1 ,.5"CC; D.XRQJY;:I8; MQ1KUQF(VCF7CF[>K OKLCUG$L-JJJ!]4*%R!JBZ7!P27V[Z.QC%@-WX>_/4YT5Y#G, MAI$Z3?%6#(+AIM"*[Y:D_.@SY9]V*<%0*G$#:Q ML;]L](C &7)_ ^3;+&22C=_%(/\H]DB__$^.1=!-++J$-J4GZNX9QGMC-_F MP6RKWG;]P+B"6]\G,ZN!<68 M,MXD[U_6;ZTF!:S8#FE[ -G>ASS&T [";:L+>87:L0)C>Z6"#]>6/^28*8Z@ M@5I3C8-3X*T5BE('G0&*;E!&V+/Q;Q4E/X/$NZ^!'3%T1$S/4N8U>'J7I+LO M1]C]85#TQA+Z85!/,@P*'38,"A^2S7_9;E3$1AI-THL2 *U AE'B_.LZP(@ :C.?LR7<3TY':7Z$W4M>F\O.Y;.OJ:K=#6 M[GGZ67(QC0-;+BMLJ=7+K-"E&KVK:Z2'$B?I//$Q5U!F76/+[2#LV$4YUR// ME_,*\RE8*/%=QS'9&M[I6W'_PIHIUKD,SYQDWU8+FR=?YK%9I?A\M8Z(-%%\ M'6&N9HL5KM0R/R_5W;NH3D?%W-#LK&CSO;DS31RR\@W6./45'E8XO=4TDC7N M4 T6LKY1>?%%%FZ8;62.A\ML!2T5WV^].3'H4-J:JR=6=M^N XS 7I-H$81U MAWN.KF?I8-$L.JF@TN(&!_)MN%>W3+5I (95-ROBD361SK,5.E?QBC'V?A,W M;..^P3 -KU&N/[^YZ#VU6E4W2"X%O(CUW%V$*GY0A^L]8.+K<57K3?TM[NDJ M['@#P;P"AO]PN7FSNYI7O![-:2-9I_N[5R] 6UUI90CN7KI]=7?+_+COFPU]3.NSYA_N;NM1ZC<>A9^B2C MW?3JVR1WR=4?@IU7Q>2"/1AC0K/%.CA?*/COHVP\O*5U:$U(^!D(J6M--3OH MKD/=B8_8F^>21CT1[22BK0'MK[FYT=ST2IHNRP_!X9RE\WWZ'/=9_JU[N1\) MM;5%?SY&*]==V[#7:EN+%]Y?9D)9C1WI%>72*0$ ,Y0;+U!PCCB#6"!/F3(W M?;$;#ML]TXCWVET= M?S?8[D-M!,=$3^3@%89B)RT6=,9WM.GLS]V=M3U.P,0X>59DL*Y2(D) Y@FF MPH;_@UY)S -S>J9EX%@"VV;%YU>T)\.*KR8$HK=T:&/FTH$\W.K>=(*Y<:,$ MT0FLL"1*>D5%8'7B!>70(V" MCF!&=U8#G[+W_XK9FM;UHX +QX'7& ,6V)E(RXT@S#@/E&50M,[6SZ^TX1D% MVX6FI\36I^8 _[U(Z408_JK!U4YM<&_O#'FUY- S1X*82$%P @< ME#93#&/$' $;;5>K;53E+OY:;:*-];_'*G5^*%;*JVH%.HMU4U+E3<:C*VF!$OFL".&:F6%PX0I"!WR1G&[ M-=-N@\-N\&ISPMU17<_]A]FA<_(D:>E-VH>'$D=;_/$OO;?:RX!2!N!:!C " MH#4" ( 1A4 K8& 0"!@YB"7@L$49T)Z?>LA 2[#=3/NZ9< .-.56C(\;6,R= MZ)WI0NO(IVPRFLZ3"#V3][ OI>56-'CGY<9,BHUIUE$>#G9[9_,W;Z#=.H4T MU=I+;R!EB@B$)&-$!.FHG =R*W@WG7Q9B;%[S)X[YYJ71%'01&OSR_DYVP4^ MV5;[=\?0G]H8!GT/F=0 IA I3X"RD&E$-=.:0H&$Y$)Z[I50CR23IF9\"Z0J,C:([.RL< MZ-@5?)G-2]F[:4,?A;,:^)?.Q\B0Y= *0)G%RFBK-$&> ^ZMW\Z>W,I9I?R% M\8N[F2M"\*VV(UZC5E@H'ZI-:)'5\#%9;30ISVH-YI+,PNL/1K-T7'641U9L MJMG]GQ6I93[* [4<6SN+NC(-8D,!5YZS"'7!O)0 2P,86T:B.")/)9TQ M69KU++T^D3HB)!D/QBRB#CM!E76:6BXI@]P@Z\!V_<+3L?0MYW482^\J-^PN M2[.NLC2L^S^0M20(?Z>=9Y2Y EI/ X59<*QU,.Z.R=*R9^GUB31& B!%@'-: M$D.H(>$7,-A,5A&&I9-X*]'S="Q]RWD=PM)Q*L!+8NE#H!&/RM*HKHE1'!LO M/-=02ZJQ5$P$]8!L4-U("KK5TM4B2^.667J7O'\I+(UKNXE;X9Q#2O!@>'ME MI/"*88*L$4ISN]4X_&0L?=MY'<;2]"5I:=SA**; M3LM"0&20\.,#8X-],)Y M'_2V!)) P>@Q;6_R:*Z^#^ITE]!O$^KTF'Q-&O-?("/*:8,4M$%5^K%EG9Q?T0P MR.4HOXI4^.$R$I$J(HZ;5&$%6_6R\+-!!Y\LXT+'BQQ*: M4R!0FMW'G.,- K':8FC"EF)F64$ (&)1P[QIQ/1_3-/MB80==2AV"X5#!4&Y'T5*/XD[DL0M.9[&'?RXCH%*! MKC],IN&5RDDEU=RP=/)[4HPB*IY?S"0H!H5.(US^>?*YF$]0WSD+BQE4@/C_ MNYQ4[S\>E2#VHVP]#2$\-1\-1^&VX;,?\FQOJBW_W*P?_1!?+E'S\/9?LL,& M$B87V7CZ[<>>H@N*GB0?!HMI1#9%Z*RNB[HQ3S66IH>_KK.RFB8M!ULMBID2 M);DG/WPN_RKJAWXLYA<>?W*@!*0QNTUA'6P^("FE'$!-0:QC15A+QH*E]]@B M*OSI*M!_WL"2N=^H*_>@V()2*=?Z/'!'8..P@>YK^,]VD>/F]R]%I0?*N"C& MI-U1?O7#NK8L64&0_;;^36D/_;@2(LT*Z".Z!A+4 6&.*)/.:LX5IL@[B9C$ M G$?73_[',''BB.#<8S;=@_(.=PQ[+U]]^" N=(K<116_WQ)PCN)!]8N <+8 M>:.Q5M;3F%4NR"=GB_)+-HGG:<),QWB45;9Y?U+I8]+.*B.4%)I M@29 6^ ,Q9A)C[U"T%D>_FO$LQ!.#$C0MLD&/U% XN! !#TL$'%,NL&-.B-L M)8'62@PPU2X6H%*.M0-4,NW8LP6R4/MT@W<,<>\@W:#]W^6'. EHY5V=)4T+ MNFR5^['PQS:_&.7!@XGVT74Z7,_9+=RSV7*>+^/TMF!UK]H9XK_#YX.K-'AU MY9#;'09_,:4LSQ9Y/)%R2-UJY-LD-@U/AM5\^"H>T7RA\S@G,5]>7Z?-B,7- M5V[ZMN&'^65%Y^$HRC%SJPL;#QMF^6 ^NBA]ZW5^L+FBL_!-'#E:Y SCG+@B M@%+ \JUN4X[ "RY-?A4GTUVE7\,SQM.BB'^2):NY],- UO7E>36!+]XI/'LC M6QF'\DTJV_8LO,R7K/!-"T>Z<(O",Z_"MIT5/OTXR_/X"M7$V=(BKASZZ*S/ MII,;N]W8J1O[L6-KSS;.-RZP&$<<8P&E<_XUN(S#\??*5ROZ7(;5'+\X%#DL M?WUUM$6*=QP-QVX*Z8.CB=%+^YS*JQY.L!Y&F>3P>C<@9Y_&'#DI:"V\LAB,<9ZF9\G_S[]EGV-9'.1#=)EGFW.0=[9 M.K,ME7835:3VU1?QL(?S]-NDZH2+3\G2^?J20A+%M=*? $AFY]?G#UDK6N$@$]9CN&<5QX6KYEGZX-N>[;Q)R5[%1,?+<@IE MM>Q\]WZ>[Z]!GIN6.\!0N\*%>CX:?LF2%;)@OTU5K*]N@*1KL;'20%$I5HWG MTYLAYG5A3E1^=TJ+HT;[J.Q;)EL(VM5V57H19&LAQ!JJ(A+#308J)FN5RG^Z M(9-1V<(N2D.U.6/W6Q#]38MT8WSRCF>LS-"5<11D9S1G&G=D6!Q,,BR)5%6=#WSYE^>:AE[I[=S/Z M>1=EZK_>F,"^/:+]SL%Q;QZ\C-9PBY*ZN:DY6?YJOKK++'CF;R^"3?+[V_0R MO.1/Z?A;1 8,O[R:5^N[ZZ6WWS%]S LF5_,HR/Z4!Y&J*5)46\\I EXAH*@2 M1#&/I:!L+T.XR(D&$C-1'#=R>O^:;F['S5.\<Q-#H:T$Q,78PG5=E M%'',>N&4#[+Y(@W_WRWGTUD6'E=<6&2C"VN_\,_KR847Z>3WXKK_2..[E;JG MC"9$RV9Z/0H.;- +5: H"-5XN^9#B_+FZOT*3SJ:33O>+8C1/"C]O)*T3EI4QNXZY+(M(QL$6BY&(]7B%=0CI>S(H ,2G\WSU=MG7*D4=CW>^G"T& MW\\K7RW&D]Z&VT^_3,*BR]C'^K&5 YLU7V!ED!15$'\4A#$L:]5;+&P(ASC< MN?RS(NJT]V%6^Q%O?!VN_7Y00G4Y29=AG[,R%!CC.\6_BCE=970A'1>%2_E5 MEAU0FE'6RZP=C")J$05]M(##Z4VF*Q-UL ST-QE\+VLYDN8 Y1]_NB% -Q%[ M;ZF[N^DNK'CKPZ4O+#,2*@\\L9@0:SRL=XX M&._I+-HO\V7V<"5VZVS>/EW\P&3Z+Z,-P#^("CA_ I8 MO2"/Q^/JVW][ ]X4?^<1S[_Z>P=AQ)!/GKS/OB4?I]?I%ACF=3K_,IJ4KY8/%)-5(>A,570^6B+$IG>?;3ZA_-72D@!M^LH8+7Z)B0O+D=2;A\ M!J(/&FF_]17;[[([ON*MW[&#K]\\A^"WE,=T+XCIR4R,WYQ&[==&QJZ*N%L0 M7]DS;-:M6W/$4=VJ\%H[-/6]&X"_K^OX'SNO?;U-^ C#"1XA,HZY,845?*M? M]S0O89LF^"OGR&/,P>@(J970V,],:ZMBER16N[QR6KM/K#VSI=2+O==#BKW8 M>UZQUY79.,\[]#U&B9LAI2=BREOW]'EWX\][+/]>\KAK&_9:[=--"\%0U*4& M6"(=D>-8;/EG$0Q,*J8Y=UI0Y\A6J<%C8H>E=K)9K1WN*OX\65^^N9\O LBNU[5;]MO^(D]SNF"ZT S2@3>&P5;F/ M'UJY#\^?9-KU-F\W1BVW WS"O7FU2/,JP='NUY$+<";O_XCF]P?MCJE4>N[ MQ0.M<5\X\])KA1CPE'*M@HPP !$*F<1*TJUAKL\1G@FG]F3F X+;K2/[RX?. M&@*GKN]?+&ORVK3GL6C1:.0(!E0*(K'Q#AFCH8),RZT1'$\=&-F'+?=7W."\ MS;#I7OJYDQ&.$^#DTU>XC8&$!$B"*?%*,!3<=261I\(YJQ5 T("M<.=S..Q/ MJ7"A;--?[Q5NKW ?Q9JX@64GL9:6""X0X)0)K@DGU&!BI/7!:]Y"E7IJ5_FI M%:Y\E0JW\'G_M>C"6'W>BI38Z*1YM9V)@2A+$*(6N\!BRW?BDO_W)X$@_$NB MB][L6-\?^]),T>36$OAM;-]?SI-5/]?E2B.'NP26+!M0(W.OFO^2=^'34J:* M%33$]31?%)UJD_!6D\DR7/TQBXC5$1D@Z/+K!(*W_UDVV U+\*+PD]&D9-4" M]6E2W.ABMM&@4\1;97V,MQKCI4.*2X$="):?<:)4 ^$T MLJ%://HY<-]6MD>SZ:30C@4P]3C(<B8ST^.=) FE^=E0AW$:'E M:[# CV<1:2\19!?)3V$+PN0^1N?-2XXH#DW6) _Q;>(_^?J.WY64,&AO\=9WZCZF4U?QQW<_=J;AZ$GEB5F;JW;9I7Z7Z6JM4,24(9[0Q M7$A3)32U0"*MJ*)0$\D]=T@@01'9KD&+)*8F-_T/M3#I?!Z]X_].Q\M;$/?; M* 'A3U(BUE>0=DWW]:+JE8JJ1CV] L10ZAQ%#%-$J7">.8F=\H0!1;=R@/N* M*O%?I.\E/$Q4/:L_WTHJ[%&AOQ6\9I%7:C%[5F*HEIB BSAX(KL7#.ODZG0J M.4 :V1NDI=1*,&P9=4 HH:C1CE!GB+%ZJRYV,VKZ?,8+IFT:+YTU0T[ VCAY M;FK,&Z"*6<%$4*48QM%^0AC!.9:6,2BI/0(WM:-?&3V)XK1N1BN.H$(WU67[ M6C*B*;^-0Q7:T9.M;G<76%[ -(_!&>_9$,I\M83W%( NDY Q4[,DE[!=H>NB]= M#;CMV(?[A55CMK-WREK#/-4J#LQ!FC*%D>.>,Q[DU9:PNK>F2=U1TW0TDX+Q M5B-S]Q%%-R-TO8SK95POXU8RCM0)46D/:,=4$:K-#Z(7*N+Y=Z'D*JN\>_=3"$*-/@ZMLN!QG'RZK3MN\&"WYRS2= MY('=_&J&9MT%>&=MM)<,6PR9T]!1H(#DR%DKF?6>$6";4XPDQM)Y@H$$FBH& MA<3$:L14D R8&'AWYXC3A$#,O,1%LD(:Z0BBAE*DD='\+7A4:?6++J3NJZ1/ MIDI:/E: R+Y&NJ^1/MT:Z?V,H:%)YV0Z)5NZ%+_LQ4G7Q8GD:W$""+)6& &,$#0BBPDN*)'8 M"H<=-UN5RX\6)RV5+)^UG!KIG#CIJ >]OVD2 1X*R(B(21.#LHO+Y7@=>COA MZL8?[F ] 5%=7\&(\)8;PQF@7AEM(7<\5ELP3/%VL?!Z1_UT;JO]W&;'8RMV MWF9MXS9='G*.;9'N+;[\JW$_3Y;Y<,U\+IC/QCJO/8V5^D!;:A35$A+GN;*L M;>9KJ;)8O$KF>S7^?,=J!KK8V?54Q00OMG5QGRH#0>L W<."\"=P4!1'_&8 MHDF"C"4""*K0;1Y!D>=4DV&1ZJQ%XOML0F@4IPIH *3EA%N\!59QB-1L+:0"VC0G3TUJ]B5:QWR) MSU=9!0(:I$ RRI,TF8<_ [U^2^?#%>IQ>G<0Z09\Z VHXEU O/>7.?6%3?<5 M-D%V;V43HB=3V72Z#WM-346OKFKK\]4\RY)?PQ=7>>(F$0!D ZSPE8LKH!4I/-D<6*%W) M)SYBOXZQ.SK[,II,8OREFN[RW,5^IQ A?TT!< A!'0&G1A'&E7$&48JQ4%@2 M9!$5WEFJ]=:(THC!5L3IUJ45>=F/G,V_9GDU9FMGSA"U4<;T).!-W8QL]_G M$ZA<[H"\ZJ9(0FPMDC"05&#"/$. $H>T,%("'CXF'!EAVA))HA61Q'H\N5[J M]";4:S.A2 UB91ST4 &D&>=4&:X\YPPC2(&7B-.MTJO]Y57GBE$[2="],.M- MJ-=H0K$&KAXTCC"-H0Z?>HP5Y!0KQ*$7PFNXA:NWKTCB+T@DO; >,=C5Y-N; MO[[/%LG@*IU_R?(X)3W[8Q9'#Y]R<]B=?"=J-"?$/;$06\$YH8YQ*2Q "@<6 M!-(BL]4<=C??F6*/AY^G9IHOPN>NW.@W.U&M_BNB6AT.\W8*$/BO*?-TLEPE MZXD26E&K$?&62D 14PIA(( !R C-$=M"PA!H45?]HQ6N@FTBDO9LU;/5_FR%&T@_ M@@!BB0[J U-NB9(8,&>@I091!;:0?EI45BVQ53\&:3OFTV%O[&^+T7CT?V7O MQ/2R;KXX>/<4G+W*(REU Q U^FFI1=AA91QQB@K$I :4.Z-8\/!(T)F/ M8V.;#9?%\VX"=+?JO+7)N >??O?Q"5YS-+B7 K=+@09LGU!*4(TXU5Y2;9EB M!"$D"!1.,D ?JI1C L Y#,^0$#!PO$4/4<"5-C#]S M"03T1/*6C8&6Q$"K$Q9/7PP\:W?U,>H&W&1X6*O 4=!V7DB)2 NCRSI9*H(; MU6O$">L 9$29X.9P*AF-$*?:$T8)H5OCR?9O .@'6PC/U,Y?7&%#_O MP1=;)*ZNS53NX=->*B6]N('+SPL6X$>341Y,R^3+=#J\I6BZ=7[K*'#"JP+^ M>(@K3TD-E28QQHP!R8FQX7.LM67A?R"@VA/'_4V'9>VFK"CLYTA@[[/%A\N5 M/W^TZ*$DH(?Y>(VU7+VD>JV2BM4(:BA(JB"B/!,04JJ%1LX0IXU7ACF,MX*. M^TFJ=O"(.'O%DNK4P@5_G\Y_?SN:O)W-IX,L?ZV((%3 FA41IY!()I2GX5NF MD)*8>(>P-=C0K2CGFA7C5KZ;_%9NY-,8#0CT0 4O0\N?/ LQT #5D4P9**CA MA%%DI=2Q[MI+)X!@3&X-Z=N/A5H:SP?:U&;=UTLO?73SQ_1;$LXR?!G.N>^. M>"23HII)F0C6I7!*(0 H148+RRW3VE-/B-_ND5HS:3B!7U<'\#1JCJ!6+.>F6]E9MP W/+$0.^Q%CAB;D&I-(*,08R!<@#Z%R^O3;PTF@, M(8JJSR.4H99:1D7'A! 7+"#].W)O=WB MI:5HPAE\)>+EB!6Y=:5IU^IQCUI\^]M\.@M$\/TLF8W3R2)))\,D^^=R-+L. M='N63+)%"S6YJX?\%A\1X0E7#[BS&A=98Z S@$DFJ;!8<2:UY< *9PSGS6I< M:XA%R$K-%*><$^7"OZ'1L1C7>$SZ:MR^&K>OQNVK<[JOEQDO6V8T<,H$]UXBYTE$8H=":.BE]D9B*@C&1C]0 M9K03F).MPBIV3F21,%&U[-YD$,Q3/5:*U2#XETSEB-":48Y MELY2#[3 1A@JF8Q3MC3?FEFWWDPU&;YK;.7/\VE^O**=& H_B=*Z5Y!(.WWV MX0U48&"P%$01* FU!"O#9=@:I@QPF#MV*/NTEDGJ*U-?5&6JJW,UE\MY./_E M/"O4UV4XWO#O@ZM53ZV 330F1@KHK40<8*QCJZ82BE$* 89&&B3$6J==Y'_\ MM-YHO]KFP)F^VN3C*C5\AD]\]G&GN+2K:O#D6%$VQTQ"C)B&CEHJ*<5$,*X MY-!@PIW4]F!6;*F.] RA5B?G=(X53\VI,^DL9KR2T20)5M27^>']AD^:&7U* M=FR,IX386R"0DMP'E@14 ,Z=ETI*"8BC6V$4,YWDBWDYJ:+HI2HV^LAJD3[E MU(K.ZL97I0)/E?5HC1\"N=,>$Z.9QI09(K5$2DL )+="JZV!RX]CO9;48*M# ME3O+>J_&B^SMTYU2,_XTZ%K=5X\O1 O^$NRFGY)T,%A>+\?I(AN&8Y_-PWD69?.]Z;J+,P.[ MU)SI 4-66*V]M-0AH"FAF'H.C-$>FJW1&:K>:MO8Z?#O<5: VT^&ZGH:=K.< M6W\K(Q\Q\@KH4XY+[ZQ6?57*\U0Y%==E,AP(XHER"!E($7$:<8N(M\PC:(G: M:MT_(J>VHVW1F:2MYDBZRJF]3_HL/;C/97WM*!4_2G-NEVL =^S! Z1=HW8) M4PX=\&!;A5?!T7)$"25DN,]S[RSEHAI^S;]R*M M%VGWB;1&/1E$% D"2016!P@I8Q QG,%M"6(;]63/5*DM55.QL4K%VD=0"PX MQCROG2_U]"_1]$62[(]9-LFSY%N:)ZL7V].-^O-=; @;H*,0<6,%U\AH1A4' MB@L6(0> L)A8M(4'TGSA-SOA$_XKPB<<#I>]G9];]?K>8+\]E5AX=K*XRO;? MZ,75:#[<^^KDG\MTOLCFR?1R_U=HMNH^^N*SX](81'7JB3%E'98,QEH,+H0 M5A!B&*: :.D>26.B-1K;+H1JB\:2$R$OT57R0G4H"'CMI<3<0&@ITU!!#2T' MD@J.( ?X\2+L'ZV0%]J!OWHT^MJM56\,ZMR!4<.T#*LF!'HE*$5<\.!J$A:X M$W),@'L+WSR'7KPJ\=%:TRPH^NX.T*V.V2VOZ ]?VX;M@.&]%T 86HP MF"^SXIY5K8+ MC.LXUNN$/(I88&N6,\)CZ9CPG'BJE-#&.<\\!AP)3^36>&EW/1M/OV?9QW(W M&T'!8^MP)O$I@![U1?PGP$"(-QC( >2@U!"A\"T5$7S/"XMIX"-%3!L,U([R M8KA'#7M)3O3'[")02(\-=I/Y2,U\6F.@N"5,:DZ%Y=H!(B4T$%+#$55-0*(J MC57MZK&U%1*GW5;:*>;KJGX[/=YC=1^II-01KKS03E$G@\K34CJID-0:>;T7 M[[749H9:!3[I'.^=FI=FBO*M+X$D(D7DHV$V;Z.9^\4RF:B9C%CB-;348!9[ MHJ"DC@JH/"+(2PBWK$N]S$>3+,_-]/IB-"EVL=Y=T]S'Y_=B:L-V9#)U5 M>*])K[U4SB*@KJBEW!#,$2)$:.J958IBR(0!F!!#X ZLYQ8YJZ7.'=QF5J/[ MZNRE.W0?%N&+(^,>G)S)21I5\,Y(9RTVED%!*0F&)A,T\*^C0&/+MX*5Q89O MER\>6^-1^)0@!]VS3SO%QUW5H:^/D0EI,+(1D@+)?;!K)4:"0Z=9M&RI$D9M M*=]',W(["I:VJF!?'B.?FJ/9K=;^IR@;?8(._@Z(GQU+?8 \8G6COB8882* M-,'< !PHB:R"*'@%@#HIM]SLI[UKPV62,:78Q4 M0J)TL'D,H%XZ!8FPW''"#%'!W3E$UK0%TQ:$XZN0-3WPQ_/T*Q;V?#*>1E;. MYM>WUV3MU;I8W/W]=#(H^>11C8M2.R$$4\!Z0YUW$G"'+66(*JLX8(W&11Y; M\KV!%!) $4+24NZY%X0C;IP5?>-BW[C8-R[VC8M]XV+?N-@W+CYK,+:GI+YQ M\4'4]&XRF%YGR2+]HV];/,EV(X;K+ 2WP1='Q#OK&!4F9A.EE%A# 2R': M4 MJ_+$2QKY'$FD=C*.U_; X4D7LW5*HG0I#MC+DL[+$HH;P0"%$& .B-@&@IU$ M4GLA".,<(,? @;*DI?9%W!?&OB2?^B$P"B=?M,=8$P%0<<^DI]IYBKR2C"-( M'9) 2,;L%@+@5H/P$RALU.I L<[JY1-0OZ?/.J)NE0*&8X,T\)P!RK017%OM M .4:*2GD@:S34N()MCDLNOMJZ*5[RT=JW#BYTC<.:CZT@E&OB1:(>ZHDE,1$ MO$M#E''2@:UDUAYUYT^AY%@/J'.J7NDKYE-4=UYAPJ2Q2& !.56&:4( 1UY0 M":,>W<*B:9M/6]*HH/?X7I+']Q0M(B^6.TFC+Y)8*:!AD#@:<::EH0P@#9$) M.A2KK=#M+07D3Z IX1E";5JUG9UYV3N,KX %6=V,933D)/"@\9Y32)F$7"#% ME6?.&LZV%.0^+-@6:MNK8,!7XW9VJ[2ZG]#XPHJQN:QK. $)3CH&6(0'J3C:E,-"> M:BTYH=8)Z3E6AD)FPW^9W,I#/TJ@M35P5O0#9Y^D[^1?;\S&>VP+0DMM)W_] M_]*"7G/DD-="(<$DI@HBZ;UPGB#+4/C$X%@;GZXNW*OUXYV D0XAH7"CYT,"@(ED$&LOX_PY M*92RAAE&*#/$^9)IPGYG0[5X]'/@@2TC6^>U*4G>?_CLDI^3__#+!D71%5,XIMGZ3B);'!)CLK;OLU MNQH-QN&&\8]!$&GI:))DJU'?Y\F>\]JNIO/%YVQ^7;+ ;\$G'7R_N]5)J(CP M3"P/M PM44)32UP@3>B\][!!]D0PHKG!'#A*#;4:$RRY#=0+/?':W*3;\AV2 M;Z/%55AEV*F@6\+&%;U>T\L$HO4HPGG8W3QLQ3Q+OF23L/OC\?=D,EV$G1Y$ MN3Y,@K*+\P\OTG%Q&/E5EBW.@A8JKHO?I/-Y.OF2Q''(0$N%>X24V?AZT7_;MYJW/P@?I(OF6%>\:Z""?3H+\ M_KX^P7!A]D>MW[;X;2QG?'&T^5\7 M\9YA6>$):1*V*JPY;&7QT[A'>5YL[O3RQJ-+>D[C1?,L7XZ+38JKN@X;$C>X M_.F]S9$K(7"3^[>KX.\1B<>(BB4Q?+NQ@.*_5_/576;IE^SM1:"(W]^FE^$E M?TK'W]+O>51F5_-J?8^3X^EC7C"YFD?1\*?<^L# 2%%M/:<(>(5 A%,ABGDL M!67[++YHF(P''W-9X0CJ(K1T(;SK<(// HL'7LZ7 M%WE0%.$:3:=&F&Z3.=1 5I< =9I>% M1(_"Y#(*JAO"IY *490,!L'HCC,7HH@*8B(;%7V_Q9NL%&WX9D//5K,:*KFX M6_SOK2.S65KF8*.%&!ZF)L/@\!3/-=/KV7022?P!JI-!::U%6&+BJ)1242.M MAB!B=]) D@W522W64 K-H464"Z&%!X8)CZWQ%- MD\\7*K$0X>'H!LNX?>%, MXYJ*K8FH\?.S0@^5V[N>$%QNWV"]CN+G\8NP46^WOXQ2.P\G,-ZZ\JQ4W 61 M_C'(9JN3CNJ@MFC*E]Q6:Q^6ZP44-M5-;1#I)+9')I4"#]1PX #I&\10NL:, M")1AV9PS:YE'A'I#-"6:214,>:J\MI"%@]G"72A=B \K0BWH)=I7'RZC+(QN MZ^Z0W__D\\7_?(PJ5/TQRHN_?@WKOU[^_^R]:7/C.)8N_%<8V;=G,B.<;A(@ M0* J;D6 6W7V5"Z==G6]=;]TT!)MLTL65:243L^O?\\!N&FQ+=N4+=N\=IFXN0J"8H?[W7;7<"%M%Z0R]T -.43XR@/G0 M'3^P2A3-0..78.J?6Q?)56V95C*X-.8BJHF6=XV+L9CA=SL\HK:\+^YY8QCG?DLDB-0H3'S1+KBZT!F]\ M0?0:1_,EB_'0.M9O /].2_#^=+SB8@:&389.8>-FNW*IIV?PH9/\PN0C.GT6U;D4W.F0<7SR1B)U_RLNMGZT6FI?H*' M]^+V6Q2T8%OC/>#I,3#9?-&QL^T(*\(B%ZY$.�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ilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 439 447 1 false 118 0 false 10 false false R1.htm 0002000 - Document - Cover Document Sheet http://www.bostonscientific.com/role/CoverDocument Cover Document Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 2 false false R3.htm 1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLoss Condensed Consolidated Statements of Comprehensive Income (Loss) Statements 3 false false R4.htm 1003000 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 4 false false R5.htm 1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.bostonscientific.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfStockholdersEquityCondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 1005001 - Statement - Condensed Consolidated Statements of Cash Flows Condensed Consolidated Statement of Cash Flows (Supplemental Disclosure) Sheet http://www.bostonscientific.com/role/CondensedConsolidatedStatementsOfCashFlowsCondensedConsolidatedStatementOfCashFlowsSupplementalDisclosure Condensed Consolidated Statements of Cash Flows Condensed Consolidated Statement of Cash Flows (Supplemental Disclosure) Statements 8 false false R9.htm 2101100 - Disclosure - Basis of Presentation Sheet http://www.bostonscientific.com/role/BasisOfPresentation Basis of Presentation Notes 9 false false R10.htm 2102100 - Disclosure - Acquisitions and Strategic Investments Sheet http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestments Acquisitions and Strategic Investments Notes 10 false false R11.htm 2104100 - Disclosure - Goodwill and Other Intangible Assets Sheet http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssets Goodwill and Other Intangible Assets Notes 11 false false R12.htm 2105100 - Disclosure - Hedging Activities and Fair Value Measurements Sheet http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurements Hedging Activities and Fair Value Measurements Notes 12 false false R13.htm 2106100 - Disclosure - Borrowings and Credit Arrangements Sheet http://www.bostonscientific.com/role/BorrowingsAndCreditArrangements Borrowings and Credit Arrangements Notes 13 false false R14.htm 2108100 - Disclosure - Supplemental Balance Sheet Information Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation Supplemental Balance Sheet Information Notes 14 false false R15.htm 2109100 - Disclosure - Leases Leases Sheet http://www.bostonscientific.com/role/LeasesLeases Leases Leases Notes 15 false false R16.htm 2110100 - Disclosure - Income Taxes Sheet http://www.bostonscientific.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 2111100 - Disclosure - Commitments and Contingencies Sheet http://www.bostonscientific.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 2112100 - Disclosure - Weighted Average Shares Outstanding Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding Weighted Average Shares Outstanding Notes 18 false false R19.htm 2113100 - Disclosure - Segment Reporting Sheet http://www.bostonscientific.com/role/SegmentReporting Segment Reporting Notes 19 false false R20.htm 2114100 - Disclosure - Revenue Sheet http://www.bostonscientific.com/role/Revenue Revenue Notes 20 false false R21.htm 2115100 - Disclosure - Changes in Other Comprehensive Income Sheet http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncome Changes in Other Comprehensive Income Notes 21 false false R22.htm 2116100 - Disclosure - New Accounting Pronouncements Sheet http://www.bostonscientific.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 22 false false R23.htm 2201201 - Disclosure - Basis of Presentation Basis of Presentation (Policies) Sheet http://www.bostonscientific.com/role/BasisOfPresentationBasisOfPresentationPolicies Basis of Presentation Basis of Presentation (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 23 false false R24.htm 2205201 - Disclosure - Fair Value Measurements Hedging Activities and Fair Value Measurements (Policies) Sheet http://www.bostonscientific.com/role/FairValueMeasurementsHedgingActivitiesAndFairValueMeasurementsPolicies Fair Value Measurements Hedging Activities and Fair Value Measurements (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 24 false false R25.htm 2209201 - Disclosure - Leases Leases (Policies) Sheet http://www.bostonscientific.com/role/LeasesLeasesPolicies Leases Leases (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 25 false false R26.htm 2211201 - Disclosure - Commitments and Contingencies Commitments and Contingencies (Policies) Sheet http://www.bostonscientific.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesPolicies Commitments and Contingencies Commitments and Contingencies (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 26 false false R27.htm 2215201 - Disclosure - Changes in Other Comprehensive Income Changes in Other Comprehensive Income (Policies) Sheet http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeChangesInOtherComprehensiveIncomePolicies Changes in Other Comprehensive Income Changes in Other Comprehensive Income (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 27 false false R28.htm 2216201 - Disclosure - New Accounting Pronouncements (Policies) Sheet http://www.bostonscientific.com/role/NewAccountingPronouncementsPolicies New Accounting Pronouncements (Policies) Policies http://www.bostonscientific.com/role/NewAccountingPronouncements 28 false false R29.htm 2302301 - Disclosure - Acquisitions (Tables) Sheet http://www.bostonscientific.com/role/AcquisitionsTables Acquisitions (Tables) Tables http://www.bostonscientific.com/role/AcquisitionsAndStrategicInvestments 29 false false R30.htm 2302302 - Disclosure - Contingent Consideration (Tables) Sheet http://www.bostonscientific.com/role/ContingentConsiderationTables Contingent Consideration (Tables) Tables 30 false false R31.htm 2302303 - Disclosure - Strategic Investments (Tables) Sheet http://www.bostonscientific.com/role/StrategicInvestmentsTables Strategic Investments (Tables) Tables 31 false false R32.htm 2304302 - Disclosure - Goodwill and Other Intangible Assets Goodwill (Tables) Sheet http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillTables Goodwill and Other Intangible Assets Goodwill (Tables) Tables http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssets 32 false false R33.htm 2305302 - Disclosure - Hedging Activities and Fair Value Measurements (Tables) Sheet http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables Hedging Activities and Fair Value Measurements (Tables) Tables http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurements 33 false false R34.htm 2306301 - Disclosure - Borrowings and Credit Arrangements (Tables) Sheet http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables Borrowings and Credit Arrangements (Tables) Tables http://www.bostonscientific.com/role/BorrowingsAndCreditArrangements 34 false false R35.htm 2308301 - Disclosure - Supplemental Balance Sheet Information (Tables) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables Supplemental Balance Sheet Information (Tables) Tables http://www.bostonscientific.com/role/SupplementalBalanceSheetInformation 35 false false R36.htm 2309302 - Disclosure - Leases Leases (Tables) Sheet http://www.bostonscientific.com/role/LeasesLeasesTables Leases Leases (Tables) Tables http://www.bostonscientific.com/role/LeasesLeases 36 false false R37.htm 2310301 - Disclosure - Income Taxes (Tables) Sheet http://www.bostonscientific.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.bostonscientific.com/role/IncomeTaxes 37 false false R38.htm 2312301 - Disclosure - Weighted Average Shares Outstanding (Tables) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables Weighted Average Shares Outstanding (Tables) Tables http://www.bostonscientific.com/role/WeightedAverageSharesOutstanding 38 false false R39.htm 2313301 - Disclosure - Segment Reporting (Tables) Sheet http://www.bostonscientific.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.bostonscientific.com/role/SegmentReporting 39 false false R40.htm 2314301 - Disclosure - Revenue (Tables) Sheet http://www.bostonscientific.com/role/RevenueTables Revenue (Tables) Tables http://www.bostonscientific.com/role/Revenue 40 false false R41.htm 2315302 - Disclosure - Changes in Other Comprehensive Income (Tables) Sheet http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeTables Changes in Other Comprehensive Income (Tables) Tables http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncome 41 false false R42.htm 2401402 - Disclosure - Basis of Presentation ASUs Implemented (Details) Sheet http://www.bostonscientific.com/role/BasisOfPresentationAsusImplementedDetails Basis of Presentation ASUs Implemented (Details) Details 42 false false R43.htm 2402404 - Disclosure - Acquisitions (Details) Sheet http://www.bostonscientific.com/role/AcquisitionsDetails Acquisitions (Details) Details http://www.bostonscientific.com/role/AcquisitionsTables 43 false false R44.htm 2402405 - Disclosure - Contingent Consideration (Details) Sheet http://www.bostonscientific.com/role/ContingentConsiderationDetails Contingent Consideration (Details) Details http://www.bostonscientific.com/role/ContingentConsiderationTables 44 false false R45.htm 2402406 - Disclosure - Strategic Investments (Details) Sheet http://www.bostonscientific.com/role/StrategicInvestmentsDetails Strategic Investments (Details) Details http://www.bostonscientific.com/role/StrategicInvestmentsTables 45 false false R46.htm 2404403 - Disclosure - Goodwill and Other Intangible Assets (Details) Sheet http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsDetails Goodwill and Other Intangible Assets (Details) Details http://www.bostonscientific.com/role/GoodwillAndOtherIntangibleAssetsGoodwillTables 46 false false R47.htm 2405403 - Disclosure - Hedging Activities and Fair Value Measurements (Details) Sheet http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsDetails Hedging Activities and Fair Value Measurements (Details) Details http://www.bostonscientific.com/role/HedgingActivitiesAndFairValueMeasurementsTables 47 false false R48.htm 2406402 - Disclosure - Borrowings and Credit Arrangements (Details) Sheet http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsDetails Borrowings and Credit Arrangements (Details) Details http://www.bostonscientific.com/role/BorrowingsAndCreditArrangementsTables 48 false false R49.htm 2408402 - Disclosure - Supplemental Balance Sheet Information (Details) Sheet http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationDetails Supplemental Balance Sheet Information (Details) Details http://www.bostonscientific.com/role/SupplementalBalanceSheetInformationTables 49 false false R50.htm 2409403 - Disclosure - Leases Leases (Details) Sheet http://www.bostonscientific.com/role/LeasesLeasesDetails Leases Leases (Details) Details http://www.bostonscientific.com/role/LeasesLeasesTables 50 false false R51.htm 2410402 - Disclosure - Income Taxes (Details) Sheet http://www.bostonscientific.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.bostonscientific.com/role/IncomeTaxesTables 51 false false R52.htm 2411402 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.bostonscientific.com/role/CommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://www.bostonscientific.com/role/CommitmentsAndContingenciesCommitmentsAndContingenciesPolicies 52 false false R53.htm 2412402 - Disclosure - Weighted Average Shares Outstanding (Details) Sheet http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingDetails Weighted Average Shares Outstanding (Details) Details http://www.bostonscientific.com/role/WeightedAverageSharesOutstandingTables 53 false false R54.htm 2413402 - Disclosure - Segment Reporting (Details) Sheet http://www.bostonscientific.com/role/SegmentReportingDetails Segment Reporting (Details) Details http://www.bostonscientific.com/role/SegmentReportingTables 54 false false R55.htm 2414402 - Disclosure - Revenue (Details) Sheet http://www.bostonscientific.com/role/RevenueDetails Revenue (Details) Details http://www.bostonscientific.com/role/RevenueTables 55 false false R56.htm 2415403 - Disclosure - Changes in Other Comprehensive Income (Details) Sheet http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeDetails Changes in Other Comprehensive Income (Details) Details http://www.bostonscientific.com/role/ChangesInOtherComprehensiveIncomeTables 56 false false All Reports Book All Reports q32019form10-q.htm bsx-20190930.xsd bsx-20190930_cal.xml bsx-20190930_def.xml bsx-20190930_lab.xml bsx-20190930_pre.xml exhibit311-ceo302q32019.htm exhibit312-cfo302q32019.htm exhibit321-ceo906q32019.htm exhibit322-cfo906q32019.htm http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2018-01-31 true true XML 71 R36.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Leases (Tables)
 9 Months Ended
Sep. 30, 2019
Lessee Disclosure [Abstract]  
Lessee Supplemental Balance Sheet Information [Table Text Block]
The following table presents supplemental balance sheet information related to our operating leases:
(in millions)
As of September 30, 2019
Assets
 
Operating lease right-of-use assets in Other long-term assets
$
306

Liabilities
 
Operating lease liabilities in Other current liabilities
62

Operating lease liabilities in Other long-term liabilities 
251
Weighted average remaining lease term and discount rate [Table Text Block]
The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
 
As of September 30, 2019
Weighted average remaining lease term
5.6 years
Weighted average discount rate
3.7%
Supplemental Cash Flow Information Related to Leases [Table Text Block]
The following table presents supplemental cash flow information related to our operating leases:
(in millions)
Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of operating lease liabilities
 
Operating cash flows from operating leases
$
55
Maturities of Lease Liabilities [Table Text Block]
The following table presents the maturities of our operating lease liabilities as of September 30, 2019:
Fiscal year
Operating Leases
(in millions)
2019 (excluding the first nine months of 2019)
$
22

2020
76

2021
65

2022
52

2023
41

Thereafter
95

Total future minimum operating lease payments
350

Less: imputed interest
37

Present value of operating lease liabilities
$
314

XML 72 R32.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets Goodwill (Tables)
 9 Months Ended
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets and Goodwill [Table Text Block]
The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:
 
As of September 30, 2019
 
As of December 31, 2018
(in millions)
Gross Carrying Amount
 
Accumulated Amortization/ Write-offs
 
Gross Carrying Amount
 
Accumulated Amortization/ Write-offs
Amortizable intangible assets
 
 
 
 
 
 
 
Technology-related
$
12,018

 
$
(5,545
)
 
$
10,197

 
$
(5,266
)
Patents
524

 
(404
)
 
520

 
(393
)
Other intangible assets
1,748

 
(1,047
)
 
1,666

 
(958
)
 
$
14,290

 
$
(6,996
)
 
$
12,383

 
$
(6,617
)
Indefinite-lived intangible assets
 
 
 
 
 
 
 
Goodwill
$
19,915

 
$
(9,900
)
 
$
17,811

 
$
(9,900
)
IPR&D
661

 
—

 
486

 
—

Technology-related
120

 
—

 
120

 
—

 
$
20,695

 
$
(9,900
)
 
$
18,417

 
$
(9,900
)
Schedule of Goodwill [Table Text Block]
The following represents our goodwill balance allocated to our global reportable segments and unallocated amounts:
(in millions)
MedSurg
 
Rhythm and Neuro
 
Cardiovascular
 
BTG Acquisition(1)
 
Total
As of December 31, 2018
$
2,063

 
$
1,924

 
$
3,925

 
$
—

 
$
7,911

Impact of foreign currency fluctuations and other changes in carrying amount
(3
)
 
—

 
2

 
1

 
(1
)
Goodwill acquired
—

 
268

 
307

 
1,549

 
2,124

Goodwill divested
—

 
—

 
(19
)
 
—

 
(19
)
As of September 30, 2019
$
2,060

 
$
2,191

 
$
4,214

 
$
1,550

 
$
10,015


(1)
As a result of the BTG Acquisition, we recognized goodwill attributable to the synergies expected to arise from the BTG Acquisition and revenue and cash flow projections associated with future technologies. The goodwill is not deductible for tax purposes. As of September 30, 2019, given the preliminary nature of the BTG Acquisition purchase price allocation, we have not yet allocated goodwill to the relevant reporting units and/or reportable segments.
XML 73 R19.htm IDEA: XBRL DOCUMENT v3.19.3
Segment Reporting
 9 Months Ended
Sep. 30, 2019
Segment Reporting [Abstract]  
SEGMENT REPORTING
NOTE K – SEGMENT REPORTING

We have three reportable segments comprised of MedSurg, Rhythm and Neuro, and Cardiovascular, which represent an aggregation of our operating segments.

Each of our reportable segments generates revenues from the sale of medical devices. We measure and evaluate our reportable segments based on reportable segment net sales, operating income of reportable segments, excluding intersegment profits, and reportable segment operating income as a percentage of reportable segment net sales. Reportable segment operating income as a percentage of reportable segment net sales is defined as operating income of reportable segments divided by reportable segment net sales. Our presentation of reportable segment net sales and operating income of reportable segments includes the impact of foreign currency fluctuations, since our chief operating decision maker (CODM) reviews operating results both including and excluding the impact of foreign currency fluctuations, and the following presentation more closely aligns to our unaudited condensed consolidated financial statements. We exclude from operating income of reportable segments certain corporate-related expenses and certain transactions or adjustments that our CODM considers to be non-operational, such as amounts related to amortization expense, intangible asset impairment charges, acquisition-related items, restructuring and restructuring-related items, litigation-related items and medical device regulation charges. Although we exclude these amounts from operating income of reportable segments, they are included in Income (loss) before income taxes on the unaudited condensed consolidated statements of operations and are included in the reconciliation below.

A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows (in millions, except percentages):
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Net sales
2019
 
2018
 
2019
 
2018
MedSurg
$
845

 
$
746

 
$
2,429

 
$
2,207

Rhythm and Neuro
780

 
740

 
2,323

 
2,252

Cardiovascular
1,011

 
908

 
3,009

 
2,806

Reportable segment net sales
2,636

 
2,393

 
7,760

 
7,262

BTG Acquisition(1)
71

 
n/a

 
71

 
n/a

Net sales
$
2,707

 
$
2,393

 
$
7,831

 
$
7,262

 
 
 
 
 
 
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
Income (loss) before income taxes
2019
 
2018
 
2019
 
2018
MedSurg
$
319

 
$
274

 
$
870

 
$
807

Rhythm and Neuro
166

 
168

 
488

 
481

Cardiovascular
281

 
268

 
857

 
858

Operating income of reportable segments
766

 
710

 
2,216

 
2,146

BTG Acquisition(1)
16

 
n/a

 
16

 
n/a

Corporate expenses, including hedging activities
(75
)
 
(97
)
 
(215
)
 
(297
)
Intangible asset impairment charges, acquisition/divestiture-related, restructuring- and restructuring-related, litigation-related net (charges) credits and medical device regulation charges
(146
)
 
(77
)
 
(210
)
 
(225
)
Amortization expense
(178
)
 
(148
)
 
(498
)
 
(437
)
Operating income (loss)
383

 
388

 
1,308

 
1,187

Other expense, net
(292
)
 
68

 
(615
)
 
(61
)
Income (loss) before income taxes
$
91

 
$
456

 
$
693

 
$
1,126

 
 
 
 
 
 
 
 
Reportable segment operating income as a percentage of reportable segment net sales
Three Months Ended September 30,
 
Nine Months Ended September 30,
2019
 
2018
 
2019
 
2018
MedSurg
37.8
%
 
36.8
%
 
35.8
%
 
36.6
%
Rhythm and Neuro
21.3
%
 
22.7
%
 
21.0
%
 
21.4
%
Cardiovascular
27.8
%
 
29.5
%
 
28.5
%
 
30.6
%

(1)
For the first nine months of 2019, there have been no changes to our internal reporting structure, and accordingly, we have not revised our segment reporting or geographic presentation. We will continue to integrate the BTG Acquisition into our operations in the fourth quarter and will reassess our operating and reportable segments as well as geographic presentation for any changes related to our internal reporting structure as well as to the information regularly reviewed by the CODM. To the extent any changes in our operating and reportable segments are identified, these will be reflected in our segment reporting information in the period in which the change occurs. Our results of operations include the results of BTG following the acquisition date of August 19, 2019. The BTG Acquisition reconciling item above excludes certain adjustments that our CODM considers to be non-operational, such as acquisition-related items.
XML 74 R11.htm IDEA: XBRL DOCUMENT v3.19.3
Goodwill and Other Intangible Assets
 9 Months Ended
Sep. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS
NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS

The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill are as follows:
 
As of September 30, 2019
 
As of December 31, 2018
(in millions)
Gross Carrying Amount
 
Accumulated Amortization/ Write-offs
 
Gross Carrying Amount
 
Accumulated Amortization/ Write-offs
Amortizable intangible assets
 
 
 
 
 
 
 
Technology-related
$
12,018

 
$
(5,545
)
 
$
10,197

 
$
(5,266
)
Patents
524

 
(404
)
 
520

 
(393
)
Other intangible assets
1,748

 
(1,047
)
 
1,666

 
(958
)
 
$
14,290

 
$
(6,996
)
 
$
12,383

 
$
(6,617
)
Indefinite-lived intangible assets
 
 
 
 
 
 
 
Goodwill
$
19,915

 
$
(9,900
)
 
$
17,811

 
$
(9,900
)
IPR&D
661

 
—

 
486

 
—

Technology-related
120

 
—

 
120

 
—

 
$
20,695

 
$
(9,900
)
 
$
18,417

 
$
(9,900
)


The following represents our goodwill balance allocated to our global reportable segments and unallocated amounts:
(in millions)
MedSurg
 
Rhythm and Neuro
 
Cardiovascular
 
BTG Acquisition(1)
 
Total
As of December 31, 2018
$
2,063

 
$
1,924

 
$
3,925

 
$
—

 
$
7,911

Impact of foreign currency fluctuations and other changes in carrying amount
(3
)
 
—

 
2

 
1

 
(1
)
Goodwill acquired
—

 
268

 
307

 
1,549

 
2,124

Goodwill divested
—

 
—

 
(19
)
 
—

 
(19
)
As of September 30, 2019
$
2,060

 
$
2,191

 
$
4,214

 
$
1,550

 
$
10,015


(1)
As a result of the BTG Acquisition, we recognized goodwill attributable to the synergies expected to arise from the BTG Acquisition and revenue and cash flow projections associated with future technologies. The goodwill is not deductible for tax purposes. As of September 30, 2019, given the preliminary nature of the BTG Acquisition purchase price allocation, we have not yet allocated goodwill to the relevant reporting units and/or reportable segments.

Goodwill and Indefinite-Lived Intangible Asset Impairment Testing

We did not have any goodwill impairments in the third quarter and first nine months of 2019 or 2018.

We test our goodwill balances in the second quarter of each year for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist. In the second quarter of 2019, we performed our annual goodwill impairment test for all of our reporting units and concluded that the fair value of each reporting unit exceeded its carrying value.

In performing the goodwill impairment assessment, we utilized both the optional qualitative assessment and the quantitative approach prescribed under FASB ASC Topic 350, Intangibles - Goodwill and Other. In 2019, we performed a qualitative assessment for our Urology and Pelvic Health, Neuromodulation and Endoscopy reporting units since their fair values have exceeded carrying value by greater than 100 percent. The remaining reporting units were quantitatively tested for impairment. For the reporting units subject to a qualitative assessment, if it is determined that it is more likely than not that the fair value of the reporting unit is less than its carrying value, the quantitative approach of the goodwill impairment test is necessary. In 2019, for all reporting units tested using the qualitative assessment, we concluded that it was unnecessary to perform the quantitative impairment test. For all reporting units tested using the quantitative approach, we concluded that the fair value of each reporting unit exceeded its carrying value.

We did not have any Intangible asset impairment charges in the third quarter of 2019 or 2018. We recorded immaterial Intangible asset impairment charges in the first nine months of 2019 and 2018.

We review intangible assets subject to amortization quarterly to determine if any adverse conditions exist or a change in circumstances has occurred that would indicate impairment or a change in the remaining useful life. If we determine it is more likely than not that the asset is impaired based on our qualitative assessment of impairment indicators, we test the intangible asset for recoverability. If the carrying value of the intangible asset or asset group exceeds the undiscounted cash flows expected to result from the use and eventual disposition of the intangible asset or asset group, we will write the carrying value down to fair value in the period impairment is identified.

In the third quarter of 2019, we performed our annual impairment test of all IPR&D projects and our indefinite-lived core technology assets using the optional qualitative assessment approach and determined that the assets were not impaired. We also verified that the classification of IPR&D projects and our indefinite-lived core technology assets we continue to recognize on our unaudited condensed consolidated balance sheets as indefinite-lived assets continues to be appropriate.

Refer to Critical Accounting Policies and Estimates within Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations contained in our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing.
XML 75 R15.htm IDEA: XBRL DOCUMENT v3.19.3
Leases Leases
 9 Months Ended
Sep. 30, 2019
Leases [Abstract]  
LEASES
NOTE G – LEASES

We have operating and finance leases for real estate including corporate offices, land, warehouse space, and vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet, unless the arrangement includes an option to purchase the underlying asset, or an option to renew the arrangement, that we are reasonably certain to exercise (short-term leases). We recognize lease expense on a straight-line basis over the lease term for short-term leases that we do not record on our balance sheet. If there is a change in our assessment of the lease term, and as a result, the remaining lease
term extends more than 12 months from the end of the previously determined lease term, or we subsequently become reasonably certain that we will exercise an option to purchase the underlying asset, the lease no longer meets the definition of a short-term lease and is accounted for as either an operating or finance lease and recognized on the balance sheet. For leases executed in 2019 and later, we account for the lease components and the non-lease components as a single lease component, with the exception of our warehouse leases. Our leases have remaining lease terms of less than 1 year to approximately 60 years, some of which may include options to extend the leases for up to 10 years. If we are reasonably certain we will exercise an option to extend the lease, the time period covered by the extension option is included in the lease term.

We determine whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of the arrangement. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, we utilize the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received.

The following table presents supplemental balance sheet information related to our operating leases:
(in millions)
As of September 30, 2019
Assets
 
Operating lease right-of-use assets in Other long-term assets
$
306

Liabilities
 
Operating lease liabilities in Other current liabilities
62

Operating lease liabilities in Other long-term liabilities 
251



The following table presents the weighted average remaining lease term and discount rate information related to our operating leases:
 
As of September 30, 2019
Weighted average remaining lease term
5.6 years
Weighted average discount rate
3.7%


Our operating lease cost was $21 million in the third quarter of 2019 and $57 million for the first nine months of 2019.

The following table presents supplemental cash flow information related to our operating leases:
(in millions)
Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of operating lease liabilities
 
Operating cash flows from operating leases
$
55



Right-of-use assets obtained in exchange for operating lease obligations totaled $84 million for the first nine months of 2019.

The following table presents the maturities of our operating lease liabilities as of September 30, 2019:
Fiscal year
Operating Leases
(in millions)
2019 (excluding the first nine months of 2019)
$
22

2020
76

2021
65

2022
52

2023
41

Thereafter
95

Total future minimum operating lease payments
350

Less: imputed interest
37

Present value of operating lease liabilities
$
314



As of September 30, 2019, we have additional leases for office space and R&D space, that have not yet commenced, of $68 million. These leases will commence during the fourth quarter of 2019 and 2020, with lease terms of 1 month to 15 years.